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Abstract
Most drugs used today demonstrate their bioactivity by acting as receptor antagonists or
as enzyme inhibitors. Due to the significant role of enzymes in the activity of a number of
disease processes, and their structural conformation that is easily accessible to inhibition by
small drug like molecules, they are widely investigated as drug targets. The first step in the
preparation of an enzyme inhibitor is defining the target enzyme whose function is going to be
interrupted or blocked in a particular disease or infection.
c-AMP Dependent protein kinase A (PKA) is an important enzyme involved in the
regulation of a large number of physiological processes. As such, the inhibition of PKA has
become an attractive drug target in a number of areas, in particular in immune function and for
memory disorders. Interestingly, despite PKA being one of the most well characterised of all
protein kinases, there are as yet no PKA inhibitors reported from marine sources.
The natural environment has provided a wealth of chemically diverse, bioactive
compounds that are responsible for over half of the medications currently available for a
multitude of diseases. Herein, ten algal species from South East Australia assigned as Prionitis
linearis, Corallina vancouveriensis, Codium fragile, Codium dimorphum, Colpomenia sinuosa,
Padina sp., Phyllospora comosa, Sargassum vestitum, Sargassum sp. and Ulva lactuca were
analysed. Extracts of different polarity were generated from each sample and tested for their
PKA inhibitory activity, haemolytic activity and brine shrimp cytotoxicity giving novel results
on bioactivity from marine algae. There are no literature data so far on the kinase inhibitory
activities of extracts isolated from these algal samples and for most of the samples haemolytic
data are also reported for the first time. Furthermore, the chemical (fatty acid and sterol)
composition of the ten algal extracts were also analysed and compared.
The bioactivity profiles of the alga samples were strongly species dependent, with no
apparent correlation between PKA inhibition, haemolysis and/or brine shrimp lethality. In
general, the non-polar fractions isolated from all alga samples were found to give potent
biological results and displayed more activity, in particular greater PKA inhibitory activity,
compared with the polar fractions. The biological activity is reflected in the different algal
divisions, with the order of PKA inhibitory activity identified as follows: brown seaweeds > red
seaweeds > green seaweeds. The main constituents of the non-polar fractions were identified as
fatty acids (FAs) and sterols in all algal samples. The FA composition was dominated by
saturated FAs, hexadecanoic acid and unsaturated 9,12-octadecadienoic acid were the most
predominant acids, while cholesterol was found to be the major sterol of all ten algal species
investigated.
The deep sea is one of the most biodiverse habitats on the planet and deep-sea sponges
are the largest source of new deep-water natural products reported and are found to contain a
xxii

rich diversity of new and unusual sterols. In this study four deep-sea sponges from North
Western Australia assigned to the genera Haliclona, Sarcotragus, Ircinia and Geodia were
investigated for their biological activities in a variety of assays (for PKA inhibition, haemolytic
activity and brine shrimp toxicity assay). The chemical composition of the extracts of different
polarity obtained from all three samples were also determined and compared.
Overall the sponge Haliclona sp. displayed greater haemolytic activity than PKA
inhibitory activity, along with low levels of brine shrimp lethality with the bioactivity mainly
found in the non-polar fractions. The Ircinia/Sarcotragus sponge species exhibited higher PKA
inhibitory activity than the activity found in the other two assays, with the two non-polar
fractions displaying activity greater than 80%. The trend of the bioactive non-polar fractions
continued for the Geodia sponge species where the non-polar extracts showed both potent PKA
inhibitory activity (97%) and brine shrimp lethality (88%), with modest haemolytic activity
observed for several fractions. Most of the identified compounds in those fractions were fatty
acids and sterols and contributed to a partial fatty acid and sterol profile of this deep-sea
demosponge. A total of 29 fatty acids and 23 sterols were identified, with the highest
proportions found in Ircinia/Sarcotragus sp. > Haliclona sp. > Geodia sp. There was no
apparent correlation amongst the sterol composition of the three deep-sea sponges. The sterol
profile varied across the sponge species either in type of sterols or in relative percentages. This
work, has however uncovered the rich potential of deep-sea sponges as sources of bioactive
metabolites. In addition, this study has laid the foundations for the future investigation and
assessment of kinase inhibitory potential of metabolites from both shallow and deep water
invertebrates.
Another aspect of drug discovery, in addition to isolating natural products, is
modification of the isolated metabolites from nature and their structural modification towards
improved bioactivity. Development of natural products includes modification of functional
groups, their removal, introduction of novel groups and stereocenters to the molecule, or
occasionally radical changes of the basic scaffold. Although the structural diversity in nature is
extraordinary, synthetic chemistry methods can provide novel structure types which cannot be
obtained from natural biosynthetic methods.
Isatin derivatives were previously investigated in our research group for cytotoxicity
against a range of human cell lines and found to display potent activity, causing decreased cell
proliferation in all cell lines studied. Previous literature research of isatin-indole compounds has
also demonstrated that these scaffolds are also important for kinase inhibitory activity, as
evidenced by the large number of indole based kinase inhibitors approved for use and currently
in clinical trials. Hence, it was of interest to further develop our isatin-based structures and test
them for potential protein kinase A inhibitory activity. The aim was to determine the structural
xxiii

requirements and the position of the different groups on the isatin molecule necessary for PKA
inhibitory activity. Herein, the synthesis of 41 novel imino isatin derivatives and 14 alkenyl
isatin analogues and evaluation of their cytotoxicity, PKA and PKB inhibitory activity is
presented, followed by a detailed analysis of their structure-activity relationships. Of a total of
77 isatin derivatives prepared four isatin derivatives displayed potent PKA inhibitory activity
(65-86%) and six displayed potent PKB inhibitory activity (57-84%). Compounds 178, 208, 209
and 246 displayed the highest PKA inhibitory activities and their IC50 values were determined
as 43.5, 51.8, 38.5, 52.2 µM respectively (at 100 µg/mL). Four isatin derivatives (175, 176, 177
and 208) were active in both PKA and PKB assay. Three isatins (163, 187, 206) displayed
selective activity over PKB than PKA, while two compounds (178, 209) were more selective
towards PKA. In addition the newly developed isatin derivatives also exhibited potent
cytotoxicity against human leukemic monocyte lymphoma cell lines U937 in the micromolar
range. This work suggests that isatin derivatives possess a real potential to be further developed
into PKA and PKB inhibitors in the future.

xxiv

Chapter 1
Introduction

Chapter 1

Introduction

1.1 Drug discovery
Modern drugs and traditional medicines are largely based on natural products (NPs).
Nature has been the cornerstone of drug development with 70% of all drugs on the market
connected with natural products, while only 30% of novel drugs have been purely synthetic.1
Discovery of novel natural product-based drugs includes isolation of new metabolites from
various natural sources such as plants, marine organisms and bacteria and also involves
structurally inspired development of previous identified natural compounds. Pharmaceutical
industries have tried to develop better novel drug sources using combinatorial chemistry and
high throughput screening on molecular targets; however natural products are still found to be
unique and irreplaceable.2,3 Research shows that nature derived compounds have better drug like
properties than compounds prepared by combinatorial chemistry, e.g. 65% of compounds from
the Dictionary of Natural Products have no violations of Lipinski’s “rule of five”, which is often
used to determine drug-likeness of chemical compounds.4-6 Additionally, naturally occurring
metabolites display greater biochemical specificity and chemical diversity than synthetic drugs
(Table 1.1).7,8 Statistical comparison of natural product derived compounds and synthetically
produced drugs shows obvious differences in their structural properties. Natural derived
compounds generally have more sp3 hybridized bridgehead atoms, stereogenic centres, number
of rings and oxygen content than synthetic compounds and more favourable chemical
complexity.9
8

Table 1.1:Some fundamental differences between biosynthesis and synthesis.
Biosynthesis
Synthesis
Few
Many
Building blocks
Branching of intermediate
Alteration of building block
Strategy
High
Low
Scaffold diversity
High
Low
Functional group tolerance
Common
Rare
Novel motifs
Common, site-specific
Rare
C–H activation
Easy, enantioselective
Difficult, case-by-case basis
Stereocontorol

1.2 Natural products as a source of novel drugs
Records of the use of natural products in traditional medicine dates back to ancient
times worldwide.10 In Greece, South America, Egypt, China and Rome, plants were widely used
as a source of both nutrition and medicine.10,11 However, <10% of the 300,000 to 500,000 plant
species are used by humans and animals as foods, while more are used for medicinal purposes
(Fig. 1.1).12 More than 3000 plant species have been reported to be used for the treatment of
cancer where 67% of the effective anticancer drugs today can be traced back to natural origin.13
Approximately two thirds of the human population generally consume plant-derived traditional
medicines for their primary health care as reported by the World Health Organization (WHO). 14
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Phytotherapy or study of the use of natural product generated extracts as medicines is not
related to history only, but has also gained attention and implementation in drug therapy in the
last few decades. The great importance of natural products is due to the fact that they are the
major source of novel drugs.6

Figure 1.1: Widely used herbs with chemopreventive efficacy.15

Natural products embody organic compounds, which are obtained from plants,
microorganisms, invertebrates and vertebrates.16 Nature can be viewed as a productive
biochemical factory for the biosynthesis of both primary and secondary metabolites because
natural molecules have numerous different biological functions (Fig. 1.2).16 Primary metabolites
play a pivotal role in the metabolism and reproduction of cells and they are crucial for the
survival and metabolic processes of an organism, while secondary metabolites are specific for
some limited range of species and they mainly appear to be superfluous to an organism. Primary
metabolites include carbohydrates, proteins, nucleic acids, fatty acids, steroids and lipids and
they occur through fundamental biosynthetic pathways. Secondary metabolites are found to be
connected with an organism’s interaction with its environment, producing novel chemical
compounds that promote their survival.17,18 Secondary metabolites are present in small amounts
and usually work by inhibiting or stimulating biological processes in other organisms and are
involved in the interactions between organisms.19 Therefore, these metabolites often attracted
scientific interest due to both the large number of different structures produced by nature and
their diverse range of biological activities. In addition, they represent the individuality of the
species at a chemical level because they are regularly found to be unique to a particular
2|
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species.20 Initially it was believed that secondary metabolites, which are found to have an array
of biological activities, were metabolic waste products. However, further research showed that
secondary metabolites serve for important defence, communication, and predation purposes.14

Figure 1.2: Outline of the biogenesis of natural products.16

As previously stated, Nature has provided the majority of drugs in use today, and
natural products (NP) are currently considered the most successful source of drugs ever, with
nearly one-third of the top-selling drugs in the world being natural products or their
derivatives.19,21 The discovery of new natural compounds can lead to new ways of enhancing
life, such as through the discovery of new classes of drugs with novel modes of actions.
Important given the growing drug tolerance and resistance in microorganisms and cancer cells.22
In the period from 2005 to 2010 19 natural product based compounds (Table 1.2) were
approved for use on the market including seven NPs, 10 semi-synthetic NPs and two NPderived drugs.17
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Table 1.2: Natural product based compounds approved in the market in the period 2005-2010.17
Year

Generic name (trade name)

Lead compound

Classification

Disease area

2005
2005
2005
2005
2005
2005

Dronabinol /Cannabidol
Fumagillin (Flisint®)
Doripenem (Finibax®/Doribax®)
Tigecycline (Tygacil®)
Ziconotide (Prialt®)
Zotarolimus (EndeavorTM stent)

Dronabinol/cannabidol
Fumagillin
Thienamycin
Tetracycline
Ziconotide
Sirolimus

NPs
NPs
NP-derived
Semi-synthetic NP
NP
Semi-synthetic NP

Pain
Antiparasitic
Antibacterial
Antibacterial
Pain

Anidulafungin (EraxisTM/EcaltaTM)
Echinocandin B
Exenatide (Byetta®)
Exenatide-4
Lisdexamfetamine (VyvanseTM)
Amphetamine
Retapamulin (AltabaxTM/AltargoTM) Pleuromutilin
Temsirolimus (ToriselTM)
Sirolimus
Trabectedin (YondelisTM)
Trabectedin
Ixabepilone (IxempraTM)
Epothilone
Methylnaltrexone (Relistor®)
Naltrexone
Everolimus (Afinitor®)
Sirolimus
Telavancin (Vibativ®)
Vancomycin
Romidepsin 27 (Istodax®)
Romidepsin
Capsaicin (Qutenza®)
Capsaicin
Monobactam aztreonam
Aztreonam
(CaystonTM)
NP = natural product; ADHD = Attention deficit hyperactivity disorder.
2006
2006
2007
2007
2007
2007
2007
2008
2009
2009
2009
2009
2010

Semi- synthetic NP
NP
NP-derived
Semi-synthetic NP
Semi-synthetic NP
NP
Semi-synthetic NP
Semi-synthetic NP
Semi-synthetic NP
Semi-synthetic NP
NP
NP
Semi-synthetic NP

Cardiovascular

surgery
Antifungal
Diabetes
ADHD
Antibacterial
Oncology
Oncology
Oncology
Pain
Oncology
Antibacterial
Oncology
Pain
Antibacterial

Some of the earliest isolated drugs from Nature are quinine, morphine and penicillin
(Fig. 1.3). Quinine (1) was an antimalaria agent, isolated from Cinchona bark found by the
French scientists Caventou and Pelletier in 1820.23 Morphine (2) was isolated in 1805 from the
plant Papaver somniferum and was the first Nature-derived compound to be commercialised.
There have been many attempts to synthesise compounds such as morphine that give less side
effects, however this natural product remained the leader in the field of analgesics until the
approval of Ziconotide in 2005. Unlike morphine, quinine has been replaced by superior,
synthetic analogues such as the drug pamaquine. Penicillin (3), discovered in 1928 by Fleming
was isolated from the culture broth of Penicillium notatum as a bioactive principle inhibiting the
growth of Gram-positive bacteria.10 Soon thereafter when research of natural products had
become popular, the isolation of new compounds included salicin from Salix alba, strychnine
and brucine from Strychnos nux-vomica, colchicine from Colchicum autumale, caffeine from
Coffea arabica, nicotine from Nicotiana tabacum, atropine from Atropa belladonna and cocaine
from Erythroxylum coca.24 Some of the most well known natural drugs and medicines used in
the health industries are the antibiotic erythromycin, the antifungal agent amphotericin B, and
the immunosuppressive agents cyclosporine A and FK506. Vinca alkaloids, vincristine sulphate
and vinblastine sulphate, are also the first plant derived anticancer agents to be approved for use
in cancer.25
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Figure 1.3: Some of the earliest isolated and characterised drugs obtained from Nature: a) quinine from Cinchona
bark;26 b) morphine from the plant Papaver somniferum;27 c) penicillin from the bacteria Penicillium notatum.28

Pharmaceutical companies use plant extracts in high-throughput screening (HTS) and
test them on a range of receptor based assays for drug discovery.6 Extracts typically contain a
complex mixture of compounds and it is a challenge to isolate a pure bioactive principle,
especially as the activity of extracts has occasionally been found to be due to the synergy of the
mixture, while the pure compounds may be inactive.23 In addition, in the process of discovering
novel bioactive metabolites, it may also occur that an isolated compound is a known compound
that was identified, characterised and analysed previously. Many natural products have complex
structures that cannot be prepared in the laboratory and therefore it is necessary to further
develop natural product screening to discover compounds more amenable for large scale
synthesis.22
1.3 Marine natural products as sources of novel drugs
Almost 75% of the Earth’s surface is covered by oceans and this huge quantity of
marine environment is a vast and fertile area presenting a large opportunity for research.29,30 For
thousands of years, natural products were obtained from terrestrial organisms but around 50
years ago, with the advent of scuba technology, scientists started to explore the marine
environment. Of the estimated 153,000 known natural products found so far, 30,000 compounds
are obtained from marine organisms and there are still many more to be discovered.31
Furthermore, of the accounted 34 fundamental phyla of life, 32 occur in the sea while only 17
occur on land.32 While there are many natural products that have been developed into drugs,
only a few are from marine sources because the interest in marine natural products (MNP) had a
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much later start.31 The marine environment is still unexplored as a rich source of novel drugs,
but extremely promising as a source of new drug candidates.11 Approximately half of the novel
MNPs reported in the literature are biologically active.33 The 60-70 years of activity in the MNP
field has resulted in 4796 distinct genera/species being recorded in the MarinLit database as
sources of novel MNPs.34 With the advent of new technologies which allow for easier collection
of marine organisms, HTS and combinatorial chemistry, marine organisms are revealing
themselves to be a vast, untapped source of new biologically active natural products.35 Kong et
al. analysed the relationship between novel chemical structures of marine products and scaffolds
of these compounds with time (Fig. 1.4) in the period of 1965-2000 and found that the ratio
linearly increased over time.36 The authors calculated that the trend would continue in the future
proving that MNPs are a rich source of novel metabolites.36

Figure 1.4: Time-dependent variation (x axis) of the ratios of novel structures (in red) and scaffolds (in blue) derived
from marine natural products.36

Although, the diversity of life in terrestrial organisms and the terrestrial environment is
extraordinary, the greatest biodiversity is found in the world’s oceans, which have the highest
number of species.37 Many of these marine organisms produce natural products that are
structurally unique with various biological activities that can not be found in terrestrial
organisms. In addition, some marine metabolites show extraordinary biological activity at very
low concentrations.38 Many marine organisms are soft bodied and slow-moving organisms that
usually lack physical protective systems. Consequently, in order to protect themselves from
predators and to adapt to different environmental conditions they produce unique metabolites
for chemical defence, of which many display potent bioactivity and have pharmaceutical
potential.39,40 Marine secondary metabolites have been found to play different functions
including a defensive role, antifouling and growth inhibition.41 There are two types of defences
that plants and marine organisms use to protect themselves from predators; constitutive and
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induced chemical defence.42 Constitutive chemicals are constantly produced whereas the
induced defence occurs only with changes in environment. Activated chemical defence is a type
of induced defence and occurs within seconds of damage of marine species. 42 Marine
organisms, react to stress and injuries by producing biologically active and toxic compounds,
typically by enzyme transformation of inactive precursors.43 Marine organisms produce
compounds with unique structures as a result of the specific environmental conditions with low
temperatures, changeable salinity and pressure and strong effects of bacteria and pathogens.44
The quantitative and qualitative effects of marine metabolites on herbivores was
investigated and it was determined that primary metabolites are the same for terrestrial plants
and marine organisms, while they differ in the composition of the secondary metabolites. For
instance, marine occurring compounds are rich in halogens, unusual nucleosides and new
peptides.45,46 An important characteristic of marine natural compounds is that marine organisms
produce products which are released into the surrounding water area and diluted. For those
compounds in order to display noticeable bioactivity they have to be very potent.44
The question of how compounds produced by marine organisms are correlated to
human health has often been posed. Production of antibacterial compounds in marine organisms
is related to the fact that marine sessile organisms receive their dietary uptake by filtering
seawater, which contains a high concentration of bacteria.44 They need to protect themselves
from these bacteria and other microorganism and hence produce antibacterial constituents.
Sponges occasionally grow together which creates competition for a place and the sponge that
produces more chemicals to harm the other sponge has the advantage. The chemicals involved
in this type of defence are mostly found to be active against human cancer.44
The first significant discovery of biologically active compound from a marine source
was reported in 1950 by Bergman et al., which encouraged further investigation into the MNP
field.47 Spongouridine (4) and spongothymidine (5) (Fig. 1.5) were isolated from the Caribbean
sponge Tethya crypta (Tethylidae).48 Structural development of these metabolites led to the
synthesis of approved antiviral drugs, ara-A (6) and ara-C (7) (Fig. 1.5), which are still in use
today.32

Figure 1.5: Bioactive compounds isolated from marine Caribbean sponge Tethya crypta (4 and 5) and their synthetic
analogues (6 and 7)
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Nowadays, hundreds of patents which describe novel bioactive MNPs have been filed
and approximately 10-15 different MNPs are in clinical trials at this time.35 Currently, there are
five approved drugs isolated from marine organisms (Table 1.3). Of the five marine derived
drugs on market, four are Food and Drug Administration (FDA)-approved in the US
Pharmacopeia while the fifth Yondelis is approved by the European Agency and is completing
Phase III clinical studies in the US for approval.49
Table 1.3: Marine derived drugs: approved and in clinical trials.49
Clinical
status
Approved

Phase III
Phase II

Phase I

Compound name
Cytarabine, Ara-C
Vidarabine, Ara-A
Ziconotide
Yondelis (ET-743)
Eribulin Mesylate (E7389) Halaven
Soblidotin (TZT 1027)
DMXBA (GTS-21)
Pinabulin (NPI-2358)
Plitidepsin
Elisidepsin
PM1004
Tasidotin (ILX-651)
Pseudopterosins
Bryostatin 1
Hemiasterlin (E7974)
Marizomib (NPI-0052)

Marine
Organism
Sponge
Sponge
Cone snail
Tunicate
Sponge
Bacterium
Worm
Fungus
Tunicate
Mollusc
Nudibranchc
Bacterium
Soft Coral
Bryozoa
Sponge
Bacterium

Chemical class

Disease area

Nucleoside
Nucleoside
Peptide
Alkaloid
Macrolide
Peptide
Alkaloid
Diketopiperazine
Depsipeptide
Depsipeptide
Alkaloid
Peptide
Diterpene glycoside
Polyketide
Tripeptide
Beta-lactone-gamma lactam

Cancer
Antiviral
Pain
Cancer
Cancer
Cancer
Cognition
Schizophrenia
Cancer
Cancer
Cancer
Cancer
Cancer
Wound healing
Cancer
Cancer

Vidarabine was approved in 1976 for the treatment of acute keratoconjunctivitis,
recurrent epithelial keratitis caused by herpes simplex virus type 1 and 2, and superficial
keratitis.49 Cytarabine (6, described earlier) was approved by the FDA in 1969 and it appears in
two formulations. Conventional cytarabine is used for lymphocytic, acute myelocytic and
meningeal leukemia while liposomal cytarabine is approved for the treatment of lymphomatous
meningitis.49 Ziconotide (8) is a natural product compound developed from the ω–conotoxin
MVIIA peptide isolated from the venom of the marine snail Conus magus, which was found to
specifically block Cav2.2 (neuronal calcium) channels.50 It was approved in 2004 for the
treatment of severe chronic pain in patients with cancer or AIDS (Fig. 1.6).49 Mangrove tunicate
Ecteinascidia turbinata yielded trabectedin (ET-743 (9), Yondelis, Fig. 1.6) which was
approved for use as an anticancer agent against soft tissue sarcoma in Europe 2007.51 In
November 2010 Halaven (eribulin mesylate, 10) was approved for metastatic breast cancer by
the FDA (Table 1.2, Fig. 1.6). Eribulin mesylate is a synthetic analogue of the complex marine
natural product halichondrin B found in the pacific sponge Halichondria okadai.52
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Figure 1.6: Marine natural products: cytarabine, vidarabine, ziconotide and ecteinascidin 743.

Marine natural products have been found to exhibit a range of activities including
antitumor,

anticancer,

antiplasmodial,

antileukemic,

biofouling,

anti-inflammatory,

antitubercular, antiviral, chemical signalling, venoms, antifouling agents, biological means of
protection from harmful environments and many other activities.53-55 Sponges are the dominant
source of new MNPs reported annually (accounting for almost 40%), followed by coelenterates
(also referred to as cnidarians) and microorganisms (Fig. 1.7).19,56
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Figure 1.7: Distribution of marine natural products by phylum.

57

1.3.1 Marine algae
Among marine natural products, marine algae are one of the most widespread species
estimated to be more than 15,000.58 Algae are known to produce a range of novel compounds
and in particular novel lipid patterns as a result of their adaptation to different environmental
conditions.59 Seaweeds have been used as a food source due to their nutritional value, mostly in
Asian countries where they have been popular for a long time, but nowadays all around the
world as well.60 Algae have become very popular in human consumption as a result of their low
calorie content, high levels of vitamin B12, iron, essential fatty acids, proteins, antioxidants,
minerals, essential and free amino acids and ability to stabilize blood sugar levels.61 The interest
in marine algae rose significantly at the beginning of the eighties and since then continues in a
similar trend.62 A number of promising anticancer compounds have been isolated from algae
including stypoldione (11) from the brown alga Stypopodium zonale, which was found to inhibit
polymerisation of microtubules and the cytotoxic dehydrothysiferol squalene derivatives,
thyresenol A (12) and B (13) isolated from the red alga Laurencia viridis, active against a
number of human breast cancer cell lines (Fig. 1.8).63-65

Figure 1.8: Bioactive compounds isolated from marine algae.
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A very important characteristic of marine algae is that they can be readily collected.
Algae are located in easily accessible coastal areas and access to a large amount of algal
material is available. Locations along the New South Wales coast of Australia have been
identified as ‘biodiversity hotspots’, providing access to a wide variety of marine life for MNP
study.66
1.3.2 Marine sponges
Sponges have been found to be the greatest source of novel MNPs reported every
year.31,67 Sponges are extremely widespread among marine organisms, with over 7000 species
described, including both shallow and deep-water sponges that are found to inhabit depths of
over 8000 m, with some deep-water species displaying carnivorous behaviour.68,69 Their
investigation started with discovery of arabinoside analogues from the sponge Tethya crypta in
the 1950s. So far, most of the bioactive metabolites have been reported from shallow-water
species, however deep-water sponges have also produced important bioactive compounds and
represent a wealthy new source of biologically and structurally interesting molecules. 68 Sponges
possess great chemical diversity and produce a variety of bioactive compounds including
hymenialdisine (14, Fig. 1. 9), a potent inhibitor of CDK-1, isolated from Axinella verrucosa
and Acanthella aurantiaca; cytotoxic β-carboline (15) and nortopsentins A-C (16-18) from
Hyrtiosreticulatus and Spongsorites ruetzleri respectively (Fig. 19); (Z)-stellettic acid C with
telomerase inhibitor activity from the sponge Stelletta sp. (19, Fig. 1.9) and girolline from
Pseudaxinyssa cantharella, which was found to be an inhibitor of protein synthesis (20, Fig.
1.9).70-74

Figure 1.9: Bioactive metabolites isolated from marine sponges.
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1.3.3 Deep-sea marine natural products
The deep-sea is classified to be the environment under the depths beyond the euphotic
zone (the bright ocean layer, upper 200-300m).75 It is one of the most biodiverse and speciesrich habitats on the planet, rivalling that of coral reefs and rainforests.76 The deep sea covers
70% of the earth’s surface and constitutes an important frontier in the progressive search for
new sources of biological and therapeutic agents. The number of species inhabiting the world’s
deep oceans is estimated to be as high as 10 million, which is 50 times greater than the number
of marine species so far reported.77 However of the 30,000 MNPs reported so far, less than 2%
come from deep-water marine organisms.68 The investigations to date have shown deep-sea
organisms to be a promising source of new and unexplored chemical diversity for drug
discovery.78 Of the various deep-sea phyla studied so far, deep-sea sponges have proven to be
the richest source of novel metabolites, accounting for over 60% of those reported, with over
half exhibiting significant cytotoxicity towards a range of human cancer cell lines. Furthermore,
the deep-sea environment is characterised by a high proportion of single rare species. More than
half of these single deep-sea species are new to science.68

Figure 1.10: World ocean bathymetric map. The vast oceans cover 70% of the world’s surface, with 95% greater
than 1000 m deep.79

Living conditions of deep-sea organisms are significantly different from the
environmental factors under which other marine organisms live.68 They live under extreme
conditions where those differences include low temperatures, high pressure and absence of light
(Fig. 1.10).80 The extreme conditions are assumed to be responsible for the production of unique
secondary metabolites as their primary metabolic pathways can also be affected and changed.81
Furthermore, as a result of having to adapt to distinctive surroundings, deep-sea marine
organisms have greater diversity of species than shallow-water species (Fig. 1.11).68
12 |

Chapter 1

Introduction

Figure 1.11: Species accumulation curves from the deep-sea and shallow-water benthos (sea floor) off the coast of
New England.82

As the depth increases the temperature decreases, down to -4ºC at depths greater than
2000 m. Pressure at those great depths is extremely high and reaches up to 1000 atm or even
more at the deepest parts. It is believed that below 250 m, light does not penetrate therefore
causing deep-sea species to live in the dark with no vision abilities required, while
chemoreception and mechanoreception becomes more important.68 There are also variations in
the other living conditions including salinity of 35%, pH values usually around 8, and deepwater currents are slower compared to the shallow-water values.83,84 As a result, all these
specific conditions cause unique processes enabling deep-sea organisms to survive in this
environment and may result in the production of structurally different metabolites. Interest in
deep-sea exploration has increased and new bioactive compounds have been reported including
three novel cytotoxic compounds (21-23) from the deep-sea fungus Phialocephala sp.,
rossinones A (24) and B (25) with anti-inflammatory, antibacterial and antiviral activity from
the deep-sea ascidian Aplidium sp. and levantilide A (26) from a deep-sea Micromonospora
strain, which displayed antiproliferative activity against several tumour cell lines (Fig. 1.12).85-87
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Figure 1.12: Bioactive metabolites isolated from deep-sea marine organisms.

Deep-sea metabolites have been reported from a range of marine phyla along with a
range of microorganisms such as archaea, bacteria and fungi. As for shallow-water organisms,
the deep-water organisms have also proven to be a prolific source of metabolites from a diverse
variety of structural classes including alkaloids (in particular bromoindoles), amino acids,
polyketides, fatty acids, macrolides, terpenes, sterols, glyosides, and products of mixed
biosynthetic pathways. The approval of eribulin mesylate (10) in 2010 by FDA, which is a
synthetic analogue of a compound firstly isolated from the shallow-water Japanese sponge
Halichondria okadai but also found in the deep sea marine sponge Lissodendoryx sp. from New
Zealand, has significantly encouraged further exploration of deep-sea bioactive metabolites.52,88
Deep sea MNPs have been derived from all parts of the world and from various
environmental conditions. Expanded access to submersibles and remotely operated vehicle
(ROV) technology through new collaborations, including with the oil and gas industry, are
providing researchers today with the equipment they need to further discover and analyse deepsea fauna and their natural products.89,90 Employing sophisticated ROV technology for deep-sea
collections, as opposed to the more commonly used trawling operations, provides the
opportunity to:
a) examine species interactions in situ, which are often important indicators of the
likehood of bioactive compound production;
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b) select specific samples, such as those that are abundant in the area, increasing the
chance of a successful scale-up procedure later on; and
c) perform sampling with minimal environmental consequences.
The investigation of deep-sea MNPs shows that the most of the deep-sea metabolites
were found in depths ranging from 100–400 m (50%), while only 10% were collected from
depths of 500–600 m (Fig. 1.13).68 Only 8% of the compounds reported were obtained at depths
below 1000 m, due to the greater difficulty in accessing bathyl and abyssal depths. Around 60%
of the deep-sea natural products are reported to possess bioactivity, with over half exhibiting
significant cytotoxicity towards a range of human cancer cell lines. This raises the question of
whether deep-sea fauna are a richer source of bioactive metabolites than their shallow-water
counterparts.
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Figure 1.13: Geographic origins of reported novel deep-sea natural products.68

1.4 Drug synthesis based on natural product scaffolds
Another aspect of drug discovery, in addition to isolating components from natural
products, is the alteration of isolated metabolites from Nature and their structural adjustment
towards improved bioactivity. Development of natural products includes modification (or
removal) of functional groups, introduction of novel groups and stereocenters into the molecule,
or occasionally more radical changes of the basic scaffold. Synthetic chemistry modifications of
molecules can involve further structural diversity that can not be obtained from natural
biosynthetic methods. NPs usually show excellent bioactivity and selectivity but might have
poor pharmacokinetics, hence synthesis can be used to improve activity and decrease toxicity.
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Three previously mentioned approved drugs, cytarabine, vidarabine and eribulin mesylate are
all synthetic analogues developed from naturally occurring metabolites (Table 1.3).
Curcumin (27) is the major pigment obtained from turmeric and it was found along with
several of its analogues to display moderate cytotoxicity (Fig. 1.14), while several synthetic
analogues of curcumin exhibited more potent anti-androgenic activities against two human
prostate cancer cell lines.91,92 Further development is underway because curcumin analogues
were found to be more potent than the currently available drug for the treatment of prostate
cancer, hydroxyflutamide.92 Betulinic acid (28) was isolated from the plant Syzygium
claviflorum and found to display anti HIV-1 activity (Fig. 1.14).93 Dihydrobetulinic acid (29),
which was obtained through hydrogenation of betulinic acid, exhibited a more potent anti-HIV
activity.94 Encouraged by the initial results Kashiwada et al. continued further modifications of
betulinic and dihydrobetulinic acid to give compounds that displayed significant activity in
acutely infected H9 lymphocytes (EC50 < 3.5 x 10-4 µM).94 In addition, many other research
groups are also engaged in the modification of 28 with the aim to achieve more potent
compounds.95 Soler et al. synthesized a novel series of betulinic acid derivatives and several
members of this new series exhibited anti-HIV-1 activities in the nanomolar range in CEM-4
(T-lymphoblastic leukemia) and MT-4 (human T cell lymphotropic) cell lines.96

Figure 1.14: Natural product based structures on which commercial drugs have been synthesized.

Not only are drugs made by modifying natural products but some natural products that
are difficult to isolate are produced synthetically. Yondelis (9), isolated from a marine tunicate,
is an example of a compound produced semi-synthetically. Yondelis is an anti-tumour drug
approved for the treatment of soft tissue sarcoma.97 Due to the difficulties in the collection of
large quantities of the producing organism and isolation of the desired compound, it is now
prepared semi- synthetically from the microbial product cyanosafracin B.97 Along with the total
synthesis of bioactive natural compounds, derived total synthesis is also used as a method that
includes preparation of less complex structures than the target molecule. An example of a
complex structure of a marine metabolite is halichondrin B (30), isolated from both shallow and
deep-water sponges (section 1.3.3). It displayed several bioactivities and 30 is now considered
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for further clinical development.5 However, due to limited sponge material and diminutive
amounts in which 30 was obtained, other methods for the preparation of these components were
explored. Aicher et al. synthesized eribulin mesylate (10, section 1.3), which is the shortened
and simplified version of halichondrin B and equally active as the parent compound. (Fig.
1.15).98 Eribulin mesylate has been approved for breast cancer treatment in 2010, while
halichondrin B is not approved as a drug.

Figure 1.15: The naturally occurring compound halichondrin B from sponge Halichondria okadai, which can now be
obtained through synthesis.

1.5 Enzymes as drug targets
Most drugs used today demonstrate their bioactivity by acting as receptor antagonists or
as enzyme inhibitors. If the drug acts as an antagonist it is interfering with an agonist in the
body, while enzyme inhibitors interfere with the normal enzyme function. Nowadays, it is
estimated that enzyme inhibitors make up almost half of the drugs in clinical use. Due to the
significant role of enzymes in the activity of a number of disease processes, and their structural
conformation that is easily accessible to inhibition of small drug like molecules, they are widely
investigated as drug targets.99 The first step in the preparation of an enzyme inhibitor is defining
which function of the target enzyme is going to be interrupted or blocked in a particular disease
or infection.
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1.6 Protein kinase inhibitors

Figure 1.16: The major classes of kinase families.100

Protein kinases are enzymes that encompass all enzymes that catalyse the chemical
transfer of a phosphate group from a high energy molecule such as adenine triphosphate (ATP)
to a specific substrate (amino acid) (Fig. 1.17). The human genome encodes for approximately
518 different protein kinases, which are divided into different kinase families on the basis of
their selectivity for substrates.101 They are one of the largest enzyme families in the human body
(Fig. 1.16).102,103 The covalent attachment of a phosphate group to a substrate requires a free
hydroxyl moiety, and there are three amino acids that can provide this; serine, threonine and
tyrosine. Therefore, serine/threonine (Ser/Thr) kinases will recognise and attach a phosphate
group to a serine or threonine amino acid, while the tyrosine-specific protein kinase family will
phosphorylate a protein at a tyrosine moiety. The vast majority of kinases are Ser/Thr kinase.
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Figure 1.17: Function of Ser/Thr kinases.104

Protein kinases are important in almost every major pathway in eukaryotic cells and
they play a central role in cellular activities and regulation, signal transduction in signal
transmission pathways. Moreover, kinases have important roles in memory metabolism, cell
growth, apoptosis, immune response, gene expression, oncogenesis, differentiation, controlling
cell differentiation, proliferation, metabolism, DNA damage repair, cell motility, response to
external stimuli and apoptosis.105,106 As a result, deregulation of kinases has been identified to be
a main cause in an increasing list of diseases.107 Thus, a major aim of several pharmaceutical
companies is to discover potent and selective inhibitors of kinases relevant to cancer, e.g.
protein kinase C (PKC) and cyclin dependent kinases (CDKs). Kinases are also important in
other diseases such as Alzheimer’s, e.g. glycogen synthase kinase 3β (GSK3β). Consequently,
protein kinase inhibitors have emerged as an important class of targeted therapeutic agents. 108

Figure 1.18: Approved small molecule kinase inhibitors.

Anticancer treatments involving kinase enzymes can be specifically targeted to cancer
cells because numerous kinases have been found to be misregulated in cancerous cells.101 The
current focus on kinases is in the development of drugs with lower side effects than previous
cancer treatments, which traditionally focused on DNA replication and chromosome regulation
and thus also affected many healthy human cells. The development of kinase inhibitors has been
predicted to be a major driver of pharmaceutical growth with more than 130 kinase inhibitors
reported to be in either Phase I or Phase II clinical trials, the majority of these being tested for
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their potential as cancer treatments.109 Nowadays, it is estimated that one-third of pharma drug
discovery programs target kinases.102 Knowledge of signalling pathways and the ways in which
a cell respond to external signals have led to protein kinases becoming important targets for
anti-cancer drug design.110 Imatinib (31) is the first small tyrosine kinase inhibitor that was
approved for clinical use and with the further approval of other inhibitors such as erlotinib (32)
and gefitinib (33) it was shown that these small molecule kinase inhibitors can be effective
drugs (Fig. 1.18).
Kinases can exist in both active and inactive conformations. While there are many
similarities in the active state, kinases exhibit many differences in an inactive state. The
catalytic subunit of kinases consists of the smaller N-terminal lobe that contains five β-sheets
and one α-helix; the C-helix and C-terminal lobe that is mostly α-helix. A hinge segment is
between the two lobes (Fig. 1.19). Important regions of the ATP binding site include the
hydrophobic purine-binding cavity, the hinge region, the P loop and the activation loop.111 ATP
binds in the cleft where the adenine ring forms hydrogen bonds with the kinase “hinge” region,
the segment that connects amino- and carboxyl-terminal kinase domains.112 The ribose and
tri-phosphate groups bind to the hydrophilic channel extending to the substrate binding site that
features conserved residues that are essential to catalysis.112

Figure 1.19: Structural basis for the action of small molecule kinase inhibitors – ATP binding region.111

All kinases have a catalytic subunit that binds ATP. Therefore, the main problem in
targeting kinases is their selectivity. Staurosporine, an inhibitor of many kinases, inhibits 104 of
113 kinases tested by Fabian et al.113 Many inhibitors failed in drug trials because of the lack of
selectivity. Imatinib is found to inhibit other kinases in addition to its primary drug target which
indicates that an inhibitor doesn’t require absolute selectivity for an acceptable safety profile but
it is essential to know its off-target effects.114 Despite concerns for kinase selectivity it has been
established that kinase specific inhibitors can be developed.111 Kinase inhibitors achieve their
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specificity by either directly targeting points that are structurally divergent in kinases or by
exploiting differences in the conformational flexibility of the ATP-binding site.111 All kinase
inhibitors that are in clinical use bind at the ATP binding site except one that targets the
mammalian target of rapamycin (mTOR).110 Most kinase inhibitors that are marketed or are in
development, inhibit multiple kinases.115 Among compounds with similar scaffolds some can be
very specific toward one particular kinase, while others can display low selectivity and bind to
several kinases.113
The majority of kinase inhibitors are ATP competitive and bind to the hinge region with
one to three hydrogen bonds (Fig. 1.19).112 Even though the ATP binding site exhibits great
similarities among protein kinases, some of the enzymes display differences in the binding
pocket.102 For instance, the ACG protein kinase subfamily that includes PKA, protein kinase B
(PKB or Akt) and Rho-associated protein kinase (ROCK) have a specific phenylalanine residue
in the adenine binding site (Fig. 1.20).102 Phenylalanine distinguishes the adenine pocket of the
AGC subfamily. It is found on the C-terminal chain of the protein kinase catalytic domain,
which folds back into the N-lobe across the catalytic cleft. As a result, the phenylalanine
aromatic ring shields one side of the adenine pocket and affects the protein-ATP or proteinkinase inhibitor contact.102 Competitive inhibitors recognize the active form of an enzyme.
Typical for these inhibitors is that they have a heterocyclic ring that mimics ATP. The other
types of inhibitors are compounds that recognize the inactive enzyme conformation. The most
selective inhibitors are allosteric inhibitors because they bind to the allosteric site of enzyme
which is unique for the particular kinase.112

Figure 1.20: View of PKA in complex with ATP. Phenylalanine is located on the C-terminal polypeptide chain
(dark blue), which folds back into the N-lobe, shields the entrance side of the adenine pocket.102
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1.6.1 cAMP-Dependant protein kinase (PKA)
cAMP-Dependant protein kinase (protein kinase A, PKA) is completely characterised
and the simplest protein kinase enzyme, which was the one of the first to be discovered,
sequenced and cloned.116,117 Its simplicity is related to the mechanism by which it is activated. In
the inactive state PKA is a tetramer, consisting of two regulatory and two catalytic subunits
(Fig. 1.21). Two catalytic subunits bind to a regulatory subunit dimer to form an inactive
holoenzyme complex.
G-protein coupled receptors (GPCR) are one of the largest gene families of signalling
proteins. When a GPCR is activated by extracellular hormones, it stimulates Ga subunits and
becomes active and activates enzyme adenylyl cyclase that synthesizes cyclic-AMP (cAMP)
from ATP (Fig. 1.21).118 Activation of cAMP signalling involves binding of an extracellular
ligand to the GPCR which through G proteins regulates one of several isoforms of adenylyl
cyclase leading to generation of cAMP.119 cAMP binds to the inactive holoenzyme PKA, in
particular to its regulatory subunit which causes dissociation of the tetramer PKA complex
giving R-dimer complex and two monomeric catalytic subunits.120 The monomeric catalytic
subunit is the active form of the PKA enzyme. The free catalytic subunits are able to catalyse
the transfer of ATP to a specific substrate (Ser or Thr protein residue).

Figure 1.21: Protein kinase cascade.

118

PKA is an ubiquitous enzyme involved in the phosphorylation of a wide range of
proteins, ion channels and transcription factors.121 It has been demonstrated to regulate a number
of physiological processes including cardiovascular function, steroid biosynthesis, reproductive
function, myogenesis, adipocyte metabolism, exocytotic processes and immune function.119,122
PKA was also found to have a key role in memory processes.123 The cAMP-PKA pathway has
been linked to the promotion of malignant phenotypes of head and neck squamous cell
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carcinoma and demonstrated to be activated in a range of tumours.124 Conversely, PKA
inhibitors have been found to display both in vitro and in vivo antitumour activity against
various human cancer cell lines and to enhance monocyte function in HIV-infected patients.125
Thus, it is becoming increasingly apparent that the ability to selectively inhibit PKA provides a
new way of potentially modulating cancer, immune function, and memory disorders such as
Alzheimer’s disease, Parkinson’s disease and schizophrenia.122,123,126
The most well known PKA inhibitors are staurosporine (34) from Streptomyces sp.,
plant-derived polyphenols such as ellagic acid (35) and piceatannol (36) and the synthetic
isoquinolinesulfonamides such as H-89 (37) and H-9 (38) (Fig. 1.22). Many of these inhibitors
have been derived from Nature, however, the marine environment has remained relatively
unexplored in this area, with no marine-derived PKA inhibitors yet reported.

Figure 1.22: Known protein kinase A inhibitors.

1.6.2 Protein kinase B (Akt kinase)
Akt belongs to a group of serine-threonine protein kinases and is component of the
phosphatidylinositol 3-kinase (PI3K)/AKT signalling pathway (Fig. 1.23).127 Akt is activated by
the phosphoinositide 3-phosphate-dependent kinases PDK1 and PDK2, receptor tyrosine
kinases and integrins.127,128 Akt belongs to the AGC family of kinases, which consists of 16
kinase families that have related catalytic domains, and shares high homology with PKA and
PKC. The PI3K/AKT signalling pathway is found to have a significant role in the organism and
its interruption leads to apoptosis in cancer cells.129 Akt kinase has an important role in cellular
processes that are involved in the formation and growth of cancer, including cell migration,
proliferation, transcription, glucose metabolism and apoptosis and its overexpression has been
detected in a number of cancer types.130
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Figure 1.23: PI3K/Akt signalling pathway.131

Since its report in 2002 it has received over 2000 citations in the literature and is
certainly one of the prime targets in the development of new kinase inhibitors. Figure 1.24
shows some of the reported Akt kinase inhibitors.

Figure 1.24: Akt (PKB) kinase inhibitors.132-134
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1.7 Kinase inhibitors from marine invertebrates
The most well-known kinase inhibitor from a marine source is bryostatin-1 (43), which
was first isolated from the marine bryozoan Bugula neritina (Fig. 1.25).135,136 Bryostatin-1 is
unique in that its mechanism involves the activation and subsequent down-regulation of protein
kinase C (PKC) and has been shown to inhibit tumour growth and invasion and also
angiogenesis.137 Bryostatin-1 has been involved in over 80 Phase I, II and III combinatorial
anticancer clinical trials during the past two decades.

138

In addition Bryostatin-1, in

combination with Taxol (Paclitaxel), was granted Orphan Drug Designation by the US FDA for
oesophageal cancer in 2001.139 Currently, 43 is in clinical trials of various phases for
Alzheimer’s disease, metastatic solid tumours, advanced kidney cancer, relapsed acute
myelogenous leukaemia, metastatic pancreatic cancer, lung cancer and ovarian and cervical
cancer.140

Figure 1.25: Marine natural product based kinase inhibitors.

The efficacy of the natural product staurosporine (34) as a PKC inhibitor has been
known since last century when the alkaloid was isolated from the bacteria Streptomyces
stauroporeus and shown more recently to have an IC50 value of 2.7 nM against PKC.141 More
recently, derivatives of 34 have also been shown to be powerful inhibitors of PKC including
11-hydroxystaurosporine (44), which was the first indolo[2,3-α]carbazole to be identified from a
marine organism.142 Isolated from the marine tunicate species Eudistoma, 44 reported an IC50
value of 2.2 nM against PKC, approximately 30% more active than the parent compound
staurosporine, both of which inhibit PKC by blocking the ATP catalytic domain. 142 Also highly
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cytotoxic, 44 has been incorporated into pharmaceuticals patented to inhibit hair growth and
tested for use as an anticancer agent although these have been limited by the high toxicity of
staurosporine at therapeutic doses caused by cross-inhibition of other critical enzymes. 135,142,143
In 1994, the sponge Xestospongia sp. collected in waters off the Papua New Guinea
coast, furnished xestocyclamine A (45) bearing a novel skeleton and found to inhibit PKC with
an IC50 value of 4 μg/ml (Fig. 1.26).144 Xestocyclamine A and its pure enantiomer
(-)-xestocyclamine A are considered critical PKC inhibitors for use in the development of
anticancer drugs and there are many research groups focused on synthesising the
stereochemically complex marine alkaloids.145,146 (Z)-Axinohydantoin (46) and debromo-Zaxinohydantoin (47) are two PKC inhibitors with respective IC50 values of 9.0 and 22.0 μM that
were isolated from the marine sponge Stylotella aurantium.147 These novel compounds were
isolated during a scale-up collection of the PKC inhibitors, hymenialdisine (48) and
debromohymenialdisine (49) from the same sponge species.147 Hymenialdisine is found to
inhibit a range of kinases. Five novel sesquiterpene derivatives, frondosins A-E (50-54), were
isolated from the marine sponge Dysidea frondosa and shown to have inhibitory activity against
PKC with reported IC50 values of 1.8, 4.8, 20.9, 26.0 and 30.6 μM respectively (Fig. 1.26).148
Frondosins A-E were also reported to be inhibitors of interleukin-8 in the low micromolar
range.148 More recently (-)-frondosin A and D have shown comparable activity against the HIV
virus.149

Figure 1.26: PKC inhibitors isolated from marine sponges.
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As previously mentioned, poor selectivity is a common problem among kinase
inhibitors due to the ATP binding site, where many inhibitors exert their actions, being
conserved amongst the majority of kinase families. Fascaplysin (55, Fig. 1.27), a red pigment
isolated from the marine sponge Fascaplysinopsis sp., has the major distinguishing feature
because it is a selective inhibitor of CDK-4.150 Fascaplysin exhibits an IC50 value of 0.35 μM
against the CDK-4/cyclin D complex, while IC50 values against other kinases were comparably
much higher.150 Fascaplysin (55) has an indole moiety which is also present in
11-hydroxystaurosporine (44) described earlier (Fig. 1.27). The indole moiety has also been
found in meridianin (e.g. 56) and granulatimide (e.g. 57) derivatives, isolated from marine
organisms that have been found to inhibit various kinases. These results indicate that a number
of indole compounds are potent kinase inhibitors, hence suggesting that the indole nucleus is
required for kinase inhibition.

Figure 1.27: Indole based kinase inhibitors isolated from marine organisms.

1.8 Isatin-indole based kinase inhibitors
A range of indole and isatin-based compounds have been developed as inhibitors of
various protein kinase families, predominantly receptor tyrosine kinases (RTKs) and
serine/threonine-specific protein kinases such as CDKs.151 Research of indole and isatin
derivatives as kinase inhibitors rose notably after the disclosure of the tyrosine kinase inhibitory
properties of semaxanib (SU-5416), sunitinib (SU-11248) and SU-9516 (Fig. 1.28).151 Sunitinib
is a multi-targeted receptor tyrosine kinase inhibitor that was approved by FDA for the
treatment of renal cell carcinoma in 2006. Semaxanib is a tyrosine kinase inhibitor and is
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currently in the experimental stage of drug development. SU-5416 and SU-11248 were reported
to exhibit protein tyrosine kinase inhibitory and antiangiogenic properties, while SU-9516 was
found to be an inhibitor of CDK that induces apoptosis in colon carcinoma cells.152 Crystal
structures of the tyrosine kinase domain of fibroblast growth factor receptor 1 (FGFR1) in
complex with the two indolin-2-one compounds was analysed previously.153 The results
indicated that two 2-oxindole compounds bind to the enzyme in the manner almost identical to
ATP binding, the oxindole part of the molecule occupies the site in which the adenine of ATP
binds. The C-3 oxindole part of the molecule takes place, that is occupied by the rest of the ATP
structure, the moieties that extend from the oxindole extend into the hinge region between the
two kinase lobes.153

Figure 1.28: Structures of 2-indoline derivatives currently approved for use, or in clinical trials as anticancer agents.

A series of N benzyl-indole-3-imine and 3-amine compounds were prepared and
analysed by Kilic et al. for their kinase activity against the pp60c-Src tyrosine kinase, as
potential new therapeutics for the treatment of hepatitis B and rheumatoid arthritis (e.g. 61, Fig.
1.29).154 The authors found that bromination at the position 5 of the indoline core was important
for the kinase inhibitory activity and also indole amine derivatives were more potent than their
imine analogues.154 Src kinase activity of indolin-2-one analogues was also reported by Guan et
al. along with the inhibitory activity against Yes kinase.155 The authors showed the importance
of the sulfonyl group at the 5-position, the tetrahydroindole ring and the 3-aminopropyl side
chain for inhibitory activity against Src (e.g. 62, Fig. 1.29).155
Indoles bearing a sugar moiety at the aromatic nitrogen of the indoline molecule were
screened for kinase inhibitory and antibacterial activity.156 The addition of the sugar residue on
the indole ring improved solubility and slightly enhanced interaction with the enzyme active
site, these analogues only exhibited low kinase inhibitory activity (e.g. 63, Fig. 1.29).156 To
further improve the activity of these compounds, isoindigo derivatives bearing a sugar moiety
with benzyl groups at the N-1-position of the molecule were prepared and they displayed potent
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activity against CDK2 (e.g. 64, Fig. 1.29).157 A range of compounds with an indolin-2-one core
as CDK2 inhibitors were reported by Tymoshenko et al. who found the importance of the
secondary amine group on the 4’-position of the phenyl group of indoline for incorporating at
the ATP binding cleft (e.g. 65, Fig. 1.29).158 Sun et al. discovered a range of indolin-2-one
derivatives as potential protein tyrosine kinase (PTK) inhibitors finding that the activity of
analogues is dependent on the substituents at position 3 of the indoline molecule.159 PTK has a
vital role in the cell controlling signal transduction processes (e.g. 66, Fig. 1.29).160 Li et al.
investigated the indolin-1-one core further and developed novel potent PTK inhibitors by
replacing the α-pyrrole ring with a β-ring and adding methyl group at the 5’-position of the
pyrrole ring (e.g. 67, Fig. 1.29).160
The activity of oxindole derivatives against janus kinase 3 (JAK 3) was demonstrated
by Adams et al. (e.g. 68, Fig. 1.29).161 Compounds with an indoline core were also found to be
potent inhibitors of Ser/Thr phosphoinositide-dependant kinase-1 (PDK1), which is the major
activator of many protein kinases in the AGC kinase family (e.g. 69, Fig. 1.29).162 Indoline
analogues are potent inhibitors of another Ser/Thr kinase, checkpoint kinase 1 (Chk1) which has
a linkage role between DNA damage repair and cell cycle arrest at G2 (e.g. 70, Fig. 1.29).163
Among many tested inhibitors compound 70 was found to be the most active with an IC50 value
of 4 nM, showing the importance of the hydroxyl group at the C4’ position and the
unsubstitution at the pyrrole ring.163 Indolin-2-ones were also found to be inhibitors of RET
tyrosine kinase, an important tyrosine receptor involved in many tumours (e.g. 71, Fig. 1.29).164
Compounds with a pyrrole ring at position 3 displayed the highest activity, which is due to the Z
configuration compared with the other analogues that usually have a predominant E
configuration such as furan-substituted analogues.164 Also, substitution of the 5 position was
important as bulky and hydrophobic groups exhibited low activity.164
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Figure 1.29: Indole and isatin based kinase inhibitors.

Synthetic isatin, firstly prepared by oxidation of indigo by Erdmann and Laurent more
than a hundred years ago, was discovered to be a natural product also from plants of the Isatis
genus, in fruits of the cannon ball tree Couroupita guianensis Aubl. and in secretions from the
parotid gland of the Bufo frog.165-170 Afterwards isatin was also isolated from the marine

bacterium, Pseudomonas C55a-2 strain, while various isatins derivatives have now been
identified in plants, fungi, bryozoan and marine molluscs (Fig. 1.30).171-178

Figure 1.30: Sources of isatins found in Nature a) Isatis tinctoria;179 b) the toad Bufo gargarizans;180 and c) the
marine mollusc Dicathais orbita.181
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Isatin was also identified in humans, however it’s biosynthetic and metabolic pathways
have not yet been discovered.182 It is assumed that isatin can be obtained through tryptophanrich food, as tryptophan can potentially be converted to an indole by bacteria from the
gastrointestinal tract and then be transported and oxidised in the liver.
1.9 Previous research in our group
A range of isatin derivatives were previously investigated in our research group for
cytotoxicity against a range of human cancer cell lines and found to display potent activity,
causing cell proliferation in all cancer cell lines studied (e.g. breast, colon, lung etc). Isatin
derivatives have been found to inhibit cell proliferation and to promote apoptosis.183
Investigation on isatin and its derivatives as potential cytotoxins started at the University of
Wollongong in 2002 during the study of egg masses of the Australian mollusc Dichathais orbita
by Benkendorff et al.184 The chloroform extract of the egg masses exhibited potent cytotoxicity
and further fractionation of the extract yielded tyrindoleninone (72), tyriverdin (73) and 6bromoisatin (74) (Fig. 1.31). Of these three compounds, tyrindoleninone was found to exhibit
the highest cytotoxicity against human monocyte-like histiocytic lymphoma cells (U937).
Tyriverdin exhibited weak activity and 6-bromoisatin moderate activity (Fig. 1.31). However,
due to the reactivity of tyrindoleninone, 6-bromoisatin was used as the starting point for the
further development and investigation of novel cytotoxin agents.

Figure 1.31: Components isolated from the egg masses of the Australian mollusc Dichathais orbita tested against
human monocyte-like histiocytic lymphoma cells (U937).

Development of more potent isatin analogues showed that electron withdrawing
groups at position 5, 6 and 7 are important for increased cytotoxicity and in particular
substitution at the 5 position was most significant.183 The results suggested that the cytotoxicity
increased with halogenation (6.8, 7.8 and 10.5 µM respectively) and was not related to their
lipophilicity.183
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Figure 1.32: Cytotoxicity of halogenated isatin derivatives (against U937 human lymphoma cell lines).185

N-alkylation of isatin analogues led to improved cytotoxicity against a variety of cancer
cell lines. Furthermore, Vine et al. found that isatin derivatives cause G2/M cell cycle arrest and
induce apoptosis via binding to the cytoskeletal protein tubulin (Fig. 1.32).186 The authors used
the fluorescence emission to monitor the rate of polymerization. The N-alkylisatins are found to
interrupt natural tubulin polymerisation by binding to mictrotubules and either stabilising or
destabilising the dynamic assembly and disassembly required for cell division, similarly to
known drugs vinblastine, taxol and colchicine (Fig. 1.33).188,189 Vinblastine has been found to be
a potent microtubule destabiliser, while paclitaxel is a known stabiliser.

Figure 1.33: Effects of N-alkyl isatins on tubulin polymerisation. DMSO was used as a control, a shift of the curve to
the left or right of the control is indicative of either an increase or a decrease, respectively, in the rate of tubulin
polymerization.189

The substituents on the isatin ring were also found to influence the mode of action of
isatin derivatives. For example, the presence of a small electron-withdrawing group(s) on the
aromatic (A) ring of the isatin core (Fig. 1.34) improves cytotoxicity.186 A one-carbon linker
attaching an alkyl group to N1 leads to the potent cytotoxicity with nanomolar activity.189
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Substitution at position C2 gives compounds that inhibit CDK1, CDK2 and GSK kinase, while
the substitution on the C3 carbonyl group provides inhibitors of VEGFR-2, PDGFR-β and
epidermal growth receptor.

Figure 1.34: Position of different substituents on isatin ring and their influence on biological activities of molecule.

Furthermore, with over 150 cytotoxic isatin derivatives previously synthetised within
our group, the next step was to conjugate these compounds to tumour target protein in pro-drug
delivery.182 The conjugated isatin drugs (79-83, Fig. 1.35) were formed from potent N-alkylated
isatin (78, 1.83 μM against U937 cells). 182 Due to the high similarity of these compounds to the
known kinase inhibitors sunitanib and semaxenib and many indole kinase inhibitors in literature
(Fig. 1.29), these compounds were screened for protein kinase A inhibitory activity. The 3iminoisatins exhibited potent PKA inhibitory activity (> 80% inhibition at 100 µg/mL),
comparable to the inhibitory activity of the commercially available PKA standards used in the
assay. These results showed a promising start for further exploration of these compounds, their
modification and kinase testing.

Figure 1.35: Synthesis of isatin-imine analogues for conjugation to tumour targeting proteins.182
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1.9 Aims of Project

The research described herein was divided into two sections:
1. Isolation, purification, identification and biological evaluation of marine natural
products from marine algae and deep-sea sponges; and
2. Structural modification of known isatin derivatives to develop novel PKA inhibitors.
In a two-pronged approach of discovering and developing new kinase inhibitors, the specific
aims of the two sections, that comprised of both classical natural product chemistry and
synthetic medicinal chemistry, were:
o

Section 1: Natural products:

-

Collection, identification and extraction of:



Local, abundant but understudied marine algae and



Rare deep-sea sponges.

-

Biological screening of the extracts for protein kinase A (PKA) inhibition, brine shrimp
cytotoxicity and haemolysis.

-

Fatty acid and sterol composition of the marine organism extracts and purification and
structure elucidation of the metabolites responsible for the bioactivity observed.

o

Section 2: Synthetic medicinal chemistry:

-

Synthesis of a wide variety of isatin-imine analogues with variations at positions N1,
C3, C5 and C7 (Fig. 1.36).

-

Biological evaluation of the above derivatives as potential new PKA and PKB
inhibitors along with their evaluation as cytotoxic agents.

Figure 1.36: General scheme of the proposed isatin based kinase inhibitors.
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Natural structures represent the core foundation for the development of new
drugs.190 Among the diverse range of organisms found in marine fauna, marine
algae have an important role as a source of novel drugs. Herein, is described the
PKA inhibitory, haemolytic and cytotoxic activities and chemical composition of
extracts obtained from ten algae collected off the South Eastern Australian coast.

2.1 Metabolites from marine algae
Marine algae produce a variety of secondary metabolites and are an exceptionally rich
source of pharmacologically active metabolites.191 About 6000 species of seaweeds have been
identified so far and are grouped into two categories: macroalgae, which includes green
(Chlorophytes), brown (Pheophytes) and red (Rhodophytes) algae; and microalgae, which
contains bluegreen (Cyanobacteria) algae. Algal species are widespread and readily available
for collection, however in many regions of the world they have not yet been explored in detail.
Every year a plethora of novel and bioactive compounds are isolated from marine algae,
in particular from brown and red algae species, while less novel metabolites have been
discovered from green algae, although they are broadly distributed.31 There are approximately
40 papers published annually about the isolation of bioactive constituents from green algae,
which are typically found to be a source of non-polar metabolites such as the known linolenic
[18:3 (n-3)] (84) and linoleic [18:2 (n-6)] acids (85) as potent peroxisome proliferator-activated
receptor gamma (PPAR a/g) agonists from Chlorella sorokiniana and two unsaturated cytotoxic
FAs 86 and 87 and the triterpenoid disulfate 88 isolated from Tydemania expeditionsis (Fig.
2.1).67 Brown algae usually produce a wide range of novel terpenoids such as the brominated
sesquiterpenoids (89, 90) from Dictyopteris divaricata and the meroditerpenoids (91, 92) from
Cystoseira baccata.31,192,193 However a wide variety of other metabolites have also been isolated
from brown algae including: the phlorotannin diphlorethohydroxycarmalol (93) with radicalscavenging activity from the Japanese alga Ishige okamurae and six bromophenols (e.g 94)
from Leathsia nana of which 94 displayed potent cytotoxicity against eight cancer cell lines
with IC50 values below 10 μg/mL (Fig. 2.1).194,195 Reports on the isolation of novel compounds
from red algae decreased in the last couple of years.31 However, research has returned to the
previous prolific levels in the last two years and red algae have proven once again to be a
productive source of novel bioactive metabolites. In particular, red algae are rich in terpenes and
polyhalogenated metabolites along with compounds such as the bromoindole alkaloids (95, 96)
from Laurencia similis and the halogenated chamigranes (97, 98) from L. saitoi.31,67
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Figure 2.1: A selection of bioactive compounds isolated from green, brown and red algal species.

2.2 Biological assays
2.2.1 Kinase inhibition assay
Natural product extracts are often screened for cytotoxicity in whole cell assays against
both human and murine cancer cell lines. However, in recent years testing for inhibition against
specific enzymes has become more widespread, as this provides greater information about a
natural product’s mode of action. Herein, screening against the enzyme PKA was performed
because c-AMP dependent protein kinase (PKA) is an important enzyme involved in the
regulation of an increasing number of physiological processes including immune,
cardiovascular and reproductive functions; steroid biosynthesis; adipocyte metabolism; and
exocytotic processes. As such, the inhibition of PKA has lately become an attractive drug target
in a number of areas, in particular in immune function and for memory disorders such as
Alzheimer’s and Parkinson’s disease and schizophrenia. However, it only recently become
studied as a drug target and not been validated for any particular disease state yet.121,122
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Protein kinase A inhibitory activity of extracts of different polarity was determined
using a Promega luminescence kinase assay. For measuring luminescence this assay uses
bioluminescence, which is one type of chemiluminesence found in living organisms. The assay
involves two reaction steps (Fig. 2.2). In the first step, the reaction between the kinase enzyme,
ATP, an appropriate protein substrate (kemptide) and sample extract as a potential kinase
inhibitor occurs. The ability of the sample to inhibit the PKA enzyme is directly proportional to
the amount of ATP left behind in the first reaction step, which is then quantified in the next step
using the enzyme luciferase (step 2). Luciferase is an enzyme isolated from firefly. This enzyme
uses ATP for catalysing beetle luciferin to form the intermediate luciferin-AMP. In the next step
another intermediate is formed of oxygen and the first intermediate-oxyluciferin, which is in a
high-energy state. Energy transition from the exited state to the ground state yields yellow-green
light with a spectral maximum of 560 nm. For mono-oxygenation, luciferase produces one
photon of light per reaction turnover.

Figure 2.2: Protein Kinase A assay method (two reaction steps).196

The common detection method in many bioassays is either colorimetric or fluorescence.
However, the luminescence method described herein, is particularly desirable for coloured
products such as marine natural products. Marine algae usually provide very colourful extracts
as a result of their high chlorophyll level, which can give false results when using absorbance as
the end point. Therefore, utilization of luminescence, can be beneficial and more useful for
biological screening as it can identify more hits with a lower number of false positives.197
To-date a number of potent kinase inhibitors have been isolated from algae species
including three cycloartanol sulfates from the green algae Tydemania expeditionis, which are
found to be modest inhibitors of protein tyrosine kinase pp60v-src (99-101).198 Furthermore, the
new terpenoid compound stypoquinonic acid (102) isolated from brown algae Stypopodium
zonale exhibited inhibition of protein tyrosine kinase p56lck and also two bioactive
glycoglycerolipids (103-104) that exhibited activity against the enzyme Myt1 kinase were
isolated from an unidentified alga species (Fig. 2.3).199,200
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Figure 2.3: Kinase inhibitors found in marine algae.

2.2.2 Haemolytic assay
Haemolysis is the release of haemoglobin and other internal components into the
surrounding fluid caused by the breakage of red blood cell membranes. 201 Haemolytic activity,
prevalent among marine organisms, is a general indicator of bioactivity and membrane-directed
cytotoxicity, which is desirable in the development of bactericidal molecules and targeted
intracellular drug delivery.202-204 Herein, a haemolysis assay was used to determine whether
samples could cause lysis of horse red blood cells, releasing haemoglobin, which is measured
on a spectrophotometer at 550 nm. Its concentration is then determined relative to positive and
negative controls giving readings of 0% and 100% haemolysis respectively. Haemolytic activity
was previously found among a range of compounds isolated from marine algae including two
novel diterpenes, amijiol acetate and amijiol-7,10-diacetate obtained from the brown alga
Dictyota dichotoma collected from the Red Sea and glycosidic toxins prymnesins isolated from
the brown alga, Prymnesium parvum.205,206
2.2.3 Brine shrimp (cytotoxic) lethality assay
In addition to screening for specific enzyme inhibitors, the brine shrimp lethality assay
is a simple and inexpensive way to screen natural product extracts for pharmacological
activity.207 Brine shrimp lethality is one of the assays that has been used for many years in
natural product discovery to determine the toxicity of both plant extracts and pure compounds.
This cytotoxic assay has to its advantage that it is fast, reliable and an easy to perform bench
assay for extracts of different polarity as well as pure compounds. Nowadays, natural product
extracts are subjected to many different assays to test for numerous activities, which can be a
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complicated and long process. Another benefit of this method is that the extracts are tested for a
broad spectrum of activities, which are usually found in natural products and therefore can give
preliminary results of the active sample.5 A strong correlation has also been found between
brine shrimp toxicity and cytotoxicity in human cancer cell lines.208 Cytotoxicity is also the
most commonly reported biological activity in marine fauna, in particular marine sponges.54
2.3. Algal collection and identification
A variety of different seaweeds were collected by hand from four different locations in
South-East Australia (Fig. 2.4; Table 2.1; Fig. 9.1). Collection places were chosen on the basis
of reports identifying them as a biodiversity hotspots.66 Samples from Bellambi and Bass point
were taken from, rocky platforms and rock pools, while samples in Austinmer where collected
from the walls of the local pool. One alga species was collected from Jones beach.

Figure 2.4: Four collection places of alga samples in South-East Australia: A) Bellambi Pt; B) Bass Pt; C)
Austinmer; and D) Jones beach.

Table 2.1: Algae samples collected from Illawarra intertidal zones
Entry Phyla
Scientific Name
Location
1
Rhodophyta
Prionitis linearis
Austinmer
2
Rhodophyta
Corallina vancouveriensis
Austinmer
3
Chlorophyta
Codium fragile
Bellambi Pt
4
Chlorophyta
Codium dimorphum
Bellambi Pt
5
Chlorophyta
Ulva lactuca
Austinmer
6
Phaeophyta
Colpomenia sinuosa
Bass Pt
7
Phaeophyta
Phyllospora comosa
Bellambi Pt
8
Phaeophyta
Padina sp.
Austinmer
9
Phaeophyta
Sargassum vestitum
Jones Beach
10
Phaeophyta
Sargassum sp.
Bellambi Pt

Habitat
PS, P
PS, P
FS
PS, RP
PS, P
FS
FS
PS, PW
PS, P
PS, RP

Weight*
45 g
53 g
129 g
90 g
65 g
230 g
140 g
195 g
500 g
30 g

*Wet weight of the collected alga samples. PS = partial shade; P = pool; S = shade; FS = full sun; RP = rock pool;
PW = pool walls.

2.4 Algal description and previous (reported) studies
Prionitis linearis: The seaweed Prionitis linearis is a red alga,
representative of the family Halymeniaceae, belonging to the Order
Halymeniales, Division Rodophyta. Prionitis linearis is up to 30 cm
tall, dark red to brown in colour, growing in clusters. It is usually
found near the shore, along the Pacific coast. To date, there have only
been a few investigations on both bioactivity and chemical composition of this red alga.
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Corallina vancouveriensis: The seaweed Corallina vancouveriensis
is a red alga, representative of the family Corallinaceae, belonging to
the order Corallinales, division Rodophyta. The thallus is calcareous,
light pink to light purple, forming dense tufts to 6 or more cm tall
from a basal crust. This species forms dense mats on emergent
bedrock or in tide pools in the mid to low intertidal zones of exposed habitats. This species have
been found to exhibit a variety of biological activities, while there have been only a few studies
on its metabolites.

Codium fragile: The seaweed Codium fragile is a shallow water green
alga, representative of the family Codiaceae, belonging to the order
Bryopsidophyceae, division Chlorophyta. The species inhabits the
middle and lower intertidal zone as well as subtidal regions of rocky
shores. The common name for this alga is dead man’s finger, which
comes from the shape of the species. It has a dark green colour and consists of branched
segments that can be up to 40 cm long. The alga is distributed worldwide. Fatty acid
composition was studied in detail of this green alga, while extracts have been found to display a
range of biological properties.

Codium dimorphum: The seaweed Codium dimorphum is a shallow
water green alga, representative of the family Codiaceae, belonging to
the

order

Bryopsidophyceae,

division

Chlorophyta.

Codium

dimorphum is a blue, dark green alga, smooth and firm, hairless on
the surface, forming rounded patches on the rock. It occurs in warm
climates like in South America, Australia and Tasmania. Although there have been investigation
in other Codium species, there are very few reports of bioactivity and chemical composition of
C. dimorphum.

Ulva lactuca: The green seaweed Ulva lactuca, commonly known as
sea lettuce, is a green alga, representative of the family Ulvaceae,
belonging to the order Ulvales, division Chlorophyta (green algae).
Ulva lactuca is commonly found on rocky shores distributed
worldwide on all continents. Sterol composition and bioactivity of
extracts isolated from the genus Ulva have been studied previously.
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Colpomenia sinuosa: The seaweed Colpomenia sinuosa is a shallow
water brown alga, representative of the family Scytosiphonaceae,
belonging to the order Scytosiphonales, division Phaeophyta. C.
sinuosa is a small, globular, hollow, and leathery alga of brownolive colour. It is distributed in the intertidal zone at the water's edge
and is widespread all over the world. The biological activities of this species have been studied,
while there is little information on the chemical composition of this alga.

Phyllospora comosa: The seaweed Phyllospora comosa is a shallow
water brown alga, which can be found up to 20 m depth,
representative of the family Seirococcaceae, belonging to the order
Fucales, division Phaeophyta. It is distributed in the intertidal zone
at the water's edge and is widespread all over the world. P. comosa
is a dark green/ brown colour, up to 3 m long, branched with single and short stipes.
Phyllospora is endemic in temperate regions of Australia. So far, only one report was published
on the chemical constituents of this alga, while there is no biological data on this alga.

Padina sp.: The brown seaweed Padina sp., which is distributed
worldwide, is a representative of the family Scarabaeoidea,
belonging to the order Dictyotales, division Phaeophyta. It is
golden-brown in colour and often found attached to a hard surface. It
has a fan like shape, consisting of a group of funnel shape
fragments, and the common name is Mermaid’s ear or fan. Extracts from Padina sp. have
showed an array of biological activities and the chemical composition concerning FA and sterol
constituents of the genus Padina was also investigated earlier.

A

B

Sargassum vestitum (A) /Sargassum sp. (B): Sargassum is
an olive green, brown colour alga, usually 1-2 m long and
consists of perennial, dark brown basal axes, and lighter
coloured annual primary laterals. This species is distributed

in tropical and subtropical areas, representative of the family Sargassaceae, belonging to the
order Fucales, division Phaeophyta. The genus Sargassum has been found to be a rich source of
bioactive compounds, in particular of meroditerpenoids.
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2.5 Biological screening of algal extracts
A total of ten alga samples collected from various Illawarra lower intertidal regions
(Table 2.1) were extracted and their extracts screened for PKA inhibitory, haemolytic and
cytotoxic activity (Fig. 2.5). The ten samples, comprising two red seaweeds, five brown
seaweeds and three green seaweeds were divided into two groups. The first group (90-500 g
each): C. fragile, C. dimorphum, C. sinuosa, Padina sp., P. comosa and S. vestitum, underwent
a more detailed extraction protocol (method A, see experimental chapter 7 for further details) to
give three extracts water (polar), butanol (intermediate polar) and dichloromethane (non-polar)
that were each tested for biological activity. Of these six algal species, four dichloromethane
extracts (C. fragile, C. sinuosa, Padina sp. and S. vestitum), which were obtained in the highest
yields were further separated using column chromatography. The second group (30-65 g):
Prionitis linearis and Corallina vancouveriensis, Ulva lactuca and Sargassum sp., underwent a
simplified extraction protocol as they were collected in low amounts (method B, see
experimental chapter 7 for further details). In this method only two extracts, an ethanol and
dichloromethane extract were screened for activity.

Figure 2.5: Two protocols used for extraction of seaweed samples.
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2.5.1. Biological screening of six seaweeds of SE Australia – Method A

Codium fragile: The non-polar dichloromethane extract of C. fragile displayed significant
haemolytic activity (67%, Fig. 2.6B) and moderate PKA inhibitory activity (26%, Fig. 2.6A). It
exhibited low cytotoxic activity towards brine shrimp after 24 h but the activity increased
significantly after 48 h (3%, 43% respectively, Fig. 2.6C). The activities of the other two polar
extracts generated from C. fragile were less active than the non-polar extract in all three
biological assays (Fig. 2.6 A-C). Only the non-polar extract, which displayed bioactivities in all
three assays was further studied (see later section).
Extracts isolated from C. fragile alga have been found to exhibit antibacterial,
cytotoxic, antiviral and anticoagulant properties.207 Polysaccharides biosynthesized by this green
alga have been found to be responsible for the potent anticoagulant activity of the species. 210
However, there are no reports on both the kinase inhibitory and haemolytic activities of either
extracts or pure compounds isolated from C. fragile.
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Figure 2.6: Biological activity of dichloromethane (DCM), butanol and water extracts generated from the green alga
C. fragile, where A is % PKA inhibitory activity; B is % haemolytic activity; C is % brine shrimp lethality (all at 100
µg/ml). Data are presented as the mean of triplicate measurements ± SEM.

Codium dimorphum: The greatest activity in the PKA inhibition assay was observed in the
butanol extract of C. dimorphum (92%, Fig. 2.7A) with the dichloromethane extract displaying
moderate activity of 28% and the water extract showing negligible activity. The
dichloromethane and butanol extracts exhibited modest haemolytic activity toward equine
erythrocytes (48% and 52%, respectively, Fig. 2.7B), while the water extract exhibited weak
activity. All three extracts showed low cytotoxicity in the brine shrimp lethality assay, with the
butanol extract displaying the highest activity of 23% after 48 h (Fig. 2.7C). The results
described herein are the first report on biological activity of green algae C. dimorphum.
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Figure 2.7: Biological activities of dichloromethane (DCM), butanol and water extracts generated from the green
alga C. dimorphum, where A is % PKA inhibitory activity; B is % haemolytic activity; C is % brine shrimp lethality
(all at 100 µg/ml). Data are presented as the mean of triplicate measurements ± SEM.

Colpomenia sinuosa: PKA inhibitory activity was observed in the non polar dichloromethane
extract (44%, Fig. 2.8A) of C. sinuosa, along with very low levels of activity in the haemolytic
and brine shrimp assays (Fig. 2.8 B and C). Substantial haemolytic activity was observed in the
intermediate polarity extract (75%), which displayed low PKA inhibitory and cytotoxic activity.
The polar water extracts displayed modest haemolytic activity of 17% but negligible PKA
inhibitory activity and cytotoxicity.
The PKA results described herein are the first report on the kinase inhibitory activity of
this brown alga. The low brine shrimp cytotoxicity results found in extracts of C. sinuosa are in
conclusion with previous studies of this algae from the Pakistani coast, which also exhibited
moderate to low activity in the brine shrimp lethality assay.211 Also, methanol extracts of C.
sinuosa previously did not have any haemolytic activity against human erythrocytes.212
In addition, although there has been no investigation into the Australian species of C.
sinuosa, antimicrobial, antiviral and antioxidant activities were detected in Colpomenia species
collected overseas.213-217 Furthermore, unusual bromophenols were isolated from this species
collected in the Gulf of Eilat, Israel, which exhibited potent cytotoxicity.218 The phenolic and
lipid composition including carotenoids and vitamins C and E of this species from India was
studied and plant extracts proved to possess potent antioxidant activity.219 The ethyl acetate
extract of C. sinuosa from Taiwan was found to be cytotoxic for human hepatoma HuH-7 cells
and induced apoptosis in human leukemia U937 and HL-60 cells.220
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Figure 2.8: Biological activities of dichloromethane (DCM), butanol and water extracts generated from the brown
alga C. sinuosa, where A is % PKA inhibitory activity; B is % haemolytic activity; C is % brine shrimp lethality (all
at 100 µg/ml). Data are presented as the mean of triplicate measurements ± SEM.
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Phyllospora comosa: The results presented in Fig. 2.12 indicate that biological activity was
mainly observed in the non polar dichloromethane extract of P. comosa. This extract exhibited
considerable activity in the kinase inhibition assay (55%) and moderate activity in the
haemolytic and brine shrimp lethality assays (33% and 30% respectively) (Fig. 2.9). The polar
extracts did not exhibit any activity as kinase inhibitors (Fig. 2.9A). The results described herein
are the first report on biological activity of brown algae P. comosa.
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Figure 2.9: Biological activities of dichloromethane (DCM), butanol and water extracts generated from the brown
alga P. comosa, where A is % PKA inhibitory activity; B is % haemolytic activity; C is % brine shrimp lethality (all
at 100 µg/ml). Data are presented as the mean of triplicate measurements ± SEM.

Padina sp.: The non-polar dichloromethane extract of Padina sp. displayed potent activity of
93% in the kinase inhibition assay, strong haemolytic activity of 72% and low brine shrimp
lethality (Fig. 2.10 A, B and C). The butanol extract showed much lower activity of 22% in the
PKA inhibition assay, and negligible activity in the other two assays. The polar water extract
possessed considerable haemolytic activity (39%), while in the kinase inhibition assay displayed
only weak activity. The cytotoxic activity of this extract was equal after 24 and 48 h (23%).
Although herein dichloromethane and water extracts of Padina sp. displayed noticeable
haemolytic activities, methanol extracts of Padina sp. analysed previously were not active.212
The ethanol extract of this brown alga has been found to display moderate brine shrimp
cytotoxicity, while here all extracts were inactive.221 This is the first report on kinase inhibitory
activity of Padina extracts.
The aqueous extract of Padina species have previously exhibited potent antioxidant and
anti-inflammatory activity.222 Antimicrobial activity was observed in the methanol extract
obtained from P. pavonica collected off the coast of Egypt, while cytotoxic diterpenes showed
in vitro antitumor activities against lung carcinoma (H460) and liver carcinoma (HepG2) human
cell lines.223-225 The dichloromethane extract of alga collected in Tunisia showed cytotoxic
activity, where sterol compounds were found to be responsible for the potent activity.226
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Figure 2.10: Biological activities of dichloromethane (DCM), butanol and water extracts generated from the brown
alga Padina sp., where A is % PKA inhibitory activity; B is % haemolytic activity; C is % brine shrimp lethality (all
at 100 µg/ml). Data are presented as the mean of triplicate measurements ± SEM.

Sargassum vestitum: The non-polar dichloromethane extract of S. vestitum displayed potent
PKA inhibitory activity (76%), higher than the other two polar extracts, following the same
trend that was also observed with the other algal samples (Fig. 2.11A). Low haemolytic activity
towards equine erythrocytes was observed in all three extracts of S. vestitum (Fig. 2.11B). The
dichloromethane extract displayed moderate brine shrimp toxicity after both 24 and 48 h (43%
and 47% respectively), while the butanol and water extracts displayed only weak activity in this
assay (Fig. 2.11C).
Sargassum swartzii from Pakistan exhibited significant brine shrimp cytotoxicity while
Sargassum miyabei from Japan displayed low haemolytic activity.211 The genus Sargassum has
been found to be a rich source of bioactive compounds including metabolites with antifouling,
antibacterial, anticancer, antitumor and cytotoxic activity.227-229
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Figure 2.11: Biological activities of dichloromethane (DCM), butanol and water extracts generated from the brown
alga S. vestitum, where A is %PKA inhibitory activity; B is % haemolytic activity; C is % brine shrimp lethality (all
at 100 µg/ml). Data are presented as the mean of triplicate measurements ± SEM.
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2.5.2. Biological screening of four seaweeds of SE Australia – Method B

Four alga samples: Prionitis linearis and Corallina vancouveriensis, Ulva lactuca and
Sargassum sp. were collected in low amounts (< 50g of wet material, method B, Fig. 2.5) and
an ethanol extract was generated using protocol C (see experimental chapter 7 for further
details). To compare PKA inhibitory activity of these samples with the other six alga species,
dichloromethane extracts were also prepared and screened in the assays. The combined
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biological results are presented in Fig. 2.12.

Figure 2.12: Biological activities of dichloromethane (DCM) and ethanol extracts generated from Prionitis linearis,
Corallina vancouveriensis, Ulva lactuca and Sargassum sp. (all at 100 µg/ml). Data are presented as the mean of
triplicate measurements ± SEM.

Prionitis linearis: The ethanol extract of the red seaweed Prionitis linearis displayed potent
haemolytic activity towards equine erythrocytes of 55%, low PKA inhibition activity of 26%
and slightly increased PKA inhibitory in the dichloromethane extract (37%) (Fig. 2.12).
Although in previous analyses, potent brine shrimp cytotoxicity was found in extracts of this
species, herein the ethanol extract exhibited only low toxicity towards A. franciscana.228
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The results described herein are the first report on
the PKA and haemolytic activity of the red alga P.
linearis. Although low brine shrimp lethality was
observed among extracts analysed herein, Bernart et al.
detected brine shrimp cytotoxicity and antimicrobial
activity in the organic crude extracts isolated from P.
lanceolata and P. linearis from Cape Perpetua on the
Oregon coast and isolated four known indoline derivatives (Fig. 2.13).230

Corallina vancouveriensis: The ethanol extract of the red seaweed Corallina vancouveriensis
displayed moderate activity in the PKA inhibition and haemolytic assays (38% and 19%
respectively) while only low cytotoxicity (10%). The PKA inhibitory activity of the
dichloromethane extract was almost identical to the activity of the ethanol extract (36%, Fig.
2.12).There is no published literature on kinase inhibitors isolated from this species and no data
on the potential activity of C. vancouveriensis in either haemolytic or brine shrimp lethality
assays so far. However, there is evidence of antiprotozoal, antimycobacterial and cytotoxic
activity of C. officinalis.231

Ulva lactuca: The ethanol extract of the green seaweed U. lactuca displayed low PKA
inhibitory activity of 12.0% and brine shrimp lethality and modest activity in the haemolysis
assay of 28% (Fig. 2.12). The dichloromethane extract of U. lactuca displayed very similar
activity as the ethanol extract in the PKA inhibition assay. So far, there are no data reported on
potential kinase inhibitors isolated from U. lactuca or kinase inhibitory activity obtained from
extracts of this alga. Ethanol extracts generated from U. fasciata from the Karachi coast
displayed cytotoxicity in the brine shrimp assay of LC50 724μg.232 Linolenic acid and linoleic
acids isolated from U. fasciata and displayed low toxicity towards brine shrimp and mammalian
cell lines (U937, HeLa, Vero, and CHO cells).231 Extracts isolated from the genus Ulva have
also exhibited antioxidant, anti-inflammatory, antibacterial and antimicrobial activity in species
collected worldwide.234-236 Sulfated polysaccharides extracted from the alga U. pertusa from
China displayed excellent antioxidant activity.237 U. lactuca have been demonstrated to contain
phenolic compounds, among them bromophenols, and the ability to produce bromoperoxidase
enzymes capable of brominating organic substances in the presence of bromide and hydrogen
peroxide that are frequently detected in marine algae.236 The crude methanol extract of this
seaweed from Egypt and three new isolated FAs from this alga displayed weak activity in a
brine shrimp assay, but the crude methanol extract exhibited potent activity when tested against
a breast carcinoma cell line.58
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Sargassum sp.: Both, the ethanol and dichloromethane extracts of the brown seaweed
Sargassum sp. was tested in all three assays where it displayed significant activity in the PKA
inhibition assay of 70% and 82% respectively, which is consistent with the potent activity of the
dichloromethane extract of S. vestitum from Jones beach which also displayed 76%. The ethanol
extract displayed only low haemolytic and cytotoxic activity towards A. franciscana (Fig. 2.12).

The results described herein are the first report on the PKA inhibitory activity of the ten
algal species under investigation. Also, haemolytic activity and brine shrimp cytotoxicity of C.
dimorphum, P. comosa and C. vancouveriensis has not been detected before. In general, the
non-polar algal extracts gave more potent biological results, in particular greater PKA inhibitory
activity, compared with the polar extracts. The bioactivity profiles of the alga samples were
strongly species dependent, with no apparent correlation between PKA inhibition, haemolysis
and/or brine shrimp lethality.
2.6 Fatty acid and sterol composition of marine algae
An additional distinction of marine algae is their complex FA composition, which is
greater than that found among terrestrial plants. Fatty acid composition, particularly the
unsaturated FAs composition, is of great importance as these compounds often contribute to the
biological activity of marine alga.239 Herein, a series of brown, red and green algae were
investigated for both their FA and sterol composition as described in the following sections
(Section 2.7). Each of the extracts was also screened for a PKA inhibitory activity.
2.6.1 Algal fatty acid composition
Each phylum of marine algae has a characteristic FA composition, although some acids
predominate in more than one phylum.240 Fatty acid composition also varies among different
species within the same genus and also among the same species collected in different
locations.241 Lang et al. analysed more than 2000 strains in their work and determined that the
difference between alga genera and species cannot be achieved by comparing their FA profile
alone due to great FA variations.242 Fatty acid composition mainly depends on algae habitat
conditions, temperature, nutrients and depth.243 Typically green algae have a high level of C16:0
and C18:0 polyunsaturated FAs (PUFAs).240 In brown algae, the two main saturated FAs are
tetradecanoic and hexadecanoic acids, along with the monounsaturated oleic acid C18:1 (n-9)
and C18 and C20 PUFAs.244 Red algae are characterised by a high content of arachidonic
[C20:4 (n-6)] and eicosapentaenoic acids [C20:5 (n-3)], but hexadecanoic acid and oleic acid
[C18:1 (n-9)] can also be abundant.245
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The antibiotic activity of some algae species has been attributed to the mixture of oleic,
palmitic, linoleic and capric acids isolated from them.246 Hexadecanoic acid was previously
found to have selective cytotoxicity to human leukemic cells and no toxicity towards human
dermal firoblast cells and moreover displayed potent antitumor activity.247 Bazes et al.
suggested usage of hexadecanoic acid as an antifouling paint as it possessed potent antibacterial
activity and didn’t display any significant cytotoxicity to normal cell lines. 248 N-3 Acids are also
found to possess kinase inhibitory activity as these FAs interact with critical calcium regulatory
enzymes, related to the activity of kinases.249 PUFAs, in particular eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA) are found to be a precursor of a range of bioactive metabolites
that have an important role in the regulation of human physiology.250 EPA and DHA have been
found to have an important role in protection against cancer, arthritis, psoriasis, lung disease and
attention-deficit disorder.251 Humans obtain these FAs through food consumption because they
are unable to synthesise them de novo.61 One of the main sources of EPA and DHA are algae,
which possess the enzymes required for the synthesis of PUFAs, which starts from
carboxylation of acetyl CoA as shown in Fig. 2.14.250
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Figure 2.14: The biosynthesis of polyunsaturated fatty acids (PUFAs).250

2.6.2 Algal sterol composition
The sterol compositions of different classes of algae have also been well studied. Some
classes of algae have a distinct sterol composition, however taxonomic classification based on
the sterol composition is not always substantiated.252 In green (Chlorophyceae) and brown algae
(Phaeophyceae) the main sterols are fucosterol (106) and isofucosterol (107), which are the
methylation products of 24-methylenecholesterol (Fig. 2.15). In green algae the reduction of the
24(28) double bond also occurs and an accumulation of sitosterol (108) can be found.252 Red
algae (Rhodophyceae) mainly contain cholesterol and its precursor cholesta-5,24(25)-dien-3β-ol
(109) as the major sterols (Fig. 2.15). Sterols with C27 are also predominant compounds in red
algae although occurrence of C24 alkylation has also been reported previously, despite earlier
suggestions that red algae are incapable of alkylation at the C24 position (Fig. 2.15).252,253 While
the main sterols of the Rhodophyceae are C27 sterols with cholesterol (110) as the predominant
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compound and the Phaeophyceae are rich in C29 sterols with the most abundant being fucosterol,
the sterol composition of Chlorophyceae is not well studied.

Figure 2.15: Sterol compounds characteristic for specific alga divisions.

2.7. Investigation of the chemical composition of the ten algal samples
Of the ten alga samples collected from SE Australia, six alga species Prionitis linearis,
Corallina vancouveriensis, Codium dimorphum, Ulva lactuca, Phyllospora comosa and
Sargassum sp. underwent a simplified FA and sterol analysis, which included GC-MS analysis
of the dichloromethane extract for each sample, while the remaining four seaweeds including
Codium fragile, Colpomenia sinuosa, Sargassum vestitum and Padina sp. were studied in more
detail (Section 2.6, Fig. 2.5).
2.7.1 GC-MS analysis of Prionitis linearis, Corallina vancouveriensis, Codium dimorphum,
Ulva lactuca, Phyllospora comosa and Sargassum sp.
The dichloromethane extracts of six algal samples were collected in only low yields
(30-65 g, Table 2.1) and therefore were analysed directly by GC-MS with the aim of identifying
the chemical constituents in each sample and making a comparison with the activity results. The
chemical composition of the six algal samples is presented in Table 2.2.

Prionitis linearis
In the dichloromethane extract of P. linearis obtained by extraction method B (Fig 2.5),
14 compounds were identified by GC-MS analysis (Table 2.2). The predominant compounds
were FAs with the major component being hexadecanoic acid (32.1%) and octadecadienoic acid
C18:1 (n-6) (26.7%). In addition to 11 FAs, one sterol was identified and two aldehydes.
Aldehydes in marine algae have been found to be involved in attractant or repellent roles and to
take an active part in higher plant-insect relationships.252 It is assumed that aldehydes present in
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marine algae are possibly derived from the PUFAs.255 There are only a few published papers on
the FA composition of P. linearis including work of Khotimchenko et al. in which P. linearis
from California was analysed among seven other algae species and C16:0 and two PUFA acids
C20:4 (n-6) and C20:5 (n-3) were identified as the dominant acids.256

Corallina vancouveriensis
In the dichloromethane extract of C. vancouveriensis obtained by extraction method A
(Fig 2.5), 26 compounds were identified by GC-MS analysis (Table 2.2) and their structural
identification was based on comparisons to the NIST 08 mass spectral database. The dominant
FA was hexadecanoic acid (24.9%) (Table 2.2), which is consistent with previous results. 251
Aldehydes contribute to the pleasant taste of some algae species that have been traditionally
used as a food source in Japan for many years.258 Three volatile alcohol compounds were
identified in the dichloromethane extract (entry 10, 11 and 13). Alcohols in terrestrial plants
have been found to serve as repellent or attractants but their role in marine algae is still
unknown.253
Table 2.2: Composition of the dichloromethane extracts from the SE Australian marine algae
Rhodophyta
Chlorophyta Phaeophyta
Fatty acids
1
2
3
4
5
6
Tetradecanoic acid
14:0
4.00
5.8
2.1
6.0
5.4
12.8
12-Methyltetradecanoic acid
15:0
0.1
0.7
0.3
3,7,11,15-Tetramethyl-2-hexadecen-1-ol
0.6
0.7
0.9
0.4
0.4
Pentadecanal
0.8
0.7
0.9
0.5
0.6
7-Tetradecenal
5.6
0.6
0.7
2.3
0.3
Hexadecanoic acid
16:0
32.1
24.9
20.6 25.5
23.3 23.3
7-Hexadecenoic acid
16:1 n-9
0.2
0.1
9-Hexadecenoic acid
16:1 n-7
6.3
2.3
15.4 3.5
4.4
3.6
2,5-Dimethyl-4-hexen-3-ol
0.4
1.9
0.8
0.5
0.3
1-Butylcyclohexanol
0.6
0.9
0.7
Isomenthol
0.3
0.7
2.9
0.2
0.9
Heptadecanoic acid
17:0
0.5
1.6
1.2
1.7
0.3
Citronellol
0.1
3.9
2.9
Octadecanoic acid
18:0
2.3
1.2
2.3
0.4
0.5
1.9
9-Octadecenoic acid
18:1 n-9
2.2
8.8
7.2
3.1
4.5
4.4
9,12-Octadecadienoic acid
18:2 n-6
26.7
19.3
22.4 14.9
20.0 16.5
6,9,12-Octadecatrienoic acid
18:3 n-6
1.8
0.9
1.9
0.7
0.4
1.2
6,9,12,15-Octadecatetraenoic acid
18:4 n-3
0.1
0.3
0.4
Eicosanoic acid
20:0
0.4
tr
0.1
11,14-Eicosadienoic acid
20:2 n-6
7.00
6.2
5.8
8.8
14.3 8.3
8,11,14-Eicosatrienoic acid
20:3 n-6
4.2
5.2
4.8
4.7
5.4
11.3
5,8,11,14-Eicosatetraenoic acid
20:4 n-6
0.9
0.5
0.9
1.4
0.5
5,8,11,14,17-Eicosapentaenoic acid
20:5 n-3
1.1
1.6
1.3
0.7
1.7
7,10,13,16,19-Docosapentaenoic acid
22:5 n-3
0.1
0.1
Tricosanoic acid
23:0
0.3
0.2
0.2
Cholesterol
27Δ5
0.9
5.6
0.1
0.2
0.6
0.9
% of total extract
95.9
87.3
89.8 80.1
90.1 91.4
Six algae species analysed: 1: Prionitis linearis; 2: Corallina vancouveriensis; 3: Codium dimorphum; 4: Ulva
lactuca; 5: Phyllospora comosa; 6: Sargassum sp.; tr – traces amounts. The relative intensity of each peak was
No
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

calculated as a percentage of the summed total.

Red algae are characteristically dominated by PUFAs, in particular C20:4 (n-6) and
C20:5 (n-3), which were found in the analysed species but in slightly lower amounts.253 Of the
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FAs identified in three Corallina species, two unsaturated hexadecanoic acids C16:1 (n-9) and
C16:2 (n-9) were the most abundant along with eicosapentadecenoic acid C20:5 (n-3).253
Cholesterol was detected in three Corallina samples collected from the Black and
Mediterranean seas where it was found to be the main sterol that was present at more than 87%,
which is in accord with the results in this study where only cholesterol among sterol compounds
was identified (5.6%).253 In the three previously analysed Corallina species four to five other
sterols were detected but in considerably lower yields, which can be related to the results of this
study where no sterols were detected, probably due to the small amount of samples for
analysis.253
The chemical compositions of the two red algae species P. linearis and C.
vancouveriensis were very similar with the same dominant FAs. Moreover, biological activities
of the two red algae species were similar, they both displayed PKA inhibitory activities in the
range of 25-37% and both exhibited low cytotoxicity levels, while P. linearis showed
significant activity in the haemolytic assay (Fig. 2.12).

Codium dimorphum
In the dichloromethane extract of C. dimorphum obtained by extraction method A (Fig.
2.5), 17 compounds were identified by GC-MS analysis (Table 2.2). Fatty acids were the
predominant compounds in C. dimorphum with the main acid found to be octadecadienoic acid
C18:2 (n-6) (22.4%). Hexadecanoic acid and hexadecadienoic acid (n-7) were also present in
high amounts (20.6% and 15.4%, respectively). In C. dimorphum collected in Chile
hexadecanoic acid was the main acid.207 Aldehydes, alcohols and cholesterol were also found in
the dichloromethane extract but in considerably lower yields compared with the amount of FAs.
Two Codium species that were collected from the same location, had similar FA
contents but the ratio of some FAs were different; in C. fragile the dominant FAs were
hexadecanoic acid followed by octadecatrienoic acids [C18:3 (n-3) and (n-6)] and low amounts
of linoleic acid 18:2 (n-6) were found. In contrast, linoleic acid was identified to be the major
acid in C. dimorphum whereas hexadecanoic acid was the second main acid. While the PKA
inhibitory and haemolytic activities of the dichloromethane extracts of the two Codium species
analysed in this work were similar, the activities of the butanol extracts were considerably
different. The butanol extract of C. dimorphum displayed more potent bioactivity (Fig. 2.12),
while the polar water extracts showed a similar trend between the two algae with low activities.

Ulva lactuca
In the dichloromethane extract of U. lactuca obtained by extraction method B (Fig. 2.5),
22 compounds were identified by GC-MS analysis (Table 2.2). The main compounds in the
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dichloromethane extract of the green alga U. lactuca were found to be FAs as previously
described here for the two red alga samples (Table 2.2). Predominant were hexadecanoic
(25.5%) octadecadienoic and octadecadienoic acid (18:2 n-6) (entry 6 and 16, Table 2.2).
Hexadecanoic acid was also identified as the major acid in U. lactuca from the Bohai Sea in
China and U. fenestrate from Japan.245 Most other FAs including unsaturated, monoenoic,
dienoic, trienoic FAs and PUFAs were detected but in different ratios compared with the sample
analysed in this work, which may be due to different environmental conditions.245,258 The only
sterol found in this alga was cholesterol, which is consistent with previous results. The main
sterol found in the genus Ulva is reported to be isofucosterol.259,260 However, in the species U.
lactuca collected from the South Adriatic the principal sterols were cholesterol (34%) and
isofucosterol (26%). The authors assume it could be due to specific ecological conditions. 250 In
the marine alga U. fasciata from Egypt the only sterol identified was cholesterol.58
Compared with the chemical constituents of the other algae species analysed in this
work and in particular with the other green alga C. dimorphum, U. lactuca had a similar FAs
composition. The two green algae species (U. lactuca and C. dimorphum) were collected from
different locations, but grew under similar environmental conditions and were collected during
the same time of year.

Phyllospora comosa
In the dichloromethane extract of P. comosa obtained by extraction method B (Fig 2.5),
24 compounds were identified by GC-MS analysis (Table 2.2). Fatty acids were the most
abundant compounds and cholesterol was the only sterol compound identified (Table 2.2). A
range of aldehydes and alcohols were also detected. Hexadecanoic acid (23.3%) was the main
acid followed by octadecadienoic acid 18:2 n-6 (20.0%) and eicosadienoic acid 20:2 n-6
(14.3%). So far, only one report was published FA composition of this alga, where
hexadecanoic acid was found to be dominant followed by octadeceneoic acid C18:1 (n-9) and
PUFA C20:4 (n-6).261

Sargassum sp.
In the dichloromethane extract of Sargassum sp. obtained by extraction method B (Fig
2.5), 26 compounds were identified by GC-MS analysis (Table 2.2). Hexadecanoic acid was the
main acid identified followed by 9,12-octadecadienoic acid and 8,11,14-eicosatrienoic acid. The
chemical composition was similar to the composition of S. vestitum collected at Jones Beach in
which hexadecanoic acid was the dominant FA and the presence of linoleic acid was also
observed. The activity of the two dichloromethane extracts of both Sargassum species displayed
potent activity in the protein kinase A inhibition assay (Fig. 2.11 and 2.12).
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In summary, among all six algal samples, hexadecanoic acid C16:0 was the most
dominant acid in five species, ranging from 23.2% to 32.1% whereas only in C. dimorphum it
was the second abundant acid (20.6%). In C. dimorphum the predominant acid was
octadecadienoic acid 18:2 (n-6) (22.4%), while this acid was the second most abundant acid in
the other five samples ranging from 14.9% to 26.7% consistent with literature reports. Only one
sterol compound was observed in all six samples. Cholesterol was detected in the range of
0.08% to 1.64%. Although there was a difference in the PKA inhibitory activity among the
samples, ranging from 12% to 73%, the chemical composition of the ten algal samples was
fairly similar and consistent with that reported for each species. 243 Notably, the algal samples all
came from similar environments, and were collected from close locations around the same date,
which may also contribute to the similar chemical profiles observed.

2.7.2 EI-MS and GC-MS analysis of Codium fragile, Colpomenia sinuosa, Padina sp. and
Sargassum vestitum
Four seaweeds including Codium fragile, Colpomenia sinuosa, Padina sp. and
Sargassum vestitum were collected in larger quantities (129-500 g, Fig. 2.5) and analysed in
more detail, which included further separation of the more biologically active dichloromethane
extract for each algae sample.

Codium fragile
The non-polar dichloromethane extract of C. fragile (1.24 g) obtained using extraction
method A (Fig. 2.8) was further purified by column chromatography over silica gel using a
gradient solvent system of Hex/EtOAc to give 27 fractions that were pooled into seven major
fractions based on their metabolite compositions as judged by TLC (Fig. 2.16).
The pooled column fractions isolated from the non-polar dichloromethane extract were
tested for their PKA inhibitory activity and the results are presented in Fig. 2.16. All extracts
were tested at a concentration of 100 µg/ml. Three of the seven column fractions displayed
activities of over 70% (fractions 1, 5 and 7), which were significantly higher than the original
extract (26%, Fig. 2.16). The column fractions were analysed by TLC and the results indicated
that each fraction was a mixture of more than two compounds. Attempts were made to further
purify these fractions, but as they were mixtures of compounds of similar structure and obtained
in low yields, it was difficult to achieve full and complete separation of the compounds.
Therefore, chemical constituents of the most active column fractions (1, 2, 5 and 7) were
analysed by GC-MS (Table 2.3). By comparison to data in the NIST mass spectral database, 11
compounds were identified in total, of which ten were FAs and one a sterol (Table 2.3).
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Figure 2.16: A: Extraction protocol of the green alga Codium fragile and B: PKA inhibitory activity of the column
fractions obtained from the dichloromethane extract.

GC-MS analysis determined that column fraction 1 consisted of FAs only (Table 2.3).
In total, nine acids were identified, where the dominant FAs were octadecatrienoic acid (18:3 n6) and hexadecanoic acid. Four FAs were saturated (C14:0, C16:0, C18:0 and C20:0), one
monoenoic [C18:1 (n-9)], one dienoic [C18:2 (n-6)], two trienoic [C18:3 (n-6), C18:3 (n-3)],
and one tetraenoic acid [20:4 n-6]. Interestingly, the chemical composition of column fraction 2
was similar to the composition of column fraction 1 but the PKA inhibitory activity results of
these two fractions were notably different (Fig. 2.16). Column fraction 2 possessed only FAs
with hexadecanoic acid as the main compound (26.9%), which was also found in fraction 1 in a
similar amount. Even though the same compounds were identified in these two column
fractions, the ratio of acids was different, which could account for the difference in the activity
results (Fig. 2.16). Hexadecanoic acid was previously also found to be the dominant acid in
Codium species collected in the Sea of Japan, South Eastern Australia, Tasmania and
Chile.241,245,262
Compared with the number of FAs identified in column fractions 1 and 2, the number of
detected FAs in the column fractions 5 and 7 was lower (Table 2.3). Five FAs were identified in
fraction 7 and two FAs in the fraction 5. Both column fractions had the same sterol compound
(entry 18, Table 2.3) present in high amounts and as the dominant compound. These active
column fractions isolated from the dichloromethane extract of C. fragile were rich in FAs, in
particular with hexadecanoic and octadecatrienoic acids [C18:3 (n-3) and (n-6)] in accord with
previous results.260
Three column fractions (3, 4 and 6, Fig. 2.16) exhibited lower activity than the other
column fractions and lower than the original dichloromethane extract. These fractions were
analysed by EI-MS (Table 2.4).
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Table 2.3: GC-MS analysis of column fractions generated from C. fragile, C. sinuosa and Padina sp.
No
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Compound name
Dodecanal
Tetradecanoic acid
Pentadecanoic acid
Hexadecanoic acid
9-Hexadecenoic acid
Octadecanoic acid
9-Octadecenoic acid
9,12-Octadecadienoic acid
6,9,12-Octedecatrienoic acid
9,12,15-Octadecatrienoic acid
Eicosanoic acid
5,8,11,14-Eicosatetreaenoic acid
Vitamin E
24-Methylcholesta-5-en-3β-ol
24-Methylcholesta-5,22-dien-3β-ol

Type

#1*

14:0
15:0
16:0
16:1 n-7
18:0
18: 1n-9
18:2 n-6
18:3 n-6
18:3 n-3
20:0
20:4 n-6

24-Methylcholesta-5,24(28)-dien-3β-ol

28Δ5,24(28)

1.1
20.2
0.1
15.1
0.1
36.7
16.4
1.3
0.2
-

28Δ5
28Δ5,22

C. fragile
#2
#5
4.1
3.6
26.9 16.7
8.3
10.1 12.0 19.8 0.9
3.6
64.8

#7
4.1
2.8
11.3
21.2
19.9
30.3

C. sinuosa
#2
#5
2.1
22.4 20.1
18.1 0.3
16.5
0.3
1.2
26.3 3.1
14.9
29.3 23.0

Padina sp.
#1
#6
2.1
3.5
20.6 11.3 0.3
3.8
16.5 40.3 2.6
21.5
1.5
18.4
39.9

Cholesta-5-en-3β-ol
27 Δ5
24-Ethylcholesta-5,24(28)-dien-3β- 29Δ5,24(2
8)
ol
19
24-Ethylcholesta-5,22-dien-3β-ol
29Δ5,22
11.1 20
24-Ethylcholesta-5-en-3β-ol
29Δ5
0.6
4.4
*Numbers #1, 2, 3 etc. refer to column fraction numbers. The relative intensity of each peak was calculated as a
percentage of the summed total.

Fractions 3 and 4 were obtained as dark green oils, suggesting that they contained a
high percentage of chlorophyll, which is common for green algae. Therefore, in order to remove
it from these fractions, the method described by Sargenti et al. was used.263 TLC analysis
indicated that these two fractions contained the same compounds. Three spots were detected on
the TLC plate and they had identical Rf values. As a result, fractions 3 and 4 were combined
giving 466 mg of the mixture. After the procedure, the fraction retained the green colour, but
lighter than the original material. EI-MS analysis was performed before and after chlorophyll
removal, giving three major compounds by comparison with library mass spectral data. The
compounds were tentatively identified as hexadecanoic acid, octadecanoic acid and
24-ethylcholesta-7,24(28)-dien-3β-ol.
Compounds identified in fraction 6 by EI-MS analysis were tentatively assigned as
retinoic acid, 5,6-epoxy-5,6-dihydro, 1-phenanthrenecarboxylic acid, squalene and C
(14a)-homo-27-nor-14β-gammacrene-3α-ol with low match in NIST library spectral data (4565%). Although the identification of these compounds is not certain, it still might be that these
particular compounds are found in the sample as it is known that squalene is the precursor in the
synthesis of sterols.264
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Table 2.4: EI-MS analysis of column fractions generated from C. fragile, C. sinuosa and Padina sp.
C. fragile
#3 #4 #6
Compounds identified
Tetradecanoic acid
6,10,14-Trimethyl-2-pentadecanone
3,7,11,15-Tetramethyl-2-hexadecen-1-ol
14-Methyl-pentadecanoic
Hexadecanoic acid 16:0
√
√
9-Octadecaenoic acid 18:1 n-9
√
√
9,12-Octadecadienoic acid 18:2 n-6
1-Phenanthrenecarboxylic acid
√
Squalene
√
Sandaracopimar-15-ene-6β, 8β-diol
Pregna-5-en-3β-ol
Pregna-5-17(20)-dien-3β-ol
Cholesta-7, 24-dien-3β-ol
Cholesta-5-en-3β-ol (Cholesterol)
24-Methylcholesta-5,24(28)-dien-3β-ol
24-Ethylcholesta-7,24(28)-dien-3β-ol
√
√
24-Methyl-26,27-dinorcholesta-5,24(28)dien-3β-ol
24-Ethylcholesta-5,22-dien-3β-ol
24-Ethylcholesta-5,24(28)-dien-3β-ol
*Numbers #1, 2, 3 etc. refer to column fraction numbers.

#1
√
-

C. sinuosa
#3 #4
√
√
√
√
√
√
-

-

#6
√
√
-

#2
√
√
√
-

Padina sp.
#3 #4
√
-

#5
√
√
-

√

-

√
√

-

√

Even though the genus Codium is a very common species, it has attracted much
attention as a result of its interesting chemical composition. It was found that C. fragile contains
unusual FAs, sterols, polysaccharides and especially essential C16 and C18 PUFAs.265 Codium
fragile, collected from different locations, have been investigated regarding their FA
composition and there were attempts to find a correlation with their collection place, however
the results were quite contradictory. While some authors state that C16:0 FA is the dominant
and characteristic acid for the genus Codium, other authors could not detect the presence of this
particular FA, or any other C16:0 FAs even when the alga species were collected from the same
area.240 Herein, the most dominant FAs among C. fragile column fractions were C16:0, 18:3 (n6) and 18:3 (n-3). It has been suggested that FA composition is not a particularly good indicator
for chemotaxonomy for alga species belonging to the genus Codium because the composition
and level of FAs is different for different locations and under different environmental
conditions.241

Colpomenia sinuosa
The dichloromethane extract of C. sinuosa obtained using extraction method A (Fig.
2.5) was further partitioned by column chromatography, using a hexane/EtOAc mixture as the
eluent to give 33 fractions that were pooled into six major fractions based on their metabolite
compositions as judged by TLC (Fig. 2.17). These column fractions were tested for their PKA
inhibitory activity and the results are presented in the Fig. 2.17. Three of the six column
fractions (2, 4 and 5) were more potent than the original dichloromethane extract with 60%,
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61% and 67% inhibition respectively, column fraction 3 displayed similar activity to the
dichloromethane extract (45%), while column fractions 1 and 6 exhibited low PKA inhibitory
activity.

Figure 2.17: A: Extraction protocol of the green alga Colpomenia sinuosa and B: PKA inhibitory activity of the
column fractions obtained from the dichloromethane extract.

The column fractions were obtained in low yields and attempts to further analyse them
and also to purify and isolate pure active compound were difficult. Column fractions 1, 3, 4 and
6 were analysed by EI-MS (Table 2.4), while the most active column fractions 2 and 5
underwent a more detailed investigation by GC-MS (Table 2.3). These results indicated that the
main constituents in each fraction were non-polar lipid compounds including FAs and sterols
with similar polarity and therefore difficult to separate and isolate.
Column fraction 1 (Fig. 2.17) was obtained as a yellow oil in low yield (32 mg). Only
14-methyl-pentadecanoic acid was identified by database matching, although the TLC analysis
indicated more than one compound was present. In fractions 3 and 4, which exhibited moderate
PKA inhibitory activities (Fig 2.17), only sterols were identified, two sterols in fraction 3 and
four in fraction 4. In fraction 4 two known short side chain sterols were found with a pregnane
structure, which was not previously detected in this species (Fig. 2.18). Short side chains sterols
have been previously found in marine organisms, mainly in sponges and corals.264 They were
also identified in some algal species such as Cladophora vagabond and Zanardinia prototypes,
which suggested that short side chain sterols are derived from algae and through the food chains
are transferred to invertebrates.265 In all three fractions fucosterol was identified, as is expected
for brown algae.217 Column fraction 6 exhibited the lowest PKA inhibitory activity and was
found to contain three sterols (Table 2.3).
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Figure 2.18: Short side chain sterols identified in column fraction 4 of C. sinuosa.

Two saturated FAs were detected along with two sterol compounds, fucosterol (26.3%)
and 24-methylcholesta-5-en-3β-ol in column fraction 2, which displayed moderate PKA
inhibitory activity (Table 2.3). Column fraction 5, which displayed the most significant activity
in the PKA inhibition assay (68%), had the highest number of identified compounds (Table 2.3).
In total, 11 compounds were identified, among them six FAs and five sterols while one was
unidentified. All five sterols identified have the Δ5 structure. The most active column fraction 5
was rich in Δ5 sterols in particular with fucosterol and cholesterol identified as the dominant
sterols. Similar sterol compositions to those described here were observed in alga samples of C.
sinuosa from Greece and C. peregrine from the Black sea.246,267 Hexadecanoic acid was the
dominant FA (20.1%) in column fraction 5 followed by octadecanoic acid (16.5%). Of five
FAs, four were saturated (C14:0, C16:0, C18:0, C20:0) and one tetraenoic acid [C20:49n-6)].
In total, in the analysed species fucosterol was detected in three of the six column
fractions (2, 5 and 6), proving that it was the main sterol of this algal species. Hexadecanoic
acid was present in the two column fractions 2 and 6 in significant quantities. Interestingly, it
was detected in a fraction which exhibited great PKA inhibitory activity. In marine algae C.
sinuosa collected in Senegal the dominant sterol proved to be fucosterol and the main FAs were
hexadecanoic acid (35.1%) and oleic acid (C22:0). Shaikh et al. also found hexadecanoic acid to
be the most dominant in the C. sinuosa.268

Padina sp.
The non-polar fraction of the dichloromethane extract of Padina sp. obtained using
extraction method A (Fig. 2.5) was separated to give 29 fractions that were pooled into six
major fractions based on their metabolite compositions as judged by TLC (Fig. 2.19). Only the
first column fraction exhibited significant PKA activity of 92% inhibition, close to the activity
of the original material, while other fractions displayed lower activity.
The two most active column fractions generated from the dichloromethane extract,
fractions 1 and 6, underwent a more detailed analysis by GS-MS (Table 2.3) while all other
column fractions were analysed by EI-MS mass spectrometry (Table 2.4). TLC analysis of all
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column fractions indicated that none of the fractions were pure and that all compounds had
similar polarity and Rf values.

Figure 2.19: A: Extraction protocol of the green alga Padina sp. and B: PKA inhibitory activity of the column
fractions obtained from the dichloromethane extract.

In the first fraction, which displayed the greatest kinase inhibitory activity, GC-MS
analysis identified eight compounds (Table 2.3) of which (α-tocopherol) vitamin E was the most
abundant compound in the mixture (40.3%). Tocopherols have been found previously among
marine algae.269,270 These compounds benefit to nutritional value and also are responsible for
antioxidant activity of algal extracts. Furthermore, tocopherols have been found to inhibit
activation of various kinases including PKC, Akt and ERK/MAP.271,272 The other compounds in
alga extracts were identified to be FAs and one aldehyde. Of six identified FAs, three were
saturated (C14:0, C16:0, C18:0), two monoenoic [C16:1, n-9)] and one trienoic acid [C18:3 (n3)]. Hexadecanoic acid was determined as the main acid (20.6%) in this column fraction. That is
consistent with the analysis of Padina vickersiae from Senegal of which the main compound
was found to be hexadecanoic acid.242 Of six identified sterols in column fraction 6, all had Δ5
structure, five of them were C24-alkylated with the ratio of C27:C28:C29 of 1:3:2. Fucosterol
(39.9%) was identified, as the main compound followed by 24-methylcholesta-5,22-dien
(21.5%) and cholesterol (18.4%).
In column fraction 2, by EI-MS three FAs were identified, one saturated (C16:0) and
two unsaturated [C18:1 (n-9); C18:2 (n-6]. The usual predominant FAs found in Padina sp. are
C14, C16 and C18 acids.244 In P. gymnospora from Qatar, hexadecanoic acid was the main acid
isolated followed by C18:1 and C20:2.271 Also, in some Padina sp., such as P. vickersia from
Turkey, the presence of only saturated FAs was detected and none of the unsaturated acids were
identified.61 So far, there are no data on the FA and sterol composition of this species from
Australia. The other three column fractions isolated from the dichloromethane extracts of
Padina sp. (3-5) analysed by EI-MS were found to contain only sterols (Table 2.4).
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In total, in the Padina sp. column fractions, fucosterol was identified in three fractions,
in fraction 6 by GC-MS analysis and in fractions 4 and 5 by EI-MS. The second most abundant
sterol in the analysed species was cholesterol that was identified in three fractions (4, 5 and 6).
The presence of fucosterol and cholesterol in many of the fractions confirms the dominance of
these two sterol compounds in Padina sp. as observed previously for P. pavonia from Adriatic
sea, P. vickersiae from Senegal, P. gymnospora from Qatar and in P. pavonica collected in
Greece.274,275 Cholesterol was the main sterol in species P. vickersia from the Senegalese coast
in the work of Aknie et al. and Combut et al.244,246,275 Fucosterol is usually a dominant sterol of
Padina species while cholesterol is generally detected in Padina species but in lower
amounts.246 However, the dominance of cholesterol in some Padina sp. was previously
observed.244

Sargassum vestitum
The non-polar dichloromethane fraction generated from S. vestitum obtained using
extraction method A (Fig. 2.5) exhibited significant biological activity in the PKA inhibition
assay (76%, Fig. 2.13 A) and it was further separated by column chromatography to yield four
column fractions judged by TLC. The four column fractions were screened for PKA inhibitory
activity and fraction 4 which displayed the highest activity was further separated (Fig. 2.20)
using column chromatography to give one pure fraction and three partially purified fractions
which were also tested for their PKA inhibitory activity.

Figure 2.20: A: Extraction protocol of the green alga Sargassum vestitum and B: PKA inhibitory activity of the
column fractions obtained from the dichloromethane extract.

Further purification of column fraction 4 by preparative HPLC gave four fractions 4.14.4 (Fig 2.20).The compound in fraction 4.4 was identified as thunbergol A or 9-(3,4-dihydro2,8-dimethyl-6-hydroxy-2H-1-benzopyran-2-yl)-6-methyl-2-(4-methyl-3-pentenyl)-(2E,6E)63 |
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nonadienoic acid (Fig. 2.21). Thunbergol A was isolated previously from Sargassum
thunbergi.276 The structure of this compound was confirmed with HRESI-MS and 1D and 2D
NMR data. Thunbergol A was screened in the PKA assay, however it did not exhibit potent
inhibitory activity (7% PKA inhibition).

Figure 2.21: Thunbergol A identified in column fraction
of S. vestitum.

Attempts were performed to purify the dichloromethane fraction of S. vestitum, due to
the complex mixture and low yield of the fraction, the non-polar fraction was analysed by GCMS method and identified 18 compounds that are presented in Table 2.5. The predominant
compounds were six FAs, three monosaturated (C14, C16 and C18), one monoenoic (C18, n-9),
one dienoic (C18:2 n-9) and one tetraenoic acid (C20:4 n-5). Along with FAs, several types of
other compounds including aldehydes and alcohols were also found to be present in this
fraction. In previous analyses of FA composition of Sargassum sp. hexadecanoic acid was
reported as the major acid along with C18, C18:1 (n-6), C20:4 (n-6) and C20:5 (n-3).61,239 It was
earlier reported Sargassum species characteristically have a high content of meroditerpenoids,
consisting of a polyprenyl chain attached to a hydroquinone ring moiety. The fact that these
compounds were not observed herein could be a result of the database used (NIST 08) and may
have been identified using alternative database such as MarinLit and Dictionary of Natural
Compounds.277, 278
Table 2.5: GC-MS analysis of the dichloromethane extract of S. vestitum
No
Compound
1
2-Methyl-1-penten-3-one
2
2,3,4-Trimethylhexane
3
3-Methylenedecan-4-ol
4
Tetradecanoic acid
5
Hexadecanal
6
6,10-Dimethyl-2-undecanone
7
Pseudoionone
8
3,7,11,15-Tetramethyl-2-hexadecen-1-ol
9
2,6,6-Trymethyl-2-cyclohexene-1-carboxaldehyde (cyclocitral)
10
1-Hexadecyne
11
1-Octadecyne
12
Hexadecanoic acid (16:0)
13
Isomenthol
14
Octadecanoic acid (18:0)
15
2-(Pentadec-12-en-1-yloxy)tetrahydro-2H-pyran
16
9,12-Octadecadienoic acid (18:2 n-6)
17
9-Octadecaenoic acid (18:1 n-9)
18
5,8,11,14-Eicosatetraenoic acid (20:4, n-6)

Rt (min)
3.84
4.72
12.35
25.72
27.85
27.98
28.12
28.30
28.40
28.64
29.04
29.39
30.90
31.29
31.76
32.24
32.33
34.85

% Area
2.37
4.25
2.56
4.87
4.54
2.34
0.14
3.94
2.84
2.02
2.76
9.02
2.01
4.65
3.09
5.12
4.99
6.03
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2.8 PKA inhibitory activity of pure fatty acids and sterols
The main constituents of the non-polar fractions were identified as FAs and sterols
mainly in all algae samples. The FAs and sterols that occurred in higher concentrations in the
algae extracts were tested for their PKA inhibition activity with the aim of relating the activity
of the sample with the concentration of the particular acid or sterol (Fig. 2.22). A series of
commercially available FAs (C14:0, C16:0, C18:0, C18:1) and a FA mixture (C14-22, C18-22)
were examined for their ability to inhibit PKA, at a concentration of 100 µg/ml. In column
fraction 1 of the dichloromethane extract of Padina sp., α-tocopherol was identified as the main
constituent (40.3%). This fraction exhibited high PKA inhibitory activity, hence pure αtocopherol was also screened in the PKA assay. Results obtained from the PKA inhibition assay
are presented in Fig. 2.22. α-Tocopherol exhibited 21% PKA inhibitory activity (data not in
figure).
These results showed that FAs were more potent than sterols. C14 acid displayed the
highest activity of (64%) while C16, C18 and C18:1 displayed moderate activity. These results
are consistent with previous research on bioactive FAs from marine algae. The results have
practical value as marine algae are rich in PUFAs of the n-3 and n-6 series, which are
considered essential FAs for humans and animals. It is also reported in the literature that the
antibiotic activity of some algae species could be attributed to the presence of a mixture of
organic acids such as: capric, lauric, linoleic, myristic, oleic, palmitic, stearic. 246 N-3 PUFAs
have been used in the cancer prevention and treatment and for modulate the immune system. 279
Linolenic acid has been found to be able to slow down cell growth in prostate, breast, and colon
cancers, while arachidonic acid can inhibit the growth of human lung tumor A549 cells.280
Because of the huge and renewable biomass, seaweeds are a potential source of FAs for
biotechnology and a dietary source of essential FAs.
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Figure 2.22: PKA inhibitory activity of fatty acid and sterols typically found in ten alga species collected from South
Eastern Australia.
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In conclusion, 10 algae species from SE Australia were analysed and the non-polar
fractions isolated from all alga samples were found to give potent biological results and
displayed more activity compared with the activity of the more polar fractions. The collection
place, environmental conditions and the date of sample collection was almost identical with all
algal species collected herein. Therefore, the activity results were found to be mainly related to
the different algae divisions. This is the first report of marine algal extracts exhibiting PKA
inhibitory activity. The dichloromethane extracts isolated from brown algae were found to
display the highest activity in the PKA inhibition assay except for C. sinuosa, which exhibited
the lowest activity compared with the other algae dichloromethane extracts. There are no
literature data so far on the kinase inhibitory of extracts isolated from these algae samples and
for most of the samples haemolytic data are reported for the first time. Although, all compounds
found in these algae were identified before, this work shows for the first time the chemical
composition and activity of ten algal extracts of algae species from Australia. The FA
composition of all ten algal species investigated was dominated by saturated FAs, and in
particular hexadecanoic, 9,12-octadecadienoic acid and unsaturated C18 FAs. The dominance of
cholesterol and fucosterol was detected in all algal non-polar extracts. The chemical
composition of the algal species analysed herein was found to be both species related due to the
similarity of our data to the literature data on fatty acid and sterol constituents of the
corresponding algal species. However, environmental conditions, as suggested in the literature
analysis, may also play a role in the similar chemical composition of algal species, as the
samples were exposed to almost identical environmental conditions.
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Sponges are the largest source of novel marine natural products published every
year.31 Herein, the PKA inhibitory, haemolytic and cytotoxic activities and
chemical composition of extracts obtained from three deep sea sponges collected
from North Western Australia are described.

3.1 Marine sponges
Sponges are the most primitive multicellular animals, belonging to the phylum Porifera
which comprise three groups: the Demospongiae, the Calcarea (calcareous sponges) and the
Hexactinellida (glass sponges), where the class Demospongiae constitutes more than 90% of
known living sponges (Fig. 3.1).281,251 Sponges belong to the group of sessile animals that also
include mollusks, tunicates and byrozans and they are characterised by a lack of physical
protection. Therefore, in order to protect themselves from predators, bacterial and fungal
infection, growth of other fouling organisms and invasion by other marine organisms, sponges
are found to produce a range of bioactive secondary metabolites that are used in ecological
interactions.282 However, it is now believed that many of the bioactive compounds extracted
from marine sponges are produced by the microbes and bacteria which are found in the sponge
tissues.283 Only a few studies have shown whether the bioactive secondary metabolites were
products of the sponge itself or the sponge symbiotic organism (e.g. bacteria).284-286

Figure 3.1: Sponges belonging to three different phyla (Demospongiae, Calcarea and Hexactinellida). 287

3.2 Metabolites from marine sponges
Sponges are found to produce the highest variety of different natural products among
Metazoa (animals) producing compounds with cytotoxic, antibacterial, haemolytic and other
biological properties.288,289 As for shallow-water sponges, the deep-water organisms have also
proven to be a productive source of bioactive metabolites with diverse structures.68 The research
on deep-sea sponges was encouraged by the isolation of bioactive halichondrin B (30, page 17)
from the deep sea marine sponge Lissodendoryx sp., of which a synthetic analogue (10, page 9)
was approved for breast cancer in 2010.52,88 The metabolites from deep-sea sponges are also of
particular interest because they account for over 60% of the deep-sea natural products
reported.68
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Some of the potent secondary metabolites with different scaffolds and biological
activities isolated from deep-sea marine sponges include: antitumor compound dericitin (114)
isolated from Dericitus sp.; sollasins A-F (115-117) with cytotoxic and antifungal activity
obtained from Poecillastra laminaris; HIV-integrase and tyrosine protein kinase inhibitors
ircinol sulfate (118) and 2-heptaprenylhydeoquinone (119) isolated from Ircinia sp.;
dragmacidin (120), isolated from Dragmasidon sp. which displayed significant cytotoxicity
towards a range of cancer cell lines and leiodolide A (121) with potent cytotoxic activity
towards ovarian and leukemia cancer cell lines, isolated from Leiodermatium sp.81,83,84,290-293 In
addition, a number of kinase inhibitors have also been isolated from both shallow- and deepwater sponges including the non-competitive inhibitor manzamine A of GSK-3β with an IC50
value of to 10.2 μM (122) from Hymeniacidon aldis, and the EGFR inhibitors aeroplysinin-1
(123) from Verongia aerophoba and halenaquinone (124) from Xestospongia exigua (Fig.
3.2).139,294,295

Figure 3.2: Bioactive compounds isolated from marine sponges.

3.3 Deep-sea sponge collection and identification
Accessing deep-sea samples is prohibitively expensive and logistically difficult which
has meant that much of the research to-date has been conducted through non-selective dredging
and trawling operations. Selective sampling, performed with manned submersibles and remotely
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operated vehicles (ROVs), has minimal environmental impact and allows for valuable in situ
ecological observations, however, it is limited to a handful of scientific institutions with access
to such equipment.68,296 In recent years, industrial collaborations have expanded access to deepsea technologies such as ROVs to a wider number of researchers, facilitating further research
into deep-sea fauna biology, physiology, and chemistry.89,296,297 Through such multidisciplinary
collaboration between a consortium of Australian universities and the Australian Oil and Gas
industry, a variety of deep-sea invertebrates were recently collected from subsea structures off
the North West (NW) Shelf of Australia. The samples were collected as part of a
decommissioning program conducted by Woodside Petroleum during Jun/July 2008. The deepsea sample collection was performed by the SEA SERPENT (Scientific and Environmental
ROV Partnership Using Existing Industrial Technology) group in June and August 2008. The
decommissioning of oil rigs located off the NW Shelf of Western Australia from 1986 to 1992
resulted in a series of abandoned wellheads that had been on the ocean floor for 30 years. These
six wellheads are at the Echo 1, Yodel 1, Coassack 2 & 3, Wanaea 5 and Goodwyn 9 oil fields.
These structures act as artificial reefs and attract a diverse array of both vertebrate and
invertebrate marine fauna including fishes, sponges, cnidarians, molluscs, echinoderms and
crustaceans.298,299

kilometres
kilometres

kilometers

kilometres

Figure 3.3: Map showing the six North West Shelf wellhead removal sites from the 2008 collecting expedition.300 kilometers
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Three demosponge samples were obtained from two subsea structures/locations, with
one sample found to comprise two species of sponge (Fig. 3.3). The three sponges were
identified as: Haliclona sp. (Order Haplosclerida, Family Chalinidae); Geodia sp. (Order
Astrophorida, Family Geodiidae); and an intertwined sample of Sarcotragus sp. and Ircinia sp.
(both belonging to the Order Dictyoceratida, Family Irciniidae) (Table 3.1).
Table 3.1: Description of collection sites. †
Sponge species
Well Site

Depth (m)*

Latitude

Longitude

Haliclona sp.

Yodel 1

135

19°44'40’’S

115°43'12"E

Geodia sp.

Yodel 1

135

19°44'40’’S

115°43'12"E

Sarcotragus sp. / Ircinia sp.

Wanaea 5

84

19°35'13"S

116°24'41"E

†
*

All locations and depths from Geoscience Australia (http://dbforms.ga.gov.au/www/npm.well.search).
Below mean sea level.

3.4 Sponge description and previous (reported) studies

A

B

C

Figure 3.4: Above water photographs of the deep-sea sponges Haliclona sp. (A), mixed Ircinia sp. / Sarcotragus sp.
(B) and Geodia sp. (C).

3.4.1 Haliclona sp. is a branching sponge with well spaced holes on its surface, which form an
encrustation on rocks. It can be yellow, light blue, purple or sometimes green in colour (Fig.
3.4A). This sponge requires light conditions and therefore occurs usually in shallow-water, the
higher intertidal zone area closer to the surface. Approximately 390 species have been found to
belong to the genus Haliclona and the sample described herein is the first report of a Haliclona
species from the deep-sea.
A diverse range of bioactive metabolites have been reported from Haliclona sp.
collected worldwide from both warm and cold waters. In particular Haliclona species have been
found to be rich in bioactive alkaloids including a range of polycyclic pyridinium alkaloids
(125), and araguspongin C (126, 127), which displayed antibacterial, cytotoxic, antimicrobial,
anti-dormant mycobacterial and antifungal activity (Fig. 3.5).301-307
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Figure 3.5: Bioactive alkaloids isolated from the sponge Haliclona sp.

Additionally, other types of metabolites have been isolated from this sponge including:
novel peptides with potent antifungal activity, the bioactive terpenes, haliclotriol A and B (128,
129), a macrocyclic diamide haliclonin A (130) with moderate cytotoxic and antibacterial
activity against diverse microbial strains; cytotoxic glycoprotein lecithin; halipeptins A and B
that exhibit potent anti-inflammatory activity in vivo and a novel ceramide (131) which acts as
an antifouling substance against macroalgae (Fig. 3.6).308-313

Figure 3.6: Bioactive compounds isolated from the sponge Haliclona sp.

Not only polar constituents were isolated from Haliclona species but also sterols and
FAs were obtained. In particular, these sponges are known as an excellent source of a high
diversity of sterol metabolites. The lipid composition of various Haliclona sp. determined by
GC and GC-MS analysis has been reported by several research groups.314-317 Cholesterol has
been characterised as the main sterol in Haliclona sp., while among the FAs the dominant acid
has been hexadecanoic acid.318 As a source of kinase inhibitors, species of Haliclona sponge
have so far only yielded p-sulfoxyphenylpyruvic acid (132) that exhibits tyrosine kinase
inhibitory activity (Fig. 3.6).319

3.4.2 Sarcotragus sp. can vary in size from a small sponge to a massive globular size. It is
usually dark in colour with a horizontally flattened surface. This species is distributed
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worldwide but some of the species are more common in the European zone. Although there
have been reports on this species from Australia, this is the first report on a deep-sea
Sarcotragus species from Australia.
Sponges of the genus Sarcotragus are reported to be a rich source of linear
sesterterpenes.320 Liu et al. isolated five new furanosesterterpene tetronic acids (e.g. 133) with
potent cytotoxicity against five human tumour cell lines from sponge material collected at the
depth of 15-25 m in Korea.321 Moreover in their continuing studies on the genus Sarcotragus the
authors isolated two new norsesterterpenoids, four new pyrroloterpenoids (e.g. 134) and known
furanosesterterpenoid (Fig. 3.7).322 Also other compounds, such as alkaloids (135-137) and
glycerolipids were isolated from this species and proven to be bioactive including two new
compounds isolated from the deep-sea Sarcotragus sponge also collected from 25 m depth off
the coast of Cheju Island in Korea.323 Barrow et al. isolated variabilin (138) from Sarcotragus
sp., which was first isolated from the sponge I. variabilis, and found to display potent antiviral
and antitumor activity (Fig. 3.7).324,325 Nortriterpenoids (e.g. 139) have also been reported from
deep-sea species of Sarcotragus sponges.326

Figure 3.7: Compounds isolated from the sponge Sarcotragus sp.

3.4.3 Ircinia sp. is usually a large size sponge with widely spaced conules. The colour is
creamy yellow or light brown. Oscules are dark and usually grouped on top of the animal.
Characteristic of this sponge is an unpleasant sulfur/garlic smell. There are 79 species belonging
to the genus Ircinia and 12 belonging to the genus Sarcotragus. Ircinia species have been found
in shallow and deep waters worldwide, however this is the first report on a deep-sea example
from Australia.
Sponges belonging to the genus Ircinia are among the most explored sponges in terms
of marine natural compounds.282 The genus Ircinia has yielded a series of novel and bioactive
compounds including: tedanolide C (140), a new 18-membered macrolide with potent
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cytotoxicity against HCT-116 cells in vitro; ircinamine (141) showing moderate activity against
the murine leukemia cell line P388; four cheilanthane sesterterpenoids (e.g. 142) as potent
kinase inhibitors; palinurin and fasciculatin sulfates and novel 5,6-epoxysterols (143) with
potent cytotoxic activity (Fig. 3.8).195,327-330 Seven new linear C-22-sesterterpenoids
(irciformonins E-K, e.g. 144), were isolated from sponge I. formosana.331 Previously, the same
authors isolated irciformonin A-D from the same species.332 All the above mentioned
compounds including many others were isolated from shallow water sponges but there are also
examples from deep-sea species such as sulfircin (145), isolated from an Ircinia sp. collected at
a depth of 119 m in the Bahamas.333

Figure 3.8: Bioactive compounds isolated from the sponge Ircinia sp.

3.4.4 Geodia sp. is a large, globular sponge often found to have a white or brown colour (Fig.
3.4C). It has a rounded shape with an irregular, largely smooth, but often encrusted surface and
it is common for it to form large colonies that resemble dots. So far approximately 115 species
belonging to the genus Geodia have been found.
There have also been several reports on bioactive compounds isolated from different
species of Geodia sponge, including a southern Australian sample collected from a depth of
51 m, which has yielded the potent nematocidal agent geodin A (146), a novel macrocyclic
polyketide lactam tetramic acid (Fig. 3.9).334 Furthermore, water and petroleum ether extracts of
the Swedish deep-water sponge G. barretti, exhibiting antibacterial and antiviral activity, have
yielded the novel diketopiperazine-containing indole alkaloid, barettin (147).335 Also, a novel
dibrominated cyclopeptide, bromobenzisoxazolone barettin which showed significant
antifouling activity, was isolated from the same species G. barretti collected in Sweden at a
depth of 50 m, by Hedner et al.336
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Figure 3.9: Bioactive compounds isolated from the sponge Geodia sp.

Sponges collected from shallow-water were also found to produce bioactive secondary
metabolites including two novel isomalabaricane-type nortriterpenoids, geoditins A and B (148,
149) and a novel sterol compound; and an unusual polyoxygenated sterol compound (150) (Fig.
3.9).337,338 Two new cyclodepsipeptdes, geodiamolide A and B, were isolated from a Geodia
sponge collected at 25 m depth in Trinidad and Tobago followed by the isolation of two novel
geodiamolide H and I a few years later from the same genus from Trinidad (20 m). 335,336 Rangel
et al. found significant antibacterial, antifungal, cytotoxic, haemolytic and neurotoxic activities
of

the

methanol

extract

generated

from

G.

corticostylifera.341

Furthermore

they

isolated cyclic peptides geodiamolides A, B, H and I with potent anti-proliferative effect
against sea urchin eggs and human breast cancer cell lines.341

3.5 Biological screening of sponge extracts
Extracts of the three seep-sea sponges collected from the NW Shelf were prepared
according to a reported procedure by Thale et al. as described in the experimental chapter 7
(method C) to give seven extracts of different polarity (hexane 1, hexane 2, dichloromethane,
10% methanol, 50% methanol, butanol and water extracts) (Fig. 3.10).257 The protocol was
designed to separate the metabolites into groups of similar compounds. This partitioning step
provided a preliminary separation of the metabolites based on their polarity, where the nonpolar fractions would be expected to be dominated by lipids, sterols, and terpenes and the polar
fractions by alkaloids, peptides, polyketides, and carbohydrates.
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Specimen

3 x 24 h, 100% MeOH
Filter
Residue

Crude MeOH
extract

Crude DCM
extract

2 x 24 h, 100% DCM

Water

Water

DCM

n-BuOH

10% MeOH

50% MeOH

10% MeOH

Hexane (2)

Hexane (1)

DCM

Figure 3.10: Partitioning method used in the preparation of the sponge extracts.

Extracts from marine organisms are widely screened for cytotoxicity against both
human and murine cancer cell lines. However, in recent years testing for inhibition against
specific enzymes has become more widespread, as this provides greater information about a
natural product’s mode of action.
The deep sea is one of the most biodiverse and species-rich habitats on the planet, and
deep-sea organisms are emerging as an important new source of unexplored chemical, genetic
and biological diversity.76 In particular, sponges have yielded a variety of novel metabolites
which display a range of biological properties. As previously discussed in Chapter 2, protein
kinases are one of the most targeted enzymes and involved in the regulation of an increasing
number of biological processes. Thus, the extracts of different polarity generated from the three
deep-sea sponges were tested for their ability to inhibit PKA; to lyse equine erythrocytes and for
their toxicity towards the brine shrimp Artemia franciscana (Fig. 3.11).

3.5.1 Haliclona sp.: The greatest activity (27%) in the PKA inhibition assay was found in the
50% methanol extracts obtained from Haliclona sp. (Fig. 3.11). The non-polar dichloromethane
fraction and the polar butanol fraction exhibited the second and third highest activity in the PKA
inhibition assay of 26% and 16% respectively, while the other four fractions had low to no
activity in the PKA inhibition assay.
Interestingly, both polar and non-polar fractions displayed stronger potency in the
haemolytic assay compared with the results from the PKA inhibition assay. Moderate to strong
haemolytic activity towards equine erythrocytes was observed in both the polar and non-polar
fractions of all extracts isolated from the sponge Haliclona sp., with the 50% methanol fraction
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exhibiting the greatest activity (75%, Fig. 3.11). The two non-polar fractions, dichloromethane
and the hexane 1 fraction, along with the more polar 10% aq. methanol fraction also displayed
significant haemolytic activity (47%, 39%, and 50% respectively). The butanol fraction
displayed moderate activity in the haemolytic assay of 38%, while the water and hexane 2
fractions displayed very low activity. Both polar and non-polar haemolytically active
compounds have been found in various marine organisms, including cone snail peptides,
dinoflagellate toxins, and echinoderm saponins. Extracts obtained from sponges H. viridis and
H. rubens were previously found to display haemolytic activity.342-344
Moderate lethality towards the brine shrimp A. franciscana was observed in the hexane
1 extract (33%, Fig. 3.11). The water extract, although displaying negligible PKA inhibitory
activity, exhibited some activity in both the haemolytic (12%) and the brine shrimp lethality
assay (13%). The 50% aq. methanol fraction and the hexane 2 extract exhibited some cytotoxic
activity (18% and 8%, respectively) while other fractions exhibited low levels of brine shrimp
lethality (< 4%). Based on these results found herein the three non-polar extracts (hexane 1,
hexane 2 and dichloromethane extracts) and 10% and 50% methanol extracts would warrant
further investigation in order to identify the metabolites responsible for the observed activity.
Brine shrimp toxicity has been reported previously for eight new cerebrosides from Haliclona
sp and three new alkaloids, isohalitulin, haliclorensin B, and haliclorensin C obtained from H.
tulearemsis.345,346

3.5.2 Geodia sp.: In the PKA inhibitory assay, the hexane 1 extract of Geodia species displayed
the most potent activity of 97% followed by the non-polar hexane 2 extract (41%). The
remaining five Geodia extracts exhibited lower activity in the PKA inhibition assay, where the
water extract exhibited the least activity, which is consistent with the results of the other two
deep-sea sponge samples where the water extracts also displayed low PKA inhibitory activity
(Fig 3.11). Previous work of Geodia sponges resulted in the isolation and identification of
receptor tyrosine kinases from Geodia species such as G. cydonium indicating that this sponge
is also likely to produce endogenous kinase modulators.347 Furthermore, the hexane 1 extract of
the Geodia sample also exhibited potent cytotoxicity in the brine shrimp assay (87%) and was
more active than other extracts generated from the sponge Geodia sp (Fig. 3.11). The other six
extracts displayed less than 10% lethality in this assay.
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Figure 3.11:% PKA inhibition, haemolysis and brine shrimp (BS) lethality of deep-sea sponge extracts.
Measurements were performed in triplicate at 100 μg/mL and data are presented as means ± S.E.M. DCM,
dichloromethane.

Moderate haemolytic activity towards equine erythrocytes was observed in both the
polar and non-polar fractions from the sponge Geodia sp. (Fig. 3.11). The greatest activity of
30-45% was found in four extracts, the hexane 1, dichloromethane, 50% methanol and water
extracts (41%, 34%, 36% and 28%, respectively). Interestingly the water extract, although
displaying negligible PKA inhibitory activity, showed some level of both haemolytic activity
and brine shrimp lethality (28% and 9% respectively). Based on the above results the most
active non-polar hexane 2 extract would warrant further investigation in order to identify the
metabolites responsible for the observed activity.
The haemolytic activity of the extracts isolated from Geodia sp. herein is consistent
with the results from Rangel et al. who demonstrated the ability of the same sponge species to
lyse equine erythrocytes.348 Haemolytic activity has been also identified in the crude extracts
from G. corticostylifera, which were found to contain antibacterial, cytotoxic and neurotoxic
cyclic peptides geodiamolides A, B, H and I.339,340,349

3.5.3 Ircinia/Sarcotragus sp.: Two non-polar fractions of Ircinia/Sarcotragus sp., the hexane 1
and dichloromethane extract, displayed significant PKA inhibitory activities of 100% and 84%
respectively. These results are consistent with the large number of non-polar kinase inhibitors
described from marine sponges, which include sesterterpenoid mitogen activated protein kinase
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MSK1 and MAPKAPK-2 inhibitors from Ircinia sp.330 Furthermore prenylhydroquinones
isolated from the sponges S. muscarum and I. fasciculate were found to inhibit various protein
kinases including EGFR, Src tyrosine kinase, vascular endothelial growth factor receptor 3 and
insulin-like growth factor I receptor.350 Unlike the other two non-polar fractions, the hexane 2
fraction exhibited low PKA inhibitory activity (8%). Similar PKA inhibitory activity was
observed among the butanol, 10% and 50% methanol fractions (20%, 20% and 22%,
respectively), while the water fraction displayed negligible PKA inhibitory activity.
When tested for haemolytic activity and brine shrimp toxicity, extracts generated from
Ircinia/Sarcotragus sp. did not give potent results. Three extracts, the hexane 1, butanol and
water extract, displayed moderate haemolytic activity towards equine erythrocytes (30%, 28%,
and 22%, respectively) while the remaining four extracts exhibited lower activity levels (Fig.
3.11). However, previous analyses of the sponge I. felix collected in Australia and the
Netherlands showed strong haemolytic activity in the organic extracts.282
Only the hexane 2 and the 10% methanol extracts of the Ircinia/Sarcotragus sp. sponge
displayed any activity towards the brine shrimp A. franciscana (10% and 9%, respectively),
while the remaining extracts were inactive (Fig. 3.11 We assumed that the extracts in the brine
shrimp lethality assay displayed very low cytotoxicity due to the fact that shrimps used the
sponge extracts as food source. However, this might suggest that extracts are of very low
cytotoxicity.351 Compounds with brine shrimp cytotoxicity toward A. salina were previously
isolated from the sponge I. spinosula.352 Furthermore, the brine shrimp cytotoxicity of methanol
extracts of Sarcotragus sp. from Korea led to isolation of the new cyclitol compound sarcotride
D.353 The above results of the hexane 1 and dichloromethane extracts indicated that these two
extracts should be further analysed in order to investigate the chemical constituents responsible
for the bioactivity of extracts.
In summary, the PKA inhibitory activity was found to follow the order
Ircinia/Sarcotragus sp. > Geodia sp. > Haliclona sp., while the haemolytic activity followed the
reverse order and all samples were relatively low in brine shrimp lethality except the hexane 1
extract of Geodia sp. In general, the non-polar extracts (hexane 1, hexane 2 and
dichloromethane) isolated from all sponge samples were found to give more potent bioactive
results, in particular greater PKA inhibitory activity, compared to the polar fractions. The most
active extracts were hexane 1 and dichloromethane extract from Ircinia/Sarcotragus sp. and the
hexane 1 and hexane 2 from Geodia sp. in the PKA inhibition assay. The results described
herein are the first report on the biological activity of deep-water sponges belonging to the
genera Haliclona and first report on the bioactivity of an Australian deep-sea Sarcotragus sp.
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3.6 Investigation of the chemical composition of three deep-sea sponges
Following from the bioactivity screening, all three sponges were further purified and
analysed to determine their chemical composition.
3.6.1 Sponge fatty acid and sterol composition
Sponges also provide a mixture of unusual and diverse sterols with unique structures
that are different from sterols found in terrestrial plants; in fact sponges are believed to be the
richest source of the most diverse sterols in the animal kingdom.292,333 Compared with terrestrial
plants, which usually contain a simple sterol composition of three to six compounds, marine
sponges possess a rich mixture of sterols.316,354 Unusual sterols are usually present in low yields,
appearing with the typical 3β-hydroxy sterols. Generally sterols are considered to have a
3β-hydroxy-Δ5-cholestane (or Δ0) structure where the number 5 indicates the number of the
double bond position with a 8-10 carbon side chain.355

Figure 3.12: Typical sterols found in marine sponges.

The differences in the sterol structure in sponges can include a modified base carbon
skeleton, oxygenation, degradation and alkylation of the side-chain giving sterols with C0-C12
side chains where alkylation usually occurs at position C-24 (Fig. 3.12). The polar sterols that
have sulfate or polyhydroxy groups are of particular interest as they have been reported to
exhibit a range of biological activities. The diversity of sterol structures in the marine
environment are likely due to the different environmental factors such as water temperature,
salinity, pollution and diet.356 The main source of marine sponge sterols is food intake, but in
general the origin of sterols in sponges comes through four pathways: de novo synthesis;
through diet; dietary origin with modification and from associated organisms attached to the
sponge surface.356,357,358 Δ5 Sterols have been found to be the dietary sterols which sponges take
up from food. Furthermore, sponges have been found to be able to transform dietary sterols to
stanols and to Δ7 sterols. Transformation of dietary Δ5 to Δ7 sterols goes through the
thermodynamically more stabile Δ5,7 sterols in sponges, but it has been found in starfishes that
this transformation can also proceed through stanols.359 The source of Δ5,7 sterols can be also a
diet as they were found to occur in marine yeasts.360
Although sponges have been characterised as a rich source of novel and unique sterols,
they are also known to be a rich source of a variety of fatty acid (FA) compounds including long
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chain FAs, and FAs with odd, even and branched chains.361 Marine sponges usually contain
long-chain Δ 5,9 FA with up to 34 carbon chain and some sponges have been found to contain
significant amount of FA with up to 60 FAs.362,363
3.6.2 Haliclona sp.
The hexane 1 fraction of the deep-water sponge Haliclona sp.: The total number of
identified fatty acids by GC-MS analysis in this fraction was 14, while only three sterol
compounds were found (Tables 3.2 and 3.3). Fatty acids make up 62.0% of the hexane 1 extract
and sterols 13.9%. The polyunsaturated fatty acid C20:4 (n-6) is present in a large amount
(21.2%) in this extract, while there was no detection of this FA in the other two non-polar
fractions obtained from Haliclona sp. The other two acids which are present in high content are
9-octadecenoic acid (6.5%) and 9-hexadecenoic acid (5.9%), but in substantially smaller
amounts when compared to the C20:4 (n-6) acid. A similar trend of FA constituents was
observed in a Haliclona sp. from India, where the main FAs were C16, C16:1, C18 and C18:1
types.318 Of the 14 fatty acids identified, 10 were saturated (C10:0, C14:0, 12-methyl C14:0,
C15:0, C16:0, C17:0, C18:0, C19:0, C20:0, C24:0), two monoenoic [C16:1, (n-9), C18:1 (n-9)],
one dienoic C20:2 (n-6) and one tetraenoic acids C20:4 (n-6), of which two are substituted
acids.
Table 3.2: Fatty acid composition of non-polar extracts from Haliclona sp., Geodia sp. and Ircinia/Sarcotragus sp.
N
1
2
3
4
5
6
7
8
9
10
11

Fatty acids
Type
2-Methylbutanoic acid
5:0
3-Methylbutanoic acid
5:0
Pentanoic acid
5:0
Hexanoic acid
6:0
Decanoic acid
10:0
10-Methylundecanoic acid
12:0
Dodecanoic acid
12:0
Tridecanoic acid
13:0
Tetradecanoic acid
14:0
12-Methyltetradecanoic acid
15:0
5,9,13-Trimethyltetradecanoic
17:0
acid
12
Pentadecanoic acid
15:0
13
Hexadecanoic acid
16:0
14
7-Methylhexadecanoic acid
17:0
15
9-Hexadecenoic acid
16:1 n-9
16
Heptadecanoic acid
17:0
17
10-Methylheptadecanoic acid
17:0
18
Octadecanoic acid
18:0
19
17-Methyloctadecanoic acid
19:0
20
9-Octadecenoic acid
18:1 n-9
21
11-Octadecenoic acid
18:1 n-7
22
9,12,15-Octadecatrienoic acid
18:3 n-3
23
Nonadecanoic acid
19:0
24
Eicosanoic acid
20:0
25
11,14-Eicosadienoic acid
20:2 n-6
26
5,8,11,14-Eicosatetranoic acid
20:4 n-6
27
Docosanoic acid
22:0
28
Tetracosanoic acid
24:0
29
Hexacosanoic acid
26:0
% of total extract
A: Methanol-derived hexane extract (hexane 1); B:
extract.

A
4.8
1.6
3.8
-

Haliclona sp.
B
C
2.4
13.5
5.3
0.3
2.2
5.3
6.4
5.7
-

1.5
0.5
1.3
2.2
7.7
3.4
1.3
5.9
0.8
2.6
3.3
3.9
6.6
0.2
6.5
0.4
2.3
1.2
1.8
3.0
2.2
2.0
7.1
3.5
21.2
1.7
0.2
3.7
1.8
1.2
62.0
23.2
67.1
dichloromethane-derived

A
0.7
0.4
0.5
0.6
-

Geodia sp.
B
1.5
3.7
2.0
2.5
-

0.6
0.3
0.4
0.4
3.9
hexane

C
1.2
2.0
1.4
-

Ircinia/Sarcotragus sp.
A
B
C
3.7
2.5
0.2
5.9
2.6
6.4
5.7
8.3
5.8
6.2
4.4
-

1.6
6.4
3.7
0.3
4.4
2.7
9.7
1.8
0.4
7.3
8.5
5.0
9.8
3.4
5.2
7.8
1.9
9.5
8.0
8.2
0.5
6.8
3.7
8.2
3.2
9.6
3.2
0.8
2.6
3.2
2.5
4.7
2.9
4.0
13.2
23.8
65.8
41.7
83.0
extract (hexane 2); C: dichloromethane
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Three sterols (Entry 3, 4 and 21, Table 3.3, 151-153) were identified in this extract, the
short side chain-sterol, pregna-5-en-3β-ol (151) is the major compound accounting for 12.7% of
the total chemical composition (Fig. 3.13). Two sterol compounds 152 and 153 are present at
lower levels. The two short side chain sterols have a Δ5 structure while the third sterol (Entry
21) has a C30Δ7 structure and has an alkylated side chain at position C24, which regularly occurs
in sponges. The main pregnane sterol was not observed in the other two non-polar extracts from
this sponge, which could contribute to the differences in the biological activities among the
extracts. Three short side chain sterol compounds have been found previously in Haliclona sp,
of which two (Entry 2 and 4) were the same as the pregnane sterols in the hexane 1 extract.364
Also, four sterols with a pregnane structure were found in H. rubens from Jamaica.365 They
were identified as 20-keto and 20-hydroxy sterols with the usual 5-en-3β-ol structure and the
authors suggested that the biosynthesis of short side-chain sterols might be achieved through
oxidative cleavage of marine sterol with longer side chains.365 Moreover, sterols with both type
of the short side chain sterol, with androstane and pregnane structures, were found in H.
flavescens from the Black Sea, and in other marine organisms such as algae and gorgonians.364
Firstly, it was assumed that short side chain sterols could be formed as artefacts through marine
sample work-up and the second assumption was that they are products of a biological
degradation process or biosynthesis from terpene precursors.366,367 Presently it is believed that
precursors of short side-chain sterols are oxidized side-chain sterols that occur through an in
vivo autoxidation process.364,366 The role of short side chain sterols in marine invertebrate is still
unknown, however these sterols are important in the reproduction system of vertebrates.368
Table 3.3: Sterol composition of non-polar extracts from Haliclona sp, Geodia sp. and Ircinia/Sarcotragus sp.
Haliclona sp.

N
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Sterols

Type
Δ5
Δ5
Δ5
Δ5,17
Δ5
Δ5,22
Δ5,22
Δ5
Δ7,22
Δ5,7
Δ5,22
Δ7
Δ0
Δ5,24
Δ5
Δ7
Δ7,24
Δ5
Δ5,24
Δ7
Δ5,24
Δ5,24
Δ5

B

Geodia sp.

C

A

B

Ircinia/Sarcotragus sp.

A
B
C
0.8
23.9
1.2
12.7
2.6
0.4
0.2
5.9
3.5
6.8
24-Norcholesta-5,22-dien-3β-ol
1.0
13.4
2.1
2.7
Cholesta-5,22-dien-3β-ol
10.2
Cholesta-5-en-3β-ol
tr.
1.5
7.3
6.5
tr.
Cholesta-7,22-dien-3β-ol
6.8
9.9
Cholesta-5,7-dien-3β-ol
0.5
0.8
24-Methylcholesta-5,22-dien-3β-ol
1.3
Cholesta-7-en-3β-ol
11.2
4α,5α-Cholestane-4,5-epoxy
14.8
24-Methylcholesta-5,24(28)- 3β-ol
9.5
7.0
0.2
24-Methylcholesta-5-en-3β-ol
4.0
1.1
3.9
24-Methylcholesta-7-en-3β-ol
2.7
5.2
5.8
-24-Methylcholesta-7,24(28)-3β-ol
3.5
24-Ethylcholesta-5-en-3β-ol
9.0
3.0
1.5
3.6
24-Ethylcholesta-5,24(28)-dien-3β-ol
1.1
1.8
20.2
4.3
1.1
24-Ethylcholesta-7-en-3β-ol
0.8
1.2
24-Propylcholesta-5,24(28)-dien-3β-ol
0.2
7.8
1.7
2.1
0.9
24-Isopropylcholesta-5,24-dien-3β-ol
4.0
22,23-Cyclopropylcholesta-5-en-3β-ol
0.3
% of total extract
13.9
28.1
13.4
72.1
50.4
46.5
16.3
6.8
8.0
A: Methanol-derived hexane extract (hexane 1); B: dichloromethane-derived hexane extract (hexane 2); C: dichloromethane extract;
tr. (trace amounts) < 0.1%.
Androst-5-en-3β-ol
21-Norpregna-5-en-3β-ol
Pregna-5-en-3β-ol
Pregna-5,17(20)-dien-3β-ol
Pregna-5-en-20-on-3β -ol

A

C
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Figure 3.13: Three sterols identified in the hexane 1 extract of the Haliclona sp.

In the Haliclona hexane 1 extract a range of aldehydes, hydrocarbons and alcohols were
also identified (Table 3.4). Hydrocarbons occur in sponges regularly and often play an
important role in the defence mechanisms.289 However there have also been sponges found that
do not to contain these compounds, indicating that they are not the only compounds responsible
for the defence mechanisms of sponges.289 Aldehydes and alcohols characteristically appear in
plants and algae where they serve as alleochemicals, protecting plants from other organisms. 369
While they have also been found to occur among marine organisms as a protection agent, the
complete role of volatile compounds and their composition in the sponges is still not completely
understood.369
Table 3.4: Chemical composition of non-polar extracts from Haliclona sp., Geodia sp. and Ircinia/Sarcotragus sp.
N
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Haliclona sp.
B
C
3.7
6.8
A

Hydrocarbons
4-Methyltridecane
1-Tetradecene
14-Noncosane
3-Tridecene
Alcohols
1,3-Propanediol, 2-dodecyl
2-Propylheptanol
1-Nonadecanol
1-Eicosanol
10-Pentadecenol
1,3-Propanediol, 2-dodecyl
Heptadecanol
2-Cyclohexyl-3-isopropyl-pent-4-en-2-ol
Aldehydes
2-Methyl-2-pentenal
2-Octanal
2-Nonenal
Octanal
Undecanal
2-Tridecanal
Ketones
6,10-Dimethyl-5,9-undecadien-2-one
Others
4-Bromo-2-methylpent-2-enoic acid
% of total extract

A
0.2

Geodia sp.
B
-

C
-

Ircinia/Sarcotragus sp.
A
B
C
6.3
-

11.6
3.9
-

21.3
2.1
2.1
-

-

0.7
1.7
-

3.8
1.7
2.4
4.4
-

4.4
0.4
-

-

4.6
5.0
2.4
2.4
-

-

0.1
0.5
-

-

2.2
3.1

2.5
3.5
-

-

22.5
-

-

-

2.7

-

0.6

1.6

-

-

-

-

22.3

6.3
38.2

0.6

3.2

19.2

2.7
13.5

6.3

36.9

0

A: Methanol-derived hexane extract (hexane 1); B: dichloromethane-derived hexane extract (hexane 2); C:
dichloromethane extract.

The hexane 2 extract of the deep-water sponge Haliclona sp.: Nine fatty acids, seven
sterols and six other non-polar compounds were identified in the hexane 2 extract of the
Haliclona sponge by GC-MS analysis (Tables 3.2 and 3.3 and 3.4). In this extract, in contrast to
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the results from the hexane 1 extract (preceding section), the sterols comprised a higher
percentage of the total chemical composition, 28.1%, compared to 23.2% for the FAs. The two
main FAs detected were hexadecanoic acid (7.7%) and 12-methyltetradecanoic acid (6.4%),
while other FAs were present in low percentages. The nine FAs identified include seven
saturated (C10:0, C15:0, C16:0, C19:0, C20:0, C24:0) and two monoenoic acids [C16:1 (n-9),
C18:1 (n-9)], of which one is a substituted acid (12-methyl C14:0). Interestingly, in some
samples of H. cinerea more than 50 FAs were found, as well as being rich in PUFAs with C22C34 carbon atoms.361
From the 13 sterols identified in the three non-polar extracts of the Haliclona sp. by
GC-MS, seven were found to be present in the hexane 2 extract (Table 3.3). The main sterols
were 24-methylcholesta-5,24(28)-3β-ol (9.5%) and 24-ethylcholesta-5-en-3β-ol (9.0%) (Fig.
3.14). Interestingly, cholesterol was only found in the hexane 2 extract of the three non-polar
extracts of Haliclona sp. (Table 3.2) and only in a very low percentage in the 50% methanol
extract. Previously, in shallow-water Haliclona sp., from Western Australia, Chile and India,
cholesterol was reported to be the main sterol.292,318,370 Although, in Haliclona sp. from
Antarctica cholesterol was observed in only minute amounts.371 The lack of cholesterol in the
analysed sample could indicate the importance of the environmental factors of the sponge
collection, as this Haliclona sp. was from 135 m depth in cold water, where the temperature and
environmental conditions may be comparable to those of sponges collected from Antarctica.

Figure 3.14: The main sterols identified in the hexane 2 extract obtained from the deep-sea sponge Haliclona sp.

In this extract, sterols with Δ5, Δ7 and Δ5,7 structures were identified with the Δ5 structure
dominant and no stanols were found. The ratio of Δ5: Δ7: Δ5,7 compounds in this sponge is 4:1:2
while the ratio of C27:C28:C29 sterols is found to be 3:1:3. Typically the family Haliclonidae, are
rich in the dietary Δ5 sterols but some sponges belonging to this family have only 5% of this
sterol and possess stanols and Δ7 sterols.364 In Haliclona sp. from the Black Sea, Δ5 sterols
accounted for only 2% of the sterol mixture and the main sterols contained either a Δ7 or stanol
structure, which indicates that transformation through stanols could also occur in sponges.
Interestingly, Elenkov et al. recently found a mixture of 4-methyl stanols and Δ7 sterols in H.
cinerea and H. flavescens.372 These unusual sterols are not regularly found among marine
sponges and are believed to be synthesised in vivo.368 The hexane 2 extract was also rich in
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aldehydes, with the 2-methyl-2-pentanal present in very high yields compared with the other
compounds identified in this extract (Table 3.4).

The dichloromethane extract of the deep-water sponge Haliclona sp.: By GC-MS
analysis, this extract had a very high percentage of FAs (67.1%) with 18 fatty acids identified in
total. Of these, 10 were saturated acids (C5:0, C6:0, C10:0, C14:0, 12-methyl C14:0, C15:0,
C16:0, C17:0, C18:0,17-methyl C18:0, C20:0, C22:0, C24:0, C26:0), two monoenoic [C16:1 (n9), C18:1 (n-9)] and one trienoic acid C18:3 (n-9), of which two were substituted acids (Table
3.2). The main FA was eicosanoic acid (7.1%) followed by octadecanoic acid (6.6%) and 12methyltetradecanoic acid (5.7%). Short chain FAs, such as butanoic, pentanoic and hexanoic
acids, were also identified in this extract. In the dichloromethane extract three saturated long
chain acids were identified (C22, C24 and C26), while in the two other non-polar extracts
(hexane 1 and hexane 2) only one was found. Characteristic for shallow-water sponges is that
they contain long chain fatty acids which can make up to 85% of the fatty acid composition. 369
However, in the dichloromethane extract of Geodia sp. analysed in this work the FA profile was
dominated by saturated C14-C20 fatty acids, while only two long chain FA were detected (C24:0
and C26:0).
Five sterols were found in the dichloromethane extract, comprising 13.4% of the total
extract determined by GC-MS (Table 3.3). Four of five sterols were identified in this extract
only, while their presence was not detected among the other two non-polar extracts obtained
from the Haliclona sample. The main sterol was 24-methylcholesta-5-en-3β-ol (Table 3.3, entry
15), although all sterol compounds were present in a similar ratio. In this extract none of the Δ 5,7
sterol was found, only Δ5 and Δ7 sterols in a ratio of 4:1.
Of the other compounds identified in the three non polar extracts only two aldehydes
were detected in the dichloromethane extract and both were present in low amounts (Table 3.4).

The 10% methanol extract of the deep-water sponge Haliclona sp.: The 10%
methanol extract (0.47 g), generated from the crude dichloromethane extract, was further
separated by silica gel column chromatography using a mixture of hexane, EtOAc and MeOH,
into the major six fractions as judged by TLC (Fig. 3.15). Although, TLC indicated that none of
these fractions were pure. The six fractions obtained from column chromatography were
analysed by EI-MS, the identified compounds are presented in Table 3.5. Even though, the
particular separation method was chosen to separate lipid and other non-polar compounds, some
non-polar compounds remained in this extract. The pooled column fractions isolated from the
10% methanol extract were tested for their PKA inhibitory activity and the results are presented
in Fig. 3.15. Only two fractions displayed PKA inhibitory activity of 17 and 21% respectively,
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while the other four fractions exhibited activity lower than 10%. Attempts were made to further
purify these fractions, but as they were mixtures of compounds of similar structure and obtained
in low yields, it was difficult to achieve full and complete separation of the compounds (chapter
2). The chemical composition of the six column fractions, analysed by EI-MS, is presented in
Table 9.1 in the Appendix section.

Figure 3.15: Extraction protocol of 10% methanol extract of the deep-water sponge Haliclona sp. and biological
activity of the column fractions obtained.

The 50% methanol extract of the deep-water sponge Haliclona sp.: The 50%
methanol extract (0.187 g), obtained from the crude methanol extract, was further purified by
silica gel column chromatography using a gradient solvent system with hexane, ethyl acetate
and methanol, which gave six major fractions as judged by TLC. The pooled column fractions
isolated from the 50% methanol extract were tested for their PKA inhibitory activity and the
results are presented in Fig. 3.16. None of the six column fractions was more potent in the PKA
inhibitory assay than the original 50% methanol extract. In this extract the main constituents
were lipid compounds. The chemical composition of the six column fractions was analysed by
EI-MS and the results obtained are presented in Table 9.2 (Appendix section).

Figure 3.16: Extraction protocol of 50% methanol extract of the deep-water sponge Haliclona sp. and biological
activity of the column fractions obtained.
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The butanol extracts of the deep-water sponge Haliclona sp.: The butanol extract was
obtained in low yield and also did not exhibit any significant bioactivity in the three assays,
hence this extract was not further studied.
3.6.3 Geodia sp.
The hexane 1 extract of the deep-water sponge Geodia sp.: Eight FAs were identified
in the hexane 1 extract by GC-MS analysis and their percentage was low at yields of less than
1% each, while the sterol compounds were present in higher quantities (Table 3.2 and 3.3). Of
the eight FAs in the hexane 1 fraction, seven were saturated (C10:0, C13:0, C14:0, 12-methyl
C14:0, C15:0, C16:0, C17:0) and one was a monoenoic acid C18:1 (n-9).
Interestingly, the dominant sterol in the hexane 1 extract was an unusual short
side-chain sterol

19-norpregna-5-en-3β-ol

present

in 23.9%

and

an

epoxy sterol

4α,5α-cholestane-4,5-epoxy (14.8%). Previously, Geodia sp. was reported to produce unusual
sterols such as 26-methylergosta-5,24(28)-dien-7-one-3α-ol along with the same sterols as
identified in this species.333 Four short side chain sterols were identified in this extract (Table
3.4). Only one short side chain sterol was found in the hexane 2 extract and none were identified
in the dichloromethane extract. The hexane 1 extract displayed potent activity in the PKA
inhibition assay (97%) and the brine shrimp lethality assay (87%) which could be due to either
the high level of sterols or the difference of the sterol composition compared with the other
fractions obtained from this sponge. There are previously reported examples of bioactive short
side-chain sterols from marine species, including the gorgonian Muricea cf. austera, which has
yielded known sterols with a pregnane structure that displayed potent antibacterial activity and
two novel pregnane glycosides with moderate cytotoxicity toward HCT-116 human colon
carcinoma.288

The hexane 2 extract of the deep-water sponge Geodia sp.: Six FAs were detected in
the hexane 2 extract with the main FA identified as dodecanoic acid (3.7%, Table 3.2). Of the
six FAs, five were saturated (C6:0, C12:0, C14:012-methyl C14:0, C15:0) and one was a
monoenoic acid C18:1(n-7). The hexane 2 extract was the richest in compound yields compared
to other non-polar extracts obtained from the same sponge.
Seven sterols were identified in the hexane 2 extract (Table 3.3). Fucosterol was
determined as the dominant sterol (20.2%), and in higher yield compared to the other two nonpolar extracts. 24-Methylcholesta-5,24(28)-dien-3β-ol was also identified in this fraction (7.0%)
(Table 3.3), although not detected in the other two non-polar fractions of Geodia sp. extracts.
These results are consistent with literature reports where this sterol was found to be the main
sterol in the sponge G. robusta from the Sea of Okhotsk and also identified as the main sterol
along with fucosterol in Geodia sp. from the Faroe Islands.373,374 The ratio of the Δ5:Δ7 sterols in
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this extract was found to be 5:2. In the hexane 2 extract and in the other two non-polar extracts
of the analysed Geoda sp. the predominant sterols also possessed a Δ5 structure.

The dichloromethane extract of the deep-water sponge Geodia sp.: In total, 10 FAs
were identified with 9-octadecenoic acid (5.2%) and octadecanoic acid (5.0%) as the dominant
acids. In G. cydonium the predominant FA was hexadecanoic acid with 31.8% followed by
octadecanoic acid with 12.3%.289 Of the 10 FAs identified in the dichloromethane extract, seven
were saturated (C6:0, C14:0, C15:0, C17:0, C18:0, C20:0, C22:0), two were monoenoic [C16:1
(n-9), C18;1 (n-9)] and one dienoic acid C20:2 (n-6).
Seven sterols were identified in the dichloromethane fraction (Table 3.3), with
24-norcholesta-5,22-dien-3β-ol (13.4%) and cholesta-7-en-3β-ol (11.2%) as the principal
sterols. The ratio of the Δ5:Δ7 sterols in this fraction was 5:3, and the ratio of C26:C27:C28:C29 was
found to be 1:2:2:2:1. The same norcholesta compound was previously identified in the G.
robusta sponge collected from Sea of Okhotsk.369 Along with the FAs and sterols, two
aldehydes and two alcohols were also identified in the dichloromethane fraction (Table 3.4).

The 10% methanol extract of the deep-water sponge Geodia sp.: The 10% methanol
extract was analysed by EI-MS and two compounds were identified by comparing the mass
spectra with data in the NIST 08 library, and tentatively characterised as a sterol cyclic ether
compounds.

The 50% methanol extract of the deep-water sponge Geodia sp.: The 50% methanol
extract was prepared from the crude methanol extract of Geodia sp. as shown in Fig. 3.11. The
50% methanol did not exhibit significant biological activity in all three assays. Due to this low
biological activity and the small amount of sample, this extract was analysed only by EI-MS.
Three sterol compounds were tentatively identified as cholesta-5-en-3β-ol, 24-methylcholesta-7en-3β-ol and 24-methylcholesta-5,24-dien-3β-ol.

The butanol extract of the deep-water sponge Geodia sp.: Although this fraction did
not display significant biological activities, it was further analysed in order to determine the
type of metabolites that occur in the more polar extract. Thus, this extract was further purified
by preparative HPLC using an isocratic mobile phase with H2O as the eluent. Five fractions
were isolated and analysed by EI-MS. The identified compounds (156-160) are presented in Fig.
3.17. Four known nucleoside compounds and one known alkaloid were identified. The structure
of thymidine was also confirmed by NMR and HRMS. NMR data of other four fractions
showed that they were not completely pure. These butanol fractions were screened for PKA
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inhibitory activity but they displayed low activity (< 11%). Nucleosides, such as thymidine,
adenosine, were previously isolated from marine organisms, including marine sponges and the
sponge Haliclona sp.374 Nucleosides isolated from marine organisms have been found to display
antiviral and anticancer activities.374

Figure 3.17: Compounds identified in the butanol fraction of the Geodia sp.

3.6.4 Ircinia/Sarcotragus sp.
The hexane 1 extract of the deep-water sponge Ircinia/Sarcotragus sp.: By GC-MS
analysis, 10 FAs comprising 65.8% in this extract were identified (Table 3.2). The dominant
acids were 7-methylhexadecanoic acid (9.7%) and eicosanoic acid (9.6%). Interestingly, of the
10 FAs identified, only one was an unsaturated tetraenoic acid C20:4 (n-6), while the other nine
were saturated acids (Table 3.2). The hexane 1 extract lacked long chain fatty acids with only
two C20 fatty acids identified, one saturated and the other an unsaturated FA. It has been
reported that Ircinia species are particularly rich in C24-C25 FAs, however none were found in
this extract.376,377
The hexane 1 extract possessed more sterols and in higher quantities compared with the
other two non-polar extracts obtained from the Ircinia/Sarcotragus sample (Table 3.3). Six
sterols were identified, comprising 16.3% of the total extract. Five of the six sterols had a Δ5
structure and there was one short side-chain sterol compound. The main sterol was cholesta5,24-dien-3β-ol. Previously, unusual sterols were isolated from I. aruensis from China,
containing a 5,6-epoxy group and displaying significant cytotoxic activity.195

The hexane 2 extract of the deep-water sponge Ircinia/Sarcotragus sp.: Twelve fatty
acids were identified in this extract by GC-MS analysis which comprised 41.7% of the total
extract (Table 3.2). Characteristic of the hexane 2 extract was the high content of aldehydes and
alcohols which were detected in this extract as well (Table 3.4). Similar to the other two nonpolar extracts obtained from this sponge, the 12 identified acids were dominated by saturated
acids, with nine saturated FAs, two monoenoic and one tetraenoic acid. The main FA detected
was 11-octadecenoic acid (9.5%). This extract contained long chain fatty acids that were in
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similar ratios as found in the dichloromethane extract of Ircinia/Sarcotragus sp. Hence, as the
hexane 2 extract had low PKA inhibitory activity, this could indicate that long chain FAs are not
responsible for the potent PKA inhibitory activity of the dichloromethane extract. The activity
could be a result of contribution of the main FA or other FAs detected in the dichloromethane
extract.
The hexane 2 extract contained four sterol compounds (Table 3.3) with the dominant
sterol being 24-isopropylcholesta-5,24-dien-3β-ol. The ratio of Δ5:Δ5,7 sterols in this extract is
3:1 while the ratio of C27:C29:C30 is found to be 1:1:2. Cholesta-5,7-dien-3β-ol was only detected
in this extract of the Ircinia/Sarcotragus sponge and represents the sole sterol with a Δ5,7
structure. Previously it was observed that some deep-sea sponge samples contain none or a very
small number of sterols.371 For example, it was reported that members of the order
Dictyoceratida generally possess low sterol content such as in the sponge S. spinulosus where
no sterols were found at all.371,378,379 On the contrary, sterol composition in shallow water
species is usually found to be very complex, which is likely to be due to the different ability of
sponges to obtain sterols. However, some shallow water sponges do have only a simple sterol
composition such as the sponge Chondrosia reniformis.286,362,364,380 It was found herein that the
Ircinia/Sarcotragus sample contains a low diversity of sterols in low amounts.
In the Ircinia/Sarcotragus hexane 2 extract a number of aldehydes, ketones and
alcohols were also identified (Table 3.6). Volatile low-molecular weight molecules have been
found to be responsible for Ircinia’s characteristic unpleasant garlic odour and may also be used
for chemical defence.381

The dichloromethane extract of the deep-water sponge Ircinia/Sarcotragus sp.: By
GC-MS analysis, 14 FAs were identified in the dichloromethane extract obtained from
Ircinia/Sarcotragus sp. and they comprised 83.0% of this extract. The 14 FAs identified
included 10 saturated, two monoenoic and one trienoic acid, of which three were substituted
acids. The dominant acid was octadecanoic acid (9.8%) but also seven other FAs were present
in high levels. Fatty acids with long chains were identified in this extract (C 22-C26, Table 3.2),
which are common for sponge samples.369 Long chain acids with 26 carbon atoms are dominant
fatty acids in the class Demospongiae whereas in contrast here, only one PUFA was identified
in the dichloromethane extracts as a minor compound. However, in some sponge samples C26
acids were either not identified or found in low percentage and fatty acids with C25 and C27 were
the major compounds.382
In addition, Δ5 sterols were identified by GC-MS analysis of the dichloromethane
extract and they comprised 8.0% of the total extract (Table 3.3). The dichloromethane extract
contained Δ5 sterols exclusively with 24-methylcholesta-5-en-3β-ol sterol as the dominant sterol
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(3.9%). Sterols were less dominant in this extract in comparison with the percentage of the FAs
identified in the same extract. In this extract short side chain sterol, 21-norpregna-5-en-3β-ol,
was identified by GC-MS. It was the only sterol with a pregnane structure identified in the
Ircinia/Sarcotragus sample. Androst-5-en-3β-ol was found in the hexane 1 extract and was the
only other the short side chain sterol identified in Ircinia/Sarcotragus sp. Interestingly,
cholesterol was only present in the dichloromethane extract and this was similar to the results
obtained from Haliclona sponge where cholesterol was only found in the hexane 2 extract.
Whilst it wasn’t detected in the other two non-polar extracts, it was identified in the more polar
extract of the same sponge.
Compared with the other two sponges, Haliclona sp. and Geodia sp., the least number
of sterols were found in this sponge. Ircinia sp. and Sarcotragus sp. belong to the order
Dictyoceratida, which has been shown before to have low sterol content. In particular, these
sponges are usually rich in terpenoid compounds which could indicate an alternative pathway of
isoprenoid metabolism or the oxidation and other modification of sterols.320,371

The 10% methanol extract of the deep-water sponge Ircinia/Sarcotragus sp.: The
10% methanol extract was generated from the crude dichloromethane extract of
Ircinia/Sarcotragus sponge in low yield and it was further purified by column chromatography
using a solvent mixture of hexane and EtOAc, to give six fractions. Column fractions were
analysed by TLC, indicating that each fraction possessed more than one compound, which was
also confirmed by EI-MS analysis. The pooled column fractions isolated from the 10%
methanol extract were tested for their PKA inhibitory activity and the results are presented in
Fig. 3.18. The actual yields of constituents were not recorded. The chemical composition of the
six column fractions was analysed by EI-MS and the results showed that the main constituents
were FAs and sterols (Table 9.3, Appendix section).

Figure 3.18: Extraction protocol of 10% methanol extract of the deep-water sponge Ircinia/Sarcotragus sp. and
biological activity of the column fractions obtained.
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The 50% methanol extract of the deep-water sponge Ircinia/Sarcotragus sp.: The
50% methanol extract, which displayed low activities in all three assays (Fig. 3.11) was
analysed by EI-MS and only 1,3,4,6-O-tetraacetyl-d-glucosamine was identified.

The butanol extract of the deep-water sponge Ircinia/Sarcotragus sp.: The butanol
extract was further purified by preparative HPLC using an isocratic mobile phase with H2O as
the mobile phase. Four fractions were isolated. The HPLC butanol fractions were analysed by
EI-MS. The structure of thymine identified in the column fraction 6 was confirmed by proton
NMR spectroscopy. Low yields of purified compounds did not enable further analysis. The
chemical constituents of the column fractions 1 and 2 were unidentified, while identified
compounds in column fractions 3-6 were 5-methyl-5-docosane, 2-(hydroxyimino)indan-1-one,
thymine and phenethylamine, respectively .

3.6.5 Investigation into the water extracts of the three deep-water sponges

The water extracts obtained from all the three deep-sea sponges were found to display
low biological activities (Fig. 3.11). Chemical composition in water extracts was analysed by
high resolution ESI-QTof-MS; the tentatively identified compounds are presented in Table 9.4
(Appendix). Compounds were identified by comparing HRMS data with those from the
Dictionary of Natural Compounds. Compounds identified were of different structures with most
of them being halogenated as is typical for marine natural products and containing heteroatoms,
mainly nitrogen.

91 |

Chapter 3

Deep-sea sponges

In summary, four deep-sea sponges from the NW Shelf in Australia were found to be a
rich source of PKA inhibitory and haemolytically active substances. Using a modified Kupchan
partitioning method, the following results were obtained: the hexane 1 extracts from the Ircinia
sp./Sarcotragus sp. and Geodia sp. displayed potent PKA inhibitory activity of 100% and 97%
respectively, with the Geodia sample also showing potent brine shrimp lethality. The 50%
methanol extract from the Haliclona sp. exhibited potent haemolytic activities of 75%. In
general, the non-polar fractions isolated from all three deep sea sponges were found to have
more biological activity compared with the activity of the more polar fractions. As this is the
first example of a Haliclona sp. of sponge obtained from the deep-sea sponge, the results
described herein are also the first report on bioactivity of deep-sea Haliclona sp. Similarly,
herein we have the first example on the deep-sea Sarcotragus and Ircinia species from Australia
and the first description of kinase inhibitory activity from any of the sponges under
investigation.
The main constituents of the non-polar fractions were identified as fatty acids and
sterols with a total of 23 known sterols and 29 known fatty acids. Similar sterol and fatty acids
were found among three sponges which could be a result of these being collected on the same
date from the same or a similar collection place. These results indicate that the small differences
that occurs among chemical composition of three sponge samples analysed is the result of the
different biodiversity of the sponges as they were collected under same environmental
conditions. The percentage of the main chemical classes in all non-polar fractions is shown in
Table 3.5. These data show that Ircinia/Sarcotragus sp. was rich in FA, followed by Haliclona
sp. and then Geodia sp., while sterols were the most abundant in Geodia sp.

Table 3.5: Summary of chemical constituents of the non-polar extracts in three deep-water sponges.

Compound Type

A
% area

Fatty acid (Table 3.2)
Sterols (Table 3.3)
Other (Table 3.4)
Unidentified

62.0
13.9
22.3
1.8

Haliclona sp.
B
C
% area
% area

23.2
28.1
38.2
10.5

67.1
13.4
0.6
18.9

A
% area

3.9
72.1
3.2
19.9

Geodia sp.
B
% area

13.2
50.4
19.2
17.2

C
% area

Ircinia/Sarcotragus sp.
A
B
C
% area
% area
% area

23.8
46.5
13.5
16.2

65.8
16.3
6.3
11.6

41.7
6.8
36.9
14.6

83.0
8.0
0
9.0

A: Methanol-derived hexane extract (hexane 1); B: dichloromethane-derived hexane extract (hexane 2); C: dichloromethane extract.
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Isatin and 2-oxindole derivatives are widely found among marine organisms as
bioactive agents. Herein, the synthesis of a series of isatin analogues based on a
natural compound isolated from a marine mollusc is described, along with
screening for their PKA inhibitory activity.

4.1 Previous research on isatin analogues
The bioactivity of egg masses of the Australian mollusc Dicathais orbita have been
extensively studied by Benkendorf et al. at the University of Wollongong, based on the concept
that they were likely to provide chemical defensive substances to promote survival.383 Indeed,
the egg masses were found to contain a range of cytotoxic and antibacterial compounds.384
Among these, tyrindoleninone (6-bromo-2-methylthio-3H-indol-3-one, 72) (Fig. 1.33, Chapter
1) exhibited specific cytotoxicity towards cancer cell lines over human mononuclear cells of 4
µM and 195 µM respectively, giving a selectivity index of almost 50.183 Attempts to prepare this
compound in the lab were unsuccessful due to the reactivity of the indoleninone nucleus. 183 6Bromoisatin was also found as a decomposition product formed through the oxidation of
tyriverdin and shown to exhibit modest cytotoxicity against a human lymphoma cell line (Fig.
1.32, Chapter 1). Based on the above, the development of a novel series of cytotoxic compounds
was undertaken starting with the readily synthetically accessible 6-bromoisatin (74).
Further developments of 6-bromoisatin (74) derivatives as potent cytotoxins included
modification of isatin (75) with a range of various substituents on the aromatic ring and
nitrogen. These results showed that the presence of an electron-withdrawing group(s) on the
aromatic ring of isatin were essential for low micromolar cytotoxicity. 186 In particular
5,7-dibromoisatin (76) was more cytotoxic than the starting compound and the activity
increased with N-alkylation of isatin, to give derivatives with submicromolar activity (Fig. 4.1).
A one-carbon linker attaching an alkyl group to the aromatic nitrogen on isatin was found to be
significant in the tubulin binding mechanism.185 Substitution at the C3 position was found to
further increase cytotoxic activity and also to impart potent kinase inhibitory activity (Fig.
4.1).189,182

Figure 4.1: Isatin derivatives displaying significant cytotoxicity. *against U937 cells.

93 |

Chapter 4

Synthesis of isatin derivatives

4.2 Initial specific targets
Previous research of isatin and indole compounds proved that these scaffolds are
important for kinase inhibitory activity, as previously discussed in Chapter 1 (Fig. 1.29). Figure
1.31 shows over 11 indole and isatin compounds that have been found to inhibit various kinases.
This was confirmed with the indole based kinase inhibitor sunitinib and semaxanib (Fig. 1.28,
Chapter 1). In particular, C3 substituted isatin derivatives have been found to display significant
kinase inhibitory properties including inhibition of firoblast growth factor receptor (VEGFR-2),
epidermal growth receptor factor, PDGFR-β and RTKs.159
These known kinase inhibitors have a very similar core to the potent cytotoxic
compounds previously analysed our group.189 Hence, it was of interest to further develop their
structures and test them for potential protein kinase inhibitory activity. The aim was to
determine the structural requirements of the different groups and their position on the isatin
scaffold necessary for PKA inhibitory activity. The imino-isatin (83) was synthesised by
Matesic as a part of a separate project involving conjugating isatins to tumour targeting proteins
and it was found to display potent PKA inhibitory activity (IC50 20.0 µM).182 The activity of 83
was comparable to the activity of the commercially available standards (staurosporine, ellagic
acid and H-89 (Chapter 1, Section 1.6.1) used in the kinase assay established within the group
(Fig. 4.2).182 Compounds 76 and 78 were also previously screened for kinase inhibitory activity.
N-alkylated isatin 78 was found to display lower activity than the imino-isatin 183 in the PKA
inhibition assay, while 5,7-dibrominated isatin 76 exhibited low inhibitory activity against
cyclin-dependent kinase 2 (CDK2). These results showed that the imino group on carbonyl C3
is important for kinase inhibition.

Figure 4.2: Isatin derivative found to be a potent
PKA inhibitor.182

Therefore, the first goal was to prepare a range of 5,7-dibromo-N-methoxybenzyl-3imine isatin analogues with different substituents on the distal phenyl ring and test their activity
(Fig. 4.3). Dibromination at position 5 and 7 and N-alkylation were found to be essential for the
cytotoxicity of these compounds. To compare whether those groups are also required for the
PKA inhibitory activity the next step was to change the groups on the aromatic isatin ring, as
well as at the aromatic N and C3 position.
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Although imines are not widely used in drug discovery due to their perceived
instability, aromatic imines with extended π–π conjugation are found to be stable at
physiological pH, while readily hydrolysing in mildly acidic solutions. 182 Aryl imines have been
used as pH-sensitive linkers in drug delivery as these compounds have been found to be stable
in contrast to alkyl imine derivatives which are known to hydrolyse at physiological pH.182,185

Figure 4.3: The aim of this project is the synthesis of a wide variety of isatin imine derivatives as potential PKA
inhibitors. PMB = para-methoxybenzyl

4.3 Preparation of isatin imine derivatives
The first N-alkylated imino-isatin derivatives were prepared as shown in Scheme 4.1.
The synthesis involved dibromination for the first step, then N-alkylation followed by
preparation of the final imine isatin derivative.

Scheme 4.1: Summary of the proposed synthetic strategies in the formation of 5,7-dibromo-1-(4-methoxybenzyl)isatin imine derivatives. PMB = para-methoxybenzyl

4.3.1. Bromination of isatin
In the preparation of the various isatin analogues, the first step involved electrophilic
aromatic substitution of isatin. This dibromination of isatin was largely performed following the
protocol reported by Lindwal et al.385
The 5,7-dibromination reaction was carried out in 95% ethanol using bromine, that was
added dropwise while maintaining the temperature at 70-75 ˚C (Scheme 4.2). Three equivalents
of bromine were used to obtain the desired 5,7-dibromoisatin compound. When lower amounts
of bromine were used, 5-bromoisatin was the major product obtained. During the reaction, at the
temperature of 75˚C, evaporation of the bromine was noticed, which resulted in the formation of
more 5-bromoisatin. The 5 position on the isatin ring is favourable for the electrophilic aromatic
substitution as a result of the electro-donating effect of the nitrogen, which has both ortho and
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para directing activity. Adding more bromine equivalents, bromination of the less active 7
position was achieved. 1H NMR spectral data, with two aromatic singlets for H4 and H6, and
LREI-MS with m/z value of 303/305/307 (9Br79Br; 79Br81Br; 81Br81Br) [M+] confirmed that the
desired product, 5,7-dibromoisatin, was generated in 85% yield. An alternative strategy to
prepare 5,7-dibromoisatin was developed by Semenov et al., which included addition of H2SO4
and acetic acid.386 Although 5,7-dibromoisatin was prepared in 95% yield, this method required
a longer reaction time of 16 h.386

Scheme 4.2: 5,7-Dibromination of isatin.

Previously, it was reported that the dibromination of isatin could be performed in
ethanol, acetic acid or methanol.387 However, when attempted the reaction in methanol was not
particularly successful and the product was mainly 5-bromoisatin. When the temperature of the
reaction and the equivalents of bromines were increased the desired 5,7-dibromoisatin was
generated. Unfortunately, the side product 5,7-dibromo-3,3-diethoxy-indoline was also
obtained. The same acetal compound was obtained when using 100% ethanol instead of 95%
ethanol. The acetal product occurs as a result of the formation of acidic hydrogen bromide,
which further catalyses the formation of the acetal groups on the highly reactive carbonyl C3
position. Due to the adjacent amide group and aromatic ring, the C3 position of isatin has strong
electrophilic affinity and is easily available for condensation and addition reactions. 388 Acetal
products are not stable and formation occurs as a reversible reaction. In the case where
bromination was performed in 95% ethanol, the presence of water molecules hydrolyses the
acetal and moves the reaction back to the starting ketone.389
4.3.2 N-alkylation of isatin
The next step in preparing 5,7-dibromo-N-alkylated imine isatin compounds was Nalkylation step, which was performed according to the protocol of Vine et al. (Fig. 4.4).186 There
are several different methods published in the literature that describe N-alkylation but, the
method established by Vine et al. in the lab has given constantly good yields previously.186 NAlkylation included formation of the dark violet isatin anion in situ with the presence of a base,
followed by nucleophilic attack of the formed anion on the appropriate alkyl halide by an SN2
mechanism. A range of bases such as NaH, CaH2, K2CO3, NaOH and Cs2CO3 can be employed
in preparation of the isatin anion and using various anhydrous solvents. Herein, the reaction was
performed using either CaH2 or NaH (as a stronger base) with DMF as a solvent, which allowed
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faster formation of the isatin anion compared with the weaker carbonate bases. The utilization
of CaH2 was preferable over NaH due to difficulties in working with sodium hydrides because
of their reactivity. Seven dibrominated-N-alkylated isatin compounds (162-168) were prepared
in this manner with yields ranging between 27 – 86% (Fig. 4.4). N-alkylated derivatives 162165 were known compounds while 166-168 are novel N-alkylated isatins.

Cpd. no

R

% Yield

Cpd. no

R

% Yield

162

86

165

78

163

67

166

39

164

69

167

27

168

78

Figure 4.4: Mechanism of formation and yields of the N-alkylated-5,7-dibromoisatins prepared.

Although the N-alkylation reaction gives good yields, there are some drawbacks to this
method. DMF was used as a solvent in the generation of the N-alkylated compounds; it has the
high boiling point so it is difficult to remove once the reaction is finished. The other
disadvantage of this method is the utilization of hazardous metal hydrides. Microwave
irradiation is one of the novel methods for the preparation of N-alkylated isatins.391 The
advantages include the reduction of reaction time, usage of very small amounts of solvents and
higher yields. The microwave method also has more benefits for the preparation using phenacyl
compounds. With weaker base used in microwave reactions, there are fewer chances of the
production of the halide anion and the occurrence of the competitive by-product and thus the
use of microwave irradiation is suggested here as a possible method for future work.391
Garden et al. observed that isatins with electron withdrawing groups on the 5 and 7
position react more easily with CaH2 in DMF and that the reaction can be performed at room
temperature.392 No dry conditions are required for the N-alkylation as the reaction works better
with wet DMF, which indicates that hydroxide ion from the DMF acts as a base.392
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In addition to the seven dibrominated-N-alkylated isatins, three known compounds with
an unsubstituted aromatic isatin ring and 5-nitro and 5-methoxy-N-alkylated isatins (169-171)
were also prepared following the same procedure for N-alkylation (Fig. 4.5).

Figure 4.5: N-alkylated isatin derivatives.

The Sandmeyer method for the synthesis of the substituted isatins, including
5-nitroisatins, is one of the oldest and the most important and utilised isatin procedures. 390 This
method involves reaction of an appropriate aniline with chloral hydrate and hydroxylamine in
water to yield the intermediate, which is than treated with conc. H2SO4 to give substituted isatin
(Scheme 4.3).390 Other methods used for the preparation of isatins are the Stolle, Martinet and
Gassman syntheses.390 However, nitration of isatin with KNO3 and H2SO4 was shown to be
successful previously in our lab; hence the same method was implemented here.184

Scheme 4.3: Sandmeyer procedure for the synthesis of isatins.390

The starting 5-methoxy isatin was commercially available while the requisite 5-nitro
isatin (172) was prepared following a literature procedure. Nitration of isatin (75) at position 5
was performed according to the protocol of Vine et al., which involved slow addition of a
solution of KNO3 in H2SO4 to the solution of isatin in conc. H2SO4 over 1 h (Scheme 4.4).183
Even though the temperature was monitored between 0-4ºC, the occurrence of the 5,7-dinitro
product (170 a) was still observed (12%). 1H NMR spectral analysis of the product indicated
that the desired compound was made, with doublet of a doublets at δ 8.79 (J = 3 Hz) for H6 and
doublets at δ 7.08 (J = 8.5 Hz) and 8.18 (J = 2.0 Hz) for H7 and H4 respectively.

Scheme 4.4: Synthesis of 5-nitroisatin derivatives.

98 |

Chapter 4

Synthesis of isatin derivatives

Using 4-(chloroacetyl)-morpholine for the preparation of the N-alkylated isatin
derivative (167) resulted in the lowest yield (27%). The possible explanation is the occurrence
of a Darzens product in addition to the desired product. Exactly the same conditions were used
for the preparation of all N-alkylated compounds; the only difference here was the starting alkyl
halide, which had an additional carbonyl group on the carbon atom next to the carbon with the
halide atom. The Darzen condition involves the reaction of the α carbon of a carbonyl
compound with a halogen that forms an α,β-epoxy ester in the presence of a base (Scheme 4.5).
The resonance stability of the anion that is formed on the carbon where the halogen atom is
attached makes the reaction occur without difficulties. Therefore the formation of the anion of
the alkyl compound is the competitive reaction for the formation of the N-isatin anion.
Nucleophilic attack on the carbonyl compound is the next step to give formation of an epoxide.

Scheme 4.3: Formation of the Darzen product of compound 167.

The identification of the ten synthesised N-alkylated analogues (162-171) were
validated by 1H and 13C NMR spectral data along with EI-MS data, which was in accordance
with the literature data for known compounds. The structure of the novel derivatives (166-168)
were additionally confirmed with HRESI-MS and 2D NMR data, using 1H NMR and gCOSY
spectra to identify protons on the N-substituted ring and HSQC and HMBC spectra to assign
carbon atoms in the 13C NMR. Compounds 162-171 were prepared in sufficient quantities, with
yields which were consistent with the literature data, for the next steps and also for kinase
inhibition screening and in vitro cytotoxicity testing.
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4.3.3 Preparation of isatin imine derivatives
The carbonyl group at position 3 of isatin is reactive towards nucleophiles which has
resulted in the generation of a series of biologically active 3-substituted isatins. Imine isatin
derivatives were previously found to inhibit various kinases. 3-Phenylhydrazones (e.g. 172) and
3-benzothiazoles (e.g. 173) have been shown to inhibit CDK (Fig. 4.6).393,394 Furthermore,
amino acid 3-substituted isatin derivatives (e.g. 174) were found to inhibit several kinases
including CDK1/cyclin B, CDK5/p25 and GSK3α/β.395

Figure 4.6: Known 3-imine-2-oxindole kinase inhibitors.

A diverse library of imine compounds were synthesized from N-alkylated isatins and an
appropriate amine compound in ethanol with acetic acid as catalyst following the method
reported by Bramson et al. (Scheme 4.6).394 Several methods describe formation of imines,
which include utilization of microwave, traditional reflux and reactions in water as a solvent.
Furthermore, a variety of solvents can be employed such as methanol, heptanes in the presence
of acetic acid or ethanol.396
Acidic catalysis is important for imine formation, otherwise the reaction proceeds very
slowly or will not run to completion. The pH of the reaction should be adjusted between 4 and 6
with acetic acid. Acid plays two roles in the formation of an imine; one is protonation of the
amine; and the second role, which is more important, is protonation of the hydroxyl group and
elimination of water at the end of the reaction.389 If the pH value is lower than 4 the reaction
proceeds slowly due to protonation of the amine. If it is higher than 6, the concentration of the
protons will be insufficient for the protonation of the OH as a leaving group in the dehydration
step.
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Scheme 4.4: Mechanism of imine formation in isatins.

With the aim of broadening the range of compounds in the isatin series with potential
biological activity, 29 imino-isatin derivatives were prepared. Table 4.1 summarizes the list of
imine compounds prepared from the starting dibrominated isatin (including the different
substitutions at the N-position of the starting isatin) and an appropriate amine. Most of the imine
derivatives, after purification with column chromatography, were obtained in good to high
yields, while lower yields were observed mainly for those analogues which were prepared from
deactivated anilines with an electron withdrawing group at the para position (e.g. NO2, COOH).
Table 4.1: Isatin imine derivatives 175- 203 prepared in the project.

Cpd. no
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189

R1
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3

R2
p-COOH
p-CH2COOH
m-CH2COOH
p-OH
p-Br
o-Br
m-Br
2,4-Br
p-Cl
p-I
p-F
p-CF3
p-OCH3
3-OCH3
2,4-CH3

% Yield
16
59
69
29
60
16
80
14
65
71
72
65
37
12
34

Cpd. no
190
191
192
193
194
195
196
197
198
199
200
201
202
203

R1
OCH3
OCH3
OCH3
CH3
CH3
CH3
Cl
Cl
Cl
I
I
I
I
I

R2
2,6-CH3
p-NO2
p-OPh
p-OCH3
m-Br
p-CF3
m-Br
p-OCH3
p-I
p-OCH3
m-CH2COOH
m-Br
p-Cl
p-F

% Yield
61
3
70
35
66
19
23
30
81
28
22
54
15
41
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Recently, Khan et al. published the preparation of imines in water instead of using an
organic solvent and acid catalyst (Scheme 4.7).397 Compared with our isatin derivatives, their
compounds were not dibrominated or N-alkylated. This method was attempted with our isatins
however they did not dissolve in water. Other authors, such as Jarrahpour et al. used water as a
solvent for imine preparation, but these methods are not applicable to our compounds.396

Scheme 4.5: Reported formation of imine-isatin analogues in water.397

Herein, the formation of imines was performed with molecular sieves and absolute
ethanol. Imines are unstable compounds with the tendency to decompose to the starting
material. Although, some imine compounds can be more stable, such as the compounds in this
work where the stability of the imine compounds increases if there is a group present which can
contribute to the delocalization and resonance stabilisation of the imine double bond.
In addition to 5,7-dibromo and N-alkylated isatin derivatives, analogues that are not
substituted at the phenyl ring and aromatic N were also prepared (Scheme 4.8). As previously
mentioned, although these substituents were required for cytotoxicity (Fig. 1.34, Chapter 1) it
was of interest to probe their role in the PKA inhibitory activity of these compounds.
Derivatives with an unsubstituted phenyl ring were synthesised from isatin after being Nalkylated and coupled with an appropriate aniline to yield the desired novel imine analogue
(204). Compounds with a free nitrogen (205, 206) were produced in good yield starting with
dibromination of isatin followed by direct preparation of the imine (Scheme. 4.8).

Scheme 4.6: Preparation of a) N-alkylated and b) 5,7-dibromo imine derivatives.

In addition to isatin imines with phenyl group on the nitrogen, three isatin imines with
morpholino groups were prepared using N-alkylated isatin 167 as a starting material and one
imine using compound 166 (Fig. 4.7). These analogues were prepared using the same protocol
for imine preparation as described previously. They were prepared in good yield (46-69%) and
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characterised using MS and NMR spectral data. Imine-morpholino derivatives were obtained
also as Z and E isomers and their ratios were identified using 1D NOE NMR analysis..

Figure 4.7: N-Morpholino-imine isatin derivatives.

4.3.3.1 E and Z imine isomers
The 3-substituted isatin analogues can exist as a mixture of E and Z isomers depending
on the substituents at the C3 position and on the characteristics of the substituent at the C4 and
C5 position of the isatin core as well (Fig. 4.8). The isomers readily interconvert in solution and
cannot be readily separated by chromatographic methods.398

Figure 4.8: E and Z isomers of imine-2-oxindole.

The ratio of E: Z isomers were determined by the integral height values of H2’ and H6’
chemical shifts of the protons on the external phenyl group and the H4 and H6 protons on the
isatin core of the E and Z isomers. 1D NOE analysis was performed in order to identify E and Z
isomers, where the E-configuration shows a NOE correlation between the H4 hydrogen atom of
the isatin and C2’ or C6’ hydrogen of the phenyl ring on the 3-position of the isatin core, while
the same NOE peak is not detected for the Z isomer due to the distance between the protons.
Another indication of the E or Z isomers is the signal of the H4 proton of the isatin
molecule, which is shifted upfield (~6.2 ppm) for the E isomer compared with the starting
material and Z isomer, which is the result of interaction with the ring current of the phenyl
substituent at the position C3 on the isatin molecule that is shielding this proton. The signal for
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the Z-isomer is close to the value of the chemical shift of the H4 of the starting isatin. Fig. 4.9
shows the 1H NMR spectrum of compound 183, where it can clearly be observed that 4E H is
further upfield at 6.88 ppm while the same H4 proton of the other Z isomer is at 7.69 ppm.
Although there are many aromatic protons in these compounds, some were clearly resolved into
doublets and singlets as seen in the figure below. However, other imino-isatin derivatives gave
complex spectra with not properly resolved peaks. In addition, NOE experiments could be used
to distinguish H2’’ and H6’’ protons in the phenyl ring at the C-3 position of the isatin core. The
chemical shifts for the protons at the C2’ and C6’ positions were shifted downfield (~7.65 ppm)
for the Z isomer, while the E isomer was found to be more upfield (~7.10 ppm). This has been
found to be due to the deshielding effect of the C-2 carbonyl of isatin ring on the H2’ and H6’
protons in the Z isomer form.159 Only imino-isatin derivative 204, which has an unsubstituted
aromatic isatin ring, was obtained as the pure E isomer.

Figure 4.9: 1H NMR spectral data of the imino isatin derivate 183 (CDCl3, 500 MHz).

Along with the series of imine derivatives already described, two novel hydrazone
compounds were also prepared following the same method as that for imine, only that an
appropriate phenylhydrazine was used in place of an aniline in the reaction giving the final
products (207 and 208) in high yields (Fig. 4.10). In contrast to imine derivatives that exist in
E/Z isomers, hydrazones appears mainly in the Z (cis) conformation while the E isomers can be
observed only as a trace in the 1H NMR spectra of 208 (Fig. 4.11). The major formation of only
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one isomer is attributed to hydrogen bonding between the carbonyl group of the indoline core
and NH group of the hydrazone linkage.

Figure 4.10: Two hydrazone derivatives 207 and 208 prepared showing intramolecular hydrogen bonding.

Figure 4.11: 1H NMR spectral data of hydrazone isatin 208 (CDCl3, 500 MHz).

Together with imine analogues that have phenyl or phenyl hydrazine groups on position
C3 on isatin, compounds with oxime group were also synthesised following the same procedure
as already described (Fig. 4.12). 1H NMR analysis of the desired products indicated that only
the Z isomer was obtained after purification (Fig. 4.13). The formation of only one isomer is
presumably due to hydrogen bonding between the carbonyl group of the isatin core and the OH
group at the 3-position of the isatin core, as seen for the hydrazine analogues. Work up of the
reactions of the oxime isatin products gave hydroxylimino-isatin compounds 209-211 in 5792% yield.
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Figure 4.12: Hydroxylimino-isatin derivatives.

Figure 4.13: 1H NMR spectral data of 209 (CDCl3, 500 MHz).

4.3.4 Synthesis of 5-nitro and 5-methoxy isatin-imine derivatives
Along with 5,7-dibromoisatin and unsubstituted phenyl ring isatin derivatives,
compounds with 5-nitro and 5-methoxy group were also synthesised. Furthermore, nitro and
methoxy indole derivatives (e.g 60 and 216, Fig. 4.14) were previously reported to inhibit
different kinase enzymes.395,399

Figure 4.14: Known 5-substituted 2-oxindole kinase inhibitors.
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Preparation of the 5-nitro and 5-methoxy-N-alkylated imine derivatives were achieved
in good yield (67-79%) following N-alkylation and imine formation procedures previously
described (section 4.3.2 and 4.3.3, Fig. 4.15). These groups were chosen with the aim to
improve the lipophilicity of the isatin compounds. Figure 4.15 also shows clogP values of isatin
derivatives bearing different groups on the aromatic ring.

Figure 4.15: 5-Nitro and 5-methoxy isatin-imine derivatives.

4.3.5 5-Sulfonyl imine isatin derivatives
Guan et al. found that substitution with a sulfonyl group at the position C5 of the indole
core was essential for Src and Yes tyrosine kinase inhibitor activity (Fig. 4.16).155 These results
were in conclusion with previous analyses where substitution at the 5-position increased
activity, including isatins as cytotoxins and indirubins which are potent CDK and GSK
inhibitors.183,400,401 Alkylaminosulfonylisatins are well studied as they have been previously
identified as potent and selective inhibitors of caspases 3 and 7.402 Based on their discovery and
to further investigate kinase inhibitory abilities of isatins, two isatin sulfonyl derivatives were
synthesised.

Figure 4.16: Structure of a 5-sufonyl isatin derivative and its Src kinase inhibitory activity. 155

The synthesis of the desired sulfonyl isatin imine (224) required four steps: substitution
at position five of isatin, N-alkylation of the newly formed sulfonyl group, N-alkylation of isatin
and condensation of the prepared isatin with aniline. To access the desired sulfonyl products,
isatin or indole ring should be substituted at position five with a sulfonyl group. The first step
was adding chlorosulfonic acid dropwise to a solution of isatin in DCM and stirring it at room
temperature for 2 h, as described by Bebernitz et al. (Scheme 4.9).403
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Scheme 4.7: Synthesis of sulfonamide isatin derivatives.

The gem-dichloro isatin-5-sulfonyl chloride derivative was then coupled to an
appropriate amine (4-aminomorpholine) in either THF or an ethanol/water mixture in a 1:1 ratio
in an overnight reaction to yield the sulfonamide products. N-Alkylated sulfonyl isatin (221)
was formed in good yield using both solvent systems (Scheme 4.9, THF (62%); EtOH/H2O
(88%)). 221 was hydrolysed before proceeding to next step to give 222.404 Sulphonamide (222)
was then coupled with an aryl alkyl halide to give the N-alkylated product (223) obtained in
62% yield (Scheme 4.10). Compound 222 was also coupled with aniline give the 3-substituted
isatin product (224), following procedures described previously (Section 4.3.3) in 59% yield.

Scheme 4.8: Synthesis of 5-sulfonyl isatin analogues.

4.3.6 5-Aryl isatin derivatives
Next, our interest turned towards the development of biaryl derivatives prepared by
metal catalysed cross coupling reactions. GW-491619 (225), a potent kinase inhibitor, has a
large group on position C-4 and C-5 (Fig. 4.17).405 Kilic et al. reported a series of 3-aryl
substituted 2-oxindoles (e.g. 226, Fig. 4.17) as potent pp60c-src tyrosine kinase inhibitors.406
Therefore, substitution of the phenyl ring with 5-phenyl and 5-pyrrole groups was also
investigated, with the aim to identify any alterations in kinase inhibitory activity between
varying hydrophobic substituents.
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Figure 4.17: Known kinase inhibitors bearing large substituents at C-5. PMB = para-methoxybenzyl.

Metal catalysed biaryl coupling reactions are used for formation of carbon-carbon
single bonds. Palladium catalysts are widely used due to their ability to catalyse a variety of
chemical reactions. Palladium catalysts are used for Suzuki coupling, which are reactions
between organoboronic acid and halides (Scheme 4.11).407 Suzuki coupling requires the
presence of a base that activates the arylboronic acid and further enhances transmetalation
process.389 Suzuki coupling is one of the methods that can be employed in the preparation of
these compounds and it is considered a ‘green’ reaction, compared with others such as the Stille
coupling, which utilizes tin molecules that are toxic and have low solubility in water.

Scheme 4.9: Mechanism of Suzuki coupling.

Preparation of compounds 228-230 was carried out by a Suzuki cross-coupling reaction
according to the method of Gerard et al.408 The Suzuki biaryl coupling between 227 and 162a
and

boronic

acid

was

performed

in

dimethoxyethane

with

palladium

(tetrakis(triphenylphosphine)palladium (0)) as the catalyst (Scheme 4.12). Target compounds
were obtained in low yield (16-24%) and examination of the 1H NMR and 13C NMR spectrum
was correlated with the literature data for the known derivatives (228, 229), while the structure
of 230 was confirmed by 2D NMR data. 1H NMR and 13C NMR data revealed five aromatic
109 |

Chapter 4

Synthesis of isatin derivatives

peaks in addition to the peaks that were attributed to starting material. Low resolution mass
spectrometry (LREI-MS) also provided further evidence with a molecular ion at m/z 343. The
yields of the products were only low, as was reported in the work of Gerard et al. due to the low
solubility of the products in the reaction solvents.408

Scheme 4.10: Preparation of biaryl isatin derivatives. PMB = para-methoxybenzyl; DME = dimethoxyethane.

4.3.7 Preparation of N-triazolo isatin imines
With the aim to further probe diversity, the library of compounds was extended to a
number of analogues with triazolo groups on the aromatic nitrogen of isatin. Click chemistry, or
the Huisgen 1,3-dipolar cycloaddition reaction between terminal alkynes and azides, has gained
interest in medicinal chemistry recently.409 1,2,3-Triazoles compounds can be used as mimics
for amides and peptide bonds and in modifications of natural products.409

4.3.7.1 Click chemistry reaction
The Cu (I)-catalysed Huisgen reaction is a 1,3-dipolar [3+2] cycloadition reaction
between a terminal alkyne and an appropriate azide, developed by Medal et al. and further
explored by Sharpless et al.410,411 As the final product, this method gives five membered 1,4disubstituted 1,2,3-triazole heterocycles.412 One of the major issue with the click chemistry
reaction is formation of 1,4 and 1,5 regioisomers (Scheme 4.13).410 However, regioselectivity
can be improved with the employment of Cu (I) salts to give only the 1,4-triazole product.411
Rostovtsev et al. found that the Cu(II) salts are better for the reaction in terms of purity of the
Cu salts and price and that they can be reduced in situ to Cu(I) salt by ascorbic acid or sodium
ascorbate.410 Various solvents can be used, including water and the reaction proceeds to
completion within 6-36 hours at room temperature giving good yields of products.410 Cu(I) salts
can also be used in the click chemistry reactions without using the reducing reagent. Still Cu(I)
salts require acetonitrile as a co-solvent and one equivalent of nitrogen base, usually 2,6-lutidine
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which enables preparation of high purity and better product yields.410 The utilization of nitrogen
base in the reaction and exclusion of oxygen also improves the regioselectivity.410

Scheme 4.11: Regioselectivity of the click chemistry reaction.410

4.3.7.2 Synthesis of N-triazolo imines
The two novel triazolo imine derivatives 234-235 were readily prepared from
N-triazoloisatin derivate 233 with hydroxyl amine and 4-aminophenol. The first step in the
preparation of the triazolo imines was synthesis of compound 168. The N-propargylisatin
derivate 168 was made following the previously described protocol of N-alkylation of isatin
using 5,7-dibromoisatin and propargyl bromide in good yield (78%). 1H NMR spectrum
confirmed the structure of the synthesised compound with additional peaks at 2.36 and 4.93
ppm compared to the starting 5,7-dibromoisatin and attributed to the propargyl hydrogen and
two protons of CH2 adjacent to nitrogen.
Derivatives with the triazolo group on the nitrogen position of the isatin core were
prepared from N-alkylated isatin 168 and 3-azidopropanol using click chemistry conditions.
3-Azidopropanol was synthesised from 3-bromopropanol and sodium azide in DMF in 4 h
according to the protocol of Riva et al. (Scheme 4.14).413 EI-MS of the reaction mixture
confirmed formation of the desired product with a m/z value of 101, comparing to a formula of
C3H7N3O. 3-Azidopropanol was used not purified and the actual yield not calculated because
small molecule azides are known to be dangerous and explosive. The reaction mixture of
3-azidopropanol 232 was extracted with ether. Into the organic layer, water was added and then
the organic solvent removed in vacuo. A solution of 232 in water was used for the next reaction
step.
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Scheme 4.12: Formation of 3-azidopropan-1-ol.

Three methods for the preparation of the triazole product were employed and all gave
the target molecule, with differences in the product yields of 6-59%. The first method for the
preparation of the N-triazoloisatin, involved utilisation of Cu(I) salt with 2,6-lutidine as a
nitrogen base. For this reaction, compounds were dissolved in H2O/ACN solvent (Scheme 4.15).
After column chromatography the product was obtained in 59% yield. The 1H NMR spectrum
of compound 233 in CDCl3 revealed that the desired compound was formed with peaks for
protons in the propyl part of the molecule at 1.91, 3.64 and 4.36 ppm and the proton peak of the
triazolo ring at 8.12 ppm.
The second protocol to access triazolo derivatives involved Cu(II) salt as CuSO4 in
H2O/tBuOH. Sodium ascorbate was used for the reduction of Cu(II) to Cu(I) in situ. The
reaction was carried at overnight at room temperature (Scheme 4.15). The yield of this reaction
after purification was 46%. 1H NMR and

13

C NMR spectra confirmed formation of 233 as

above.

Scheme 4.13: Formation of triazolo N-substituted isatin.

In the last attempt, the click product was prepared in a one-pot synthesis. Low
molecular weight organic azides can be dangerous. Therefore, Fokin et al. developed a method
which included preparation of the 1,4-triazole product in a one pot, two step synthesis.414 NAlkylated isatin (168) was mixed with 3-bromopropanol, sodium-azide, copper salt and sodium
ascorbate in the presence of Na2CO3 and in 9:1 DMSO/H2O. The mixture was stirred at 65ºC
overnight, however after the purification of the product the yield of the reaction was only 6%
(Scheme 4.16). Thus the original method was chosen for any future scale-up procedures.

Scheme 4.14: On-pot synthesis of isatin triazolo derivatives.
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The final step in the preparation of the two imine derivatives (234-235) was reaction of
dibrominated triazolo product and an appropriate amine to give C3 substituted product
following a previously described procedure (Section 4.3.3). The 1H NMR spectrum of the
product revealed that 234 was prepared as a mixture of E and Z isomers, while 235 was
obtained as the pure Z isomer, presumably due to intramolecular H-bonding (Fig. 4.18).

Figure 4.18: Triazolo isatin imines 234 and 235 and their yields.

The E stereochemistry of 234 was assigned as previously described to a particular
isomer based on the signal from H4 (on the isatin core) (Section 4.3.3.1). The E isomer in the 1H
NMR spectrum was shifted upfield 1.2-1.4 ppm relative to the H4 signals of the Z isomer which
occurs as a result of shielding by the ring current on the iminophenyl ring. The isomeric ratios
of each compound were therefore determined by comparing the size of the integrals from the H4
signals of the E and Z isomers, as described earlier. As previously mentioned 3-substituted
isatins exist as the E and Z isomers that interconvert rapidly in solution at room temperature,
although some C3-substituted derivatives have been reported to appear as mainly E isomers.159
In Fig. 4.19, the 1H NMR spectrum of compound 234 is presented where it is easily seen that
the 4H proton is significantly moved upfield compared to the corresponding proton of the Z
stereoisomer.

Figure 4.19: 1H NMR spectral data of triazolo-imine derivative 234 (CDCl3, 500 MHz).
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4.4 Preparation of 3-substituted indolin-2-ones (alkenyl-isatins)
4.4.1 Synthetic targets
Along with the series of isatin imines, a variety of alkene analogues were also prepared,
with the aim to test their activity and because these type of structures are similar to reported
kinase inhibitors. For example, the alkenyl isatin 236 was found to be highly specific against
vascular endothelial growth factor (VEGF), (Flk-1) RTK, and related compound 237 also
displayed high selectivity towards epidermal growth factor (EGF) and Her-2 RTKs (Fig.
4.20).159 The alkenyl isatin 238 was prepared by Islam et al. and was found to be selective to
PDK1 and cAKT2 over PKA.162 In modelling studies of 238 it was confirmed, as predicted
earlier, that the indolinone core occupies the same site of the enzyme as the adenosine moiety of
ATP and it makes three H-bonds with the hinge region.162

Figure 4.20: Known alkene 2-oxindole compounds as kinase inhibitors.

4.4.2 Synthesis of alkenyl isatin derivatives
The step required for the preparation of 3-substituted alkenyl isatin derivatives are
shown in Scheme 4.17. The first step in the synthesis of the desired alkenyl-isatin compounds
was 5,7-dibromination of 2-oxindole (239), followed by N-alkylation and substitution at C3
(Scheme 4.17). A literature search provided two methods for the synthesis of 5,7-dibromo-2oxindole. Sumpter et al. performed dibromination of the 2-oxindole ring using Br2 and a KNO3
solution.415 Crestini et al. published another procedure, where preparation of 5,7-dibromo-2oxindole was carried out using 5,7-dibromoisatin, which was reduced using hydrazine
hydrate.416

Scheme 4.15: Summary of the proposed synthetic strategies in the formation of 5,7-dibromo-1-(4-methoxybenzyl)isatin alkenyl derivatives.
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Taking these literature examples into consideration, we first tried the method which
utilizes 2-oxindole as the starting material described by Sumpter et al.415 Bromine and KNO3
were dissolved in water and it was slowly added to the hot solution of oxindole in water. A light
yellow crude product was crystallized from ethanol. EI-MS analysis of the product indicated the
presence of 5,7-dibromooxindole (240), but also of 3,5,7-tribromooxindole (241) and 3,3,5,7tetrabromooxindole (242) (Scheme 4.18). By column chromatography compounds were purified
and the yield of the dibrominated product was very low (<15%), where the side products
yielded more. Initially, two equivalents of bromine were used, as described in the protocol, but
as we could not obtain the desired product in the good yield we optimised conditions. The
bromine equivalents used were reduced to 1.5 and 1.2 but it did not result in improvement of the
final yield. Instead of using water, isatin was dissolved in 95% ethanol but still the major
occurrences of the polybrominated compounds were detected.

Scheme 4.16: Bromination of 2-oxindole.415

4.4.3 Wolff-Kishner reduction of isatin derivatives
Following on from the unsuccessful attempt to prepare dibromnated oxindole 240 by
dibromination of 2-oxindole, a Wolff-Kishner reduction method described by Crestini et al. was
used.416 N-Alkylated isatins (241 and 242) were reduced with hydrazine hydrate by a modified
Wolff-Kishner method that reduces the C3 carbonyl group to an alkanes (Scheme 4.19). The
successful mechanism of the reaction is due to the structure of the isatin molecule and the
ability of the α-ketoamide to promote the stage of the decomposition of hydrazone. Instead of
water molecules that drive the reaction forward, the possibility of intermolecular hydrogen
bonding could lead to the formation of the intermediate and through the enol form the final
reduced product can be formed.416 Crestini et al. employed the same method for the preparation
of the similar compounds, except their N-alkyl substituent were hydrogen, methyl or methoxy
group and they were using only 5-substituted isatins.416 The slight difference in the molecule
structures could result in the reaction time required for the reaction. While Crestini et al.
performed their reactions in 30 minutes, preparation of the compounds in this project needed a
longer time of 2 h. 5-Bromo-1,3-dihydroindole was synthesized previously as well by Wilk et
al., although they used ethylene glycol in addition and performed the reaction over 6 h.417
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Scheme 4.17: Wolff-Kischner reduction of 5,7-dibromo-N-alkylated 2-oxindoles (241-242).416

The formation of the desired products was confirmed via 1H and

13

C NMR spectral

analysis. Compared to the 1H NMR spectra of N-alkylated isatin 162, proton NMR of the
reduced isatin compound (241) was similar with the addition of a signal at 3.63 ppm, which
belongs to the two protons at the 3 position of the isatin core. As a by-product in this reaction
formation of a corresponding 5-bromo-2-oxindoles (241a and 242 a) was also observed and
confirmed by 1H NMR (Fig. 4.21 and 4.22). N-alkylated-2-oxindoles 241 and 242 was obtained
in 63% and 57% yields, comparable to yields reported in the literature (76-92%).

Figure 4.21: 1H NMR spectral data of 5,7-dibromo-2-oxindole (241) (CDCl3, 500 MHz).
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Figure 4.22: 1H NMR spectral data of 5-bromo-2-oxindole ( 241a) (CDCl3, 500 MHz).

4.4.4 Preparation of 3-substituted indolin-2-ones
Following on from the method of Sun et al., who made numerous C3-substituted
indoles, reaction of N-alkylated indoles 241and 242 with an appropriate aldehyde provided the
desired product.159 The reaction was refluxed for 3-6 h in ethanol with piperidine base as the
catalyst, giving good yields (>60%) of the desired product (Scheme 4.20).

Scheme 4.18: Synthesis of 3-substituted indolin-2-ones (alkenyl isatin derivatives).

The formation of 3-substituted products is performed by a Knoevenagel condensation
mechanism, which includes nucleophilic attack of the active hydrogen compound (2-oxindole)
to a carbonyl group (aldehyde) followed by elimination of water (Scheme 4.21).
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Scheme 4.19: Knoevenagel condensation reaction of 5,7-dibromo-N-alkylated-isatina and an appropriate aldehyde.

3-Substituted indolin-2-ones may also exist as either Z or E isomers as previously
reported for 3-substituted isatins. The isomer ratio is also found to depend on the substituents on
the C4 and C5 positions on the aromatic ring of oxindole and characteristics of the substituents
at the C3 position of the 3-substituted 2-oxindole. Although imino-isatins isomers cannot be
separated, alkenyl isatin derivatives are able to be obtained as pure isomers using column
chromatography. As for the imino-isatins, the two isomer forms could be distinguished by 1D
NOE analysis, with additional correlation for the Z-configured alkenyl isatin isomers, which
show a NOE effect between the proton at the C4 position of oxindole core and the vinyl proton.
Also for these isomers, NOE experiments can be used to the distinguish protons at the C2’ and
C6’ positions in the phenyl ring at the C3 position of the 3-substituted-2-oxindoles with
different chemical shifts for the Z and E isomers due to deshielding effect of the C-2 carbonyl of
the 2-oxindole ring in the Z isomer form. Five of 10 alkenyl isatin derivatives were synthesised
as the mixtures of both Z and E isomer forms (Table 4.2).

Table 4.2: Isatin alkene derivatives 243-252 prepared in the project.

Cpd. no
243
244
245
246
247

R1
OCH3
OCH3
OCH3
OCH3
OCH3

R2
4-Cl
2-Cl
4-NO2
4-OH
4-OCH3

Yield E/Z (%)
16 / 0
0 / 31
17 / 0
26/ 0
27 / 0

Cpd. no
248
249
250
251
252

R1
OCH3
OCH3
CH3
CH3
CH3

R2
4-CH3
4-CH2CH3
4-Cl
4-CH3
4-CH2CH3

Yield E/Z (%)
21 / 33
8 / 27
33 / 10
36 / 14
16 / 39
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In addition to ten isatin alkenes with substituted phenyl group on the C3-position, three
compounds with a pyrrole group were synthesised (253-255) and they were obtained
exclusively as Z isomers.

Figure 4.23: Pyrrolo alkene isatin derivatives prepared in this work.

4.4.5 Preparation of 2,4-dimethyl-1H-pyrrole-3-carbaldehyde
In the preparation of the alkene isatin derivatives, one of the aldehydes needed for the
Knoevenagel reaction with isatin compound was prepared by a Vilsmeier reaction. The
Vilsmeier reaction is used for formylation of electron-rich arenes. It is an alternative reaction to
Friedel-Crafts acylation and avoids the use of strong Lewis acids such as AlCl3.389
The procedure for the preparation of 2,4-dimethyl-1H-pyrrole-3-carbaldehyde was
based on the protocol described by Terenin et al. (Scheme 4.22).418 POCl3 in DMF was added
slowly to 2,4-dimethylpyrrole in DMF and stirred at 20ºC for 24 h. TLC analysis of the
reaction showed that the starting material was consumed and 1H NMR and MS were compared
with the literature data and the formation of the desired product confirmed.

Scheme 4.20: Formation of pyrrole-carbaldehyde
257 by the Vilsmeier reaction.

4.4.6 Sulfonyl alkenyl-isatin derivatives

In addition to dibrominated alkene and sulfonyl imino-isatin derivatives, alkene isatin
compound (260, Scheme 4.23) with a sulfonyl group at position five was prepared. Alkenyl
sulfonyl compound 260 was synthesised in three steps, following a procedure for the synthesis
of imine derivatives, discussed in section 4.3.5 including substitution at the position five of 2oxindole, N-alkylation of the formed sulfonyl group and condensation of the prepared
compounds with aldehyde (Scheme 4.23).
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Scheme 4. 21: Synthesis of sulfonamide alkene-isatin derivative.

In summary, this chapter reported the successful synthesis of 41 novel imino-isatin and
14 novel alkenyl-isatin derivatives under various conditions. The main aim was to modify the
isatin core in order to obtain new potent and selective kinase inhibitors.
Evaluation of protein kinase A and B inhibitory activity of the novel compounds and
their precursors are presented in the Chapter 5. Chapter 5 also includes testing of 16 isatin
compounds against MAPK. Isatin derivatives were also screened for their cytotoxicity to test
how this modification affected their activity.
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The 77 isatin-based compounds synthesised in Chapter 4 were screened for their
PKA inhibitory activity. In addition, selected isatin derivatives were also
screened for Akt and MAPK kinase inhibitory activity. Isatins are known to
display potent cytotoxicity, therefore the majority of the isatin analogues were
also tested in an anti-proliferative assay using U937 lymphoma and MBA-MD231 breast cancer cell lines.
5.1 Biological assays
Chapter 4 described the synthesis of 77 isatin derivatives, including 41 novel iminoisatin and 14 novel alkenyl isatin derivatives. These compounds were designed as potential
kinase inhibitors and were tested for PKA inhibitory activity using a kinase assay developed in
our laboratory. Previously, a number of indolin-2-one analogues have been found to display
activity against both serine/threonine and tyrosine kinases. c-AMP Dependent protein kinase
(protein kinase A, PKA) is an important serine/threonine kinase involved in the regulation of an
increasing number of physiological processes including immune, cardiovascular and
reproductive functions; steroid biosynthesis; adipocyte metabolism; and exocytotic processes.119
As such, the inhibition of PKA has become an attractive drug target in a number of areas, in
particular in immune function and for memory disorders such as Alzheimer’s and Parkinson’s
disease and schizophrenia.123,126 In addition to PKA testing, compounds were also screened for
inhibitory activity against Ser/Thr MAPK and Akt (PKB) kinases.
Within previous research in our group, isatin compounds were found to exhibit
significant cytotoxicity. The characteristic feature of isatins to inhibit cell proliferation and
hence cause apoptosis was suggested to be through intercalation with extracellular signal-related
protein kinase enzyme (ERKs).151,182,186,419 Cytotoxic screening of a range of isatin derivatives
was performed on several cell lines but isatins display the most potent activity when the tests
were carried out on a U937 lymphoma cell line. This cell line has been used widely within our
research group to test the cytotoxicity of isatin derivatives.186,189 Consequently, compounds
prepared in Chapter 4 were also screened for their ability to cause cell death in U937 cells.
Isatin derivatives that expressed the highest activity were also screened against MDA-MB-231
breast adenocarcinoma cell lines. The cytotoxicity results are presented in IC 50 values, the
concentration which is required to inhibit 50% cell viability after a 24 h incubation period.
5.1.1 Protein kinase A inhibition testing
All synthesised compounds were tested for their potential PKA inhibition ability as
described in Chapter 2 and experimental protocol (Chapter 6). Tests were carried out on the
purified enzyme PKA, where all compounds were initially tested at a concentration of 100
µg/ml, finding a single point inhibitory concentration for each sample (Chapter 2). To further
test the specificity of inhibitor to a specific enzyme, compounds were tested for inhibitory
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activity against MAPK and Akt kinase. Kinase inhibitory activity results are expressed in
percent inhibition for all isatin derivatives tested. IC50 values were determined for those
compounds that showed the highest percent inhibition (>70%). Standards used in the kinase
assay included three know potent PKA inhibitors: staurosporine (IC50 23 nM),

420

ellagic acid

(IC50 2 µM)421 and H-89 (IC50 135 nM) (Chapter 1, Section 1.6.1).422
5.1.2 Protein kinase B (Akt) inhibition testing
Protein kinase B belongs to the group of serine/threonine kinases and begins to attract
more attention because of the important signalling role in cancer.423 The protein kinase B
inhibition testing was performed at Illawarra Health and Medical Research Institute (IHMRI), in
collaboration with Dr. Jiezhong Chen. All compounds were tested at concentration of 100 µM.
Phosphor-Akt levels were determined by Western blotting to indicate Akt activity (Appendix,
9.5).
5.1.3 MAPK kinase inhibition testing
The MAPK enzyme belongs to the serine/threonine family of protein kinases, the same
as PKA and Akt. MAPK signalling is involved in peripheral tissue inflammatory disorders and
recognised as the drug target to treat Alzheimer's disease (Fig. 5.2). 424 Sixteen isatin derivatives
were screened for MAPK inhibitory activity at University of Sydney in collaboration with Dr.
Lenka Munoz from the Faculty of Pharmacy at the University of Sydney.

Figure 5.1: p38 MAPK participates in different cell types and mechanisms in Alzheimer's disease.424
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5.1.4 The MTS cell proliferation assay
The MTS cell proliferation assay is an in vitro cytotoxicity assay that is found to be
very accurate, reliable and a convenient method for determining cell viability with good
sensitivity and specificity.425 This MTS assay gauges the interaction between potential drug and
whole intact cells and allows detection of a variety of bioactive compounds. The MTS CellTiter
96®

AQueous assay

utilizes

3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-

sulfophenyl)-2H-tetrazolium, inner salt and an electron coupling reagent (phenazine ethosulfate)
PES.422 The MTS cell proliferation assay determines the number of viable cells which is
measured through colourimetry. This assay works on the principle that the mitochondrial
dehydrogenase enzymes, bioreduces the colourless tetrazolium salt (MTS reagent) into a
coloured aqueous soluble formazan product by the mitochondrial activity of viable cells at 37°C
(Fig. 5.2). The reduction of MTS reagent is accompanied by production of NADH or NADPH
by these enzymes. The amount of formazan produced by dehydrogenase enzymes is directly
proportional to the number of living cells in culture and can be measured at 492 nm. The
quantity of the coloured product is directly proportional to the number of live cells in the culture
since MTS can only be reduced to formazan by metabolically active cells.

Figure 5.2: The reduction of the MTS tetrazolium salt to the red formazan product by viable cells.

5.2 Structure-activity relationship studies
5.2.1 Biological activities of N-alkylated isatin derivatives
N-Alkylated compounds were prepared as the starting material for the synthesis of the
imine and alkene derivatives (Chapter 4). Eleven compounds were made including compounds
with an unsubstituted aromatic isatin ring, 5,7-dibromo, 5-nitro and 5-methoxyisatin analogues,
of which seven derivatives were novel. All N-alkylated isatins were screened for their PKA
inhibitory activity and MTS cytotoxicity. In addition, five compounds were screened for Akt
(PKB) and one compound was tested for MAPK kinase inhibitory activity (Table 5.1).
There are several conclusions that can be drawn from the testing results presented in
Table 5.1. It can be observed that N-alkylated derivatives displayed weak to moderate activity in
the PKA inhibition assay only giving a maximum of 23% inhibition. Only para-substituted
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phenyl derivatives were prepared as these compounds were previously found to display better
cytotoxicity over ortho and meta analogues.183 The para-substituted phenyl derivatives were
weakly active, displaying similar inhibitory activity. Changes of the different substitution of the
phenyl ring did not change the biological results of these compounds (e.g. entries 162-165,
Table 5.1). Both, electron withdrawing and donating groups on the phenyl ring did not
significantly alter the PKA inhibitory activity.
Table 5.1: Biological results of N-alkylated isatin derivatives

clog P

% PKA
Inhibition†

% Akt
inhibition‡

MTS
IC50 (µM)a

H

2.25

12

8

46.8

OCH3

H

2.53

1

nt

nt

170

NO2

H

2.37

3

nt

nt

162*

Br

Br

4.21

10

25

0.5

163

Br

Br

4.79

23

67

1.8

164

Br

Br

5.00

21

nt

1.0

165

Br

Br

5.41

13

0

2.3

166

Br

Br

2.63

11

nt

21.3

167

Br

Br

2.28

14

0

21.4

168

Br

Br

2.09

22

nt

29.5

233*

Br

Br

1.25

5

0

10.5

Cpd. no

R1

R2

169

H

171

R3

*Compounds screened for MAPK kinase inhibitory activity; †at 100 µg/ml; ‡ at 100 µM; nt-compounds which were
not tested. a tested on U937 lymphoma cell lines.

Modification of the compounds which led to increased polarity of the molecules, using
morpholino or triazolo groups instead of a phenyl group on the aromatic nitrogen of isatin,
didn’t improve kinase inhibition. A comparison of the PKA inhibitory activity and their
corresponding calculated logP (clogP) values found no correlation. The kinase assay results
indicate that the activity of N-alkylated derivatives observed was not related to lipophilicity.
The N-propargyl isatin derivative 168 was the only derivative that did not have a ring appended
to the aromatic nitrogen of the isatin and its modification did not significantly affect the PKA
inhibitory activity and cytotoxicity. It also appeared that the presence of bromine atoms on the
aromatic isatin ring increased PKA inhibitory activity while a methoxy, nitro group or
unsubstitution let to a decrease in activity.
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Although these compounds were not found to be potent PKA inhibitors, 163 was shown
to have good Akt (PKB) kinase inhibitory properties (Table 1). Akt results also showed that
dibromination was important for activity. Compound 169 which has an unsubstituted aromatic
isatin ring, displayed low Akt inhibitory activity, and the other three tested analogues exhibited
no Akt inhibitory activity at all, although compounds 166, 167 and 233 were prepared with the
aim to increase the polarity of the products. In addition, compounds 162 and 233 were screened
for MAPK kinase inhibitory activity but were not found to be active.
The N-alkylated derivatives were previously found to exhibit potent cytotoxicity against
a variety of tumour cell lines, and to cause G2/M cell cycle arrest, and inducing apoptosis via
binding to the cytoskeletal protein tubulin.186,189 Cytotoxicity of isatin compounds 162-165 and
169 were determined in earlier work, while compounds 166-168 and 233 were tested here
(Table 5.1).186 Cytotoxic data confirmed prior results that attachment of an aromatic ring via a
1-carbon linker on the aromatic nitrogen was required for the antiproliferative activity. Hence,
compounds which did not have an aryl group that is attached to the nitrogen via one carbon
linker and had either morpholino, triazolo or an alkene group on the isatin nitrogen resulted in
lower activity (higher IC50 values) (166-168, 233).
The biological screening of a series of N-alkylated isatin derivatives for kinase
inhibition indicated that these starting compounds are not particularly potent PKA inhibitors aas
was to be expected. However, isatin derivative 163 exhibited potent Akt kinase inhibitory
activity. These results are significant because they indicate that compound 163 showed
selectivity for Akt over PKA, which is significant as selectivity is one of the major issues in the
development of novel kinase inhibitors.
5.2.2 Isatin imine derivatives
A range of C3-substituted analogues were prepared as described in Chapter 4, followed
by the investigation of their activity as kinase inhibitors and also their cytotoxicity. The results
of the kinase inhibition and MTS assays on these analogues are summarised in Table 5.2. The
biological data of the isatin imine derivatives indicate varying degrees of kinase inhibitory
activity and cytotoxicity.
Investigation on isatins as kinase inhibitors started with imino-isatin 83 (Fig. 4.2,
Chapter 4), which was found to exhibit significant PKA inhibitory activity with a IC50 value of
20.0 µM. Firstly, compounds 175-177 with a carboxyl group attached to a different position of
the distal phenyl ring on isatin and also via a varying length carbon linker were prepared and
tested. To further probe the ability of isatins to inhibit PKA, the first objective was to change the
para-carboxyl group on the distal phenyl ring with other functional groups. The synthesis
included compounds with substitution at position 4 and also other positions on the distal phenyl
ring on C3 position and multisubstitution of the phenyl ring at position C3 as well. Compounds
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were analysed with a range of different substituents having either electron acceptor or donor
properties (Table 5.2).
PKA inhibitory activities of three of the isatin derivatives with a carboxyl group (175177) and PMB group on the aromatic isatin nitrogen were higher than 70%. However, the
results indicated that when the carboxyl group was replaced, not all C3-substituted derivatives
displayed as high PKA inhibitory activity (Table 5.2). Of the 29 isatin derivatives in Table 5.2,
four compounds displayed activity higher that 70%. It is evident to observe that the most active
compounds were carrying either a COOH or OH group on the phenyl ring, while all other
derivatives where those groups were replaced by other moieties, exhibited lower activity. These
results highlighted the impact of the carboxylic and hydroxyl function upon the inhibition of the
PKA kinase. However, the analogue 200 with iodo-phenyl N-substituted isatin, which also had
COOH group, did not exhibit potent kinase inhibitory activity, suggesting that PMB group also
contributed to kinase inhibitory activity.
Table 5.2: Biological activity of isatin imine derivatives.

Cpd. no

R1

R2

clogP

175*
176
177
178*
179
180
181
182
183*
184
185*
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203

OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
CH3
CH3
CH3
Cl
Cl
Cl
I
I
I
I
I

4-COOH
4-CH2COOH
3-CH2COOH
4-OH
4-Br
2-Br
3-Br
2,4-di Br
4-Cl
4-I
4-F
4-CF3
4-OCH3
3-OCH3
2,4-CH3
2,6-CH3
4-NO2
4-OPh
4-OCH3
3-Br
4-CF3
3-Br
4-OCH3
4-I
4-OCH3
3-CH2COOH
4-Cl
3-Br
4-F

6.68
6.21
6.21
6.27
7.80
7.80
7.80
8.66
7.65
8.06
7.08
7.82
6.86
6.86
7.94
7.94
6.68
9.04
7.44
8.38
8.40
8.60
7.65
8.64
8.06
7.41
8.64
9.01
8.29

PKA
% Inhibition†
78
75
91
86
9
28
30
4
12
21
30
16
26
19
12
14
19
27
20
1
1
14
24
14
6
27
12
2
4

AKt
% Inhibition ‡
72
70
84
nt
nt
nt
nt
nt
24
17
1
nt
60
nt
nt
nt
0
14
nt
nt
nt
nt
nt
nt
nt
nt
nt
nt
nt

MTS
IC50 (µM) a
1.95 182
2.13 182
0.46 182
3.8¥
6.6
na
2.8
na
2.1
9.2
3.1
10.1
4.3
na
na
25.1
4.1
5.9
na
1.9
na
2.9
1.6
na
6.8
1.4
7.0
1.0
na

*Compounds screened for MAPK kinase inhibitory activity; † at 100 µg/ml; ‡ at 100 µM; nt-compounds which were
not tested; a tested on U937 lymphoma cell lines; ¥ tested on MDA MB 231 breast cell lines.
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Three imine isatins (175-177) which displayed significant activity in the PKA inhibition
assay were also found to exhibit potent Akt inhibitory activity. In addition, six more imine
isatins were screened in the Akt assay but they showed low activities. Akt assay results also
suggested that the carboxyl group was beneficial for potent activity (Table 5.2).
Introducing groups on the imino-phenyl ring of isatin gave little effect on the potency.
There was no clear correlation between the activity of ortho, meta and para iminophenyl-isatin
derivatives, as compounds with a COOH group at either the meta or para position displayed
significant PKA inhibition activity, while derivatives with OCH3 (187 and 188) or halogen
groups (179-181) present at the different positions of the phenyl ring exhibited low PKA
inhibitory activity with no apparent influence of their position (Fig. 5.3). Changing small groups
on the phenyl ring at the C3 position of isatin to a bulkier phenyl group to make a phenoxy
phenyl derivative (192) also had no effect on the activity.

Figure 5.3: PKA inhibitory activity of different phenyl substituted isatin analogues.

Compound 209 which had hydroxyl-amino group at the 3-position of isatin instead of
the arylimino group also displayed strong PKA inhibitory activity (65%) indicating that the
bulkiness of the C3 substituent is not important for activity (Fig. 5.4). This compound also
exhibited 34% Akt inhibitory activity.

Figure 5.4: PKA and Akt inhibitory activity of hydroxylimino-isatin derivative (209).

Two analogues with a hydrazone group (Fig. 5.5) in the PKA inhibition assay showed
that compounds with a carboxyl group on the distal phenyl ring displayed higher inhibitory
activity (84%) than the imine analogues with a para-Cl group (6%). These results were similar
to the results obtained from the imine analogues. The hydrazone imine derivative 208 was
equally potent as imine derivatives in the PKA inhibition assay (175-177), while 207 was less
active than the imino-isatin analogue 183 (Fig 5.5). These two compounds (207 and 208) were
also screened in the Akt inhibition assay and compound 208 showed 57% inhibition, while 207
exhibited 42% inhibition, which was higher than the result obtained in PKA inhibition assay.
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These two hydrazone containing isatins were additionally evaluated against MAPK, however
they were found to be inactive.

Figure 5.5: PKA inhibitory activity of hydrazone and imine isatins.

To investigate the importance of the dibromination and N-alkylation of the isatin
molecule for the PKA and Akt kinase inhibitory activity, two compounds that were not
substituted at the aromatic isatin ring (204, 210) were also prepared. The activity of these
compounds was compared with their analogues and the results indicate that removal of the
dibromine as well as removing groups from the aromatic nitrogen led to a decrease in PKA
inhibitory activity (Table 5.2, Fig. 5.6). Dibromination on the phenyl ring of isatin or
substituents with electron withdrawing ability were found to be beneficial for cytotoxicity of
these analogues. N-alkylation of isatin resulted also in compounds with more potent kinase
inhibitory activity, thus confirming the positive effect of the N-alkylation upon potency (205,
211, Fig. 5.6). A comparison of the inhibitory activity and their corresponding, calculated logP
(clogP) values, found no correlation. Although compounds with two bromine groups on the
aromatic ring were less polar, they displayed higher PKA inhibitory activity. Compounds 209211, screened for Akt inhibitory activity, showed the same trend as in the PKA assay with low
inhibitory results when dibromination and N-alkylation was removed. In addition, imino-isatin
derivative 206 exhibited 68% PKB inhibition while it was not active in the PKA inhibition
assay (12%). Compounds with a 5-nitro group (217, 14% PKA inhibition) were also found to be
inactive as well as compounds with a 5-methoxy group (218, 31% PKA inhibition) on the isatin
benzene ring. These compounds were also made with the aim to reduce clogP values of the
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isatin analogues and make them more polar. The results indicated that the kinase inhibitory
activity of imine derivatives observed was not based on lipophilicity alone. In addition, four
compounds (175, 178, 183, 185 and 209), were tested for p38 mitogen activated protein kinases
(MAPK) activity, however none displayed any significant activity.

Figure 5.6: Influence of bromination and N-alkylation of isatins on PKA and Akt inhibitory activities.

All imine compounds prepared were also screened for cytotoxicity against U937 human
lymphoma cell lines and the activities for most appear to be in the micromolar range (Table
5.2). Activity against U937 cells of the hydrazone derivatives was found to be lower than the
cytotoxicity of imine analogues which was also observed earlier.183 Oxime isatins (209-211) did
not display any significant cytotoxicity and their IC50 values have not been determined. All
imine compounds exhibited activity in low micromolar range regardless of the clogP value.
Cytotoxicity of compounds 178, 205, 208 and 209 were additionally evaluated against
MDA-MB-231 breast cancer cell lines (Table 9.7, Appendix). The IC50 values of the three tested
compounds showed that 178, 208 and 209 were more susceptible to U937 cell lines and were
less potent against cancer breast cell lines.

5.2.3 More polar isatin analogues
It has often been noted in the literature that for isatin derivatives there was no
significant correlation between clogP values and their bioactivity results. Solomon et al. studied
the cytotoxicity of isatin derivatives and did not find any correlation between activity and logP
values of all 30 compounds prepared.152 The authors concluded that differences in lipophilicity
may not be a significant factor for the difference in cytotoxicity.152
In order to improve polarity of the starting isatin compounds which had PMB group on
the nitrogen of the isatin ring, more polar groups were introduced. Isatin was N-alkylated with
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morpholino (212), acetomorpholino groups (213-215) and triazole ring (234, 235). Two
compounds, using a Suzuki coupling to introduce an aromatic ring at the position 5, were also
prepared and tested. All compounds were screened for PKA inhibitory activity and cytotoxicity
and some of these were also tested for Akt and MAPK kinase as well as described below.

5.2.3.1 Morpholino-isatin derivatives
Analysis of the kinase inhibitory activity results of the isatin analogues 212-215
revealed that morpholino groups were deleterious for the kinase inhibitory activity of these
compounds. Neither N-morpholno nor N-acetomorpholino isatin analogues exhibited any
activity (Table 5.3). It appeared that the more polar substituents decreased the kinase inhibitory
activity as they all displayed less than 5% inhibition. The target compound 212 was also
screened against other two kinases, Akt and MAPK, but also did not display any positive
results.
N-Alkylation of 5,7-dibromo derivatives of isatin with morpholino substituents also
resulted in lower cytotoxicity against U937 human lymphoma cell lines compared with imine
derivatives with higher clogP values. These cytotoxic results indicate the importance of the
aromatic phenyl ring at the aromatic nitrogen for cytotoxicity as has been found previously.

Table 5.3: Biological data of isatin morpholino derivatives.

PKA
Akt
Cytotoxicity
% Inhibition†
% Inhibition‡
IC50 (μM)a
OCH3
5.55
3
0
15.1
212*
F
5.21
0
nt
na
213
CF3
5.55
1
nt
20.7
214
OCH3
4.59
0
0
19.4
215*
*Compound screened for MAPK kinase inhibitory activity; † at 100 µg/ml; ‡ at 100 µM; nt-compounds which were
not tested. a tested on U937 lymphoma cell lines.
Cpd. no

R

clogP

5.2.3.3 5-Aryl isatin derivatives
Isatin derivatives with aryl groups on the 5-position, which were prepared using a
Suzuki coupling, were screened for PKA inhibitory activity and cytotoxicity (Fig. 5.7). The
three 5-substituted compounds 228 - 230 showed only weak PKA inhibitory activity of 16, 28
and 25%, respectively. Compound 228 was also screened for MAPK inhibitory activity but
found to display low activity (<5%). Cytotoxicity against U937 cells of these three compounds
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could not be determined as an IC50 value was not reached within the concentration range tested.
Based on these results it was concluded that substitution of the isatin nucleus at the 5-position
was detrimental to both kinase inhibitory activity and cytotoxicity.

Figure 5.7: PKA inhibitory results of aryl isatin derivatives

5.2.3.2 Triazole isatin compounds
Triazole compounds, that can be synthesised through a Huisgen 1,3-dipolar
cycloadition, also known as the click chemistry reaction between azides and terminal alkynes,
are widely used in drug discovery projects. The interests of these compounds in medicinal
chemistry are due to their ability to mimic amides and peptide bonds.409,427 N-triazolo isatin 233
was introduced in section 5.2.1. It was prepared as the starting point for the synthesis of imine
and oxime analogues (234 and 235). The triazolo isatin imine derivatives 234 and 235 displayed
higher PKA inhibitory activity than the starting material (168 and 233) (Fig. 5.8). However,
PKA testing results revealed that these compounds were less active than other imine derivatives
with the phenyl group on the aromatic nitrogen of isatin. The triazolo derivative 234 was also
screened for Akt kinase inhibitory activity but results indicate that this compound had also weak
activity (15% inhibition). These two imines were also tested for cytotoxicity (U937 and MDA
MB 231 cell lines) however they were found to exhibit low activity, again supporting the
conclusion that a benzyl or phenyl group is required at this position for optimum activity.

Figure 5.8: PKA inhibitory activity of triazolo isatin imine derivatves 234 and 235.
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5.2.3.4 Sulfonyl isatin derivatives
A range of compounds that have the sulfonyl group on position 5 of the isatin ring were
prepared as compounds bearing an indole ring were previously found to be inhibitors of Src and
Yes kinase.155 Both imine and alkenyl derivatives of sulfonyl products were prepared along with
compounds that are N-alkylated but unsubstituted on the C3position. All compounds were tested
for PKA inhibitory activity and cytotoxicity against U937 cell lines. In addition, three of seven
compounds were screened for Akt and one for MAPK inhibitory activity (Table 5.4).

Table 5.4: Biological testing of sulfonyl isatin compounds
Cpd.
no

clogP

PKA
% Inhibition†

Akt
% Inhibition‡

Cytotoxicity
IC50 (μM) a

0.07

17

0

na

-0.03

6

31

21.4

1.71

27

nt

28.3¥

2.75

8

nt

18.8¥

258

-1.265

14

nt

na

259

1.50

30

34

113.1

260

3.36

57

nt

63.6

261

0.31

19

nt

49.4
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*Compound screened for MAPK kinase inhibitory activity; † at 100 µg/ml; ‡ at 100 µM; nt-compounds which were
not tested. a tested on U937 lymphoma cell lines; ¥ tested on MDA MB 231 breast cell lines.

In the sulfonyl series it appeared that only one, the sulfonyl isatin derivative 260,
exhibited significant PKA inhibitory activity of 57% while others displayed low to moderate
activity. Replacement of two bromines at positions 5 and 7 of isatin with a sulfonyl group
reduced activity. These derivatives possess better solubility than their bromine analogues and
their clogP values are within the Lipinski rule range, but increased polarity and solubility did
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not improve their activity. Replacing the bromine atoms with SO2 did not result in improving
cytotoxicity as well (Table 5.4). The IC50 values of these compounds were all higher compared
to their bromine analogue. Replacing the bromine atoms with SO2 did not result in improving
cytotoxicity as well (Table 5.4). The IC50 values of these compounds were all higher compared
to their bromine analogues (i.e. less active). These results might be due to the size of the
sulfonyl side group.

5.2.4 Alkenyl-isatin derivatives
In total, 13 alkenyl isatin derivatives were prepared and tested for PKA inhibitory
activity and cytotoxicity, of which five were obtained as single isomers and five as mixtures of
E and Z isomers (Table 5.5). PKA inhibitory results indicated that these compounds were less
active than their imine analogues (Table 5.2 and 5.3). Similar trends to those observed for the
imine derivatives were also noticed for the alkene analogues. The alkenyl-isatin 246, with the
OH group on the distal phenyl ring, displayed the highest PKA inhibitory activity (61%).
However, alkenyl-isatin derivative 246 was less potent than its imine-isatin analogue 178. Of
those alkenyl isatin derivatives that were obtained as E and Z isomers, each isomer was tested
separately in the PKA inhibition assay, whereas only the isomer obtained in greater yield was
screened for cytotoxicity. E and Z isomers displayed a little difference in the kinase inhibitory
activity. The MTS results show that the potency of alkenyl analogues was lower than that of the
imine isatin compounds.

Table 5.5: Alkenyl-isatin derivatives and their biological activity results.
Cpd. no
243
244
245
246*
247
248
249
250
251
252

R1
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
OCH3
CH3
CH3
CH3

R2
4-Cl
2-Cl
4-NO2
4-OH
4-OCH3
4-CH3
4-CH2CH3
4-Cl
4-CH3
4-CH2CH3

CLogP
7.65
7.65
6.59
6.18
6.77
7.35
7.88
8.14
7.93
8.46

%PKA
Inhibition†
8 (E)
13 (Z)
41 (E)
61 (E)
18 (E)
12 (E)/9 (Z)
3 (E)/7 (Z)
9 (E)/6 (Z)
4 (E)/9 (Z)
14 (E)/7 (Z)

Cytotoxicity
IC50 (µM)a
na
na
na
na
35.1
na
na
na
22.3
22.1

*Compound screened for MAPK kinase inhibitory activity; † at 100 µg/ml; ‡ at 100 µM; a tested on U937 lymphoma cell lines; nanot active.

2-Oxindole derivatives with a pyrrole group appended to the C3 atom were previously
found to be potent kinase inhibitors. However, herein introducing a pyrrole group on the C3
position of isatin resulted in low PKA inhibitory activity (Table 5.6). The pyrrole isatin
derivative 253 was also screened for MAPK and Akt kinase inhibitory activity and found to be
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not particularly active. Cytotoxicity of these compounds was found to be in the micromolar
range, but higher than the results obtained for imine derivatives.
Table 5.6: Alkene-isatin derivatives and their biological activity results

Cpd. no

R1

R2

253*
254
255

PMB
PMB
Ph-CH3

2,4-CH3
2,4-H
2,4-CH3

CLogP
6.45
5.45
7.03

%PKA
Inhibition†
17
7
6

Cytotoxicity
IC50 (µM)a
19.5
27.2
29.2

*Compound screened for MAPK kinase inhibitory activity;† at 100 µg/ml; ‡ at 100 µM; a tested on U937 lymphoma cell lines.

In summary 77 compounds were screened for PKA inhibitory activity and 62 for
cytotoxicity against U937 cells, eight against MDA-MB-231 breast cancer cells and 33 for Akt
and 16 for MAPK inhibitory activities. Compounds imino-isatin 178, hydrazine-isatin 208,
hydroxylimino-isatin 209 and alkenyl-isatin derivative 246 displayed the highest PKA
inhibitory activities and their IC50 values were determined as 43.5, 51.8, 38.5, 52.2 µM
respectively. Seven compounds exhibited potent Akt inhibitory activities, higher than 55%
inhibition (163, 187, 175-177, 206, 208). Four isatin derivatives (175, 176, 177 and 208) were
found to be active in both the PKA and PKB assay, which may be due to the fact that both PKA
and PKB enzymes belong to the same group of Ser/Thr AGC kinase. However, three isatins
(163, 187 and 206) displayed selective activity for PKB over PKA, while two compounds (178,
209) were more selective towards PKA. All 16 isatin derivatives tested in the MAPK assay
were inactive. In addition the newly developed isatin derivatives also exhibited potent
cytotoxicity against U937 human leukemic monocytic lymphoma cell lines in the micromolar
range. This work suggests that isatin derivatives possess the potential to be used as PKA and
PKB inhibitors in the future. The isatin derivatives warrant further investigation to improve both
the potency and selectivity for PKA (or Akt) over other kinases and their drug like properties
given they have high clogP values. So far, potent and selective PKA inhibitor has not been
found. Although, PKA inhibitors used as the standards in PKA inhibition assay herein display
low micromolar to nanomolar inhibitory activity, they inhibit various other kinases and are not
selective.
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Conclusions
6.1. Isolation, purification, identification and biological evaluation of marine natural
products
In this project significant progress was made towards the analysis of the bioactivity
from marine natural products including common but under explored local algal species and rare
and unique deep-sea sponge samples from the North West Shelf of Australia including the first
example of a deep-sea Haliclona sponge and the first Australian deep-sea Ircinia and
Sarcotragus sponges. Marine organisms have previously displayed a range of potent biological
properties, which were also found in this study. The key findings from this study are described
below.
6.1.1 Marine algae
Biological screening of extracts obtained from ten algal species including five brown,
three green and two red algae collected from South Eastern Australia and their chemical
constituents were investigated and described in Chapter 2. The bioactivity profiles of the algal
samples were strongly species dependent, with no apparent correlation between PKA inhibition,
haemolysis and/or brine shrimp lethality. Different biological results were obtained for samples
collected from the same location even though they had been exposed to the same conditions
(temperature, salinity) indicating that influence of the locations from which the samples were
collected was not important for the bioactivity. Furthermore, there was no significant correlation
in biological activities between two species that belong to the same genus Sargassum, but were
collected from different locations. The results described herein are the first to show kinase
inhibitory activity of South East Australian alga species and for most of the samples haemolytic
data are reported for the first time.
In general, the non-polar algal extracts gave more potent biological results, in particular
greater PKA inhibitory activity, compared to the polar extracts. The dichloromethane extracts
isolated from brown algae were found to display the highest activity in the PKA inhibition
assay. In summary, the PKA inhibitory activity of the more active non-polar extracts was found
to follow the order brown algae > red algae > green algae. The most active extracts were
dichloromethane extracts obtained from Padina sp., Sargassum sp., Sargassum vestitum and
Phyllospora comosa (with 93%, 82%, 76% and 54% inhibition, respectively). Further
purification of the dichloromethane extracts of C. fragile, C. sinuosa and S. vestitum yielded
even more potent extracts than the original dichloromethane fraction.
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Figure 6.1: %PKA inhibitory activity at 100 µg/ml of the dichloromethane extracts of ten SE Australia algal species.

The main constituents of the non-polar fractions were identified as fatty acids and
sterols in all algae samples. Hexadecanoic acid occurred in all algae species and in many of
them as the main acid including P. linearis, C. vancouveriensis, C. fragile, C. sinuosa, P.
comosa, Sargassum sp. and U. lactuca. The main acid in C. dimorphum was linoleic acid C18:2
(n-6), although hexadecanoic acid also appeared in high yield. The dominance of cholesterol
was detected in all algal non-polar extracts. Cholesterol was the only sterol identified among six
algal samples including the two green algae C. dimorphum and U. lactuca, two red algae P.
linearis and C. vancouveriensis and two brown algae P. comosa and Sargassum sp. Cholesterol
was also the main sterol in the brown algae S. vestitum, while in the other two brown species (C.
sinuosa and Padina sp.) and in the green algae C. fragile the main sterol was fucosterol
consistent with previous literature reports for those species. The chemical composition of the
algal species analysed herein was found to be both species related due to the similarity of our
data to the literature data on chemical constituents of the corresponding algal species, however,
environmental conditions may also play a role as the samples were exposed to similar
environmental conditions.
6.1.2 Deep-sea sponges
In the second part of the study four deep-sea sponges assigned to the genera Haliclona,
Sarcotragus, Ircinia and Geodia were investigated for their biological activities in a variety of
assays. The PKA inhibition, haemolytic activity, and brine shrimp toxicity of 21 partitioned
extracts obtained from four deep-water sponges were investigated. The sponges were collected
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from the North West Shelf of Australia from depths of 84-135 m using remotely operated
vehicles.
Overall the sponge Haliclona sp. displayed greater haemolytic activity than PKA
inhibitory activity, along with low levels of brine shrimp lethality with the bioactivity mainly
found in the less polar fractions. The Ircinia/Sarcotragus sponge exhibited higher PKA
inhibitory activity than the brine shrimp toxicity and haemolytic activity, with the two non-polar
fractions displaying PKA inhibitory activity greater than 80%. The trend of the bioactive nonpolar fractions continued for the Geodia sponge species where the non-polar hexane 1 extract
showed both potent PKA inhibitory activity (97%) and brine shrimp lethality (88%), with
modest haemolytic activity observed for the other fractions. The most active fractions isolated
from the four sponges were the hexane 1 extracts from Ircinia/Sarcotragus sp. and Geodia sp.
with PKA inhibitory activities of 100 and 97% respectively (at 100 μg/mL), the methanol
extract from Haliclona sp. with haemolytic activity of 75% and the hexane extract from Geodia
sp. with high toxicity of 88% to the brine shrimp Artemia franciscana.
As the three non-polar extracts (hexane 1, hexane 2 and dichloromethane extracts) from
all samples gave the greatest PKA inhibition, these were further analysed by GC-MS. Most of
these compounds were fatty acids and sterols and contributed to a partial fatty acid and sterol
profile of these deep-sea demosponges. A total of 29 fatty acids were identified in the highest
proportions according to the following order Ircinia/Sarcotragus sp. > Haliclona sp. > Geodia
sp. In contrast to shallow-water sponges that are dominated by polyunsaturated fatty acids with
a high percentage of long chain fatty acids, LCFAs (C24-C30), the deep-sea sponges investigated
herein were all found to be rich in saturated fatty acids, in particular C14-C20 fatty acids,
including odd and branched chain fatty acids, with only low levels (0-10%) of LCFAs, which
may be a result of the different environmental parameters in the deep sea. In total 23 different
sterols were identified by GG/MS analysis with the greatest sterol diversity found in Geodia sp.
In the Haliclona sponge the main sterol, which occurred in high yield in the hexane 1
fraction, was found to be pregna-5-en-3β-ol (Table 3.3) followed by sitosterol (24ethylcholesta-5-en-3β-ol) in the hexane 2 extract. The predominant fatty acids were C16:0,
C18:1 (n-9), C20:0 and C20:4 (n-5) FAs. The main FAs of the Ircinia/Sarcotragus sample were
similar to the dominant acids found in the Haliclona sample including C20:0 and C20:4 (n-5) as
well as C18:1 (n-9), 12-methyltetradecanoic and octadecanoic acids (Table 3.2). The main sterol
in Ircinia/Sarcotragus sponge was found to be cholesta-7,22-dien-3β-ol identified in the hexane
1 extract, although overall sterols were identified in a much lower yield in this sample compared
with the other two deep-sea sponges (Table 3.3). The Geodia sp. was rich in two C18 FAs
including one saturated C18:0 and one monoenoic acid C18:1 (n-9) FA, while among the sterols
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fucosterol and an unusual nor-pregna-5-en-3β-ol were detected as the major sterols (Table 3.2
and 3.3).
There was no apparent correlation amongst the sterol composition of the three deep-sea
sponge samples. The sterol profile varied across the sponge species either in type of sterols or in
relative percentages. Two of the samples (Haliclona and Geodia) that were obtained from the
identical depth, location and on the same date, possessed different sterol profiles, indicating that
sterol composition in the deep-sea sponges under investigation is largely species dependent. Of
the 23 sterols identified amongst the three deep-sea sponges, 70% of the sterols possessed a Δ5
structure including those with an additional double bound at positions C22 or C24. The ratio of
Δ5:Δ7:Δ5,7 sterols among the three deep sponge samples was 16:5:1, along with one Δ0 sterol that
was detected in the Geodia sp. consistent with literature reports for marine sterols.
The FAs and sterols that were found to be dominant in marine algae and deep sea
sponges were also screened in the PKA inhibition assay. A series of commercially available
FAs (C14:0, C16:0, C18:0, C18:1), fatty acid mixtures (C14-22, C18-22) and pure sterols
(stigmasterol, campesterol, fucosterol, sitosterol and cholesterol) were examined for PKA
inhibitory activity (Fig. 2.22, Chapter 2). These results showed that FAs were more potent than
sterols at inhibiting PKA. The C14 FA displayed the highest activity of (64%) while C16, C18
and C18:1 displayed moderate activities. These results have practical value as marine algae are
rich in PUFAs of the n-3 and n-6 series, which are considered essential fatty acids for humans
and animals. Because of the huge and renewable biomass, seaweeds are a potential source of
FAs for biotechnology and a dietary source of essential fatty acids. Our bioassay results showed
that some of the dominant short side chain FAs such as C14:0 may be contributing to the PKA
inhibitory activity observed in analysed marine extracts, which is consistent with other reports
that have previously shown that FAs exhibit kinase inhibitory activity.

6.2. Structure modification of known isatin derivatives to develop potent kinase inhibitors

The third part of this project included synthesis of isatin derivatives as potential protein
kinase A and B inhibitors. Numerous literature studies of isatin-indole compounds have proved
that these scaffolds are important for kinase inhibitory activity, as evidenced by the fact that
several indole based compounds have been approved as kinase inhibitor drugs. The successful
synthesis of 77 novel derivatives under various conditions was achieved in good – excellent
yields. The synthesis involved preparation of 41 imino and 14 alkenyl isatins.
Imino isatin derivative 83, with potent PKA inhibitory activity (20 µM), was used as a
starting point for the preparation of isatin-based kinase inhibitors. Initially, the carboxyl group
on the distal phenyl ring was replaced by a range of different substituents. Further modification
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included replacement of bromine at position 5 and 7 of the aromatic ring with sulfonyl, aryl,
nitro and methoxy groups. N-substitution of the parent compound with a PMB group was also
changed and morpholino, triazolo, chloro, iodo and methyl substituted phenyl groups were
incorporated into the isatin molecule. The biological results indicated that dibromination and Nalkylation are important both for cytotoxicity and for kinase inhibitory activity. When the
dibrominated aromatic ring was replaced with other derivatives or the isatin aromatic ring was
unsubstituted, the activity decreased in both the PKA and PKB inhibition assays (Fig. 6.2). It
can be considered that a certain number of bromine atoms may be important to bring
compounds into a suitable geometric orientation or favourable energetic states which alter the
activity of enzyme. A similar trend was also observed when other groups were placed on the
nitrogen instead of the PMB group. The PKA inhibition results showed that COOH, OH and NOH groups contributed positively to the PKA inhibitory activity of the isatin derivatives. On the
other hand, the position of the functional groups on the distal phenyl ring did not affect the
activity. With respect to substitution on the C3 position of isatin, all imino isatin derivatives
displayed more potent activities than their alkenyl analogues in the kinase inhibition assay.

Figure 6.2: PKA inhibitory structure-activity relationships for the various isatin derivatives described herein.

Of the 77 isatin derivatives synthesised, four novel compounds displayed potent PKA
inhibitory activity (>70%, at 100 µg/ml). The most active compounds were found to be the
imino isatin 178, hydrazone isatin 208, oxime isatin 209 and alkenyl isatin 246 and their IC50
values were determined as 43.5, 51.8, 38.5, 52.2 µM respectively (Fig. 6.3). A comparison of
the inhibitory activity and their corresponding, calculated logP (clogP) values, found no
correlation, indicating that the activity of the isatin derivatives was not based on lipophilicity
alone.
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Figure 6.3: IC50 values of the most active isatin derivatives in the PKA inhibition assay.

Of the thirty-three compounds screened for Akt (PKB) inhibitory activity, three isatin
derivatives displayed ≥70% inhibitory activity and another three ≥60% inhibition. Of these six
most active compounds, imino isatin compounds 175, 176 and 177 were also found to display
potent PKA inhibitory activity, while N-alkylated isatin 163, imino isatin derivates 187 and 206
exhibited low PKA inhibition (Fig. 6.4). These results show potential for further investigation
especially because the active molecules have ready synthetic availability and structural
simplicity. PKA and Akt (PKB) enzymes belong to the same group of ACG kinases and have
similar homology. However, selective inhibitors for one enzyme over another have not been
identified previously. Co-crystal structures of these two kinase enzymes show that PKA has a
smaller and more lipophilic hinge region compared to Akt. Therefore, selective inhibitors can be
designed considering the difference in the hinge region of the enzymes. Sixteen compounds
were screened for MAPK inhibitory activity, however none of the isatins was found to be active
in this assay. These results are significant and they can further contribute to the selectivity
profile of the isatin derivatives synthesised herein.

Figure 6.4: The three most active Akt (PKB) inhibitors that also showed selectivity for Akt over PKA.

All the compounds synthesised were evaluated for their cytotoxic effects on human
leukemic monocyte lymphoma U937cell line and eight compounds were screened for
cytotoxicity on breast cancer MDA-MB-231 cell line. Cytotoxicity data confirms previous
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results that the presence of an electron-withdrawing group(s) on the aromatic ring of the isatin
core, as well as a one-carbon linker attaching an aryl group to N1, are required for potent
cytotoxicity. Introduction of morpholino or triazolo groups on the nitrogen and aryl and sulfonyl
groups on the aromatic isatin ring resulted in lower cytotoxic activity (Table 5.2 and 5.3; Fig.
5.8).

6.2 Future work
Both the various algal species and the deep-sea sponge extracts displayed significant
PKA inhibitory activity along with haemolysis and brine shrimp cytotoxicity. Algal samples are
widespread along the Australian coast and their advantage is being able to be hand collected
easily. Therefore, future work should include the collection of a variety of algal species,
preferably in higher quantities, followed by extraction and isolation of pure bioactive
constituents. On the other hand, deep-sea samples are difficult to collect but they were found to
be a prolific source of bioactive compounds. However, for their collection, continued
collaboration with researchers and industry involved in the deep-sea work is essential.
Marine organisms are found to contain a large number of non-polar metabolites such as
fatty acids and sterols. These compounds were found to display a range of biological activities.
However, due to their dominance in marine extracts, other compounds were hard to detect. An
extraction protocol that can separate polar and non-polar constituents is important, followed by
extensive rounds of purification using HPLC or column chromatography.
To further improve PKA inhibitory activity of our compounds, future work of this
project could involve the development of further novel analogues. The main problem with isatin
derivatives synthesised in this work was their lipophilicity. To improve this, analogues with
different groups on nitrogen can be made. Herein, we tried with triazolo and morpholino groups
but found that activity decreased. However, compounds with a sugar moiety can be prepared as
similar compounds have previously shown promising kinase inhibitory activity. Also, instead of
an isatin core, other more polar starting cores can be used such as 7-azaindole (Fig. 6.5).

Figure 6.5: Structures of proposed analogues for future work.

141 |

Chapter 6

Conclusions and Future directions

The most active compounds in this work were those containing a carboxyl group. It is
know that the presence of this acidic functional group is not particularly desirable for drug
development. Therefore, the carboxyl functional group is often converted into another
functional group that has similar physicochemical properties and will result in similar biological
properties. Hence, the carboxyl acid moiety could be transformed into a tetrazole group
(tetrazolic acids) and then those derivatives tested for PKA inhibitory activity (Fig. 6.5).

Figure 6.6: Conversion of carboxyl group into the tetrazole group.

The isatin derivatives described in this project could also be tested against a wider range
of other kinases to examine the selectivity of the compounds. In particular several indole
derivatives were found to be CDK inhibitors; hence these compounds should also be tested
against that enzyme. Over 20 isatin analogues are currently being sent to Prof. Laurent Meijer,
Centre National de la Recherche Scientifique), one of the world experts in kinase inhibition, for
further kinase testing, however selectivity results have yet not been received at the time of
writing. In addition, chemical genetic screening by A/Prof. Paul Teesdale Spittle, Victoria
University of Wellington, is also under way to determine a complete bioactivity profile of
selected isatin derivatives (175 and 204).
Future work could also include molecular modelling studies of the isatin derivatives that
displayed the highest inhibitory activities in the PKA inhibition assay. In order to fully evaluate
the SAR of these analogues computational docking studies can be performed with cAMPdependent protein kinase catalytic subunit, for which a crystal structure is available from the
protein data bank.
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7.1 General experimental
All chemicals were purchased from Crown Scientific or Sigma Aldrich Chemical Co
(St. Louis, MO, USA) and used as received. All solvents were either AR or HPLC grade for
extractions and synthesis and HPLC grade for HPLC purification. Solvents were purified by
short path distillation, while solvents for HPLC were filtered through membrane filters
(Membrane nylon filters, #7404-009, Whatman®) and degassed in the sonicator. Sonication of
samples was performed using a Soniclean 250HT ultrasonic bath (Soniclean, Thebarton,
Australia). Solvents were mixed in volume to volume ratio. Evaporation of solvents was
performed on a Büchi R-114 or R200 rotary evaporator, under vacuum and under 40 °C to avoid
decomposition of samples. Water was removed from samples on a CHRIST ® LDC-1M
lyophiliser. Marine samples were homogenised using either an InvitroTM IKA® T10 basic
Ultra-Turrax® homogeniser or a Waring® blender. Melting pointes were determined using a
Reichert melting points apparatus and are uncorrected. The reaction yields were obtained after
drying procedure, performed under high vacuum.
7.1.1 Chromatography
Thin layer and silica gel chromatography
Thin layer chromatography (TLC) was performed on Merck thin layer aluminium
sheets or Macherey-Nagel Polygram® Sil G/UV254 thin layer pre-coated plastic TLC sheets both
with fluorescent indicator UV254. Various staining reagents were used including cerium
sulphate, dinitrophenylhydrazine (DNP), vanillin, and a natural product stain (polyethylene
glycol (PEG) 4000 (5%w/v) solution in ethanol) for the natural product extracts while isatin
compounds were coloured and directly visible on the TLC. Colourless compounds were
visualised under UV light at λ 254 nm. For the natural product analysis three solvent systems
were typically used to separate compounds on the TLC plates: a non-polar system (ethyl acetate
– hexane, 1:1), an intermediate polarity (ethyl acetate – methanol, 19:1) and a polar solvent
system (n-propanol - ethyl acetate – water, 7:2:1). Silica gel used for column chromatography
was Merck silica gel 60 (230-400 mesh). Column chromatography was done according to the
protocol described in Vogel et al.428 Preparative TLC was performed on silica or 20 x 20 glass
plates of Merck silica Gel 60 F254 plates.
HPLC chromatography
Analytical HPLC was performed on a Shimadzu system with either a dual UV detector
or a PDA detector. Columns used for analytical HPLC are Phenomenex Luna C18, Waters
SunFire C18 and C8, all with the same size of 4.6 nm x 250 nm. Preparative HPLC was
performed on a Waters system with a dual UV detector. Columns used for preparative HPLC
were C18 Waters 19 x 150 mm for samples up to 100 mg and C18 Waters 30 x 100 mm for
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samples up to 500 mg. Samples for HPLC analysis were removed by passing through a syringe
filter (Filter device puradisctm 25TF, # 6784-2504, Whatman®).
7.1.2 Nuclear magnetic resonance (NMR) spectroscopy
Nuclear magnetic resonance (NMR) spectra were obtained for all samples either on a
Varian Unity 500 MHz Inova, where proton and carbon spectra were obtained at 500 MHz and
126 MHz respectively, or a Varian Unity 300 MHz spectrometer, where proton and carbon
spectra were obtained at 300 MHz and 75 MHz respectively, Shigemi NMR tubes were used for
samples less than 5 mg. The samples were dissolved in deuterated solvents as indicated in
brackets. Chemical shifts are reported in parts per million (ppm) downfield from
tetramethylsilane (TMS), which was used as internal standard. Coupling constants (J) are given
in Hertz. Hydrogen and carbon assignments were performed using gradient correlation
spectroscopy (gCOSY), gradient heteronuclear single quantum correlation (gHSQC) and
gradient heteronuclear multiple bond correlation (gHMBC) spectroscopic techniques, nuclear
Overhauser effect spectroscopy (NOESY). Multiplets were reported as singlet (s), doublet (d),
doublet of doublets (dd), doublet of triplets (dt), triplet (t) and multiplet (m). Samples were
subjected to high vacuum overnight before performing NMR. The superscript symbol * in the
13

C NMR data denotes coincident peaks.

7.1.3 Mass spectrometry
Low resolution direct insertion electron impact mass spectrometry (EI-MS) was
performed on a Shimadzu QP-5050A system. The probe was heated from 40 ºC to 200 ºC. Gas
chromatography mass spectrometry (GCEI-MS) was performed on a Shimadzu QP-5050A GCMS system equipped with a BP-5 fused silica Rxi-5ms capillary column (5% phenyl/95%
dimethyl polysiloxane, 30 m x 0.25 mm, 0.25 μm film thickness, Resrek), using a helium carrier
gas (1.0 mL/mn) and samples of 1 μL over the temperature range 80-300 °C. The relative
intensity of each peak was calculated as a percentage of the summed total. Electrospray
ionisation low resolution mass spectrometry (ESI-MS) was performed on Waters Platform LCZ
spectrometer. High resolution electrospray ionisation mass spectra HRESI-MS was obtained
using a Waters Q-Tof Ultima spectrometer using leucine enkephalin (LeuEnk) as the internal
standard. All compounds were identified by comparing with compounds in the NIST 02 and
NIST 08 spectral database, with identification based on matches of greater than 75%.
7.2 Biological assays
7.2.1 The kinase inhibition assay
Protein kinase inhibitor activity was determined using the Kinase Glo® Luminescent Kinase
Assay (Promega Co, Madison, WI, USA).196 Purified PKA and specific kinase substrate
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(kemptide) were purchased from Promega and used as supplied. The PKA inhibitory activity of
the extracts was determined in opaque 96 white well plates (Corning) according to the
manufacturer’s instructions. Each well contained 5 μl of sample (e.g. 1mg/ml in 20% dimethyl
sulfoxide [DMSO] or ethanol), 25 μl of ATP (20 μM), and 20 μl of a mixture of kinase enzyme
(0.1unit/μL) and kemptide substrate (140 μM) in reaction buffer (40 mM Tris, 20mM MgCl2,
BSA 0.1mg/mL, pH 7.4). After 1 hour incubation at room temperature, 50 μl of the Kinase Glo®
Reagent was added and the mixture incubated for a further 15 min, after which the
luminescence was measured using a BMG Labtech FLUOstar Optima® luminometer (BMG
Labtech Pty. Ltd., Mornington, Australia). The data were determined relative to the positive
controls, which contained solvent (2% ethanol or 2% DMSO) in place of the sample. Negative
controls contained no substrate. Staurosporine, elagic acid or H-89 were used as internal
standards. All assays were conducted at 100 µg/ml (in 2% DMSO or 2% ethanol).
Measurements were performed in triplicate and data are presented as means ± S.E.M.
7.2.2 Haemolytic assay
The haemolytic activity of the extracts was determined for samples prepared in either
DMSO or ethanol as follows: 0.5% haemolytic solution was prepared using defibrinated horse
blood (Oxoid Australia Pty Ltd). A suspension of horse blood erythrocytes in phosphate buffer
saline (PBS) was centrifuged at 3000 rpm for 5 min at 6°C on a Sorvall SuperT21 Centrifuge and
diluted with PBS to reach 0.5% erythrocyte suspension. The reaction mixture contained 100 µl
of extracts (1mg/ml), 100 µl of PBS and 0.9 µl of erythrocyte suspension. The mixtures were
incubated for 30 min at 37 °C, then 100 µl of reaction mixture was transferred to sterile clear 96
well microplates (Greiner Bio-one) and absorbance was measured at λ 550 nm on a
Spectramax® 250 UV plate reader using Softmax Pro® program. All samples were done in
triplicate and in at least two separate experiments.
7.2.3 Brine shrimp (cytotoxic) lethality assay
The brine shrimp lethality assay was performed as follows: brine shrimp eggs (Artemia
franciscana) were hatched for 48 hours at 26-28°C in a light source in a 36 g/L salt solution
(Coral Reef, Marine Reef Salt), prior to the tests being run. Each well of a sterile clear 96 well
microplate (Greiner Bio-one) contained 10 animals, 20 µl of sample (1mg/ml in 20% DMSO or
ethanol) and 180 ml of salt solution was added to each well to bring the volume to 200 µl. Each
sample was done in triplicate in two separate experiments. The final concentration of the
extracts was 100 µg/ml in 2% DMSO or ethanol. The incubation time was 48 hours under a
light source and surviving animals were counted after 24 hours and percent mortality calculated.
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7.2.4 MTS Cell proliferation assay
Cytotoxicity of the isatin derivatives was determined using the CellTiter 96 ® AQueous
One Solution Cell Proliferation Assay, which emplys [3-(4,5-dimethylthiazol-2- yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] (MTS) reagent (Promega
Co., Madison, WI, USA). MTS assays were performed in clear 96-well microplates, including:
various dilutions of the test compounds dissolved in a final concentration of 2.5% DMSO, a
negative solvent control (2.5% DMSO) and background controls (containing test compounds
but no cells). Plates were incubated for 24 h at 37 °C in a 5% CO2 atmosphere, following the
addition of the test compounds and then again incubated for another 24 h (2 x 24 h incubation).
MTS reagent was added to each well and the assays were incubated at 37 °C for a further 3 h.
Assays were analysed in a Spectromax 250 plate reader at 490 nm using Softmax Pro software
(Molecular Devices, USA). The IC50 values were determined from sigmoidal dose-response
curves (variable slope) using GraphPad Prism 4.00 (GraphPad Software, Inc., San Diego, CA,
USA) and are presented as the mean of triplicates ± SEM.
Cell lines and cell culture conditions
Human, leukemic, monocyte-like, histolytic lymphoma (U937) and human, metastatic
breast adenocarcinoma (MDA-MB-231) cancer cells were obtained from American Type
Culture Collection (ATCC, VA, USA) distributed by Cryosite, NSW, Australia. Cells were
regularly cultured in vitro in culture medium consisting of RPMI-1640 medium, along with 2
mM L-glutamine, 5.6% (2 g/L) NaHCO3 and 5% foetal calf serum. The cells were maintained
in a Huracell incubator (Kendro Laboratory Products, Langenselbold, Germany) at 37 °C with a
humidified atmosphere containing 5% CO2. Viability of the cells was determined by the trypan
blue exclusion method. The number of viable cells was counted with the aid of a
haemocytometer.
7.3 Plant material
7.3.1 Shallow water algal species
Ten algal samples were collected from four locations along the New South Wales coast
of Australia (Table 2.1, Chapter 2). The algae were collected from the intertidal zone by hand
during the period March/April 2008 under Scientific Research Permit Number F95/269-4.0
issued by the New South Wales Department of Fisheries and stored frozen (-20 °C) until
extraction. Voucher specimens are held at the University of Wollongong (AZ050, AZ56, AZ59,
AZ061, AZ072, AZ073, AZ074, AZ076, AZ077 and AZ081). The collection of local marina
algal species was fully documented (time, date, location, organism description, interaction with
other organisms and habitat). Photographs of collected samples were taken at both the collection
place and in the laboratory.
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7.3.2 Deep-water sponge species
The deep-sea sponge samples were collected during a well head removal program
conducted by Woodside Pty Ltd in conjunction with TS Marine and Well Ops. Three different
subsea structures (well heads), which were abandoned on the ocean floor off the NW Australian
coast at depths of 82-135 m during the period 1986-1992, were brought to the surface by
remotely operated vehicle aboard the Havilla Harmony between June and August of 2008.
Immediately upon being brought to the surface, the specimens were collected from the structure,
frozen (-20 oC) and transported to the laboratory on dry ice. In situ video recording of the
heavily encrusted well heads on the ocean floor was also performed using ROVs.
The deep-sea sponges were collected in the North West Shelf of Australia in JuneAugust of 2008 and identified as: Haliclona sp., Geodia sp., and a mixed sample of intertwined
Sarcotragus sp. and Ircinia sp. by Dr Jane Fromont, Western Australian Museum. The former
two were obtained from the same location (depth 135 m), and the latter from a location 80 km
away (depth 84 m) (Chapter 3, Table 3.1). Samples were collected under permit AUCOM2008032 issued by the Australian Government and voucher specimens (WAMZ45792WAMZ45795) are held at the Western Australian Museum.
7.4 Extract preparation
Algal extracts were prepared using either extraction method A or B, while sponge
extracts were prepared following method C, as described below.
7.4.1 Extraction method A
The frozen algal material was thawed and cut into small pieces using a scalpel or
blender. Algae samples were extracted with methanol and left overnight in the fridge. The
suspension was gravity filtered through a Whatman filter paper No. 1. The obtained tissue
residue (marc) was re-extracted with methanol followed by two extractions with
dichloromethane (DCM) where all extracts were left to stay for at least one hour on a magnetic
stirrer. All organic extracts were combined, with a final solvent ratio 1:1 methanoldichloromethane and solvents were evaporated in vacuo on a rotary evaporator to dryness to
give a crude extract. The amount of solvent which were used in the above extraction 20-50 ml
of solvent per one gram wet weight of sample.

Liquid-liquid partitioning of crude extract
The crude extracts were further separated into polar (water), intermediate polarity
(butanol) and non-polar (dichloromethane, DCM) extracts. First, the crude extracts were
dissolved in a small amount of DCM and then separated between DCM and water three times.
The aqueous layer was further separated into water and butanol extracts. Solvents were removed
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from all fractions in vacuo yielding different polarity fractions. Before removing the solvents,
DCM and n-BuOH layers were dried over anhydrous MgSO4.
7.4.2 Extraction method B
The DCM and water extracts were prepared as described in extraction method A (Fig.
2.5, Chapter 2). The frozen algal material was extracted with methanol and DCM, the solvents
combined and evaporated to dryness, and the crude extract weighed and then partitioned
between water and dichloromethane. The DCM layer was treated with anhydrous MgSO4 and
the solvent removed in vacuo to yield non-polar DCM extract. The stock solutions of 1mg/mL
in DMSO of DCM extract were prepared and further diluted by 1:10 in the assay to give a final
concentration of 100 µg/mL (in 2% DMSO or 2% ethanol).
The generation of ethanol or ‘quick” extracts was performed based upon the procedure
of Wright et al.429 The ethanol extracts were obtained from approximately 8 g of frozen material
cut into small pieces. Frozen samples were suspended in 20 ml of non-denatured 100% ethanol
for 2 min, using a magnetic stirrer or INVITRO® homogeniser. Extracts were transferred into a
scintillation screw cap glass vial and left overnight in the fridge. Extracts were gravity filtered
and the filtrate used for biological testing. The concentration of prepared ethanol extract were
approximately 9 mg/mL, but can range in value of 1 – 20 mg/mL for the reason that some
organisms can give low yields of metabolites and concentration thus depends on the nature of
the extracted sample.
7.4.3 Extraction method C
The extracts were prepared according to the method of Thale et al. (Fig 3.10, Chapter
3).255 The frozen sponge samples were cut into small pieces and suspended in 100% methanol
(300 ml) for 24 hours at 4°C. The sample was filtered and the process repeated twice. The three
methanol filtrates were combined and the solvent evaporated to give the crude methanol extract
which was further partitioned between water and dichloromethane. The dichloromethane extract
was then partitioned with 10% methanol and hexane. The 10% methanol extract was further
partitioned between dichloromethane and 50% methanol. The water fraction was further
partitioned between water and n-butanol to give another two extracts (Chapter 3, Fig. 3.10).
The solid residue, obtained from the original methanol was suspended in 100%
dichloromethane for 24 hours at 4°C. The sample was filtered and the process repeated and the
two dichloromethane extracts combined and the solvent removed in vacuo to give the crude
dichloromethane extract. The dichloromethane was further partitioned between 10% methanol
and hexane (Fig. 3.10, Chapter 3).
The organic fractions were treated with anhydrous MgSO4 and the solvent removed in
vacuo to yield dried extracts. The above procedure gave a total of seven extracts;
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dichloromethane, hexane 1, hexane 2, 10% methanol, 50% methanol, butanol and a water
extract.
7.5 Shallow water algal species (Chapter 2)
Prionitis linearis
Ethanol (0.09 g) and DCM extracts (0.31g) of the red algae Prionitis linearis
(approximately 45 g of wet weight) were prepared according to method B (Fig. 2.5, Chapter 2)
and tested in three biological assays (PKA inhibition, haemolytic and brine shrimp, Fig. 2.12).
The DCM extract was subjected to GC-MS analysis.

Corallina vancouveriensis
Ethanol (0.071 g) and DCM (0.36 g) extracts of the red algae Corallina vancouveriensis
(approximately 53 g of wet weight) were prepared according to method B (Fig 2.5, Chapter 2)
and extracts were tested in three biological assays (PKA inhibition, haemolytic and brine
shrimp, Fig. 2.12). The DCM extract was subjected to GC-MS analysis.

Codium fragile
The crude extract (4.12 g) of the green alga Codium fragile (approximately 129 g wet
weight) was prepared according to method A and further partitioned to give a non-polar DCM
extract (dark green oil, 1.24 g), an intermediate polarity butanol extract (dark yellow solid, 1.61
g) and a polar water extract (white solid, 1.42 g). Extracts were tested in three biological assays
(PKA inhibition, haemolytic and brine shrimp, Fig. 2.6). The non-polar extract was further
purified by column chromatography (Fig. 2.16). The intermediate and polar extracts didn’t show
activity in any of the assays and were not further analysed.

Non-polar DCM extract of the green algae Codium fragile
The non-polar dichloromethane fraction (1.24 g) was chromatographed over silica gel
using a gradient solvent system of 10:1 Hex/EtOAc through to 1:5 Hex/EtOAc to give seven
fractions (Fig. 2.16). Column fractions 1, 2, 5 and 7 were subjected to GC-MS analysis and their
chemical constituents are shown in Table 2.3 (Chapter 2). Column fractions 3, 4 and 6 were
analysed by EI-MS and their constituents are shown in Table 2.4 (Chapter 2).
Removal of chlorophyll.
Chlorophyll was removed from the non-polar extracts 3 and 4 following procedure of
Sargeneti at al.263 The extracts were mixed with silica gel and activated charcoal, in ratio of
extract: silica: charcoal 1:3:1. The mixture was stirred for 15 minutes and than filtered. The final
purified material was washed with hexane, dichloromethane and methanol.
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Codium dimorphum
The crude extract (2.41 g) of the green algae Codium dimorphum (approximately 90 g
wet weight) was prepared according to method A and further partitioned to give a non-polar
dichloromethane extract (dark green oil 0.82 g), an intermediate polarity butanol extract (orange
solid, 1.08 g) and a polar water extract (white solid, 2.21 g) with water fraction containing a
small amount of residual water. Extracts were tested in three biological assays (PKA inhibition,
haemolytic and brine shrimp, Fig. 2.7). The non-polar and intermediate polarity extracts were
investigated by TLC and LREIMS but due to the complex nature of these extracts and small
amount of material and low bioactivity they were not further purified. The polar extract was not
studied further because it was not active in any assays. The DCM fraction was further analysed
by GC-MS method (Chapter 2, Table 2.2).
Ulva lactuca
Ethanol (0.067 g) and DCM extracts (0.41 g) of the green algae Ulva lactuca
(approximately 65 g of wet weight) were prepared according to method B and tested in the three
biological assays (PKA inhibition, haemolytic and brine shrimp, Fig. 2.12). The DCM extract
was subjected to GC-MS analysis (Table 2.2, Chapter 2).

Colpomenia sinuosa
The crude extract (5.83 g) of the brown algae Colpomenia sinuosa (approximately
230 g of wet weight) was prepared according to method A and further partitioned to give a
non-polar DCM extract (dark green oil, 1.01 g), an intermediate polarity butanol extract (dark
yellow solid, 1.82 g) and a polar water extract (white solid, 1.86 g) as described in method A
(Fig 2.5, Chapter 2). Extracts were tested in three biological assays (PKA inhibition, haemolytic
and brine shrimp, Fig. 2.8). The non-polar extract was further purified by column
chromatography. The intermediate polarity and polar extracts didn’t show activity in the kinase
assay and were not studied further.

Non-polar dichloromethane extract of Colpomenia sinuosa
The non-polar extract (1.01 g) was separated by silica gel column chromatography
using a gradient solvent system of 100% hexane followed by Hex/EtOAc 4:1; 3:2; 1:1; 2:3;
100% EtOAc and than EtOAc/Methanol 2:3, which gave six major components as judged by
TLC (Fig. 2.17). Column fractions 2 and 5 were subjected to GC-MS analysis and their
chemical constituents are shown in Table 2.3 (Chapter 2). Column fractions 1, 3, 4 and 6 were
analysed by EI-MS and their constituents are shown in Table 2.4 (Chapter 2).
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Phyllospora comosa
The crude extract (4.6 g) of the brown algae Phyllospora comosa (approximately 140 g
of wet weight) was prepared according to method A and further partitioned to give a non-polar
dichloromethane extract (green oil, 1.40 g), an intermediate polarity butanol extract (orange
solid, 2.54 g) and a polar water extract (light yellow solid, 3.23 g) as described in method A.
Extracts were tested in three biological assays (PKA inhibition, haemolytic and brine shrimp,
Fig. 2.9).The non-polar and intermediate polarity extracts were investigated by TLC and EIMS.
All three extracts were not further purified due to low activity in the PKA assay. The chemical
composition of the DCM extract was analysed by GC-MS method and results are shown in
Table 2.2 (Chapter 2).

Padina sp.
The crude extract (2.34 g) of the brown algae Padina sp. (approximately 190 g of wet
weight) was prepared according to method A and further partitioned to give a non-polar DCM
extract (green oil, 1.04 g), an intermediate polarity butanol extract (orange solid, 1.17 g) and a
polar water extract (light yellow solid, 2.26 g) as described in method A. Extracts were tested in
three biological assays (PKA inhibition, haemolytic and brine shrimp, Fig. 2.10). The non-polar
extract was further purified by column chromatography while butanol and water extracts were
not further purified because they didn’t show any activity in the kinase assay.

Non-polar dichloromethane extract of Padina sp.
The non-polar extract (1.04 g) of Padina sp. was separated by silica gel column
chromatography using a gradient solvent system of 100% Hex; Hex/EtOAc 9:1; 6:1; 1:1; 2:8;
EtOAc/Methanol 95:5, to give six major partially purified fractions (Fig. 2.19). Column
fractions 1 and 6 were analysed by GC-MS method (Table 2.3, Chapter 2) while fractions 2, 3, 4
and 5 were subjected to EI-MS analysis (Table 2.4, Chapter 2).

Sargassum vestitum
The crude extract of the brown alga Sargassum vestitum (5.21 g, approximately 500 g
wet weight) was prepared according to method A. The crude extract yield three different
polarity extracts as follows: water (3.81 g, brown solid), butanol (0.62 g, brown oil) and DCM
(1.05 g, dark green oil). Extracts were tested in three biological assays (PKA inhibition,
haemolytic and brine shrimp, Fig. 2.11). Only the non-polar extract was further purified by
column chromatography.
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Non-polar dichloromethane extract of Sargassum vestitum
Dichloromethane fraction was further separated using column chromatography with
hexane, ethyl acetate and methanol as a gradient solvent system10:1 Hex/EtOAc, 1:5
Hex/EtOAc. Monitored by TLC, four major fractions were isolated, where all were mixtures
(Fig. 2.21). Further purification of column fraction 4 by preparative C18 HPLC (95% MeOH)
gave compound 113.
Thunbergol A, colourless solid (0.009
g).

HREI-MS:

calcd

for

(M+H+)

C27H38O5 442.2724 found 442.2719.
1

HNMR (CDCl3, 500 MHz) δ 1.30 (s,

3H, H17’), 1.51-1.53 (m, 2H, H1’),
1.51-1.54 (m, 3H, H16’), 1.60-1.68 (m, 6H, H13’, H14’) 2.12-2.15 (m, 9H, H2’, H5’, H10’,
H18’), 2.18 (t, J = 7.0 Hz, 2H, H9’), 2.58-2.60 (m, 2H, H6’), 3.01 (dd, J = 16.0, 5.0 Hz, 1H,
H4), 3.07 (dd, J = 16.0, 5.0 Hz, 1H, H4), 3.61 (dd, J = 4.0, 4.0 Hz, 1H, H3), 4.80 (t, J = 7.0 Hz
1H, H3’), 5.15-5.18 (m, 1H, H11’), 5.96 (t, J = 7.0 Hz, 1H, H7’), 6.4 (s, J = 2.0 Hz, 1H, H7),
6.51 (s, 1H, H5).278
Sargassum sp.
The ethanol (0.059 g) and dichloromethane extracts (0.11 g) of the brown algae
Sargassum sp. (approximately 30 g of wet weight) was prepared according to method B and
tested in the three biological assays (PKA inhibition, haemolytic and brine shrimp, Fig. 2.12).
The DCM extract was subjected to GC-MS analysis (Table 2.2, Chapter 2).
7.6 Deep-sea sponge samples (Chapter 3)
Haliclona sp.
The sponge Haliclona sp. (500 g wet weight) was separated according to extraction
method C (section 7.4.3), to give seven different polarity extracts as follows: water (198 mg, a
yellowish powder), butanol (156 mg, an orange gum), 10% methanol (117 mg, a pale yellow
solid), dichloromethane (10.6 mg, yellow oil), hexane 1 (146 mg, orange oil), 50% methanol
(102 mg, a pale yellow gum) and hexane 2 (174 mg, light orange oil) extract. The three nonpolar extracts, dichloromethane, hexane 1 and hexane 2 were analysed by GC-MS (Tables 3.2,
3.3 and 3.4, Chapter 3) while the water extract was analysed by high resolution ESI-QTof-MS
(Table 9.4, Appendix). Analyses of the remaining extracts are described below.

10% Methanol extract of the deep-sea sponge Haliclona sp.
The 10% methanol extract (97 mg) was separated by silica gel column chromatography
using a gradient solvent system of 100% Hex; through to 100% EtOAc, and EtOAc/methanol
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1:4, which comprised six components by TLC. Six major column fractions were screened for
kinase inhibitory activity and subjected to EI-MS analysis (Fig 3.15, Table 9.1).

50% Methanol extract of the deep-sea sponge Haliclona sp.
The 50% methanol extract (20.1 mg) was separated by silica gel column
chromatography using a gradient solvent system of 100% Hex; Hex/EtOAc 3:1; 1:1; 2:3; 1:3;
EtOAc 100%, EtOAc/Methanol 2:3; 1:4; 1:5, which gave six major fractions as judged by TLC,
which were screened for kinase inhibitory activity and subjected to EI-MS analysis (Fig 3.16,
Table 9.2).

Geodia sp.
The sponge Geodia sp. (500 g wet weight) was separated according to method C
(7.4.3), to give seven different polarity extracts as follows: water (198 mg, a yellowish powder),
butanol (156 mg, an orange gum), 10% methanol (97 mg, a pale yellow solid), dichloromethane
(10.6 mg, yellow oil), hexane 1 (146 mg, orange oil), 50% methanol (20.1 mg, a pale yellow
gum) and hexane 2 (174 mg, light orange oil) extract. The three non-polar extracts,
dichloromethane, hexane 1 and hexane 2 were analysed by GC-MS (Tables 3.2, 3.3 and 3.4,
Chapter 3), while the water extract was analysed by high resolution ESI-QTof-MS (Table 9.4,
Appendix). Analyses of the remaining extracts are described below.

Butanol extract of the deep-sea sponge Geodia sp.
The butanol extract (BE, 156 mg) was purified by preparative RP-HPLC (isocratic
mobile phase: H2O, flow rate 43.5 ml/min). The collected fractions were tested on analytical
HPLC (C18, mobile phase: H2O), and of these fractions 6, 7/8 (these two fractions were
identical), 9 and 11 appeared pure, while all others were mixtures and were combined. The four
pure fractions were further analysed.

Fraction 1-5 (0.4 mg, white powder)
LREI-MS: m/z 152 (75) [M+], 109 (74), 54 (98). This data matches that of 1H-pyrolo[2,3b]-pyridine. HREI-MS: calcd for C7H8N2O2 (M+H+) 153.0592 found 153.0586.
Fraction 6 (0.9 mg, white solid)
LREI-MS: m/z 326 [M+], 135 (100), 108 (35), 81 (28), 66 (20), 53 (42), 36 (49). This mass
spectral data has a 68% match to that of septacidin aminonucleoside (C12H18N6O5) in the NIST
08 database.
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Fraction 7 & 8 (1.0 mg, white solid)
LREI-MS: m/z 226 [M+], 117 (100), 96 (39), 73 (54), 69 (511), 54 (25), 40 (38). This mass
spectral data has a 71% match to that of 2’,5’-dideoxy-uridine (C9H12N2O5) in the NIST
database. HREI-MS: calcd for C9H12N2O5 (M+H+) 227. 0757, found 227.0746.
Fraction 9 (0.9 mg, white solid)
LREI-MS: m/z 242 (12) [M+], 136 (100), 108 (23), 97 (20), 81 (44), 63 (20), 54 (79), 53 (61),
44 (78), 36 (65). This mass spectral data has a 62% match to that of 2’-deoxy-inosine
(C10H12N4O4) in the NIST 08 database.
Ircinia/Sarcotragus sp.
The sponge Ircinia/Sarcotragus sp. (500 g wet weight) was separated according to
method C (section 7.4.3), to give seven different polarity extracts as follows: water (126 mg, a
yellowish powder), butanol (180 mg, an orange gum), 10% methanol (96 mg, an orange gum),
dichloromethane (230 mg, yellow oil), hexane 1 (231 mg, orange oil), 50% methanol (374 mg, a
pale yellow) and hexane 2 (261 mg, light orange oil) extract. The three non-polar extracts,
dichloromethane, hexane 1 and hexane 2 were analysed by GC-MS (Tables 3.2, 3.3 and 3.4,
Chapter 3), while the water extract was analysed by high resolution ESI-QTof-MS (Table 9.4,
Appendix). Analyses of the remaining extracts are described below.
Butanol extract of the deep-sea sponge Ircinia/Sarcotragus sp.
The butanol extract (180 mg) was purified by preparative RP-HPLC (isocratic mobile
phase: H2O, flow rate 43.5 ml/min). The thirty seven fractions collected were analysed on
analytical HPLC to give 1 pure fraction and 3 fractions which were mixtures.

Fraction 3.1.1 (1 mg, white solid)
LREI-MS: m/z 44 (97), 136 (21), 176 (56). This data has a 82% match to that of
2-phenylethylamine in the NIST 08 database. 1H NMR (CDCl3, 500 HZ): δ 2.95 (t,
2H, J = 7.5), 3.16 (t, 2H, J = 7.5 Hz), 7.26-7.28 (m, 2H), 7.35-7.37 (m, 3H).431

Fraction 3.1.2 (7.6 mg, white solid)
LREI-MS: m/z 55 (80), 69 (100), 81 (41), 322 (56). This data has a 65% match to that of
5-methoxy-dokosanein the NIST 08 database.

Fraction 3.1.3 (83.6 mg, white solid)
LREI-MS: m/z 63 (21), 89 (43), 116 (58), 144 (97), 161 (35). This data has a 70% match to
that of indanone-2-hydroxyimino in the NIST 08 database.
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Fraction 3.1.4 (23.0 mg, white solid)
LREI-MS: m/z 126 (89), 55 (100). This data has a 74% match to that of thymidine in the NIST
08 database.

10% Methanol extract of the deep-sea sponge Ircinia/Sarcotragus sp.
The 10% methanol extract (231 mg), was subjected to silica gel column
chromatography, with increasing polarity of solvent, from 100% hexane to 100% EtOAc and
then to 70/30 EtOAc/methanol. Thirty nine fractions were collected and combined according to
TLC, to give a total number of six major fractions (3.2.1 -3.2.6), all of which were obtained as
mixtures and screened for kinase inhibitory activity and subjected to EI-MS analysis (Fig 3.18,
Table 9.3).
7.7 Experimental for Chapter 4
The novel compounds synthesised in this work are assign with 1H NMR, 13C NMR and
2D NMR data. The structure of the known compounds was confirmed by 1H NMR and MS.
Isatin derivatives that were obtained in low yield were only assigned by 1H NMR due to
insufficient material for 2D NMR spectra.
Synthesis of 5,7-dibromoisatin (76)
The title compound (76) was synthesised according to the protocol of
Vine et al.183 Isatin (5 g, 0.034 mol) was warmed in ethanol (95%, 100
ml) with stirring until it dissolved. Bromine (5 ml, 102 mmol) was
added dropwise to the stirred solution whilst maintaining the
temperature between 70 - 75°C. The solution was cooled to room
temperature and ice was placed into the solution. The precipitate was filtered, washed with
water and cold ethanol and the product recrystallised from ethanol to yield an orange solid (7.8
mg, 84.9%), m.p. 260-261ºC (lit. 261–263 ºC),431 Rf 0.24 (DCM). LREI-MS: m/z 303; 305;
307 [M+] 79Br79Br; 79Br81Br; 81Br81Br. 1H NMR (CDCl3, 500 MHz) δ 7.67 (s, 1H), 8.03 (s, 1H),
11.43 (s, 1H).

5,7-Dibromo-3,3-diethoxyindolin-2-one (161)
The title compound (161) ) was synthesised according to the
protocol of Vine et al.183 Isatin (5 g, 0.034 mol) was warmed in
ethanol (100%, 100 ml) with stirring until it dissolved. Bromine
(5 ml, 102 mmol) was added dropwise to the stirred solution
whilst maintaining the temperature between 70 - 75°C. The
solution was cooled to room temperature and ice was placed into the solution. The precipitate
was filtered, washed with water and cold ethanol and the product recrystallised from ethanol to
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yield an orange solid (6.3 mg, 79%), m.p. 267-269 ºC, Rf 0.31 (DCM). LREI-MS: m/z 375;
377; 379 [M+]

79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: C12H13Br2NO3

79

Br81Br (M+Li+)

381.9422 found 381.9387. 1H NMR (CDCl3, 500 MHz) δ 1.11 (t, J = 7 Hz, 6H, CH3), 3.63 (q, J
= 7.5 Hz, 2H, CH2), 3.82 (q, J = 7.5 Hz, 2H, CH2), 7.56 (s, 1H, H4), 7.78 (s, 1H, H6), 11 (s, 1H,
NH).

Synthesis of 5-nitroisatin (170)
5-nitroisatin was synthesized according to the protocol of Vine et al.183
Isatin (500 mg, 0.0034 mol) was mixed with concentrated H2SO4 (3.2
ml). A solution was added dropwise to the solution of KNO3 (344 mg,
0.0034 mol) in conc. H2SO4 (3.8 ml) over a period of 1h. Temperature was maintained between
0 and 4°C. The solution was poured into 25 ml of crushed ice and the precipitate filtered and
washed with water. The product was purified by column chromatography with DCM/MeOH
(98:2, 95:5) to yield a yellow/orange sold (0.26 g, 41%), m.p. 250-253 ºC (lit. 252-254 ºC),186 Rf
0.48 (DCM/MeOH 98:2). LREI-MS: m/z 192 [M+]. 1H NMR (DMSO-d6, 500 MHz) δ 7.03 (d,
J = 8.5 Hz, 1H, H7), 8.16 (d, J = 2.0 Hz, 1H, H4), 8.81 (dd, J = 3, 8.5 Hz, 1H, H6), 10.80 (br s,
1H, NH).

7.7.1 General method for N-alkylation of 5,7-dibromoisatin (Method A)
Method A: N-Alkylated isatin derivatives were synthesised according to the protocol of Vine et
al.183 and Garden et al.392 The isatin derivative (1 equiv.) and calcium hydride (1.2 equiv.) were
combined in DMF (8 mL per 100 mg of isatin derivative) and the solution stirred with gentle
warming. After 45 minutes an appropriate benzyl halide (1.0 equiv) and potassium iodide (0.2
equiv.) were added to the reaction and reaction mixture was stirred at 80°C for 15-24 hour.
Once the reaction had run to completion (as judged by TLC) the reaction mixture was poured
into acidified aqueous solution (0.2 M HCl) and extracted with EtOAc. The extracts were
combined and washed with a salt solution, dried over anhydrous MgSO4 and the solvent
removed under reduced pressure. The product was purified using column chromatography on
silica gel.

5,7-Dibromo-N-(p-methoxybenzyl)isatin (162)
The title compound (162) was synthesised from 76 and pmethoxybenzylchloride according to Method A and purified
by flash chromatography on silica gel (DCM) to give a redorange solid (2.4 g, 86%), m.p. 165-166 ºC (lit. 166–167
ºC),186 Rf 0.52 (DCM). LREI-MS: m/z 423; 425; 427 [M+]
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Br79Br; 79Br81Br; 81Br81Br. 1H NMR (CDCl3, 500 MHz) δ 3.81 (s, 3H, OCH3), 5.38 (s, 2H,

79

CH2), 6.87 (d, J = 8.5 Hz, 2H, H3’/H5’), 7.22 (d, J = 8.0 Hz, 2H, H2’/H6’), 7.72 (d, J = 2.0 Hz,
1H, H4), 7.84 (d, J = 2.0 Hz, 1H, H6).

5-Bromo-N-(p-methoxybenzyl)isatin (162 a)
The title compound (162 a) was obtained as a by-product in the
above reaction and purified by column chromatography to
yield a dark orange solid (0.045 g, 2%), m.p. 143-145 ºC (lit.
144–146 ºC),186 Rf 0.57 (DCM). LREI-MS: m/z 345; 347
[M+] 79Br79Br; 81Br81Br. 1H NMR (CDCl3, 500MHz) δ 3.77 (s,
3H, CH3), 4.85 (s, 2H, CH2), 6.70 (d, J = 2.0 Hz,1H, H7), 6.85 (d, J = 8,0 Hz,2H, H3’/H5’),
7.23 (d, J = 8.0 Hz, 2H, H2’/H6’), 7.57 (dd, J = 2 Hz, 2.0 Hz, 1H, H6), 7.66 (d, J = 2,0 Hz,1H,
H4).

5,7-Dibromo-N-(p-methylbenzyl)isatin (163)
The

title

compound

(163)

was

synthesised

from

5,7-

dibromoisatin and p-methylbenzylchloride according to Method
A and purified by flash chromatography on silica gel (DCM) to
yield an orange solid (0.89 g, 67%), m.p. 122-124 ºC (lit. 121123ºC),186 Rf 0.71 (DCM). LREI-MS: m/z 407; 409; 411 [M+]
Br79Br; 79Br81Br; 81Br81Br. 1H NMR (CDCl3, 500 MHz) δ 2.32 (s, 3H, CH3), 5.36 (s, 2H, CH2),

79

7.09 (d, J = 8.0 Hz, 2H, phenyl), 7.12 (d, J = 8.0 Hz, 2H, phenyl), 7.72 (d, J = 2.0 Hz, 1H, H4),
7.80 (d, J = 2.0 Hz, 1H, H6).

5,7-Dibromo-N-(p-chlorobenzyl)isatin (164)
The title compound (164) was synthesised from 5,7dibromoisatin and p-chlorobenzylchloride according to Method
A and purified by flash chromatography on silica gel (DCM) to
yield an orange solid (0.97 mg, 69%), m.p. 158-161 ºC (lit. 159161 ºC),186 Rf 0.89 (DCM). LREI-MS: m/z 427; 429; 431 [M+]
Br79Br; 79Br81Br; 81Br81Br. 1H NMR (CDCl3, 500MHz) δ 5.38 (s, 2H, CH2), 6.87 (d, J = 8.0 Hz,

79

2H, H2’H6’), 7.22 (d, J = 8.0 Hz, 2H, H3’/H5’), 7.72 (d, J = 2.0 Hz, 1H, H4), 7.84 (d, J = 2.0
Hz, 1H, H6).

157 |

Chapter 7

Experimental

5,7-Dibromo-N-(p-iodobenzyl)isatin (165)
The title compound (165) was synthesised from 5,7-dibromoisatin
and p-iodobenzylchloride according to Method A and purified by
flash chromatography on silica gel (DCM) to yield an orange solid
(0.66 mg, 78%), m.p. 139-142 ºC (lit. 141-142 ºC)186, Rf 0.89
(DCM). LREI-MS: m/z 519; 521; 523 [M+]
81

79

Br79Br;

79

Br81Br;

Br81Br. 1H NMR (CDCl3, 500 MHz) δ 5.37 (s, 2H, CH2), 6.87 (d, J = 8.0 Hz, 2H, H2’/H6’),

7.22 (d, J = 8.0 Hz, 2H, H3’/H5’), 7.72 (d, J = 2.0 Hz, 1H, H4), 7.84 (d, J = 2.0 Hz, 1H, H6).

5,7-Dibromo-N–(2-morpholinoethyl)isatin (166)
The title compound (166) was synthesised from 5,7-dibromoisatin
and 4-(2-chloroethyl)morpholine hydrochloride according to Method
A and purified by flash chromatography on silica gel (DCM/EtoAc
6:1) to yield a red solid (0.18 g, 27%), m.p. 124-126 ºC, Rf 0.30
79

Br79Br;

(DCM/EtOAc 4:1). LREI-MS: m/z 416; 418; 420 [M+]
79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C14H15Br2N2O3

79

Br81Br

(M+H+) 416.9330 found 416.9324. 1H NMR (CDCl3, 500 MHz) δ 2.47 (t, J = 4.5 Hz, 4H, H2’’/
H6’’), 2.61 (t, J = 6.5Hz, 2H, H2’), 3.57 (t, J = 4.5 Hz, 4H, H3’’/ H5’’), 4.28 (t, J = 6.5 Hz, 2H,
H1’), 7.70 (s, 1H, H4’), 7.87 (s, 1H, H6’).

C NMR (CDCl3, 126 MHz): δ 39.4 (C1’), 53.8

13

(C2’’/C6’’), 56.6 (C2’), 67.2 (C3’’/C5’’), 106.3, 118.4, 121.5, 127.7 (C4), 145.1 (C6), 146.9
(C7a), 158.8 (C2), 181.8 (C3).

5,7-Dibromo-N-(2-morpholino-2-oxoethyl)isatin (167)
The title compound (167) was synthesised from 5,7-dibromoisatin
and p-(chloroacetyl)morpholine according to Method A and purified
by flash chromatography on silica gel (DCM/EtOAc 10:1, 6:1) to
give a dark red solid (0.923 g, 39%), m.p. 164-167 ºC, Rf 0.29
(DCM/EtOAc 4:1). LREI-MS: m/z 430; 432; 434 [M+]
79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C14H13Br2N2O4

79

Br79Br;

79

Br81Br

(M+H+) 430.9242 found 430.9258. 1H NMR (CDCl3, 500 MHz) δ
3.71 (s, 2H, H1’), 3.72-3.76 (m, 8H, H2,’/H3’’/H5’’/H6’’), 7.71 (s, 1H, H4), 7.81 (s, 1H, H6).
13

C NMR (CDCl3, 126 MHz): δ 42.7 (C2’’/C6’’), 43.2 (C2’’/C6’’), 45.4 (C1’), 66.5

(C3’’/C5’’), 66.3 (C3’’/C5’’), 105.6 (C3a), 117.2 (C5), 121.6 (C7a), 127.7 (C4), 144.9 (C6),
147.4 (C7), 158.5 (C2), 164.6 (C2’), 181.1 (C3).
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5,7-Dibromo-N-propargylisatin (168)
The title compound (168) was synthesised from 5,7-dibromoisatin
and 3-bromo-1-propyne according to Method A and purified by
flash chromatography on silica gel (DCM) to give a dark red solid
(0.26 g, 78%), Rf 0.79 (DCM). LREI-MS: m/z 341; 343; 345 [M+]
79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C11H6Br2NO2

Br81Br (M+H+) 341.8765 found 341.8725. 1H NMR (CDCl3, 500 MHz) δ 2.36 (s, 1H, H3’),

79

4.93 (s, 2H, H1’), 7.01 (s, 1H, H4), 7.91 (s, 1H, H6). 13C NMR (CDCl3, 126 MHz): δ 32.1
(C1’), 74.1 (C2’, C3’), 103.0 (ArC), 118.7 (ArC), 121.1 (ArC), 128.2 (C4), 144.5 (C6), 144.9
(C7a), 158.3 (C2), 180.6 (C3).

N-(4-Methoxybenzyl)isatin (169)
The title compound (169) was synthesised from isatin and
p-methoxybenzylchloride according to Method A and purified
by flash chromatography on silica gel (DCM) to give a red solid
(0.66 g, 83%), m.p. 170-172 ºC (lit. 169-171 ºC),186 Rf 0.62
(DCM). LREI-MS: m/z 267.28 [M+] 1H NMR (CDCl3, 500
MHz) δ 3.79 (s, 3H, OCH3), 4.87 (s, 2H, CH2), 6.80 (d, J = 8 Hz, 1H, H7), 6.87 (d, J = 8 Hz,
2H, H3’/H5’), 7.09 (t, J = 8 Hz, 1H, H5), 7.25 (d, J = 8 Hz, 2H, H2’/H6’), 7.51 (t, J = 1.8 Hz,
1H, H6), 7.61 (d, J = 7 Hz, 1H, H4).

5-Nitro-N-(4-chlorobenzyl)isatin (170)
The title compound (170) was synthesised from 5nitroisatin and p-methoxybenzylchloride according to
Method A and purified by flash chromatography on silica
gel (DCM/MeOH 15:1, 10:1) to give a dark yellow solid
(0.25 g, 79%), Rf 0.48 (DCM/EtOAc 5:1). LREI-MS: m/z
312 [M+]. 1H NMR (CDCl3, 500 MHz) δ 3.79 (s, 3H, OCH3), 4.95 (s, 2H, CH2), 6.88 (d, J = 8.5
Hz, 2H, H3’/H5’), 6.96 (d, J = 8.5 Hz, 1H, H7), 7.26 (d, J = 8.5 Hz, 2H, H2’/ H6’), 8.45 (d, J =
9.0 Hz, 1H, H6), 8.45 (s, 1H, H4).

5-Methoxy-N-(4-methoxybenzyl)isatin (171)
The title compound (171) was synthesised from 5-methoxyisatin and p-methoxybenzylchloride
according to Method A and purified by flash chromatography on silica gel (D DCM/MeOH
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15:1, 10:1) to give a dark red solid (0.65 g, 74%), Rf
0.52 (DCM/EtOAc 5:1). LREI-MS: m/z 297 [M+]. 1H
NMR (CDCl3, 500 MHz) δ 3.77 (s, 3H, OCH3), 3.79
(s, 3H, OCH3), 4.83 (s, 2H, CH2), 6.70 (d, J = 8.5 Hz,
1H, H6), 6.87 (d, J = 8.0 Hz, 2H, H3’/H5’), 7.08 (d, J
= 8.0 Hz, 1H, H7), 7.13 (s, 1H, H4), 7.25 (d, J = 8.5 Hz, 2H, H2’/H6’).

7.7.2 General method for 3-imino-substituted-N-alkylated-5,7-dibromoisatin derivatives
Method B: The imine isatin derivatives were all synthesized using the same protocol
with the only difference being the reaction time.159,398 N-alkylated-5,7-dibromoisatin (1 equiv.
0.2 g) was dissolved in ethanol (8 mL per 100 mg of isatin derivative) and mixture was
sonicated for 5 min, until the isatin was totally dissolved. Molecular sieves (1g per 100 mg of
compound) were added to the mixture, which was sonicated for another 5 min, followed by the
addition of acetic acid (200 µL per 100 mg of compound) and the appropriate aniline (1 equiv.).
The reaction mixture was refluxed for 2-48 h until the product was formed by TLC. The mixture
was then poured into water and extracted with EtOAc, the solvent removed and the product
purified by column chromatography.

Synthesis

of

(E

and

Z)-4-[5,7-dibromo-1-(4-methoxybenzyl)-2-oxoindolin-3

-ylideneamino]benzoic acid (175)
The

title

compound

(175)

was

1-(4-methoxybenzyl)-5,7-dibromoisatin

synthesised
(162)

and

from
p-

aminobenzoic acid according to method B and purified by
flash chromatography on silica gel (CHCl3/MeOH 95:5) to
give a red powder (0.041 g, 16 %), m.p. 251-254 ºC (lit.
250-252 ºC),182 Rf 0.25 (DCM), mixture of isomers (E:Z
/47:53). LREI-MS: m/z 542; 544; 546 [M+] 79Br79Br; 79Br81Br; 81Br81Br. 1H NMR (DMSO-d6,
500 MHz) δ 3.69 (s, 3H, OCH3, Z), 3.72 (s, 3H, OCH3, E), 5.14 (s, 2H, CH 2, E), 5.28 (s, 2H,
CH2, Z), 6.42 (s, 1H, H4’’, E) 6.86 (d, J = 8.0 Hz, 2H, H3’’’/H5’’’, Z), 6.88 (d, J = 8.0 Hz, 2H,
H3’’’/H5’’’, E), 7.11 (d, J = 7.5 Hz, 4H, H2’/H6’, E + Z), 7.16 (d, J = 8 Hz, 2H, H2’’’/H6’’’,
Z), 7.22 (d, J = 8.0 Hz, 2H, H2’’’/H6’’’, E), 7.84 (s, 1H, H6’’, E), 7.83 (s, 1H, H4’’, Z), 7.90 (d,
J = 8.5 Hz, 2H, H3’/H5’, Z), 7.94 (s, 1H, H6’’, Z), 8.09 (d, J = 8.0 Hz, 2H, H3’/H5’, E).
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Synthesis of (E and Z)-4-[5,7-dibromo-1-(4-methoxybenzyl)-2-oxoindolin-3 -ylideneamino]
benzoic acid (176)
The title compound (176) was synthesised from
1-(4-methoxybenzyl)-5,7-dibromoisatin

(162)

and

(p-aminophenyl)acetic acid according to Method B and
purified

by

flash

chromatography

on

silica

gel

(CHCl3/MeOH 95:5) to give a red powder (0.15 g, 59 %),
m.p. 153-156 ºC (lit. 151-153 °C)182, Rf 0.25 (DCM), mixture of isomers (E:Z/58:42). LREIMS: m/z 556; 558; 560 [M+]

79

Br79Br;

79

Br81Br;

Br81Br. 1H NMR (DMSO-d6, 500 MHz) δ

81

3.55 (s, 2H, H2, Z), 3.62 (s, 2H, H2, E), 3.70 (s, 3H, OCH3, Z), 3.74 (s, 3H, OCH3, E), 5.14 (s,
2H, CH2, Z), 5.28 (s, 2H, H1 CH2, E), 6.61 (d, J = 1.5 Hz, 1H, H4’’, E), 6.80 (d, J = 9 Hz, 2H,
H3’’’/H5’’’, Z), 6.91 (d, J = 8.5 Hz, 2H, H3’’’/H5’’’, E), 7.05 (d, J = 8.5 Hz, 2H, H2’/H6’, E),
7.12 (d, J = 8.5 Hz, 2H, H2’’’/H6’’’, Z), 7.16 (d, J = 8.0 Hz, 2H, H2’’’/H6’’’, E), 7.25-7.27 (m,
4H, J = 7.5 Hz, H2’/H6’ Z + H3’/H5’, Z), 7.45 (d, J = 8.5 Hz, 2H, H3’/H5’, E), 7.84 (d, J = 2.0
Hz, 2H, H4’’, Z + H6’’, E), 7.91 (d, J = 2.0 Hz, 1H, H6’’, Z).

Synthesis

of

(E

and

Z)-2-{4-[5,7-Dibromo-1-(4-methoxybenzyl)-2-oxoindolin-3-

ylidenoamino]phenyl}acetic acid (177)
The title compound (177) was synthesised from 1-(4-methoxybenzyl)-5, 7-dibromo-indoline2,3-dione and (m-aminophenyl)acetic acid according to
Method B and purified by flash chromatography on silica
gel (CHCl3/MeOH 95:5) to give a red powder (0.13 g, 69
%), m.p. 181-184 ºC (lit.182-184 ºC)182, Rf 0.36
(DCM/MeOH 9:1), mixture of isomers (E:Z/57:43).
LREI-MS: m/z 557; 559; 561 [M+]

79

Br79Br;

79

Br81Br;

Br81Br. 1H NMR (DMSO-d6, 500 MHz) δ 3.54 (s, 2H, H2, Z), 3.68 (s, 2H, H2, E), 3.69 (s, 3H,

81

OCH3, Z), 3.73 (s, 3H, OCH3, E), 5.16 (s, 2H, CH2, Z), 5.32 (s, 2H, CH2, E), 6.60 (s, 1H, H4’’,
E), 6.90 (d, J = 8 Hz, 2H, H3’’’/H5’’’, Z), 6.93 (d, J = 8.5 Hz, 2H, H3’’’/H5’’’, E), 6.97 (d, J =
8.5 Hz, 1H, H4’, E), 7.05 (s, 1H, H2’, E), 7.09 (d, J = 8.0 Hz, 1H, H4’, Z), 7.17 (d, J = 8.5 Hz,
2H, H2’’’/H6’’’, Z), 7.21 (d, J = 8.0 Hz, 1H, H6’, E), 7.25 (d, J = 8.0 Hz, 1H, H6’, Z), 7.28 (d,
J = 7.5 Hz, 2H, H2’’’/H6’’’, E), 7.31 (t, J = 7.5 Hz, 1H, H5’, Z), 7.46 (t, J = 7.5 Hz, 1H, H5’,
E), 7.79 (s, 1H, H6’’, E), 7.82 (s, 1H, H2’, Z), 7.91 (s, 1H, H4’’, Z), 8.02 (s, 1H, H6’’, Z), 12.19
(br s, 2H, OH, E + Z).
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Synthesis

of

(E

and

Z)-1-(4-methoxybenzyl)-3-(4-hydroxyphenylimino)-5,7-

dibromoindolin-2-one (178)
The

title

compound

(178)

was

synthesised

5,7-dibromo-N-(4-methoxybenzyl)isatin

from

(162)

and

4-aminophenol according to method B and purified by flash
chromatography on silica gel (DCM; DCM/EtOAC 4:1) to
give an orange powder (0.071 g, 29% as a mixture of E and
Z isomers (E:Z 43:57)), m.p. 214-216 ºC, Rf 0.29
(DCM/MeOH 9:1). LREI-MS: m/z 514; 516; 528 [M+] 79Br79Br; 79Br81Br; 81Br81Br. HRESIMS: calcd for C22H17N2O3Br2 79Br79Br (M+H+) 514.9487 found 514.9524. 1H NMR (DMSO-d6,
500 MHz) δ 3.69 (s, 3H, OCH3, Z) , 3.71 (s, 3H, OCH3, E), 5.18 (s, 2H, CH2, Z), 5.28 (s, 2H,
CH2, E), 6.79 (d, J = 8.5 Hz, 2H, H3’’/H5’’, Z), 6.85 (d, J = 8.0 Hz, 2H, H3’/H5’, Z), 6.87-6.89
(m, H3’/H5’, E, H2’’/H6’’, E) 6.96 (s, 1H, H4, E) 6.97 (d, J = 8.5 Hz, 2H, H3’’/H5’’, E), 7.14
(d, J = 8.5 Hz, 2H, H2’/H6’, Z), 7.20 (d, J = 8.5 Hz, 2H, H2’/H6’, E), 7.48 (d, J = 9 Hz, 2H,
H2’’/H6’’, Z), 7.61 (s, 1H, H6, E), 7.69 (s, 1H, H4 Z), 7.71 (s, 1H, H6, Z). 13C NMR: (DMSOd6, 126 MHz): δ 43.9 (CH2, Z), 44.4 (CH2, E), 55.7 (OCH3, E+Z), 103.7 (ArC), 104.6 (ArC),
114.6 (C3’/C5’, E+Z), 114.8 (Arc), 115.6 (C3’’/C5’’, Z), 115.8, 116.8 (C2’’/C6’’, E), 120.7
(C3’’/C5’’, E), 124.1 (C6, E) 126.7 (C4, E), 127.1 (C2’’/C6’’, Z), 128.1 (C2’/C6’, E+Z), 129.5
(C1’, E + Z), 131.4, 139.2 (C4, Z), 139.3 (C1’’, Z), 140.5 (C6, Z), 141.4 (C4’’, Z), 144.0 (ArC),
146.1 (ArC), 149.1, 149.9 (C3, Z), 151.4 (C3, E), 156.9 (C1’’, E), 158.9 (C2), 159.0 (C4’’, Z;
C4’, E+Z), 164.0 (C2).

Synthesis of (E and Z)-1-(4-methoxybenzyl)-3-(4-bromophenylimino)-5,7-dibromoindolin2-one (179)
The title compound (179) was synthesised from 5,7-dibromo-N-(4-methoxybenzyl)isatin and
4-bromoaniline according to method B and purified by flash
chromatography on silica gel (DCM; DCM/EtOAC 9:1) to
give (0.16 g, 60%, as a mixture of E and Z isomers (E:Z
/48:52)) as an orange solid, m.p. 189-191ºC, Rf 0.85 (DCM).
LREI-MS: m/z 576; 578; 580 [M+]
79

81

Br Br;

79

81

81

Br Br Br;

81

81

79

Br79Br79Br;

79

Br

81

Br Br Br. HRESI-MS: calcd for

C22H16Br3N2O2 79Br81Br (M+H+) 576.8729 found 576.8762. 1H NMR (CDCl3, 500 MHz) δ 3.42
(s, 3H, OCH3, Z), 3.70 (s, 3H, OCH3, E), 5.19 (s, 2H, CH2, Z), 5.37 (s, 2H, CH2, E), 6.75 (d, J =
8.5 Hz, 2H, H3’/H5’, Z), 6.78 (d, J = 8.5 Hz, 2H, H3’/H5’, E), 6.80 (s, 1H, H4, E), 6.82 (d, J =
8.5 Hz, 2H, H2’’/H6’’, E), 6.94 (d, J = 8.5 Hz, 2H, H2’’/H6’’, Z), 7.09 (d, J = 7.5 Hz, 2H,
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H2’/H6’, Z), 7.15 (d, J = 8.5 Hz, 2H, H2’/H6’, E), 7.42 (d, J = 8.5 Hz, 2H, H3’’/H5’’, Z), 7.52
(d, J = 8.5 Hz, 2H, H3’’/H5’’, E), 7.55 (s, 1H, H6, E), 7.63 (s, 1H, H4, Z), 7.76 (s, 1H, H6, Z).
C NMR (CDCl3, 126 MHz) δ 44.0 (CH2, Z), 44.6 (CH2, E), 55.5* (OCH3, E + Z), 104.0

13

(ArC), 104.8 (ArC), 114.3* (C2’/C6’, E + Z), 114.4 (ArC), 115.9 (ArC), 116.3 (ArC), 119.5*
(C2’’/C6’’, E), 122.2 (C2’’/C6’’, Z), 125.6 (C6, Z), 126.1 (ArC), 128.2 (C3’/C5’, E+Z)*, 128.7,
129.3, 131.9 (C3’’/C5’’, Z), 132.6, 133.1* (C3’’/C5’’, E), 136.7, 141.1 (C4, Z), 141.8, 142.0
(C6, E), 147.3 (C1’’, Z), 148.5 (C1’’, E), 149.4 (C3, Z), 151.8 (C3, E), 157.7* (C4’, E+Z),
158.2* (C4’’, E+Z), 164.4 (C2, Z), 172.3 (C2, E).

Synthesis of (E and Z)-1-(4-Methoxybenzyl)-3-(2-bromophenylimino)-5,7-dibromoindolin2-one (180)
The

title

compound

(180)

was

synthesised

5,7-dibromo-N-(4-methoxybenzyl)isatin

from

(162)

and

2-bromoaniline according to method B and purified by flash
chromatography on silica gel (DCM) to give an orange solid
(0.032 g, 16%, as a mixture of E and Z isomers (E:Z/48:52)),
m.p. 167-170 ºC, Rf 0.70 (DCM). LREI-MS: m/z 576; 578;
580; 582 [M+]

79

Br79Br79Br;

79

Br 79Br81Br;

79

Br81Br81Br;

81

Br81Br81Br. HRESI-MS: calcd for

C22H16Br3N2O2 79Br79Br79Br (M+H+) 576.8762 found 576.8749. 1H NMR (CDCl3, 500 MHz) δ
3.77 (s, 3H, OCH3, Z), 3.79 (s, 3H, OCH3, E), 5.24 (s, 2H, CH2, Z), 5.29 (s, 2H, CH2, E), 6.58
(s, 1H, H4, E), 6.82 (d, J = 8.5 Hz, 2H, H3’/H5’, Z), 6.83 (d, J = 8.5 Hz, 2H, H3’/H5’, E), 6.95
(t, J = 8.5 Hz, 1H, ArH), 7.07-7.10 (m, 2H, ArH), 7.14 (d, J = 8.5 Hz, 2H, H2’/H6’, Z), 7.23 (d,
J = 9 Hz, 2H, H2’/H6’, E), 7.30-7.32 (m, 2H), 7.41 (t, J = 9 Hz, 1H), 7.61 (s, 1H, H6, E), 7.61
(s, 1H, H3’’, Z), 7.61 (s, 1H, H3’’, E), 7.73 (d, 1H, J = 2.0 Hz, H4, Z), 7.91 (s, 1H, J = 2.0 Hz,
H6, Z).

C NMR (126 MHz, CDCl3) δ 40.0* (CH2, E+Z), 51*.1 (OCH3, E + Z), 98.3, 99.0,

13

99.6, 101.7, 102.7, 103.8, 110.2, 110.4* (C3’/C5’, E+Z), 112.0, 112.9, 113.5, 114.8, 123.5,
123.7, 123.9, 124.5, 124.7, 125.0, 125.4, 128.7 (C2’/C6’, E+Z), 131.0, 132.4, 133.3, 133.9,
137.4*, 137.8, 143.8, 144.1, 153.7, 155.6, 156.8, 175.6, 176.0.

Synthesis of (E and Z)-1-(4-Methoxybenzyl)-3-(3-bromophenylimino)-5,7-dibromoindolin2-one (181)
The

title

compound

(181)

was

5,7-dibromo-N-(4-methoxybenzyl)isatin

synthesised
(162)

from
and

3-bromoaniline according to method B and purified by flash
chromatography on silica gel (DCM) to give an orange solid
(0.22 mg, 80%, as a mixture of E and Z isomers (E:Z/ 46:54))
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as, m.p. 154-157 ºC, Rf 0.67 (DCM). LREI-MS: m/z 576; 578; 580; 582 [M+] 79Br79Br79Br; 79Br
79

Br81Br; 79Br81Br81Br; 81Br81Br81Br. HRESI-MS: calcd for C22H16Br3N2O279Br79Br79Br (M+H+)

576.8643 found 576.8639. 1H NMR (CDCl3, 500 MHz) δ 3.77 (s, 3H, OCH3, Z), 3.79 (s, 3H,
OCH3, E), 5.25 (s, 2H, CH2, Z), 5.43 (s, 2H, CH2, E), 6.77 (s, 1H, 4E), 6.85 (d, J = 8.5 Hz, 2H,
H3’/H5’, E), 6.79 (d, J = 8.5 Hz, 2H, H3’/H5’, Z), 6.90 (d, J = 8.5 Hz, 2H, H6’’, E), 6.99 (d, J
= 8.0 Hz, 1H, H6’’, Z), 7.14-7.16 (m, 3H, ArH), 7.20-7.24 (m, 4H, H2’/H6’, E+Z), 7.30-7.33
(m, 1H, ArH), 7.42 (s, 1H, H2’’, Z), 7.61 (s, 1H, 4H, Z), 7.70 (s, 1H, 6H, Z), 7.82 (s, 1H, 6E).
13

C NMR (126 MHz, CDCl3): δ 44.0 (CH2, Z), 44.6 (CH2, E), 55.4* (CH3, E+Z), 103.8, 104.6,

114.1* (C3’/C5’, E+Z), 114.2, 115.7, 115.8, 116.6, 118.1, 119.3, 120.4, 122.4, 122.7, 123.4,
125.5 (C6, E), 128.1* (C2’/C6’, E+Z, C1’, E+Z), 128.3 (C4, E), 128.9, 129.0, 129.9, 131.1,
139.0, 141.2 (C6, Z), 141.9 (C4, Z), 142.3 (C7a, Z), 149.4, 150.3, 150.6, 151.8, 157.8 (C2, Z),
158.6* (C4’, E+Z), 163.5 (C2, E).

Synthesis

of

(E

and

Z)-1-(4-methoxybenzyl)-3-(2,4-dibromophenylimino)-5,7-

dibromoindol-2-one (182)
The

title

compound

(182)

was

synthesised

5,7-dibromo-N-(4-methoxybenzyl)isatin

(162)

from
and

2,4-dibromoaniline according to method B and purified by
flash chromatography on silica gel (100% DCM) to give an
orange powder (0.011 g, 14%, as a mixture of E and Z
isomers (E:Z/27:73)) as, m.p. 194-196 ºC, Rf 0.81 (DCM).
LREI-MS: m/z 654; 656; 658; 660; 662 [M+]
79

Br79Br81Br81Br;

79

Br

81

Br81Br81Br8;

81

79

Br79Br79Br79Br;

79

Br79Br79Br81Br;

Br81Br81Br81Br. HRESI-MS: calcd for C22H15Br4N2O2

(M+H+) 658.7867 found 658.7876. 1H NMR (CDCl3, 500 MHz) δ 3.79 (s, 3H, OCH3, Z), 3.81
(s, 3H, OCH3, E), 5.27 (s, 2H, CH2, Z), 5.49 (s, 2H, CH2, E), 6.73 (s, 1H, H4, E), 6.84-6.87 (m,
5H, H4’’ Z, H5’’ E+Z, H3’/H5’ Z), 7.17 (d, J = 8.5 Hz, 2H, H2’/H6’, Z), 7.24 (d, J = 8.0 Hz,
2H, H3’/H5’, E), 7.44 (d, J = 8.0 Hz, 2H, H2’/H6’, E), 7.56 (d, J = 8.5 Hz, 1H, H4’’, E), 7.67
(s, 1H, H6, E), 7.75 (s, 1H, H4, Z), 7.79 (s, 1H, H2’’, Z), 7.89 (s, 1H, H2’’, E), 7.92 (s, 1H, H6,
Z).

C NMR (CDCl3, 126 MHz) δ 43.2* (CH2, E+Z), 56.1* (OCH3, E + Z), 110.2, 110.4*

13

(C3’/C5’, E+Z), 112.0, 112.9, 113.5, 114.8, 123.5, 123.7, 123.9, 124.5, 124.7, 125.0, 125.4,
127.2*, 128.7* (C2’/C6’, E+Z), 131.0, 132.4, 133.3, 133.9, 134.6, 135.2, 137.4*, 137.8, 140.2,
140.9, 143.8, 144.1, 153.7, 155.6, 156.8, 175.6, 176.0.
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Synthesis of (E and Z)-1-(4-methoxybenzyl)-3-(4-chlorophenylimino)-5,7-dibromoindolin2-one (183)
The title compound (183) was synthesised from
5,7-dibromo-N-(4-methoxybenzyl)isatin

(162)

and

p-chloroaniline according to method B and purified by
flash chromatography on silica gel (DCM) to give an
orange solid (0.15 g, 65% as a mixture of E and Z isomers
(E:Z/48:52)), m.p. 179-181 ºC, Rf 0.87 (DCM). LREIMS: m/z 532; 534; 536 [M+]
C22H16Br2ClN2O2

79

79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: calcd for

Br81Br (M+H+) 532.9243 found 532.9267. 1H NMR (CDCl3, 500 MHz) δ

3.77 (s, 3H, OCH3, Z), 3.79 (s, 3H, OCH3, E), 5.26 (s, 2H, CH2, Z), 5.44 (s, 2H, CH2, E), 6.82
(d, J = 8.5 Hz, 2H, H3’/H5’, Z), 6.85 (d, J = 8.5 Hz, 2H, H3’/H5’, E), 6.89 (s, 1H, H4, E), 6.94
(d, J = 8.5 Hz, 2H, H2’’/H6’’, E), 7.08 (d, J = 8.5 Hz, 2H, H2’’/H6’’, Z), 7.16 (d, J = 7.5 Hz,
2H, H2’/H6’, Z), 7.21 (d, J = 8 Hz, 2H, H2’/H6’, E), 7.34 (d, J = 8.5 Hz, 2H, H3’’/H5’’, Z),
7.45 (d, J = 8.5 Hz, 2H, H3’’/H5’’, E), 7.61 (s, 1H, H6, E), 7.69 (s, 1H, H4, Z), 7.83 (s, 1H, H6,
Z). 13C NMR (CDCl3, 126 MHz) δ 44.2 (CH2, Z), 44.8 (CH2, E), 55.7* (OCH3, E + Z), 105.1
(ArC), 109.4 (ArC), 114.5* (C4’/C6’, E + Z), 116.0 (ArC), 116.9 (ArC), 119.4* (C2’’/C6’’, E),
122.2 (C2’’/C6’’, Z), 125.8 (C6, Z), 126.4 (ArC), 127.8, 128.3 (C6, Z), 128.5, (C2’/C6’, E+Z)*,
129.2 (C3’’/C5’’, Z), 130.4 (C3’’/C5’’, E), 132.7, 133.2, 137.4, 139.0, 141.3 (C4, Z), 142.2 (C6,
E), 148.4 (C1’’, Z), 149.2 (C1’’, E), 149.9 (ArC), 152.7 (ArC), 158.7* (C4’, E+Z), 160.0*
(C4’’, E+Z), 164.6 (C2, Z), 172.9 (C2, E).

Synthesis of (E and Z)-1-1-(4-methoxybenzyl)-3-(4-iodophenylimino)-5,7-dibromoindolin2-one (184)
The title compound (184) was synthesised from 5,7-dibromo-N-(4-methoxybenzyl)isatin (162)
and 4-iodoaniline according to method B and purified by flash
chromatography on silica gel (DCM) to give an orange
powder (0.21 g, 71% mixture of E and Z isomers (E:Z /48:52),
m.p. 192-195 ºC, Rf 0.85 (DCM). LREI-MS: m/z 624; 626,
628 [M+]

79

Br79Br;

C22H16Br2IN2O2

79

79

Br81Br;

81

Br81Br. HRESI-MS: calcd for

Br79Br (M+H+) 624.8528 found 624.8525.

H NMR (CDCl3, 500 MHz) δ 3.77 (s, 3H, OCH3, E), 3.79 (s, 3H, OCH3, Z), 5.26 (s, 2H, CH2,

1

E), 5.43 (s, 2H, CH2, Z), 6.76 (d, J = 8.5 Hz, 2H, H2’’/H6’’, E), 6.82 (d, J = 8.5 Hz, 2H, H3’/
H5’, E), 6.83 (s, 1H, H4, E), 6.87 (d, J = 8.0 Hz, 2H, H2’’/H6’’, Z), 6.89 (d, J = 8.0 Hz, 2H,
H3’/H5’, Z), 7.15 (d, J = 8.0 Hz, 2H, H2’/H6’, E), 7.21 (d, J = 8.0 Hz, 2H, H2’/H6’, Z), 7.62 (s,
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1H, H4, Z), 7.68 (d, J = 8.5 Hz, 2H, H3’’/H5’’, E), 7.69 (s, 1H, 6, Z), 7.79 (d, J = 8.5 Hz, 2H,
H3’’/H5’’, Z), 7.83 (s, 1H, H6, E). 13C NMR (CDCl3, 126 MHz): δ 43.5 (OCH3, E), 43.6
(OCH3, Z), 57.1* (CH2, E+Z), 90.0 (C4’’, E), 90.2 (C4’’, Z), 106.0 (ArC), 106.7 (ArC), 114.0
(C3’/C5’, E), 114.1 (C2’’/C6’’, Z), 116.3 (ArC), 116.9 (ArC), 119.5* (C2’’/C6’’, Z), 122.0*
(C3’/C5’, Z) , 125.4 (C6, E), 125.8 (ArC), 126.2 (ArC), 127.3* (C2’/C6’, E), 127.6* (C2’’/C6’’,
Z), 127.9* (C2’’/C6’’, E), 128.2 (C4, E), 137.6* (C3’’/C5’’, E), 138.7* (C3’’/C5’’, Z), 140.6
(C6, Z), 141.1 (C4, Z), 142.0 (C7a, E), 142.4 (C7a, Z) 148.2 (C3, E), 148.9 (C3, Z) 149.6 (C1’’,
E), 152.2 (C1’’, Z), 159.3 (C2, E), 159.2* (C4’, E; C4’, Z), 164.2 (C2, Z).

Synthesis

of

(E

and

Z)-1-1-(4-methoxybenzyl)-3-(4-fluorophenylimino)-5,7-

dibromoindolin-2-one (185)
The

title

compound

(185)

was

synthesised

5,7-dibromo-N-(4-methoxybenzyl)isatin

(162)

from
and

4-fluoroaniline according to method B and purified by flash
chromatography on silica gel (100% DCM) to give an
orange powder (0.17 g, 72% as a mixture of Z and E isomers
(E:Z/48:52)), m.p. 165-167 ºC, Rf 0.59 (DCM). LREI-MS:
m/z 516; 518; 520 [M+]
79

79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C22H16N2O2FBr2

Br79Br (M+H+) 516.9545 found 516.9563. 1H NMR (CDCl3, 500 MHz) δ 3.77 (s, 3H, OCH3,

E), 3.79 (s, 3H, OCH3, Z), 5.26 (s, 2H, CH2, E), 5.44 (s, 2H, CH2, Z), 6.82 (d, J = 8.5 Hz, 2H,
H4’/H6’, E), 6.85 (d, J = 8.5 Hz, 2H, H3’/H5’, Z), 6.89 (s, 1H, H4, Z), 6.98 (dd, J = 5, 7.5 Hz,
2H, H3’’/H5’’, Z), 7.08 (t, J = 9 Hz, 2H, H3’’/H5’’, E), 7.16 (d, J = 9 Hz, 4H, H2’/H6’, E+Z),
7.21 (d, J = 8.5 Hz, 4H, H2’’/H6’’, E+Z), 7.61 (s, 1H, H6, Z), 7.69 (s, 1H, H4, E), 7.82 (s, 1H,
H6, E).

C NMR: (CDCl3, 126 MHz): δ 44.0 (CH2, Z), 44.6 (CH2, E), 55.5 (OCH3, E+Z)*,

13

103.8, 104.8, 114.3* (C3’/C5’, E+Z), 116.8* (C3’’/C5’’, E), 117.1, 119.6* (C2’/C6’, Z), 119.7*
(C3’’/C5’’, Z), 123.3* (C2’’/C6’’, Z), 125.4 (C6, E), 126.0, 126.4, 127.7* (C4, Z, C2’/C6’, E),
127.9* (C2’’/C6’’, E), 127.6*, 128.1, 129.6, 131.1, 132.0, 140.8 (C4, E), 142.4, 142.9, 143.6
(C6, Z), 144.3 (ArC), 149.3 (ArC), 152.2 (ArC), 157.9 (C4, Z), 159.3 (C4, E), 164.3 (C2), 165.2
(C2).
Synthesis of (E and Z)-1-(4-methoxybenzyl)-3-(4-(trifluoromethyl)-phenylimino)-5,7dibromo-indolin-2-one (186)
The title compound (186) was synthesised from 5,7-dibromo-N-(4-methoxybenzyl)isatin (162)
and p-(trifluoromethyl)aniline according to method B and purified by flash chromatography on
silica gel (DCM) to give a red solid (0.27 g, 65%, as a mixture of Z and E isomers (E:Z/44:56)),
m.p. 147-149 ºC, Rf 0.73 (DCM). LREI-MS: m/z 566; 568; 570 [M+]
81

79

Br79Br;

79

Br81Br;

Br81Br. HRESI-MS: calcd for C23H16N2O2F3Br2 79Br81Br (M+H+) 566.9495 found 566.9531.
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H NMR (CDCl3, 500 MHz) δ 3.74 (s, 3H, OCH3, Z), 3.77 (s, 3H, OCH3, E), 5.22 (s, 2H, CH2,

1

Z), 5.42 (s, 2H, CH2, E), 6.60 (s, 1H, H4, E), 6.79 (d, J = 8.5 Hz, 2H, H3’/H5’, Z), 6.83 (d, J =
8.5 Hz, 2H, H3’/H5’, E), 7.04-7.07 (m, 4H, H2’’/H6’’, E +
Z), 7.12 (d, J = 8.5 Hz, 2H, H2’/H6’, Z), 7.20 (d, J = 8.0
Hz, 2H, H2’/H6’, E), 7.59 (d, J = 8.5 Hz, 2H, H3’’/H5’’,
Z), 7.61 (s, 1H, H6, E), 7.71 (d, J = 8.5 Hz, 2H, H3’’/H5’’,
E), 7.73 (s, 1H, H4, Z), 7.82 (s, 1H, H6, Z).

13

C NMR

(CDCl3, 126 MHz): δ 43.8 (CH2, Z), 44.2 (CH2, E), 55.5
(OCH3, Z+E)*, 104.0, 104.8, 114.4* (C3’/C5’, E+Z), 115.8, 116.4, 117.5 (C2’’/C6’’, E+Z),
119.3 (C2’/C6’, E+Z), 125.6, 126.2*, 126.4, 127.6, 128.3* (C3’’/C5’’, E+Z), 128.6,* 129.9,
130.3, 140.1, 141.3, 142.8 (C4, Z), 143.6 (C6, E), 144.3, 151.2 (C1’’, Z), 151.9 (C2’’, Z),
152.4* (C4’, E+Z), 157.8 (C4’’, Z), 159.2 (C4’’, E), 159.3 (C2, Z), 161.8 (C2, E).

Synthesis

of

(E

and

Z)-1-(4-Methoxybenzyl)-3-(4-methoxyphenylimino)-5,7-

dibromoindolin-2-one (187)
The

title

compound

(187)

was

5,7-dibromo-N-(4-methoxybenzyl)isatin

synthesised
(162)

from
and

4-methoxyaniline according to method B and purified by
flash chromatography on silica gel (DCM) to give an orange
solid (0.092 g, 37%, as a mixture of Z and E isomers (E:Z/
48:52)), m.p. 143-145 ºC, Rf 0.39 (DCM). LREI-MS: m/z
528; 530, 532 [M+] 79Br79Br; 79Br81Br; 81Br81Br. HRESI-MS: calcd for C23H19Br2N2O3 9Br79Br
(M+H+) 528.9734, found 528.9742. 1H NMR (CDCl3, 500 MHz) δ 3.76 (s, 3H, OCH3, Z), 3.78
(s, 3H, OCH3, E), 3.84 (s, 3H, OCH3, Z), 3.88 (s, 3H, OCH3, E), 5.31 (s, 2H, CH2, Z), 5.44 (s,
2H, CH2, E), 6.81 (d, J = 8.0 Hz, 2H, H3’/H5’, E), 6.84 (d, J = 8.5 Hz, 2H, H3’/H5’, Z), 6.91
(d, J = 8.5 Hz, 2H, H3’’/H5’’, E), 6.99 (d, J = 8.5 Hz, 2H, H3’’/H5’’, Z), 7.03 (d, J = 8.5 Hz,
2H, H2’’/H6’’, E), 7.16 (d, J = 8.5 Hz, 2H, H2’/H6’, Z), 7.18 (s, 1H, H4, E), 7.21 (d, J = 8.5
Hz, 2H, H2’/H6’, Z), 7.49 (d, J = 8.5 Hz, 2H, H2’’/H6’’, E), 7.58 (s, 1H, H6, E), 7.63 (s, 1H,
H4, Z), 7.82 (s, 1H, H6, Z). 13C NMR (126 MHz, CDCl3): δ 43.7 (CH2, Z), 44.3 (CH2, E), 55.5*
(OCH3, Z), 55.6* (OCH3, E), 103.3, 104.3, 113.7* (C3’’/C5’’, E), 114.7* (C3’/C5’, E+Z),
115.1* (C3’’/C5’’, Z), 119.8, 120.3 (C2’’/C6’’, Z), 124.6 (C6, Z), 125.6 (C2’’/C6’’, E), 127.3
(C1’, E), 127.8 (C1’, Z), 128.0* (C4, E, C2’/C6’, E+Z), 130.3, 135.1, 139.6 (C4, Z), 140.1 (C6,
E), 141.9, 143.5, 150.5, 158.1, 158.6, 158.9 (C4’), 159.3 (C4’’), 160.5 (C4’’), 161.9 (C4’),
162.2 (C4’’, Z), 163.4 (C4’’, E), 165.9 (C2), 168.1 (C2).
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Synthesis

of

(E

and

Z)-5,7-dibromo-1-(4-methoxybenzyl)-3-((3-

methoxyphenyl)imino)indolin-2-one (188)
The

title

compound

(188)

was

synthesised

from

(162)

and

5,7-dibromo-N-(4-methylbenzyl)isatin

4-methoxyaniline according to method B and purified by
flash chromatography on silica gel (DCM) to give a dark
red solid (0.029 g, 12%, mixture of E and Z isomers
E:Z/39:61), m.p. 152-154 ºC. Rf 0.43 (DCM). LREI-MS:
m/z 528; 530, 532 [M+]

79

Br79Br;

79

Br81Br;

81

Br81Br.

HRESI-MS: calcd for C23H19Br2N2O3 9Br79Br (M+H+) 528.9254, found 528.9272. 1H NMR
(CDCl3, 500 MHz) δ 3.65 (s, 6H, OCH3, Z), 3.78 (s, 6H, OCH3, E), 5.28 (s, 2H, CH2, Z), 5.46
(s, 2H, CH2, E), 6.58 (s, 1H, H4, E), 6.82 (d, J = 7.0 Hz, 2H, H3’/H5’, Z), 6.82 (d, J = 7.0 Hz,
1H, H4’’, Z), 6.95 (m, 3H, H6’’, E; H3’/H5’, E), 7.02 (t, J = 8.0 Hz, 1H, H5’’, Z), 7.15 (d, J =
7.5 Hz, 2H, H2’/H6’, Z), 7.23 (d, J = 7.5 Hz, 2H, H2’/H6’, Z), 7.30-7.33 (m, 2H, H6’’, Z; H4’’,
E), 7.41 (t, 1H, J = 7.5 Hz, H5’’, E), 7.61 (s, 1H, H4, Z), 7.63 (s, 1H, H6, E), 7.00 (s, 1H, H2’’,
E), 7.12 (s, 1H, H6, Z), 7.92 (s, 1H, H2’’, Z). 13C NMR (126 MHz, CDCl3): δ 44.7 (CH2, Z),
44.9 (CH2, E), 55.8* (OCH3, E+Z), 56.1* (OCH3, E+Z), 104.8, 113.9* (C3’’/C5’’, E), 114.2,
114.9* (C3’/C5’, E+Z) 116.0* (C3’’/C5’’, Z), 119.6, 120.0, 120.9* (C2’’/C6’’, Z), 125.0 (C6,
Z), 125.9 (C2’’/C6’’, E), 127.6 (C1’, E), 128.4 (C1’, Z), 128.5* (C2’/C6’, E+Z), 129.6 (C4, E),
140.2 (C4, Z), 140.9 (C6, E), 142.3, 144.8, 146.9, 150.9, 156.2, 157.8 (C4’), 158.8, 160.0
(C4’’), 160.9 (C4’’), 161.8 (C4’), 163.2 (C4’’, Z), 163.9 (C4’’, E), 166.7 (C2), 168.2 (C2).

Synthesis

of

(E

and

Z)-1-(4-methoxybenzyl)-3-(2,4-dimethylphenylimino)-5,7-

dibromoindolin-2-one (189)
The

title

compound (189)

was

synthesised from

5,7-dibromo-N-(4-methoxybenzyl)isatin

(162)

and

2,4-dimethylaniline according to method B and purified by
flash chromatography on silica gel (DCM) to give a red
solid (0.084 g, 34%, as a mixture of Z and E isomers
(E:Z/67:33)), m.p. 149-151 ºC, Rf 0.54 (DCM). LREI-MS: m/z 526; 528, 530 [M+] 79Br79Br;
79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C24H21Br2N2O2

79

Br79Br (M+H+) 526. 9907 found

526. 9885. 1H NMR (CDCl3, 500 MHz): δ 2.13 (s, 3H, H7’’, E), 2.23 (s, 3H, H7’’, Z), 2.32 (s,
3H, H8’’, Z), 2.38 (s, 3H, H8’’, E), 3.76 (s, 3H, OCH3, Z), 3.78 (s, 3H, OCH3, E), 5.27 (s, 2H,
CH2, Z), 5.44 (s, 2H, CH2, E), 6.68 (d, J = 8.5 Hz, 1H, H6’’, E), 6.78 (s, 1H, H4, E), 6.81 (d, J
= 8.5 Hz, 2H, H3’/H5’, Z), 6.85 (d, J = 8.5 Hz, 2H, H3’/H5’, Z), 6.90 (d, J = 8.5 Hz, 1H, H6’’,
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Z), 6.96 (d, J = 8.5 Hz, 1H, H5’’, Z), 7.05 (s, 1H, H3’’, Z), 7.06 (d, J = 8.5 Hz, 2H, H5’’, E),
7.13 (s, 1H, H3’’, E), 7.16 (d, J = 8.5 Hz, 2H, H2’/H6’, Z), 7.21 (d, J = 8.5 Hz, 2H, H2’/H6’,
E), 7.57 (s, 1H, H6, E), 7.67 (s, 1H, H6, Z), 7.84 (s, 1H, H4, Z). 13C NMR (CDCl3, 126 MHz): δ
17.9 (C7’’, E), 18.1 (C7’’, Z), 22.0 (C8’’, E), 22.3 (C8’’, Z), 44.1 (CH2, Z), 43.5 (CH2, E), 55.8*
(CH3, E+Z), 103.8, 104.4, 114.2 (C4, E), 114.4* (C3’/C5’, E+Z), 115.8, 116.1 (C6’’, E), 116.4,
118.7 (C6’’, Z), 120.8 (ArC), 125.2 (C4, Z), 126.7 (C2’’, E), 126.8 (C5’’, Z), 127.8 (C3’’, Z),
128.2* (C2’/C6’, E+Z), 128.4 (C1’, E), 128.9 (C1’, Z), 129.0, 130.2, 121.5 (C5’’, E), 132.3
(C3’’, E), 136.0 (ArC), 136.8 (ArC), 140.8 (C6, Z), 121.1 (C6, E), 142.0, 143.7, 144.2 (C1’’, Z),
146.0 (C1’’, E), 148.8, 151.7, 158.0 (C2, Z), 158.6 (C4’, E+Z), 164.0 (C2, E).

Synthesis of (E and Z)-1-(4-methoxybenzyl)-3-(2,6-dimethylphenylimino)-5,7dibromoindolin-2-one (190)
The

title

compound

(190)

was

synthesised

5,7-dibromo-N-(4-methoxybenzyl)isatin

(162)

from
and

2,6-dimethylaniline according to method B and purified by
flash chromatography on silica gel (DCM) to give a dark
red solid (0.15 g, 61%, as a mixture of Z and E isomers
(E:Z/80:20)), m.p. 143-146 ºC, Rf 0.54 (DCM). LREI-MS:
m/z 526; 528, 530 [M+]

79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C24H21Br2N2O2

Br79Br (M+H+) 526.9970 found 526.9971. 1H NMR (CDCl3, 500 MHz) δ 2.04 (s, 6H, 2 x

79

CH3, E), 2.05 (s, 6H, 2 x CH3, Z), δ 3.79 (s, 3H, OCH3, Z), 3.80 (s, 3H, OCH3, E), 5.25 (s, 2H,
CH2, E), 5.45 (s, 2H, CH2, Z), 6.46 (s, 1H, H4, Z), 6.87 (d, J = 8.5 Hz, 2H, C3’/C5’, E), 6.91 (d,
J = 8.5 Hz, 2H, C3’/C5’, Z), 7.05 (d, J = 8.5 Hz, 2H, C3’/C5’, Z), 7.08-7.11 (m, 5H, E + Z),
7.18 (d, 3H), 7.26 (s, J = 8.5 Hz, 2H, C2’/C6’, Z), 7.63 (s, 1H, C6, Z), 7.63 (s, 1H, C4, E), 7.99
(s, 1H, C6, Z). 13C NMR (CDCl3, 126 MHz): 17.3 (2 x CH3, Z)*, 17.4 (2 x CH3, E)*, 44.1 (CH2,
E), 44.8 (CH2, Z), 55.4 (OCH3, E), 55.6 (OCH3, Z), 107.5 (ArC, Z), 112.9, 114.1 (C3’/C5’, E)*,
114.4 (C3’/C5’, Z)*, 116.2, 116.5, 116.9, 119.0, 120.3, 123.9 (C3’’/C5’’, Z), 124.3 (ArC, E),
125.3 (C6, Z), 126.3, 127.1 (C4. Z), 128.0 (C2’/C6’, Z)*, 128.1 (C1’, Z), 128.9 (C3’’/C5’’),
129.0 (C1’’), 130.4, 131.5, 136.2,* 138.1, 138.0,* 140.3 (C3, Z), 141.0 (C4, E), 141.6 (C6, Z),
142.6 (C7a, Z), 146.1, 151.4, 158.3 (C4’, Z), 159.1 (C4’, E), 164.0 (C2, Z), 164.5 (C2, Z).
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Synthesis of (E and Z)-1-(4-methoxybenzyl)-3-(4-nitrophenylimino)-5,7-dibromoindolin-2one (191)

The

title

compound

(191)

was

synthesised

5,7-dibromo-N-(4-methoxybenzyl)isatin

from

(162)

and

4-nitroaniline according to method B and purified by flash
chromatography on silica gel (100% DCM, DCM/EtOAc
4:1) to give an orange/red solid (0.0038 g, 3%, as a mixture
of Z and E isomers (E:Z 27:73)), Rf 0.37 (DCM/EtOAc 5:1).
LREI-MS: m/z 543; 545; 547 [M+]
81

79

Br79Br;

79

Br81Br;

Br81Br. HRESI-MS: calcd for C22H16Br2N3O4 79Br79Br (M+H+) 543.9961 found 543.9997. 1H

NMR (CDCl3, 500 MHz) δ 3.77 (s, 3H, OCH3, Z), 3.79 (s, 3H, OCH3, E), 5.23 (s, 2H, CH2, Z),
5.23 (s, 2H, CH2, E), 6.65 (s, 1H, H4, E), 6.83 (d, J = 7.5 Hz, 2H, H3’/H5’, Z), 6.87 (d, J = 8.0
Hz, 2H, H3’/H5’, E), 7.04 (d, J = 8.0 Hz, 2H, H2’’/H6’’, E), 7.10 (d, J = 8.0 Hz, 2H,
H2’’/H6’’, Z), 7.15 (d, J = 8.5 Hz, 2H, H2’/H6’, Z), 7.23 (d, J = 8.5 Hz, 2H, H2’’/H6’’, E), 7.53
(s, 1H, H6, E), 7.76 (s, 1H, H4, Z), 7.85 (s, 1H, H6, Z), 8.25 (d, J = 8.0 Hz, 2H, H3’’/H5’’, Z),
8.37 (d, J = 8.0 Hz, 2H, H3’’/H5’’, E). 13C NMR (CDCl3, 126 MHz) δ 43.2 (CH2, Z), 43.9
(CH2, E), 55.8* (OCH3, E + Z), 106.9, 110.3, 116.0* (C4’/C6’, E + Z), 116.9, 119.7*
(C2’’/C6’’, E), 120.3, 122.3 (C2’’/C6’’, Z), 124.5, 125.7 (C6, Z), 126.5, 128.5 (C6, Z), 128.7*
(C2’/C6’, E+Z), 129.6 (C3’’/C5’’, Z), 130.2, 130.5 (C3’’/C5’’, E), 133.2, 137.3, 139.2, 141.9
(C4, Z), 143.2 (C6, E), 148.6 (C1’’, Z), 149.5 (C1’’, E), 150.2, 152.8, 158.6* (C4’, E+Z), 160.1*
(C4’’, E+Z), 164.7 (C2, Z), 172.0 (C2, E).

Synthesis of (E and
Z)-1-(4-methoxybenzyl)-3-(4-phenoxyphenylimino)-5,7-dibromoindolin-2-one (192)
The title compound (192) was synthesised from
5,7-dibromo-N-(4-methoxybenzyl)isatin

(162)

and

4-phenoxyaniline to method B and purified by flash
chromatography on silica gel (DCM) to give a dark red
solid (0.19 g, 70%, as a mixture of Z and E isomers
(E:Z/48:52)), m.p. 209-211 ºC, Rf 0.83 (DCM). LREIMS: m/z 590; 592; 594 [M+] 79Br79Br; 79Br81Br; 81Br81Br.
HRESI-MS: calcd for C28H21Br2N2O3 (M+H+) 592.9820
found 592.9813. 1H NMR (CDCl3, 500 MHz) δ 3.74 (s, 3H, OCH3), 3.79 (s, 3H, OCH3), 5.30
(s, 2H, CH2, Z), 5.45 (s, 2H, CH2, E), 6.82-6.84 (m, 4H, H3’/H5’, E+Z), 6.84-6.87 (m, 5H, H4,
E; H2’’/H6’’; H2’’’/H6’’’), 6.97-6.99 (m, 4H, H2’’’/H6’’’, H3’’/H5’’), 7.02-7.05 (m, 4H,
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H2’’/H6’’; H2’/H6’), 7.22 (d, J = 8.5 Hz, 2H, H2’/H6’), 7.34-7.37 (m, 6H, H3’’’/H5’’’, E+Z,
H4’’’), 7.61 (s, 1H, H4, Z), 7.67 (s, 1H, H6, Z), 7.84 (s, 1H, H6, E). 13C NMR (CDCl3, 126
MHz): δ 43.7 (CH2, Z), 44.3 (CH2, E), 55.2 (OCH3, E+Z), 103.4, 104.2, 114.1* (C3’/C5’, E+Z),
116.3, 118.1, 118.7, 119.4, 119.6, 120.1, 123.5, 123.7, 124.4, 124.8 (C6, E), 126.7* (C1’, E+Z),
126.9* (C2’/C6’, E+Z), 127.8, 128.3, 128.4, 129.3, 129.6*, 129.8*, 132.1, 132.8, 136.7, 138.5,
140.0 (C6, Z), 141.2 (C4, Z), 141.3 (ArC), 142.1 (ArC), 143.6 (ArC), 144.6 (ArC), 147.8 (ArC),
151.6 (ArC), 155.6 (C4’’), 156.5 (C4’’), 157.2* (C1’’’, E+Z), 157.8 (C2, Z), 158.9* (C4’, E+Z),
159.1, 160.4, 163.7 (C2, E).

Synthesis of (E and Z)-1–(4-methylbenzyl)-3 -(4-methoxyphenylimino)-5,7-dibromoindol-2
–one (193)
The

title

compound

(193)

was

5,7-dibromo-N-(4-methylbenzyl)isatin

synthesised

from

(163)

and

4-methoxyaniline according to method B and purified by
flash chromatography on silica gel (DCM) to give a dark red
solid (0.021 g, 35%, as a mixture of Z and E isomers
(E:Z/48:52)), m.p. 137-139 ºC, Rf 0.43 (DCM). LREI-MS:
m/z 512; 514; 516 [M+]

79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C23H19Br3N2O2

Br79Br (M+H+) 512.9694 found 512.9691. 1H NMR (CDCl3, 500 MHz) δ 2.29 (s, 3H, CH3,

79

Z), 2.31 (s, 3H, CH3, E), 3.83 (s, 3H, OCH3, Z), 3.86 (s, 3H, OCH3, E), 5.32 (s, 2H, CH2, Z),
5.45 (s, 2H, CH2, E), 6.78 (s, 1H, H4, E), 6.90 (d, J = 8.5 Hz, 2H, H3’’/H5’’, Z), 6.99 (d, J =
8.5 Hz, 2H, H3’’/H5’’, E), 7.07 (d, J = 8.5 Hz, 2H, H2’’/H6’’, E), 7.08-7.11 (m, 8H,
H2’/H3’/H5’/H6’), 7.50 (d, J = 9 Hz, 2H, H2’’/H6’’, Z), 7.56 (s, 1H, H6, E), 7.61 (s, 1H, H4,
Z), 7.82 (s, 1H, H6, Z). 13C NMR (CDCl3, 126 MHz): δ 20.4* (CH3, E+Z), 42.1 (CH2, E), 42.3
(CH2, Z), 55.7 (OCH3, Z), 55.8 (OCH3, E), 113.9, 115.0, 116.6 (C3’’/C5’’, E), 117.2 (C3’’/C5’’
Z), 120.5 (C2’’/C6’’, E), 124.5, 125.9, 126.7, 126.8, 127.1* (C2’/C6’, Z), 127.3* (C2’/C6’, E),
128.5, 128.9* (C3’/C5’, E+Z), 129.6, 130.2* (C2’’/C6’’, Z), 131.3, 134.6, 137.1, 137.2, 138.0,
138.7, 139.1, 140.3, 140.5, 143.7, 145.0, 151.1, 157.4 (C4’’, E), 158.2 (C4’’, Z), 158.8 (C2),
160.2 (C2).

Synthesis

of

(E

and

Z)-1–(4-methylbenzyl)-3

-(3-

bromophenylimino)-5,7-dibromoindol-2-one (194)
The

title

compound

(194)

was

5,7-dibromo-N-(4-methylbenzyl)isatin

synthesised

from

(163)

and

3-bromoaniline according to method B and purified by flash
chromatography on silica gel (DCM) to give an orange powder
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(0.090 g, 66%, as a mixture of Z and E isomers (E:Z/48:52)), m.p. 140-144 ºC, Rf 0.83 (DCM).
LREI-MS: m/z 562; 564; 566 [M+]

79

HRESI-MS: calcd for C22H16Br3N2O

79

Br79Br79Br;

79

Br

79

Br81Br;

79

Br81Br81Br;

81

Br81Br81Br.

Br79Br (M+H+) 562.8813 found 562.8808. 1H NMR

(CDCl3, 500 MHz) δ 2.29 (s, 3H, CH3, Z), 2.32 (s, 3H, CH3, E), 5.27 (s, 2H, CH2, Z), 5.44 (s,
2H, CH2, E), 6.77 (s, 1H, H4, E), 6.91 (d, J = 8.5 Hz, 1H, H4’’, Z), 6.98 (d, J = 8.5 Hz, 1H,
H4’’, E), 7.13 (s, 4H, H2’/H3’/H5’/H6’, Z), 7.16 (s, 4H, H2’/H3’/H5’/H6’, E), 7.19 (bd, 1H,
H6’’, E), 7.21 (s, 1H, H2’’, Z), 7.24 (t, J = 6.5 Hz, 1H, H5’’, Z), 7.33-7.35 (m, 2H, H5’’, E,
H6’’, Z), 7.41 (s, 1H, H2’’, E), 7.59 (s, 1H, H4, Z), 7.61 (s, 1H, H6, E), 7.80 (s, 1H, H6, Z). 13C
NMR (CDCl3, 126 MHz): δ 22.4 (CH3, E+Z), 44.3 (CH2, Z), 45.4 (CH2, E), 104.1, 104.8, 115.9,
116.1 (C4’’, Z), 116. 7, 118.4 (C4’’, E), 120.6 (C6’, Z), 122.6 (Arc), 122.9 (C4’’, E), 124.3,
125.7 (C6, Z), 126.7 (C2’/C6’, E+Z)*, 128.4 (C4, E), 129.1* (C2’, E+Z), 129.2* (C6’’, E+Z),
129.7* (C3’/C5’, E+Z), 130.1 (C2’, E), 131.3 (C5’’, Z), 133.4* (C4’, E+Z), 137.5* (C1’, E+Z),
141.4 (C6, E), 142.1 (C4, E), 143.5 (C7a, E), 144.2 (C7a, Z), 149.7 (C1’’, Z), 150.3 (Arc), 150.4
(C1’’, E), 151.2, 157.8 (C2, E), 163.8 (C2, Z).

Synthesis

of

(E

and

Z)-1–(4-methylbenzyl)-3-(4-trifluoromethylphenylimino)-5,7-

dibromoindol-2–one (195)
The

title

compound

(195)

was

synthesised

from

(163)

and

5,7-dibromo-N-(4-methylbenzyl)isatin

4-(trifluoromethyl)aniline according to method B and purified
by flash chromatography on silica gel (DCM) to give a dark
red solid (0.0012 g, 19%, as a mixture of Z and E isomers
(E:Z/48:52)), m.p. 131-135 ºC, Rf 0.87 (DCM). LREI-MS:
m/z 550; 552; 554 [M+]
79

79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C23H16Br2F3N2O

Br79Br (M+H+) 550.9577 found 550.9581. 1H NMR (CDCl3, 500 MHz) δ 2.30 (s, 3H, CH3, Z),

2.33 (s, 3H, CH3, E), 5.26 (s, 2H, CH2, Z), 5.45 (s, 2H, CH2, E), 6.62 (s, 1H, H4, E), 7.07-7.10
(m, 8H, H2’/H3’/H5’/H6’, E, Z), 7.15-7.18 (m, 4H, H2’’/H6’’, E+Z), 7.60 (s, 1H, H6, E), 7.61
(d, J = 8.0 Hz, 2H, H3’’/H5’’, Z), 7.71 (s, 1H, H4, Z), 7.72 (d, J = 8.0 Hz, 2H, H3’’/H5’’, E),
7.84 (s, 1H, H6, Z). 13C NMR (CDCl3, 126 MHz): δ 21.3 (CH3, E+Z), 44.4 (CH2, E), 44.9 (CH2,
Z), 108.3, 108.9, 114.7, 116.8, 117.6, 119.3, 125.4, 125.9 (C6, Z), 126.2 (C3’’/C5’’, Z), 126.3,
126.7 (C2’/C6’, E+Z), 126.8 (C2’’/C6’’, E+Z), 127.3 (C4, Z), 127.4 (C3’’/C5’’, E), 128.0, 128.3
(C4, E), 129.0, 129.6, 129.7 (C3’/C5’, E+Z), 131.0, 133.3, 137.6, 141.6, 142.2, 146.2, 151.6,
151.9, 158.7 (C1’’, E), 159.1 (C1’’, Z), 161.4 (C2, Z), 162.3 (C2, E).
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Synthesis of (E and Z)-1–(4-chlorobenzyl)-3-(3-bromorphenylimino)-5,7-dibromoindol-2–
one (196)
The

title

compound

(196)

was

synthesised

5,7-dibromo-N-(4-chlorobenzyl)isatin

from

(164)

and

3-bromoaniline according to method B and purified by flash
chromatography on silica gel (DCM) to give an orange powder
(0.015 g, 23%, as a mixture of Z and E isomers (E:Z/44:56)),
m.p. 127-129 ºC, Rf 0.49 (DCM/Hex 5:2). LREI-MS: m/z 580;
582; 584; 586 [M+H+]

79

Br79Br79Br;

79

Br

79

Br81Br;

79

Br81Br81Br;

81

Br81Br81Br. HRESI-MS:

calcd for C21H13Br3ClN2O 79Br79Br79Br (M+H+) 580.8266 found 580.8259. 1H NMR (CDCl3,
500 MHz) δ 5.28 (s, 2H, CH2, E), 5.46 (s, 2H, CH2, Z), 6.80 (s, 1H, H4, E), 6.89 (d, J = 8.5 Hz,
1H, H6’’, E), 6.92 (d, J = 8.5 Hz, 1H, H6’’, Z), 7.01-7.02 (m, 3H), 7.15 (d, J = 8.5 Hz, 1H, Z),
7.23-7.25 (m, 3H, ArH), 7.28-7.30 (m, 2H, ArH), 7.35-7.37 (m, 4H, ArH), 7.45 (d, J = 8.0 Hz,
1H), 7.62 (s, 1H, H6, E), 7.71 (s, 1H, H4, Z), 7.84 (s, 1H, H6, Z).

Synthesis of (E and Z)-1–(4-Chlorobenzyl)-3-(4-methoxyphenylimino)-5,7-dibromoindol-2one (197)
The

title

compound

(197)

was

5,7-dibromo-N-(4-chlorobenzyl)isatin

synthesised

from

(164)

and

4-methoxyaniline according to method B and purified by
flash chromatography on silica gel (DCM) to give a dark red
solid (0.018 g, 30%, as mixture of E and Z isomers
E:Z/48:52), Rf 0.72 (DCM/Hex 2:1). LREI-MS: m/z 532; 534; 536 [M+]

79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C22H16Br2ClN2O2 79Br79Br (M+H+) 532.9267 found 532.9244.

H NMR (CDCl3, 500 MHz) δ 3.79 (s, 3H, OCH3, E), 3.86 (s, 3H, OCH3, Z), 5.37 (s, 2H, CH2,

1

E), 5.43 (s, 2H, CH2, Z), 6.90 (d, J = 1.5 Hz, 1H, H4, E), 6.97 (d, J = 8.5 Hz, 2H, H3’’/H5’’, E),
7.07 (d, J = 8.5 Hz, 2H, H3’’/H5’’, Z), 7.19 (d, J = 8.5 Hz, 2H, H2’’/H6’’, E), 7.23 (d, J = 8.5
Hz, 2H), 7.32-7.36 (m, 6H), 7.54 (d, J = 8.5 Hz, 2H, H2’’/H6’’, Z), 7.59 (s, 1H, H6, E), 7.64 (s,
1H, H4, Z), 7.79 (s, 1H, H6, Z). 13C NMR (CDCl3, 126 MHz): δ 44.0, 44.5, 55.7, 55.7, 103.4,
104.2, 113.9, 115.0. 115.9, 116.4, 119.9, 120.6, 125.0, 126.1, 127.5, 128.2, 128.3, 129.1, 130.2,
130.9, 132.4, 132.9, 133.5*, 133.7, 135.3, 135.4*, 139.7, 140.1, 140.6, 141.2, 141.9, 142.8,
144.1, 146.5, 150.3, 151.2, 158.3, 158.9, 160.4, 161.3, 162.8, 164.1.
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Synthesis of (E and Z)-1–(4-Chlorobenzyl)-3-(4-iodophenylimino)-5,7-dibromoindol-2–one
(198)
The

title

compound

(198)

was

5,7-dibromo-N-(4-chlorobenzyl)isatin

synthesised
(164)

from

and

4-

chloroaniline according to method B and purified by flash
chromatography on silica gel (DCM) to give an orange solid
(0.12 g, 81% as a mixture of E and Z isomers (E:Z/42:58)),
m.p. 180-182 ºC, Rf 0.72 (DCM/Hex 1:1). LREI-MS: m/z
628; 630; 632 [M+]
79

79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C21H13Br2ClIN2O

Br79Br (M+H+) 628.8128 found 628.8102. 1H NMR (CDCl3, 500 MHz): δ 5.23 (s, 2H, CH2,

E), 5.43 (s, 2H, CH2, Z), 6.75 (d, J = 8.5 Hz, 2H, H2’’/H6’’ E), 6.86 (d, J = 8.5 Hz, 2H,
H3’/H5’ E), 6.89 (s, 1H, H4, E), 7.14 (d, J = 8.5 Hz, 2H, H2’/H6’, Z), 7.18 (d, J = 8.5 Hz, 2H,
H2’/H6’, E), 7.25 (d, J = 8.5 Hz, 2H, H3’/H5’, Z), 7.29 (d, J = 8.5 Hz, 2H, H2’’/H6’’, Z), 7.60
(s, 1H, 6 E), 7.68 (d, J = 8.5 Hz, 2H, H3’’/H5’’, Z), 7.69 (s, 1H, H4, Z), 7.77 (d, J = 8.5 Hz, 2H,
H3’’/H5’’ E), 7.83 (s, 1H, 6 Z). 13C NMR: (CDCl3, 126 MHz): δ 44.0 (CH2, E), 44.6 (CH2, Z),
90.4 (C4’’, E), 91.6 (C4’’, Z), 104.3 (ArC, E), 104.7 (ArC, Z), 116.1 (ArC, E), 116.9 (ArC, Z),
119.7* (C2’’/C6’’, E), 122.3* (C2’’/C6’’, Z), 125.8 (C6, Z), 128.2* (C2’/C6’ E; C2’/C6’, Z; C4,
E), 129.1* (C3’/C5’, E; C3’/C5’, Z), 130.1, 130.9, 132.4, 133.7* (C4’, E+Z), 135.1* (C1’,
E+Z), 137.9 (C3’’/C5’’, Z), 138.4, 139.1 (C3’’/C5’’, E), 140.2, 141.1 (C4, Z), 141.9 (C6, E),
143.5 (C3, E), 147.6 (C1’’, E), 148.6 (C1’’, Z), 157.7 (C2, Z), 163.6 (C2, E).

Synthesis of (E and Z)-5,7-dibromo-1-(4-iodobenzyl)-3-((4-methoxyphenyl)imino)indolin2-one (199)
The

title

compound

(199)

was

5,7-dibromo-N-(4-iodobenzyl)isatin

synthesised
(165)

from
and

4-methoxyaniline according to method B and purified by
flash chromatography on silica gel (DCM) to give a dark red
solid (0.011g, 28% as a mixture of E and Z isomer (E:Z
48:52)), Rf 0.55 (DCM). LREI-MS: m/z 624; 626; 628 [M+]
79

Br79Br; 79Br81Br; 81Br81Br. HRESI-MS: calcd for C22H16Br2IN2O2 79Br79B (M+H+) 624.8623

found 624.8607. 1H NMR (CDCl3, 500 MHz) δ 3.84 (s, 3H, OCH3, Z), 3.89 (s, 3H, OCH3, E),
5.29 (s, 2H, CH2, Z), 5.43 (s, 2H, CH2, E), 6.75 (s, 1H, H4, E), 6.90-6.93 (m, 4H, H3’’/H5’’,
E+Z), 6.97 (d, J = 8.5 Hz, 2H, H2’/H6’, Z), 7.05 (d, J = 8.5 Hz, 2H, H2’/H6’, E), 7.22-7.25 (m,
4H, H2’/H6’, E+Z), 7.52 (d, J = 7.5 Hz, 2H, H3’/H5’, E), 7.58 (s, 1H, H6, E), 7.62 (d, J = 7.5
Hz, 2H, H3’/H5’, Z), 7.65 (s, 1H, H4, Z), 7.84 (s, 1H, H6, Z).
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Synthesis

of

(E

and

Z)-2-(3-((5,7-dibromo-1-(4-iodobenzyl)-2-oxoindolin-3-

ylidene)amino)phenyl)acetic acid (200)
The title

compound (200)

was

synthesised from

5,7-dibromo-N-(4-iodobenzyl)isatin

(165)

and

(3-aminophenyl)acetic acid according to method B and
purified by flash chromatography on silica gel (DCM,
DCM:EtOAc 7:1) to give a dark red solid (0.042 g, 22%,
mixture of E and Z isomers (E:Z/64:36)), m.p. 182-186 ºC, Rf 0.49 (DCM). LREI-MS: m/z
652; 654; 656 [M+]

79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C23H16N2O3Br2I

Br79Br (M+H+) 652.9451 found 652.9509. 1H NMR (DMSO-d6, 500 MHz) δ 3.62 (s, 2H,

79

CH2, Z), 3.65(s, 2H, CH2, E), 5.25 (s, 2H, CH2, Z), 5.43 (s, 2H, CH2, E), 6.81 (d, J =1.5 Hz,1H,
H4’’, E), 6.89 (d, J = 8.0 Hz, 1H, H4’, E), 6.93 (s, 1H, H2’, E), 6.95 (d, J = 8.0 Hz, 1H, H4’, Z),
7.02 (m, 3H, H2’’’/H6’’’, E, H6’, E) 7.08 (s, 1H, H2’, Z), 7.15 (d, J = 8.0 Hz, 2H, H2’’’/H6’’’,
Z), 7.21 (d, J = 7.5 Hz, 2H, H3’’’/H5’’’, Z), 7.33 (t, J = 8.0 Hz, 1H, H5’, Z), 7.43 (t, J = 7.5 Hz,
1H, H5’, E), 7.59 (d, J = 2.0 Hz, 1H, H6’’, E), 7.61 (d, J = 8.5 Hz, 2H, H3’’’/H5’’’, E), 7.67 (d,
J = 8.5 Hz, 1H, H6’, Z), 7.69 (d, J = 2.0 Hz, 1H, H4’’, Z), 7.85 (d, J = 2.0 Hz,1H, H6’’, Z). 13C
NMR (DMSO-d6, 126 MHz): δ 41.1 (CH2, E), 41.4 (CH2, Z), 44.1 (CH2, Z), 44.5 (CH2, E),
101.7 (C4’’’, E), 102.3 (C4’’’, Z), 104.1, 104.7, 114.6, 114.6, 114.8, 116.0, 118.3, 120.7, 120.9,
122.0 (C2’, E), 124.5, 125.2, 126.6, 127.5, 128.1* (C2’’’/C6’’’, E), 128.2* (C2’’’/C6’’’, Z),
129.3 (C2’, Z), 129.4, 130.8* (C3’’’/C5’’’, E), 132.1 (C3’’’/C5’’’, Z), 140.8, 141.0, 143.1
(C7a’’, Z), 144.5 (C7a’’, E), 149.1, 150.4, 151.2, 153.0 (C3, E), 158.1 (C2’’, Z), 159.0* (C4’, E
+Z), 163.6 (C2’’, E), 167.5 (C3’’, Z), 168.0 (C3’’, E), 169.8 (COOH, Z), 170.3 (COOH, E).

Synthesis of (E and Z)-1-(4-iodobenzyl)-3-(3-bromophenylimino)-5,7-dibromoindol-2–one
(201)
The

title

compound

(201)

was

synthesised

from

1-(4-iodobenzyl)-5,7-dibromoisatin (165) and 3-bromoaniline
according to method B and purified by flash chromatography on
silica gel (DCM) to give a red solid (0.069 g, 54% as mixture of
E and Z isomers (E:Z/42:58)), Rf 0.87 (DCM). LREI-MS: m/z
672;
79

674;

Br81Br81Br;

676;
81

678

[M+]

Br81Br81Br.

79

Br79Br79Br;

HRESI-MS:

79

Br79Br81Br;

calcd

for

C21H13Br3IN2O 79Br79Br79Br (M+H+) 672.7623 found 672.7584. 1H NMR (CDCl3, 500 MHz) δ
5.25 (s, 2H, CH2, Z), 5.43 (s, 2H, CH2, E), 6.81 (s, 1H, H4, E), 6.92 (d, J = 8.0 Hz, 1H, H6’’,
E), 6.97 (d, J = 8.0 Hz, 2H, H2’/H6’, Z), 7.00-7.03 (m, 2H, H2’/H6’, E), 7.18 (s, 1H, H2’’, E),
7.21-7.24 (m, 2H, ArH), 7.31-7.33 (m, 2H, H2’’, Z, H5’’, E), 7.42-7.44 (m, 2H, ArH), 7.61-7.62
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(m, 3H, H3’/H5’, H4, Z), 7.65 (d, J = 8.5 Hz, 2H, H3’/H5’), 7.71 (s, 1H, H6, Z), 7.84 (s, 1H,
H6, E). 13C NMR (126 MHz, CDCl3): 44.2 (CH2, E), 44.8 (CH2, Z), 93.2* (C4’, E+Z), 103.9,
104.7, 116.0, 116.2, 117.0, 118.4, 119.5, 120.6, 122.6, 122.9, 123.7, 125.8 (C6, E), 128.5 (C4,
E), 128.7* (C2’/C6’, E+Z), 129.2, 129.3, 130.2 (C5’’, Z), 131.1, 131.4, 136.3 (C1’, E+Z), 138.1
(C3’/C5’, E+Z), 141.4, 142.0, 142.1, 143.8, 149.4, 150.2 (C1’’, Z), 150.7 (C1’’, E), 152.2, 157.5
(C2, E), 163.5 (C2, Z).

Synthesis of (E and Z)-1-(4-iodobenzyl)-3 -(4-chlorophenylimino)-5,7-dibromoindol-2-one
(202)
The

title

compound

(202)

was

synthesised

from

5,7-dibromo-N-(4-iodobenzyl)isatin (165) and 4-chloroaniline
according to method B and purified by flash chromatography
on silica gel (DCM/Hex 7:1; 3:1) to give an orange solid
(0.027 g, 15% mixture of E and Z isomers (E:Z/44:56)), Rf
0.72 (DCM/Hex 5:2). LREI-MS: m/z 628; 630; 632 [M+]
79

Br79Br; 79Br81Br; 81Br81Br. HRESI-MS: calcd for C21H13Br2ClIN2O 79Br79Br (M+H+) 628.8128

found 628.8124. 1H NMR (CDCl3, 500 MHz) δ 5.32 (s, 2H, CH2, Z), 5.42 (s, 2H, CH2, E), 6.87
(s, 1H, H4, E), 6.95-6.99 (m 4H, H2’’/H6’’, E, H2’/H6’, E), 7.01 (d, J = 8.5 Hz, 2H, H2’’/H6’’,
Z), 7.08 (d, J = 8.5 Hz, 2H, H2’/H6’, Z), 7.32 (d, J = 8.5 Hz, 2H, H3’’/H5’’, E), 7.42 (d, J = 8.5
Hz, 2H, H3’’/H5’’, Z), 7.60 (d, J = 9 Hz, 2H, H3’/H5’, E), 7.62 (s, 1H, H6, E), 7.65 (d, J = 8.5
Hz, 2H, H3’/H5’, Z), 7.67 (s, 1H, H4, Z), 7.82 (s, 1H, H6, Z). 13C NMR (CDCl3, 126 MHz): δ
45.4 (CH2, E), 45.7 (CH2, Z), 92.3 (C4’, E), 93.2 (C4’, Z), 104.5, 104.9, 116.5, 117.0, 120.8*
(C2’’/C6’’, E), 122.5* (C2’’/C6’’, Z), 126.3 (C6, Z), 127.6* (C2’/C6’ E+Z), 128.2 (C4, E),
129.1* (C3’’/C5’’, E+ Z), 130.3, 130.8, 132.4, 133.7 (C4’, E), 134.5 (C4’, Z), 135.1 (C1’, E),
136.2 (C1’, Z), 137.7* (C3’/C5’, Z), 138.8, 139.2* (C3’/C5’, E), 140.3, 141.4 (C4, Z), 141.6
(C6, E), 144.0 (C3, E), 147.5 (C1’’, E), 148.9 (C1’’, Z), 160.3 (C2, Z), 163.6 (C2, E).

Synthesis of (E and Z)-1-(4-iodobenzyl)-3-(4-fluorophenylimino)-5,7-dibromoindol-2–one
(203)
The

title

compound

(203)

was

synthesised

from

5,7-dibromo-N-(4-iodobenzyl)isatin (165) and 4-fluoroaniline
according to method B and purified by flash chromatography on
silica gel (DCM/Hex 7:1; 3:1) to give an orange powder (0.073
g, 41%, as a mixture of E and Z isomers (E:Z/42:58)), Rf 0.49
(DCM). LREI-MS: m/z 612; 614; 616 [M+] 79Br79Br; 79Br81Br;
81

Br81Br. HRESI-MS: calcd for C21H13Br2FIN2O

79

Br81Br (M+H+) 612.8423 found 612.8392.
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H NMR (CDCl3, 500 MHz) δ 5.26 (s, 2H, CH2, E), 5.42 (s, 2H, CH2, Z), 6.90 (s, 1H, H4, E),

1

6.97- 7.00 (m, 4H, H2’/H6’, E+Z), 7.06 (t, J = 8.0 Hz, 2H, H3’’/H5’’, Z), 7.17 (t, J = 8.5 Hz,
2H, H3’’/H5’’, E), 7.20-7.23 (m, 4H, H2’’/H6’’, E, H2’’/H6’’, Z), 7.61 (s, 1H, H6, E), 7.62 (d, J
= 8.0 Hz, 2H, H3’/H5’, E), 7.64 (d, J = 9 Hz, 2H, H3’/H5’, Z), 7.68 (s, 1H, H4, Z), 7.84 (s, 1H,
H6, Z).

C NMR (CDCl3, 126 MHz): δ 43.8 (CH2, E), 44.3 (CH2, Z), 100.3 (C4’, E), 100.9

13

(C4’, Z), 103.7, 104.6, 115.6, 116.9* (C3’’/C5’’, Z), 117.5* (C3’’/C5’’, E), 118.3, 119.6, 121.5,
122.4, 123.3* (C2’’/C6’’, Z), 124.8* (C2’’/C6’’, E), 125.0, 125.5, 126.5, 127.7* (C2’/C6’, E),
128.6 (C2’/C6’, Z), 130.2, 130.9, 136.4, 138.1*(C3’/C5’, E), 139.0* (C3’/C5’, Z), 140.8, 141.6,
158.2, 158.5, 159.5, 159.9, 160.2 (C2, Z), 160.9 (C2, E).

Synthesis of E-3-((4-hydroxyphenyl)imino)-N-(4-methoxybenzyl)isatin (204)
The title compound (204) was synthesised from 4-aminophenol
(169) and 1-(4-methoxybenzyl)isatin according to the method A
and

purified

by

flash

chromatography

on

silica

gel

(DCM/EtOAc 5:1) to give a red solid (0.044 g, 65%), m.p. 207209 ºC, Rf 0.57 (DCM/EtOAc 5:1). LREI-MS: m/z 358.39
[M+]. HRESI-MS: C22H19N2O3 (M+H+) 359.1396 found
359.1389. 1H NMR (CDCl3, 500 MHz) δ 3.78 (s, 3H, OCH3), 4.95 (s, 4H, CH2), 6.73-6.78 (m,
4H, H3’/H5’, H3’’/H5’’), 6.84-6.87 (m, 4H, H2’/H6’, H2’’/H6’’), 6.91 (d, J = 9 Hz, 1H, H4),
6.97 (t, J = 9 Hz, 1H, H5), 7.24 (t, J = 9 Hz, 1H, H6), 7.31 (d, J = 9 Hz, 1H, H7). 13C NMR
(CDCl3, 126 MHz): δ 43.9 (CH2), 55.2 (OCH3), 110.6 (C7), 114.5 (C3a), 114.6* (C3’/C5),
116.5* (C3’’/C5’’), 120.7* (C2’’/C6’’), 122.9 (C5), 122.0 (C6), 127.5 (C1’), 129.2* (C2’/C6’),
130.1 (C4), 143.1 (C1’’), 147.3 (C7a), 154.0 (C3), 154.4 (C4’’), 159.6 (C4’), 163.9 (C2).

Synthesis of (E and Z)-5,7-dibromo-3-((4-hydroxyphenyl)imino)indolin-2-one (205)
The

title

compound

(205)

was

synthesised

from

5,7-dibromoisatin (76) and 4-methoxyaniline according to
method B and purified by flash chromatography on silica gel
(DCM) to give a dark yellow powder (0.20 g, 63%, mixture of
E and Z isomers (E:Z/64:36), m.p. 229-231 ºC, Rf 0.46
(DCM/EtOAc 4:1) LREI-MS: m/z 394; 396; 398 [M+]
79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C14H9Br2N2O2

79

Br79Br (M+H+) 394.9089

found 394.9104. 1H NMR (DMSO-d6, 500 MHz) δ 6.72 (d, 2H, J = 9 Hz, H3’/H5’, Z), 6.86 (d,
J = 1.5 Hz,1H, H4, E), 6.89 (d, 2H, J = 8.5 Hz, H3’/H5’, E), 6.92 (d, 2H, J = 8.5 Hz, H2’/H6’,
E), 7.36 (d, 2H, J = 8.5 Hz, H2’/H6’, Z), 7.58 (d, J = 2.0 Hz, 1H, 4Z), 7.74 (d, J = 2.0 Hz, H6,
Z), 7.81 (d, J = 1.5 Hz, H6, E). 13C NMR (126 MHz, DMSO): δ 104.7, 105.7, 113.8* (C3’/C5’,
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Z), 114.5, 115.6* (C2’/C6’, E), 116.7, 119.5, 120.9* (C3’/C5’, E), 123.8 (C4, Z), 124.7*
(C2’/C6’, Z), 126.5 (C4, E), 137.1 (C6, Z), 138.3 (C6, E), 139.0, 141.4, 141.8 (C1’, Z), 145.8
(C1’, E), 148.3, 152.8, 156.8, 158.8 (C4’, E), 160.0 (C4’, Z), 165.3 (C2, Z), 169.5 (C2, E).

Synthesis of (E and Z)-5,7-dibromo-3-((4-methoxyphenyl)imino)indolin-2-one (206)
The

title

compound

(206)

was

synthesised

from

5,7-dibromoisatin (76) and 4-methoxyaniline according to
method B and purified by flash chromatography on silica gel
(DCM) to give a dark yellow powder (0.174 g, 65%, mixture
of E and Z isomers (E:Z/65:35)), m.p. 277-279 ºC, Rf 0.53
(DCM/EtOAc 4:1) LREI-MS: m/z 408; 410; 412 [M+]

79

Br79Br;

79

Br81Br; 81Br81Br. HRESI-

MS: calcd for C15H11Br2N2O2 79Br79Br (M+H+) 408.9089 found 408.9104. 1H NMR (DMSO-d6,
500 MHz) δ 3.79 (s, 3H, OCH3, Z), 3.81 (s, 3H, OCH3, E), 6.65 (s, 1H, 4E), 6.92 (d, 2H, J = 9
Hz, H3’/H5’, Z), 7.00 (d, 2H, J = 9 Hz, H2’/H6’, E), 7.06 (d, 2H, J = 9 Hz, H3’/H5’, E), 7.33 (d,
2H, J = 9 Hz, H2’/H6’, Z), 7.60 (s, 1H, 4Z), 7.76 (s, 1H, 6E), 7.81 (s, 1H, 6E). 13C NMR (126
MHz, DMSO): δ 56.0 (OCH3, Z), 56.1 (OCH3, E), 104.8, 106.1, 112.9, 114.2* (C3’/C5’, Z),
115.4* (C2’/C6’, E), 119.8, 120.4* (C3’/C5’, E), 124.1 (C4, Z), 124.8* (C2’/C6’, Z), 126.6 (C4,
E), 126.9, 127.6, 128.3, 137.4 (C6, Z), 138.3 (C6, E), 138.6, 140.9 (C1’, Z), 143.2 (C1’, E),
154.8, 158.2 (C4’, E), 159.1 (C4’, Z), 160.1, 165.4 (C2, Z), 170.1 (C2, E).

Synthesis of 5,7-dibromo-3-(2-(4-chlorophenyl)hydrazono)-1-(4-methoxybenzyl)indolin-2one (207)
The

title

compound

(207)

was

synthesised

5,7-dibromo-N-(4-methoxybenzyl)isatin

from

(162)

and

4-chlorophenylhydrazine hydrochloride according to method
B and purified by flash chromatography on silica gel (DCM;
DCM/EtOAC 7:1; 4:1) to give a yellow powder (0.09 g,
44%), m.p. 216-218 ºC, Rf 0.63 (DCM/EtOAC 9:1). LREIMS: m/z 547; 549; 551 [M+]

79

Br79Br;

79

Br81Br;

81

Br81Br.

HRESI-MS: calcd for C22H17Br2N3O2Cl 79Br79Br; (M+H+) 547.9376 found 547.9384. 1H NMR
(CDCl3): δ 3.76 (s, 3H, OCH3), 5.40 (s, 2H, CH2), 6.83 (d, 2H, J = 9.5, H2’/H6’), 7.15 (d, 2H, J
= 9 Hz, H3’/H5’), 7.29-7.32 (m, 4H, H2’’/H3’’/H5’’/H6’’), 7.49 (d, 1H, J = 3.5 Hz, H4), 7.73
(d, 1H, J = 3.5 Hz, H6).

13

C NMR (CDCl3, 126 MHz): δ 43.5 (CH2), 55.4 (OCH3), 103.8,

114.3* (C3’/C5’), 115.9, 116.1* (C2’’/C6’’), 120.9 (C6), 124.6 (C3), 126.1, 127.9* (C2’/C6’),
129.0 (C1’), 129.4 (C4’’), 129.8* (C3’’/C5’’), 135.2 (C4), 136.3 (C7a), 140.6 (C1’’), 158.4
(C4’), 162.4 (C2).
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of

4-(2-(5,7-dibromo-1-(4-methoxybenzyl)-2-oxoindolin-3-

ylidene)hydrazinyl)benzoic acid (208)
The title compound (208) was synthesised from 5,7-dibromo-N-(4-methoxybenzyl)isatin (162)
and 4-hydrazinobenzoic acid according to method B and
purified by flash chromatography on silica gel (DCM;
DCM/EtOAC 6:1; 3:1) to give a yellow powder (0.22 g,
85%), m.p. 248-250 ºC, Rf 0.55 (DCM/EtOAC 9:1). LREIMS: m/z 557; 559; 561 [M+]

79

Br79Br;

HRESI-MS: calcd for C23H16Br2N3O4

79

Br81Br;

81

Br81Br.

79

Br79Br; (M-H+)

556.9375 found 556.9383. 1H NMR (DMSO-d6, 500 MHz):
δ 3.69 (s, 3H, OCH3), 5.33 (s, 2H, CH2), 6.81 (d, J = 8.5Hz,
2H, H3’/H5’); 7.00 (d, J = 8.5 Hz, 2H, H2’/H6’); 7.03 (s, 1H, H4), 7.44 (d, J = 8.5 Hz, 2H,
H2’’/H6’’); 7.83 (d, J = 8.5 Hz, 2H, H3’’/H5’’); 8.59 (s, 1H, C6). 13C NMR (126 MHz, DMSOd6, 126 MHz): δ 43.6 (CH2), 55.8 (OCH3), 100.8, 113.2, 114.4* (C3’/C5’), 119.2* (C2’’/C6’’),
120.8 (C6), 125.6, 126.8, 128.0* (C2’/C6’), 129.8 (C1’’), 130.8* (C3’’/C5’’), 132.1 (C1’),
132.5, 153.3, 158.6 (C4’), 159.0 (C4’’), 166.8 (C2), 174.2 (COOH).

Synthesis of (Z)-5,7-dibromo-3-(hydroxyimino)-1-(4-methoxybenzyl)indolin-2-one (209)
The

title

compound

(209)

was

5,7-dibromo-N-(4-methoxybenzyl)isatin

synthesised
(162)

from
and

hydroxylamine hydrochloride according to method B and
purified by flash chromatography on silica gel (DCM/EtOAc
5:1) to give a yellow powder (0.19 g, 92%), Rf 0.67
(DCM/EtOAc 5:1). LREI-MS: m/z 438; 440; 442 [M+] 79Br79Br; 79Br81Br; 81Br81Br. HRESIMS: calcd for C16H13N2O3Br2 9Br79Br (M+H+) 438.9059 found 430.9089. 1H NMR (DMSO-d6,
500 MHz) δ 3.69 (s, 3H, OCH3), 5.21 (s, 2H, CH2), 6.83 (d, J = 8.5 Hz, 2H, H3’/H5’), 7.08 (d, J
= 8.5 Hz, 2H, H2’/H6’), 7.23 (s, 1H, H4), 8.18 (s, 1H, H6). 13C NMR: (DMSO-d6, 126 MHz): δ
43.2 (CH2), 56.8 (OCH3), 104.0, 114.7* (C3’/C5’), 115.6, 120.3, 128.1 (C2’/C6’), 129.1 (C1’),
129.7 (C6), 138.9 (C4), 140.1 (C7a), 142.0 (C3), 159.1 (C4’), 164.5 (C2).

Synthesis of (Z)-3-(hydroxyimino)-1-(4-methoxybenzyl)indolin-2-one (210)
The title compound (210) was synthesised from hydroxylamine
hydrochloride (169) and 1-(4-methoxybenzyl)isatin according to
method B and purified by flash chromatography on silica gel
(DCM) to give an orange/red solid (0.23 g, 67%), Rf 0.62 (DCM).
LREI-MS: m/z 282.29 [M+] 1H NMR (CDCl3, 500 MHz) δ 3.70
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(s, 3H, OCH3), 4.85 (s, 2H, CH2), 6.86 (d, J = 8.0 Hz, 2H, H3’/H5’), 7.00 (d, J = 8.0 Hz, 1H,
H7), 7.06 (t, J = 8.0 Hz, 1H, H5), 7.26 (d, J = 8.0 Hz, 2H, H2’/H6’), 7.34 (t, J = 1.8.0 Hz, 1H,
H6), 7.98 (d, J = 7.0 Hz, 1H, H4).

Synthesis of (Z)-5,7-dibromo-3-(hydroxyimino)indolin-2-one (211)
The title compound (211) was synthesised from hydroxylamine
hydrochloride and 5,7-dibromoisatin (76) according to Method A and
purified by flash chromatography on silica gel (DCM/EtOAc 3:1; to
100% EtOAc) to give a red solid (0.09 g, 57%), Rf 0.62 (DCM/EtOAc 5:1). LREI-MS: m/z
318; 320; 322 [M+]. HRESI-MS: C8H5Br2N2O3 79Br81Br (M+H+) 317.9289 found 317.9301.1H
NMR (DMSO-d6, 500 MHz) δ 8.79 (s, 1H, H4), 8.03 (s, 1H, H6), 11.15 (s, 1H, NH). 13C NMR
(DMSO-d6, 126 MHz): δ 103.0 (C5), 118.6 (C3a), 121.1 (C7), 127.8 (C4), 145.2 (C6), 145.3
(C7a), 158.6 (C2), 180.1 (C3).

Synthesis

of

(E

and

Z)-5,7-dibromo-3-(4-methoxyphenylimino)-1-(2-

morpholinoethyl)indolin-2-one (212)
The title compound (212) was synthesised 5,7-dibromo-N-(2-morpholinoethyl)isatin (166) and
p-methoxyaniline according to method B and purified by flash chromatography on silica gel
(DCM/DCM:EtOAc 6:1; 4:1) to give a dark yellow powder
(0.078 g, 52%, as a mixture of E and Z isomers (E:Z/42:58)),
Rf 0.26 (DCM) LREI-MS: m/z 521; 523; 525 [M+] 79Br79Br;
79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C21H22Br2N3O3

79

Br79Br (M+H+) 521.9604 found 521.9758.

1

H NMR

(CDCl3, 500 MHz) δ 2.52-2.53 (m, 12H, H2’, H2’’/H6’’,
E+Z), 3.62-6.38 (m, 4H, H1’, E+Z), 3.85 (s, 3H, OCH3, Z),
3.88 (s, 3H, OCH3, E), 4.21-4.24 (m, 8H, H3’’/H5’’, E+Z),
6.92 (d, 2H, J = 8.5, H3’’’/H5’’’, Z), 7.00-7.02 (m, 4H, H2’’’/H3’’’/H4’’’/H5’’’, E), 7.15 (d,
1H, J = 1.5, 4H, E), 7.43 (d, 2H, J = 9 Hz, H2’’’/H6’’’, Z), 7.64 (d, 1H, J = 1.5 Hz, H6, E), 7.68
(d, 1H, J = 1.5 Hz, H6, Z), 7.80 (d, 1H, J = 1.5 Hz, H4, Z). 13C NMR (CDCl3, 126 MHz): δ 54.0
(C2’’/C6’’, E+Z) *, 55.7* (OCH3, E+Z), 57.1 (C2’, E+Z), 68.4* (C1’, E+Z; C3’’/C5’’, E+Z),
114.0* (C3’’’/C5’’’, Z), 115.0* (C3’’’/C5’’’, E), 116.8, 117.2, 120.4* (C2’’’/C6’’’, E), 124.9
(C4, Z), 125.2* (C2’’’/C6’’’, Z), 127.4 (C4, E), 128.2, 128.8, 129.0 9 (ArC), 131.1 (ArC), 139.6
(C6, Z), 139.9 (C3a, Z), 140.9* (C6, E; C1’’’, E+Z), 141.3 (C3a, Z), 142.1, 142.9, 160.1*
(C4’’’, E+Z), 167.5* (C2, E+Z).
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of

(E

and

Z)-1–(4-morpholino-2-oxoethyl)-3-(4-fluorophenylimono)-5,7-

dibromoindolin-2-one (213)
The

title

compound

(213)

was

synthesised

5,7-dibromo-N-(2-morpholino-2-oxoethyl)isatin

from

(167)

and

4-fluorolaniline according to method B and purified by flash
chromatography on silica gel (DCM/EtOAc 6:1) to give a dark
yellow powder (0.097 g, 52%, mixture of E and Z isomers
(E:Z/54:46)), Rf 0.53 (DCM/EtOAc 6:1/4:1) LREI-MS: m/z
523; 525; 527 [M+]

79

Br79Br;

calcd for C20H17Br2FN3O3

79

79

Br81Br;

81

Br81Br. HRESI-MS:

Br79Br (M+H+) 523.9379 found 523.9396. 1H NMR (CDCl3, 500

MHz) δ 3.45- 3.78 (m, 16H, H2’, H3’, H5’, H6’, E+Z), 4.94 (s, 2H, CH2, Z), 5.09 (s, 2H, CH2,
E), 6.87 (d, J = 1.5 Hz, 1H, H4, E), 6.95-6.97 (m, 2H, ArH), 7.02-7.04 (m, 2H, ArH), 7.14-7.16
(m, 4H, ArH), 7.59 (d, J = 1.5 Hz, H6, E), 7.66 (d, J = 1.5 Hz, 1H,H6, Z), 7.81 (d, J = 1.5 Hz,
1H, H4, Z).

13

C NMR (126 MHz, CDCl3): δ 42.8 (C1’, Z), 43.5 (C1’, E), 45.5* (C2’’/C6’’,

E+Z), 66.6* (C3’’/C5’’), 67.0* (C3’’/C5’’), 105.0*, 115.5, 115.8*, 116.8, 117.0*, 119.7*
(C2’’’/C6’’’, E), 123.1*, 125.6 (C4, Z), 128.0 (C4, E), 133.6*, 139.9*, 140.3 (C6, Z), 141.3 (C6,
E), 145* (C1’’’, E+Z), 149.3, 156.1, 162.9 (C4’’’, E+Z), 179.5 (C2, Z), 181.4 (C2’’), 182.1
(C2’’), 201.4 (C2, E).

Synthesis of (E and Z)-1–(4-morpholino-2-oxoethyl)-3-(4-trifluoromethylphenylimono)5,7-dibromoindolin-2-one (214)
The

title

compound

(214)

was

synthesised

from

5,7-dibromo-N-(2-morpholino-2-oxoethyl)isatin (167) and
4-(trifluoromethyl)aniline according to method B and
purified by flash chromatography on silica gel (DCM/EtOAc
6:1) to give a dark red solid (0.131 g, 46%, mixture of E and
Z isomers (E:Z/56:44)), Rf 0.68 (DCM/EtOAc 6:1) LREIMS: m/z 573; 575; 577 [M+]

79

Br79Br;

79

Br81Br;

81

Br81Br.

HRESI-MS: calcd for C21H17Br2F3N3O3 79Br79Br (M+H+) 574.9470 found 574.9470. 1H NMR
(CDCl3, 500 MHz) δ 3.46-3.79 (m, 16H, H2’, H3’, H5’, H6’, E+Z), 4.91 (s, 2H, CH2, E), 5.11
(s, 2H, CH2, Z), 6.64 (s, 1H, H4, E), 7.06 (d, J = 8.0 Hz, 2H, H2’’/H6’’, E), 7.10 (d, J = 8.0 Hz,
2H, H2’’/H6’’, Z), 7.60 (s, 1H, H4, Z), 7.62 (d, J = 8.5 Hz, 2H, H3’’/H5’’, Z), 7.72 (d, J = 8.5
Hz, 2H, H3’’/H5’’, E+Z), 7.83 (s, 1H, H6, Z), 7.85(s, 1H, H6, E). 13C NMR (CDCl3, 126 MHz):
δ 42.6 (C1’, C3’’/C5’’), 43.4 (C1’), 45.2* (C3’’/C5’’), 66.3* (C2’’, C6’’), 66.9* (C2’’, C6’’),
104.1, 104.9, 115.7, 116.6, 117.4* (C2’’’/C6’’’), 119.0* (C2’’’/C6’’’), 125.8 (C3’’’/C5’’’, Z),
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125.9 (C6, E), 127.1* (C4’’’, E+Z), 127.3 (C6, Z), 128.2 (C4, E), 133.4, 139.6, 140.9*
(C3’’’/C5’’’, E), 141.5* (C3’’’/C5’’’, Z, C4, Z), 142.7, 144.3, 150.5 (C7a), 151.6 (C1’’’),
152.2* (C1’’’, C7a), 157.5 (C2’’, E), 163.2 (C2’’, Z), 164.6 (C2), 164.7 (C2).

Synthesis of (E and Z)-1–(4-morpholino-2-oxoethyl)-3-(4-methoxyphenylimono)-5,7dibromoindolin-2-one (215)
The

title

compound

(215)

was

synthesised

from

5,7-dibromo-N-(2-morpholino-2-oxoethyl)isatin (167) and
4-methoxyaniline according to method B and purified by
flash chromatography on silica gel (DCM/EtOAc 5:1; 3:1)
to give a dark red solid (0.16 g, 69%, as a mixture of E and
Z isomers (E:Z/42:58)), m.p. 121-124 ºC, Rf 0.41
(DCM/EtOAc 4:1). LREI-MS: m/z 537; 537; 539 [M+]
79

Br79Br;

79

Br81Br;

C21H20Br2N3O4

81

Br81Br.

HRESI-MS: calcd for

Br Br (M+H ) 536.9821 found 536.9816. 1H NMR (CDCl3, 500 MHz) δ

79

79

+

3.48-3.59 (m, 16H, H2’, H3’, H5’, H6’), 3.84 (s, 3H, OCH3, Z), 3.87 (s, 3H, OCH3, E), 4.91 (s,
2H, H1’, Z), 5.06 (s, 2H, H1’, E), 6.88 (d, J = 8.5 Hz, 2H, H3’’/H5’’), 6.99 (d, J = 8.5 Hz, 2H,
H3’’/H5’’), 7.03 (d, J = 8.5 Hz, 2H, H2’’/H6’’), 7.18 (d, J = 1.5Hz, 1H, H4, E), 7.45 (d, J = 8.5
Hz, 2H, H2’’/H6’’), 7.58 (d, J = 1.5Hz, 1H, H4, Z), 7.62 (d, J = 1.5Hz, 1H, H6, Z), 7.81 (d, J =
1.5Hz, 1H, H6, E). 13C NMR (CDCl3, 126 MHz): δ 42.1* (C2’’/C6’’, Z), 42.4* (C2’’/C6’’, E),
55.7* (CH2, E+Z), 55.8* (OCH3, E+Z), 62.3* (C3’’/C5’’, E), 62.5* (C3’’/C5’’, Z), 106.9, 107.1,
113.8* (C3’’’/C5’’’, Z), 114.9* (C3’’’/C5’’’, E), 115.2, 115.6, 120.5* (C2’’’/C6’’’, E), 125.2
(C6, E), 125.6* (C2’’’/C6’’’, Z), 127.4, 127.8 (C4, E), 130.8, 138.5 (C6, Z), 140.2 (C1’’’, Z),
141.5 (C4, Z), 141.8 (C7a, Z), 142.1 (C1’’’, E), 144.1 (C2’’, Z), 150.6, 158.0, 158.8 (C4’’’, E),
160.1 (C4’’’, Z), 164.0 (C2, E), 165.7 (C2, Z), 165.6 (C2’, E), 171.8 (C2’, Z).

Synthesis

of

(E

and

Z)-2-(4-((1-(4-methoxybenzyl)-5-nitro-2-oxoindolin-3-

ylidene)amino)phenyl)acetic acid (217)*
The title compound (217) was synthesised from 5-nitroN-(4-chlorobenzyl)isatin (170) and (4-aminophenyl)acetic
acid according to method B and purified by flash
chromatography on silica gel (DCM/MeOH 15:1, 10:1) to
give an orange powder (0.017 g, 24%, as a mixture of E
and Z isomers (E:Z/64:36)), Rf 0.43 (DCM/RtOAc 4:1).
LREI-MS: m/z 445 [M+]. HRESI-MS: calcd for C24H19N3O6 (M+H+) 445.8941 found
445.8964. 1H NMR (DMSO-d6, 500 MHz) δ 3.25 (s, 2H, H2, Z), 3.28 (s, 2H, H2, E), 3.90 (s,
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3H, OCH3, Z), 3.94 (s, 3H, OCH3, E), 5.01 (s, 2H, CH2, Z), 5.18 (s, 2H, CH2, E), 6.89 (d, J = 8.5
Hz, 2H, H3’’’/H5’’’, E), 6.91 (d, J = 8.5 Hz, 2H, H3’’’/H5’’’, Z), 7.02 (d, J = 8.5 Hz, 2H,
H3’/H5’, E), 7.19 (d, J = 8.0 Hz, 1H, H2’’’/H6’’’, Z), 7.22 (d, J = 8.0 Hz, 1H, H2’/H6’, Z), 7.35
(d, J = 8.0 Hz, 2H, H2’’/H6’’, E), 7.39 (d, J = 8.5 Hz, 2H, H3’/H5’, Z), 7.46 (d, J = 8.0 Hz, 2H,
H2’/H6’, E), 7.51 (d, J = 2.0 Hz, 1H, H4’’, E), 8.20 (d, J = 8.0 Hz, 1H, H7’’, E), 8.32 (d, J = 8.0
Hz, 1H, H7’’, Z), 7.48 (d, J = 8.5 Hz, 1H, H6’’, E), 8.50 (d, J = 8.5 Hz, 1H, H6’’, Z), 8.45 (s,
1H, H4’’, Z).

Synthesis

of

(E

and

Z)-2-(4-((5-methoxy-1-(4-methoxybenzyl)-2-oxoindolin-3-

ylidene)amino)phenyl)acetic acid (218)
The title compound (218) was synthesised from
5-nitro-N-(4-chlorobenzyl)isatin

(171)

and

(4-aminophenyl)acetic acid according to method B and
purified by flash chromatography on silica gel
(DCM/MeOH 15:1, 10:1) to give an orange powder
(0.027 g, 31%), to give an orange powder (0.017 g,
24%, as a mixture of E and Z isomers (E:Z/54:46), Rf 0.52 (DCM/RtOAc 4:1). LREI-MS: m/z
430 [M-H]-. HRESI-MS: calcd for C25H22N2O5 (M-H+) (M+H+) 430.9021 found 430.9048. 1H
NMR (CDCl3, 500 MHz) δ 3.25 (s, 2H, H2, Z), 3.28 (s, 2H, H2, E), 3.90 (s, 6H, OCH3, Z+E),
3.94 (s, 6H, OCH3, E+Z), 5.01 (s, 2H, CH2, Z), 5.18 (s, 2H, CH2, E), 6.01 (d, J = 2.0 Hz, 1H,
H4’’, E), 6.21 (d, J = 8.0 Hz, 2H, H3’’’/H5’’’, Z), 6.31 (d, J = 8.5 Hz, 2H, H3’’’/H5’’’, E), 6.45
(d, J = 8.5 Hz, 2H, H2’/H6’, E), 6.62 (d, J = 8.0 Hz, 1H, H7’’, Z), 6.71 (d, J = 8.0 Hz, 1H, H7’’,
E), 6.83 (d, J = 8.0 Hz, 2H, H2’’’/H6’’’, Z), 6.91 (d, J = 8.0 Hz, 2H, H2’’’/H6’’’, E), 7.01(d,
2H, J = 8.0 Hz, H2’/H6’, Z), 7.10 (d, 2H, J = 8.0 Hz, H3’/H5’, Z), 7.16 (d, J = 8.5 Hz, 2H,
H3’/H5’, E), 7.25 (d, J = 8.0 Hz, 1H, H6’’, Z), 7.44 (d, J = 8.0 Hz, 1H, H6’’, E), 7.49 (s, 1H,
H4’’, Z).

Synthesis of 3,3-dichloro-2-oxoindoline-5-sulfonyl chloride (220)
The title compound 220 was synthesised according to the protocol by
Bebernitz et al.403 To the cooled solution of chlorosulfonic acid (150
ml) was added dropwise a solution of isatin (76) (150 mmol) in DCM
(25 ml). Solution was stirred at rt for 2h, poured into ice and extracted
with EtOAc. The organic layer was dried over MgSO4, filtered and solvent removed in vacuo.
Product was purified by column chromatography to yield an orange powder (0.23 g, 58%).
LREI-MS: m/z 301 [M+] 1H NMR (DMSO-d6, 500 MHz) δ 7.46 (d, J = 8.5 Hz, 1H, H7), 8.20
(d, J = 2.0 Hz, 1H, H4), 8.61 (dd, J = 3 Hz, 1H, H6), 10.76 (br s, 1H, NH).
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Synthesis of 3,3-dichloro-5-(morpholinosulfonyl)indolin-2-one (221)
The title compound 221 was synthesised according to the
protocol by method of Ivachtchenko et al.432 220 (1 equiv.) was
dissolved in either THF (8 ml) or mixture EtOH/H2O 1:1 (8 ml)
and morpholine (2 equiv.). Mixtures were stirred at the rt for 3h
followed by the extraction with EtOAc. Organic layer was dried and solvent removed in vacuo.
The product was purified by column chromatography using DCM/EtOAc. Both reactions gave
the desired product EtOH/H2O (0.2805g, 88%), THF (0.1036g, 62%), m.p. 231-233 (lit 233
ºC).432 LREI-MS: m/z 350 [M+]. 1H NMR (CDCl3, 500 MHz) δ 3.38 (t, J = 3.5 Hz, 4H,
H2’/H6’), 3.77 (m, 4H, H3’/H5’), 6.79 (d, J = 9 Hz, 1H, H6), 7.62 (d, J = 8.5 Hz, 1H, H7), 7.93
(s, 1H, H4).

Synthesis of 1-(4-methoxybenzyl)-5-(morpholinosulfonyl)isatin (223)

The title compound (223) was synthesised from 5-(morpholinosulfonyl)indoline-2,3-dione (222)
and p-methoxybenzylchloride according to Method A and purified by flash chromatography on
silica gel (DCM/EtOAc 4:1/2:1) to give a red solid
(0.087 g, 62%), m.p. 203-205 (lit 205.1-206.0 ºC), Rf
0.28 (DCM/EtOAc 3:4). LREI-MS: m/z 416 [M+].
HRESI-MS: calcd for C20H21N2O6S (M+H+) 416.9622
found 416.9632. 1H NMR (DMSO-d6, 500 MHz) δ 2.85
(t, J = 4 Hz, 4H, H2’/H6’), 3.60 (t, J = 4 Hz,2H, H3’/H5’), 3.71 (s, 3H, OCH3), 4.88 (s, 2H,
CH2), 6.89 (d, J = 9 Hz, 2H, H3’’/H5’’), 7.20 (d, J = 8.5 Hz, 2H, 1H, H7), 7.38 (d, J = 8.5 Hz,
2H, 2H, H2’’/H6’’), 7.73 (d, J = 1.5 Hz, 2H, 1H, H4), 7.91 (dd, J = 1.5 Hz, 8.5 Hz, 1H, H6).

Synthesis of 3-((4-methoxyphenyl)imino)-5-(morpholinosulfonyl)indolin-2-one (224)
The title compound (224) was synthesised from
5-(morpholinosulfonyl)indoline-2,3-dione

(222)

and 4-methoxyaniline according to method B and
purified by flash chromatography on silica gel
(DCM/EtOAc 3:1/2:1) to give an orange powder
(0.068 g, 59%, mixture of E and Z isomers (E:Z/38:62), Rf 0.28 (DCM/EtOAc 3:4). LREI-MS:
m/z 401 [M+]. HRESI-MS: calcd for C19H20N3O5S (M+H+) 401.9871 found 401.9882. 1H
NMR (CDCl3, 500 MHz) δ 2.99-3.02 (m, 8H, H2’/H6’, E+Z), 3.75-3.78 (m, 8H, H3’/H5’,
E+Z), 3.85 (s, 6H, OCH3, E+Z) 6.82 (d, J = 8.5 Hz, 1H, H7, Z), 6.92 (d, J = 8.0 Hz, 2H,
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H3’’/H5’’, E), 6.98 (s, J = 7.5 Hz, 2H, H3’’/H5’’, Z), 7.11-7.15 (m, 3H, H7, E; H2’’/H6’’, Z),
7.36 (s, 1H, H4, E), 7.44 (d, J = 8.5 Hz, 2H, H2’’/H6’’, E), 7.60 (d, J = 9 Hz, 1H, H6, Z), 7.40
(d, J= 8.0 Hz, 1H, H6, E), 7.931 (s, 1H, H4, Z).

C NMR (CDCl3, 126 MHz): δ 46.3*

13

(C2’/C6’, E+Z), 66.4* (C3’/C5’, E+Z), 67.0 (CH3, E+Z), 112.6 (C7, E), 113.3, 114.1*
(C3’’/C5’’, E), 115.2 (C3’’/C5’’, Z), 116.7, 118.2 (C7, Z), 121.1 (C2’’/C6’’, Z), 122.3, 125.3*
(C2’’/C6’’, E, C4, E), 126.4, 129.8, 139.1 (C6, E), 134.5 (C6, Z), 135.0 (C4, Z), 142.3* (C1’’,
E+Z), 149.6 (C7a, E), 152.6, 154.9 (C7a, Z), 159.3* (C4’’, E+Z), 164.9 (C2), 165.2 (C2).

Synthesis of 5-(2-furyl)isatin (228)
The title compound (228) was synthesised according to the protocol
of Gerard et al.408 To a solution of 5-bromoisatin (227) (1 equiv.) in
DME under nitrogen Pd(PPh3)4 (0.05equiv.) was added. After 5 min
stirring at RT, arylboronic acid (3.6 mmol, 1.2 equiv.) and
sodiumhydrogen carbonate (2 equiv.) in H2O (10 mL) were added. Mixture was refluxed for 6h.
It was extracted with EtOAc, organic layer dried over MgSO4 and solvent removed in vacuo.
The product was purified by column chromatography (DCM/EtOAC 4:1; 1:1) to yield purple
solid (0.034 g, 19%), m.p. 211-214 ºC (lit 214 ºC)408, Rf 0.41 (DCM/ /EtOAc 4:1). LREI-MS:
m/z [M+] 213. 1H NMR (DMSO-d6, 500 MHz) δ 6.49 (s, 1H, Hfur), 6.63 (d, J = 1 Hz, 1H,
Hfur), 6.93 (d, J = 7.5 Hz, 1H, H7), 7.48 (s, 1H, Hfur), 7.89 (m, 2H, H4 +H6), 11.1 (s, 1H, NH).

Synthesis of 5-phenylisatin (229)
The title compound (229) was synthesised according to the protocol
of Gerard et al.408 To a solution of 5-bromoisatin (227) (1 equiv.) in
DME under nitrogen Pd(PPh3)4 (0.05equiv.) was added. After 5 min
stirring at RT, arylboronic acid (3.6 mmol, 1.2 equiv.) and
sodiumhydrogen carbonate (2 equiv.) in H2O (10 mL) were added.
Mixture was refluxed for 6h. It was extracted with EtOAc, organic layer dried over MgSO 4 and
solvent removed in vacuo. The product was purified by column chromatography (DCM/EtOAC
4:1; 1:1), to give a red solid (0.021 g, 24%), m.p. 267-269 ºC (lit 260 ºC)408, Rf 0.64
(DCM/Hex/EtOAc 4:1:2). LREI-MS: m/z [M+] 223. 1H NMR (DMSO-d6, 500 MHz) δ 6.99
(d, 1H, J = 8, H6), 7.35 (m, 1H, phenyl), 7.45 (m, 2H, phenyl), 7.65 (d, J = 7.5 Hz, 2H, phenyl),
7.53 (s, 1H, H4), 7.89 (d, 1H, J = 8.0 Hz, H6), 11.16 (s, 1H, NH).

Synthesis of 5-phenyl-N-(p-methoxybenzyl)isatin (230)
The title compound (230) was synthesised according to the protocol of Gerard et al.404 To a
solution of 5-bromo-1-(4-methoxybenzyl)isatin (162 a) (1 equiv.) in DME under nitrogen
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Pd(PPh3)4 (0.05equiv.) was added. After 5 min stirring at RT, arylboronic acid (3.6 mmol, 1.2
equiv.) and sodiumhydrogen carbonate (2 equiv.) in H2O (10 mL) were added. Mixture was
refluxed for 6h. It was extracted with EtOAc, organic
layer dried over MgSO4 and solvent removed in vacuo.
The product was purified by column chromatography
(DCM/EtOAC 4:1; 1:1), to give a red solid (0.016 g,
16%), m.p. 135-137 ºC, Rf 0.64 (DCM/Hex/EtOAc
4:1:2). LREI-MS: m/z [M+] 343. HRESI-MS: calcd for C22H18NO3 (M+H+) 343.9772 found
343.9781. 1H NMR (CDCl3, 500 MHz) δ 3.69 (s, 3H, OCH3), 5.28 (s, 2H, CH2), 6.87 (d, J = 8.5
Hz, 2H, H3’/H5’), 6.92 (q, J = 8.0 Hz, 3H, phenyl Arc), 7.24 (d, J = 6 Hz, 2H, H2’/H6’), 7.37
(d, J = 2.0 Hz, 1H, H6), 7.49 (sept, J = 8.5 Hz, 2H, phenyl Arc), 7.69 (d, J = 2.0 Hz, 1H, H7),
7.82 (d, J = 1Hz, 1H, H4).

13

C NMR (CDCl3, 126 MHz) δ 42.4 (CH2), 54.1 (OCH3), 110.6

(ArC, isatin), 114.2* (C3’/C5’), 117.9 (C1’), 123.4 (C7), 126.1* (C2’’/C6’’), 127.2 (C6),
128.7* (C3’’/C’5’), 130.1 (C1’), 130.8 (C2’/C6’), 136.3 (C4), 137.0 (C5), 138.7 (C1’’), 149.2
(C7a), 158.3 (C4’), 156.0 (C2), 182.7 (C3).

Synthesis of 3-azidopropan-1-ol (232)
The title compound 232 was synthesised according to the protocol of Engels
et al.433 To the solution of bromoporpanol (231) in anhydrous DMF (10 ml) sodium azide was
added at rt. Mixture was stirred slowly and the temperature brought up to 90-95°C. After 4 h
mixture was cooled and extracted with ether. Water was added into the organic layer and then
solvent removed in vacuo. TLC and MS indicated the formation of the product. Without further
purification product was used in the next step. LREI-MS: m/z 101 [M+].

Synthesis of 5,7-dibromo-1-((1-(3-hydroxypropyl)-1H-1,2,3-triazol-4-yl)methyl)isatin (233)
Method 1: The title compound 233 was synthesised
according to the protocol by Chang et al.429 5,7-dibromo1-(prop-2-yn-1-yl)isatin (168) was added (1 equiv.) to
the solution of azidopropanole (232) (1.2 equiv) in
H2O/ACN followed by the addition of CuI (0.05 equiv.)
and 2,6-lutidine (0.6 equiv.). After stirring on at rt, mixture was extracted with EtOAc, washed
with brine, dried over MgSO4, filtered and concentrated. Product was purified by column
chromatography using DCM/EtOAc 1:1, and EtOAc to yield an orange solid (0.152 g, 59%),
TLC: Rf 0.41 (DCM/MeOH 9:1) LREI-MS: m/z 442; 444; 446 [M+]
81

79

Br79Br;

79

Br81Br;

Br81Br. HRESI-MS: calcd for C14H13Br2N4O3 79Br79Br (M+H+) 442.9129 found 442.9211 1H

NMR (DMSO-d6, 500MHz) δ 1.90-1.93 (m, 2H, H7’), 3.63-3.65 (m, 2H, H8’), 4.36 (t, J = 7.0
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Hz, 2H, H6’), 5.31 (s, 2H, CH2), 7.18 (s, 1H, H4), 8.05 (s, 1H, H6), 8.12 (s, 1H, H5’). 13C NMR
(DMSO-d6, 126 MHz) δ 32.9 (C8’), 37.2 (CH2), 46.6 (C9’), 57.3 (C7’), 104.4, 115.7, 122.5,
122.8 (C6’), 126.3 (C4), 142.9 (C4’), 143.4 (C6), 146.0 (C7a), 158.6 (C2), 180.6 (C3).
Method 2. 233 was also synthesised by method of Sharpless et al. and Chang et al.406,430 168
was added (1 equiv.) to the solution of 232 (1 equiv) in H2O/tBuOH. To the mixture, solution of
CuSO4 in H2O and sodium ascorbate (freshly prepared 1M solution in H2O). The mixture was
stirred at rt followed by the purification protocol as described above in Method 1 to yield 0.12 g,
46% of 233.
Method 3. 233 was also synthesised according to the protocol by Fokin et al.410 168 (1 equiv.)
was added to the solution of bromopropanol (231) (1 equiv.) in DMF/ H2O. To the mixture,
sodium azide (1.2 equiv.) CuSO4.5 H2O (0.05 equiv.), sodium ascorbate (0.1 equiv.), Na2CO3
(0.2 qeuiv) and L-proline (0.2 equiv.) were added. Mixture was stirred at 60°C over-night.
Product was purified by column chromatography to yield 0.0162 g, 6% of 233.

Synthesis

of

5,7-dibromo-1-((1-(3-hydroxypropyl)-1H-1,2,3-triazol-4-yl)methyl)-3-((4-

methoxyphenyl)imino)indolin-2-one (234)
The title compound (234) was synthesised from 5,7dibromo-1-((1-(3-hydroxypropyl)-1H-1,2,3-triazol-4yl)methyl)isatin (233) and p-methoxyaniline according
to method B and purified by flash chromatography on
silica gel (DCM; DCM:EtOAc 2:1) to give a red solid
(0.083 g, 67%, mixture of E and Z isomers (E:Z/43:57)),
Rf 0.31 (DCM/EtOAC 1:1). LREI-MS: m/z 547; 549;
551 [M+] 79Br79Br; 79Br81Br; 81Br81Br. HRESI-MS: calcd for C21H20Br2N5O3 79Br79Br (M+H+)
547.9834 found 547.9827. 1H NMR (DMSO-d6, 500 MHz) δ 1.89-1.92 (m, 4H, H7’, E+Z),
3.33-3.35 (m, 4H, H8’, E+Z), 3.81 (s, 2H, OCH3, E+Z), 4.36 (t, J = 7.5 Hz, 2H, H6’, E+Z); 5.27
(s, 2H, CH2, Z); 5.39 (s, 2H, CH2, E), 6.84 (s, 1H, H4, E), 6.96 (d, J = 9 Hz , 2H, H3’’/H5’’, Z),
7.04 (d, J = 8.5 Hz, 2H, H3’’/H5’’, E), 7.08 (d, J = 8.5 Hz, 2H, H2’’/H6’’, E), 7.43 (d, J = 9
Hz, 2H, H2’’/H6’’, Z), 7.75 (s, 1H, H4, Z), 7.83 (s, 1H, H6, E), 7.86 (s, 1H, H6, Z), 8.05 (s, 1H,
H5’, Z), 8.09 (s, 1H, H5’, E). 13C NMR (DMSO-d6, 126 MHz): δ 33.5 (C7’, E+Z), 37.5 (C8’,
E+Z), 47.2 (C6’, E+Z), 56.0 (OCH3, E+Z), 57.9 (CH2, E+Z), 104.0, 104.8, 114.2* (C3’’/C5’’,
Z), 114.8* (C3’’/C5’’, E), 115.5*, 115.8* (C2’’/C6’’, E), 120.1 (C4, Z), 120.5, 123.4 (C5’, Z),
124.3 (C5’, E), 125.5* (C2’’/C6’’, Z), 127.6, 139.6, 140.6 (C1’’, Z), 140.7 (C1’’, E), 141.7,
142.8, 143.5, 144.0, 147.7, 152.1, 153.4, 158.0 (C4’’, E), 158.4 (C4’’, Z), 159.7 (C2, Z), 163.4
(C2, E).
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Synthesis

of-

(Z)-5,7-dibromo-3-(hydroxyimino)-1-((1-(3-hydroxypropyl)-1H-1,2,3-triazol-4-yl)methyl)i
ndolin-2-one (235)
The title compound (235) was synthesised from
5,7-dibromo-1-((1-(3-hydroxypropyl)-1H-1,2,3-triazol-4yl)methyl)isatin (233) and hydroxylamine hydrochloride
according

to

method

B

and

purified

by

flash

chromatography on silica gel (DCM/MeOH 9:1) to give a
red solid (0.048 g, 47%), Rf 0.52 (DCM/MeOH 9:1). LREI-MS: m/z 457; 459; 461 [M+]
79

Br79Br; 79Br81Br; 81Br81Br. HRESI-MS: calcd for C14H14Br2N5O3 79Br79Br (M+H+) 457.9702

found 457.9719. 1H NMR (DMSO-d6, 500 MHz) δ 1.90-1.93 (m, 2H, H7’), 3.31-3.33 (m, 2H,
H8’), 4.33 (t, J = 7.5 Hz, 2H, H6’), 5.34 (s, 2H, CH2), 7.22 (s, 1H, H4), 7.99 (s, 1H, H5’), 8.25
(s, 1H, H6). 13C NMR (DMSO-d6, 126 MHz): δ 33.6 (C7’), 37.5 (C8’), 47.3 (C6’), 58.1 (CH2),
115.3, 120.5, 123.3 (C5’), 124.8 (C6), 131.2 (C4’), 137.6 (C4), 139.8 (C7a), 142.3, 144.1 (C3),
164.6 (C2).

Synthesis of 5,7-dibromo-2-oxindole (240)
The title compound (240) was synthesised according to the protocol of
Sumpter et al.431 2-Oxindole (1 equiv.) was dissolved in water and into
the hot mixture, solution containing bromine (2 equiv.) and potassium
bromide in water was added slowly. The reaction mixture was filtered
and the solid purified by column chromatography (DCM/EtOAc 9:1; 5:1) as a brown powder
(0.040 g, 21%), m.p. 258-261 °C, Rf 0.19 (DCM). LREI-MS: m/z 289; 291; 293 [M+] 79Br79Br;
79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C8H6Br2NO

79

Br79Br (M+H+) 289.8714 found

289.8717. 1H NMR (DMSO-d6, 500 MHz) δ 3.29, (s, 2H); 7.36, (s, 1H); 7.56, (s, 1H); 10.75, (s,
1H). 13C NMR (DMSO-d6, 126 MHz): δ 36.7 (C3), 113.1 (C7), 126.4 (C6), 129.7 (C5), 131.9
(C4), 132.1 (C4’), 141.8 (C7’), 178.8 (C2).

3,5,7-Tribromooxindole (240 a)
The title compound (240a) was isolated as a by-product of the above
reaction (0.041 g, 17%), Rf 0.52 (DCM). LREI-MS: m/z 367; 369; 371;
373 [M+]

79

Br79Br79Br;

79

Br

79

Br81Br;

79

Br81Br81Br;

81

Br81Br81Br. 1H

NMR (DMSO-d6, 500 MHz) δ 5.78 (s, 1H, C3); 7.54 (s, 1H, C4); 7.73
(s, 1H, C6); 11.24 (s, 1H, NH).
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3,3,5,7-Tetrabromooxindole (240 b)
The title compound (240b) was isolated as a by-product of the above
reaction (0.046 g, 19%) Rf 0.47 (DCM). LREI-MS: m/z 367; 369;
371; 373. 1H NMR (DMSO-d6, 500 MHz) δ 5.78 (s, 1H, C3); 7.54 (s,
1H, C4); 7.73 (s, 1H, C6); 11.24 (s, 1H, NH).

Synthesis of 5,7-dibromo-N–(4-methoxybenzyl)-indolin-2-one (241)
The compound 241 was synthesised according to the protocol
of Crestini et al.416 162 (2 g) was dissolved in hydrazine
hydrate (15 ml) and refluxed for 4 h. The reaction mixture
was extracted with EtOAc, dried over MgSO4 and solvent
removed on the rotary evaporator. The product was purified by column chromatography using
DCM/hexane mixture to yield brown powder (1.243 g , 63%), m.p. 116-118 °C, Rf 0.61 (DCM)
LREI-MS: m/z 409; 411; 413 [M+]

79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: calcd for

C16H14Br2NO2 79Br79Br (M+H+) 409.9391 found 409.9378. 1H NMR (CDCl3, 500 MHz) δ 3.63
(s, 2H, H3, CH2), 3.77 (s, 3H, OCH3), 5.30 (s, 2H, CH2), 6.83 (d, J = 8.5 Hz, 2H, H3’/H5’),
7.15 (d, J = 8.5 Hz, 2H, H2’/H6’), 7.31 (s, 1H, H4), 7.51 (s, 1H, H6). 13C NMR (CDCl3, 126
MHz): δ 35.8 (C3), 45.1 (CH2), 56.1 (OCH3), 102.5 (C5), 114.8* (C3’/C5’), 116.7 (C7), 126.8
(C6), 129.4* (C2’/C6’), 130.0 (C1’), 131.7 (C3a), 135.6 (C4), 141.7 (C7a), 159.5 (C4’), 174.5
(C2).

1-(4-Methoxybenzyl)-5-bromooxindole (241 a)
The title compound (241 a) was isolated as a by-product of
the above reaction (0.218 g, 14%), m.p. 151-154 °C, Rf 0.53
(DCM) LREI-MS: m/z 331; 333; [M+]
HRESI-MS: calcd for C16H15Br NO2

79

Br79Br;

81

Br81Br.

79

Br79Br (M+H+)

332.0283 found 332.0286. 1H NMR (CDCl3, 500 MHz) δ
3.59 (s, 3H, OCH3), 3.77 (s, 2H, H3), 4.82 (s, 2H, CH2), 6.60 (d, J = 8.5 Hz, 1H, H7), 6.84 (d, J
= 8.5 Hz, 2H, H3’/H5’), 7.21 (d, J = 8.5 Hz, 2H, H2’/H6’), 7.28 (d, J = 8.5 Hz, 1H, H6), 7.35
(s, 1H, H4).

13

C NMR (CDCl3, 126 MHz): δ 31.8 (C3), 39.6 (CH2), 51.6 (CH3), 106.7 (C7),

110.5* (C3’/C5’), 122.8 (C5), 123.7 (C3a), 123.9 (C1’), 125.0* (C2’/C6’), 126.9 (C4), 127.2
(C6), 139.6 (C7a), 155.5 (C4’), 170.6 (C2).

1–(4-Methoxybenzyl)-3-hydrazyl-5,7-dibromo-indolin-2one (241 b)
The title compound (241 b) was isolated as a by-product of
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the above reaction as the orange powder (0.098 g, 5%), Rf 0.58 (DCM/EtOAc 1:1) LREI-MS:
m/z 437; 439; 441 [M+]
79

79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C16H14Br2N3O2

Br79Br (M+H+) 437.9354 found 437.9348. 1H NMR (CDCl3, 500 MHz) δ 3.76 (s, 3H, OCH3),

5.37 (s, 2H, CH2), 6.83 (d, J = 8.5 Hz, 2H, H3’/H5’), 7.13 (d, J = 8.5 Hz, 2H, H2’/H6’), 7.47 (s,
1H), 7.61 (s, 1H), 10.9 (NH2).
5,7-dibromo-1-(4-methylbenzyl)indolin-2-one (242)
The compound 242 was synthesised according to the protocol of
Crestini et al.

431

242 (0.5 g) was dissolved in hydrazine hydrate

(8 ml) and refluxed for 4 h. The reaction mixture was extracted
with EtOAc, dried over MgSO4 and solvent removed on the
rotary evaporator. The product was purified by column chromatography using DCM/hexane
mixture to yield brown powder (0.275 g, 57%), Rf 0.71 (DCM) LREI-MS: m/z 393; 395; 397
[M+]

79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C16H14Br2NO

79

Br79Br (M+H+)

393.9008 found 393.9006. 1H NMR (CDCl3, 500 MHz) δ 2.38 (s, 2H, CH3), 3.64 (s, 2H, H3,
CH2) , 5.39 (s, 2H, CH2), 6.83 (d, J = 8.5 Hz, 2H, H3’/H5’), 7.15 (d, J = 8.5 Hz, 2H, H2’/H6’),
7.29 (s, 1H, H4), 7.47 (s, 1H, H6). 13C NMR (CDCl3, 126 MHz) δ 20.1 (CH3), 35.7 (C3), 44.5
(CH2), 101.8 (C5), 116.8 (C7), 116.7 (C6), 126.5* (C3’/C5’), 129.5* (C2’/C6’), 130.0 (C1’),
134.7 (C3a, C3)*, 141.7 (C7a), 156.2 (C4’), 176.5 (C2).

5-bromo-1-(4-methylbenzyl)indolin-2-one (242 a)
The title compound (242 a) was isolated as a by-product of the
above reaction as the brown solid (0.046 g, 12%) Rf 0.38
(DCM/EtOAc 4:1) LREI-MS: m/z 315; 317; [M+]
81

79

Br79Br;

Br81Br. 1H NMR (CDCl3, 500 MHz) δ 2.31 (s, 3H, CH3), 3.60

(s, 2H, H3), 4.85 (s, 2H, CH2), 6.58 (d, J = 8.5 Hz, 1H, H7), 7.16 (m, 4H, H2’/H3’/H5’H6’),
7.26 (d, J = 8.5 Hz, 1H, H6), 7.38 (s, 1H, H4). 13C NMR (CDCl3, 126 MHz): δ 21.4 (CH3), 35.8
(C3), 43.8 (CH2), 110.7, 115.2, 126.7 (C3a), 127.5* (C2’/C6’), 127.8 (C4), 129.4* (C3’/C5’),
129.8, 132.6 (C1’), 137.8 (C4’), 143.6 (C3), 174.6 (C2).

7.7.3 Method for the preparation of 3-alkenyl- -N-alkylated-5,7-dibromoisatin derivatives
General Method C: Alkene isatin derivatives were synthesised according to the protocol of
Hung et al.432 The isatin derivative (1 equiv.) was dissolved in ethanol (10 ml per 0.15 g of
isatin derivative) and to the stirred solution piperidine (0.1 equiv.) and an appropriate aldehyde
(1equiv.) were added at 0°C. The reaction mixture was refluxed for 4h than extracted with
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EtOAc, dried over MgSO4 and the solvent removed on the rotary evaporator. The product was
purified by column chromatography.

Synthesis of 1–(4-methoxybenzyl)-3-(4-chlorophenylmethylidenyl)-5,7-dibromoindolin-2–
one (243)
The title compound (243) was synthesised from
5,7-dibromo-N–(4-methoxybenzyl)-indolin-2-one (241)
and 4-chlorobenzaldehyde according to method C and
purified by flash chromatography on silica gel
(DCM/EtOAc 8:1) to give a yellow powder (0.021 g,
16% E isomer), m.p. 180-182 ºC, Rf 0.71 (DCM/Hex
79

Br79Br;

calcd

for

5:1),. LREI-MS: m/z 531; 533; 535 [M+]
79

Br81Br;

81

Br81Br.

C23H17Br2ClNO2

HRESI-MS:

Br79Br (M+H+) 531.9243 found 531.9267. 1H NMR (CDCl3, 500 MHz) δ

79

3.77 (s, 3H, OCH3), 5.40 (s, 2H, CH2), 6.82 (d, J = 8.5 Hz, 2H, H3’/H5’), 7.15 (d, J = 8.5 Hz,
2H, H2’/H6’), 7.44-7.46 (m, 3H, H4, H3’’/H5’’), 7.84 (d, J = 7.5 Hz, 2H, H2’’/H6’’), 7.67 (s,
1H, H-vinyl), 7.90 (s, 1H, H6). 13C NMR (126 MHz, CDCl3): δ 45.0 (CH2), 58.0 (OCH3), 114.3
(C3’/C5’), 115.0, 124.9, 125.3, 128.2* (C2’’/C6’’), 128.5 (C6), 129.1, 129.5* (C3’’/C5’’),
130.8* (C2’/C6’), 133.8 (C4), 134.1 (C4’’), 136.5, 137.4, 139.1, 141.1, 159.8 (C4’), 167.0 (C2).

Synthesis of 1–(4-methoxybenzyl)-3-(4-methylphenylmethylidene)-5,7-dibromo-indol-2one (244 a and 244 b)
The title compounds (244 a and 244 b) were synthesised
from

5,7-dibromo-N–(4-methoxybenzyl)-indolin-2-one

(241) and o-chlorobenzaldehyde according to method C
and purified by flash chromatography on silica gel (DCM)
to give two isomers (E, Z).

E isomer, a dark yellow solid (0.021 g, 31%), m.p. 173-175 ºC/ LREI-MS: m/z 531; 533; 535
[M+]

79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C23H17Br2ClNO2

79

Br79Br (M+H+)

531.9323 found 513.9315. 1H NMR (CDCl3, 500 MHz) δ 3.71 (s, 3H, OCH3), 5.31 (s, 2H,
CH2), 6.77 (d, J = 8.5 Hz, 2H, H3’/H5’), 7.10 (d, J = 8.5 Hz, 2H, H2’/H6;), 7.29-7.31 (m, 2H,
H4’’, H5’’), 7.40 (d, J = 8.5 Hz, 1H, H3’’), 7.48 (s, 1H, H4), 7.60 (s, 1H, H6), 7.86 (s, 1H, Hvinyl), 8.39 (d, J = 8.0 Hz, 1H, H6’’).

C NMR (126 MHz, CDCl3): δ 44.2 (CH2), 57.6

13

(OCH3), 114.1* (C3’/C5’), 115.1, 122.0, 125.0, 125.2, 127.9, 126.5 (C6), 128.2, 126.4 (C1’’),
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128.5* (C2’/C6’), 132.1 (C4), 133. 1 (C1’), 135.8 (C4’’), 136.5, 137.2, 139.3, 141.0, 159.1
(C4’), 168.1 (C2).
Z isomer, a dark yellow solid (0.009 g, 14%), LREI-MS: m/z 531; 533; 535 [M+]
79

79

Br79Br;

Br81Br; 81Br81Br. 1H NMR (CDCl3, 500 MHz) δ 3.73 (s, 3H, OCH3), 4.83 (s, 2H, CH2), 6.79

(d, J = 8.5 Hz, 2H, H3’/H5’), 7.15 (d, J = 9 Hz, 2H, H2’/H6’), 7.38 (s, 1H, H4), 7.39-7.40 (m,
H4’, H5’), 7.42 (s, 1H, H6), 7.51 (d, J = 8.5 Hz, 1H, H3’’), 7.58 (d, J = 8.5 Hz, 1H, H6’’), 7.98
(s, 1H, H-vinyl).

Synthesis of 1–(4-Methoxybenzyl)-3-(4-nitrophenylmethylidenyl)-5,7-dibromoindolin-2–
one (245) 71:29
The title compound (245) was synthesised from 5,7-dibromoN–(4-methoxybenzyl)-indolin-2-one

(241)

and

p-nitrobenzaldehyde according to method C and purified by
flash chromatography on silica gel (DCM/EtOAc 8:1) to give
a yellow powder (0.034 g, 17%), Rf 0.87 (DCM), Z isomer.
LREI-MS: m/z 542; 544; 546 [M+]
81

79

Br79Br;

79

Br81Br;

Br81Br. HRESI-MS: calcd for C23H17Br2N2O4 79Br79Br (M+H+) 542.9555 found 542.9535. 1H

NMR (CDCl3, 500 MHz) δ 3.78 (s, 3H, OCH3), 5.42 (s, 2H, CH2), 6.84 (d, J = 8.5 Hz, 2H,
H3’/H5’), 7.18 (d, J = 8.5 Hz, 2H, H2’/H6’), 7.48 (s, 1H, H4), 7.49 (s, 1H, H-vinyl), 7.51, (d, J
= 7.5 Hz, 2H, C3’’/H5’’), 7.94 (s, 1H, H6), 8.36 (d, J = 8.5 Hz, 2H, H2’’/H6’’).

13

C NMR

(CDCl3, 126 MHz): δ 42.8 (CH2), 55.6 (CH3), 114.3* (C3’/C5’), 115.1, 124.5* (C3’’/C5’’),
124.9, 125.0, 127.0, 128.0 * (C2’’/C6’’), 129.0 (C1’), 130.1* (C2’/C6’), 132.4, 136.8, 138.5,
140.8 (C1’’), 141.0 (CH), 148.8 (C4’’), 158.0 (C4’), 168.0 (C2).

Synthesis

of

(Z)-1–(4-methoxybenzyl)-3-(4-hydroxyphenylmethylidenyl)-5,7-

dibromoindolin-2-one (246) 73:27
The

title

compound

(246)

was

synthesised

5,7-dibromo-N–(4-methoxybenzyl)-indolin-2-one

from
(241)

and p-hydroxybenzaldehyde according to method C and
purified

by

flash

chromatography

on

silica

gel

(DCM/EtOAc 6:1) to give a yellow powder (0.032 g, 26%),
Rf 0.81 (DCM), Z isomer. LREI-MS: m/z 513; 515; 517 [M+]
HRESI-MS: calcd for C23H18Br2NO3

79

79

Br79Br;

79

Br81Br;

81

Br81Br.

Br79Br (M+H+) 513.9638 found 513.9653. 1H NMR

(DMSO-d6, 500 MHz) δ 3.67 (s, 3H, OCH3), 3.68 (s, 2H, CH2), 6.38 (d, J = 8.5 Hz, 2H,
H3’/H5’), 6.81 (d, J = 8.0 Hz, 2H, H3’’/H5’’), 6.97 (d, J = 8.5 Hz, 2H, H2’/H6’), 6.36 (s, 1H,
H4), 7.86, (s, 1H, H-vinyl), 7.90 (s, 1H, H6), 8.41 (d, J = 8.5 Hz, 2H, H2’’/H6’’). 13C NMR
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(DMSO-d6,126 MHz): 43.4 (CH2), 55.4 (OCH3), 102.4, 114.3* (C3’/C5’), 114.6, 115.9*
(C3’’/C5’’), 116.2, 121.3 (C6), 125.5 (C1’’), 127.7* (C2’/C6’), 130.2 (C1’), 132.1, 134.1 (C4),
136.4* (C2’’/C6’’), 136.6 (C7a), 142.0 (CH), 158.6 (C4’), 161.9 (C4’’), 166.3 (C2).

Synthesis of 1–(4-methoxybenzyl)-3-(4 -methoxyphenylmethylidenyl)-5,7-dibromoindolin20one (247)
The

title

compound

(247)

was

synthesised

from

5,7-dibromo-N–(4-methoxybenzyl)-indolin-2-one (241) and
p-methoxybenzaldehyde according to method C and
purified by flash chromatography on silica gel (DCM) to
give a dark yellow powder Z isomer (0.017 g, 26%), Rf 84
(DCM). LREI-MS: m/z 527; 529; 531 [M+] 79Br79Br; 79Br81Br; 81Br81Br. HRESI-MS: calcd for
C24H20Br2NO3 79Br79Br (M+H+) 527.9810 found 527.9816. 1H NMR (CDCl3, 500 MHz) δ 3.74
(s, 3H, OCH3), 3.78 (s, 3H, OCH3), 5.39 (s, 2H, CH2), 6.80 (d, J = 8.5 Hz, 2H, H3’/H5’), 6.94
(d, J = 8.0 Hz, 2H, H3’’/H5’’), 7.14 (d, J = 8.5 Hz, 2H, H2’/H6’), 7.44 (s, 1H, H4), 7.48 (s, 1H,
H-vinyl), 7.55 (s, 1H, H6), 8.41 (d, J = 8.0 Hz, 2H, H2’’/H6’’). 13C NMR (CDCl3, 126 MHz): δ
38.1 (CH2), 50.0 (OCH3), 50.1 (OCH3), 108.9* (C3’/C5’), 109.0* (C3’’/C5’’), 118.0, 118.1
(C4), 121.0, 122.8* (C2’/C6’), 123.0* (C2’’/C6’’), 123.2, 124.2 (C6), 128.3 (C1’’), 130.3 (C1’),
130.4, 135.1, 138.0, 157.0 (C4’), 159.1 (C4’’), 161.0 (C2).
Synthesis of 1–(4-methoxybenzyl)-3-(4-methylphenylmethylidene)-5,7-dibromo-indol-2one (248)
The title compounds (248a and 248b) were synthesised from
5,7-dibromo-N–(4-methoxybenzyl)-indolin-2-one (241) and
p-methylbenzaldehyde according to method C and purified by
flash chromatography on silica gel (DCM/EtOAc 8:1) to give
two isomers.

Z isomer (0.020 g, 33%, a dark orange solid), Rf 0.87 (DCM). LREI-MS: m/z 511; 513; 515
[M+]

79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C24H20Br2NO2

79

Br79Br (M+H+)

511.9851 found 511.9861. 1H NMR (CDCl3, 500 MHz) δ 2.41 (s, 3H, CH3), 3.79 (s, 3H,
OCH3), 5.41 (s, 1H, CH2), 6.81 (d, J = 8.5 Hz, 1H, H3’’/H5’’), 7.14 (d, J = 8.5 Hz, 1H,
H3’/H5’), 7.26 (d, J = 8.5 Hz, 1H, H2’/H6’), 7.42 (s, 1H, H4), 7.54 (s, 1H, H-vinyl), 7.96 (s,
1H, H6), 8.25 (d, J = 8.5 Hz, 1H, H2’’/H6’’). 13C NMR (CDCl3, 126 MHz): δ 22.0 (CH3), 43.8
(CH2), 55.4 (OCH3), 113.0, 114.2* (C3’/C5’), 114.9, 121.1, 122.6* (C2’/C6’), 127.9, 129.0*
(C2’’/C6’’), 129.5, 129.8, 130.1* (C3’’/C5’’), 131.1 (C1’’), 133.0, 135.8 (C4’’), 140.4 (CH),
142.8 (C4’’), 156.8 (C4’), 168.2 (C2).
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E isomer (0.014 g, 21%, a dark orange solid). LREI-MS: m/z 511; 513; 515 [M+]
79

79

Br79Br;

Br81Br; 81Br81Br. 1H NMR (CDCl3, 500 MHz) δ 2.43 (s, 3H, CH3), 3.75 (s, 3H, OCH3), 5.40

(s, 1H, CH2), 6.82 (d, J = 8.5 Hz, 1H, H3’’/H5’’), 7.15 (d, J = 8.5 Hz, 1H, H3’/H5’), 7.28 (d, J
= 8.5 Hz, 1H, H2’/H6’), 7.42 (s, 1H, H6), 7.50 (d, J = 8.5 Hz, 1H, H2’’/H6’’), 7.81 (s, 1H, H4),
7.96 (s, 1H, H-vinyl). 13C NMR (CDCl3, 126 MHz): δ 21.3 (CH3), 44.3 (CH2), 55.5 (OCH3),
111.2, 114.2* (C3’/C5’), 123.3, 124.6* (C2’’/C6’’), 126.4* (C3’’/C5’’), 127.9, 128.0 (C1’),
129.7, 129.9* (C3’’/C5’’), 131.2, 134.3, 136.1, 138.9 (CH), 140.1 (C1’’), 141.3 (C4’’), 158.2
(C4’), 169.1 (C2).

Synthesis of 1–(4-methoxybenzyl)-3-(4-ethylphenylmethylidene)-5,7-dibromoindol-2-one
(249a and 249b)
The title compound (249a and 249b) was synthesised from
5,7-dibromo-N–(4-methoxybenzyl)-indolin-2-one (241) and
p-ethylbenzaldehyde according to method C and purified by
flash chromatography on silica gel (DCM/EtOAc 8:1) to give
E and Z isomer.

Z isomer 249a (0.035 g, 27%, a dark yellow solid), Rf 0.90 (DCM). LREI-MS: m/z 525; 527;
529 [M+]

79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C25H22NO2Br2

79

Br79Br (M+H+)

526.0017 found 526.0005. 1H NMR (CDCl3, 500 MHz) δ 1.20-1.22 (m, 3H, CH3), 2.64-2.67
(m, 2H, CH2), 3.71 (s, 3H, OCH3), 5.35 (s, 2H, CH2), 6.75 (d, J = 8.5 Hz, 2H, H3’’/H5’’), 7.11
(d, J = 8.0 Hz, 2H, H3’/H5’), 7.24 (d, J = 8.5 Hz, 2H, H2’/H6’), 7.43 (s, 1H, H6), 7.50 (s, 1H,
H-vinyl), 7.56 (s, 1H, H4), 8.23 (d, J = 8.5 Hz, 1H, H2’’/H6’’). 13C NMR (CDCl3, 126 MHz): δ
15.4 (CH3), 29.2 (CH2), 44.3 (CH2), 55.5 (OCH3), 102.4, 114.2* (C3’/C5’), 115.1, 120.8,
124.6* (C3’’/C5’’), 126.3, 128.0* (C32’’/C6’’), 128.7* (C2’/C6’), 129.8, 130.5, 132.6, 133.2,
136.0, 136.9, 139.9, 140.4, 141.3, 146.7, 148.6, 158.7, 164.9 (C2).
E isomer 249b (0.010 g, 8%, a dark yellow solid). LREI-MS: m/z 525; 527; 529 [M+] 79Br79Br;
79

Br81Br; 81Br81Br. 1H NMR- (CDCl3, 500 MHz) δ 1.31 (t, J = 7.5 Hz, 3H, CH3-ethyl), 2.75 (q, J

= 7.5 Hz, 2H, CH2-ethyl), 3.77 (s, 3H, OCH3), 5.42 (s, 2H, CH2), 6.84 (d, J = 8.5 Hz, 1H,
H3’’/H5’’), 7.17 (d, J = 9 Hz, 1H, H3’/H5’), 7.34 (d, J = 9 Hz, 1H, H2’/H6’), 7.48 (s, 1H, H4),
7.55 (d, J = 8.5 Hz, 1H, H2’’/H6’’), 7.83 (s, 1H, H6), 7.98 (s, 1H, H-vinyl). 13C NMR (CDCl3,
126 MHz): δ 18.3 (CH3), 24.6 (CH2), 44.3 (CH2), 55.5 (OCH3), 102.3, 114.2* (C3’/C5’), 123.7,
124.6* (C3’’/C5’’), 128.0* (C2’’/C6’’), 128.7, 129.8* (C2’/C6’), 130.1, 134.2, 137.0, 141.3,
148.6, 158.2 (C4’), 162.5 (C2).
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Synthesis of 1–(4-methylbenzyl)-3-(4-methylphenylmethylidene) 5,7-dibromoindolin-2-one
(250a and 250b)
The title compounds (250a and 250b) were synthesised from
1-(4-methylbenzyl)-5,7-dibromo-indoline-2,3-dione (242) and
p-chlorobenzaldehyde according to the method C and purified
by flash chromatography on silica gel (DCM. EtOAc/DCM
9:1) to give two isomers (E: Z).

E isomer 250a (0.020 g, 33%), m.p. 180-182ºC (dark yellow solid), Rf 0.63 (DCM/Hex 5:1).
LREI-MS: m/z 515; 517; 519 [M+]
C23H17Br2ClNO

79

79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: calcd for

Br79Br (M+H+) 515.9278 found 515.9385. 1H NMR (CDCl3, 500 MHz) δ

2.32 (s, 3H, CH3), 5.44 (s, 2H, CH2), 7.11 (s, 4H, H2’/H3’/ H5’/ H6’), 7.49 (d, J = 8.5 Hz, 2H,
H2’’/ H6’’), 7.50 (s, 1H, H6), 7.56 (d, J = 8.5 Hz, 2H, H4’’/ H6’’), 7.68 (s, 1H, H4), 7.92 (s,
1H, H-vinyl). 13C NMR (126 MHz, CDCl3): δ 21.3 (CH3), 46.8 (CH2), 109.4, 116.0, 126.8 (C6),
127.1* (C2’/C6’), 127.8* (C3’/C5’), 128.5* (C3’’/C5’’), 129.3* (C2’’/C6’’), 129.8, 132.5*
(C1’’), 134.7 (C1’), 137.4 (CH), 142.2 (C6, E), 149.9, 152.7, 158.7 (C4’), 160.0 (C4’’), 164.6
(C2).
Z isomer 250b (0.009 g, 10%, dark yellow solid). LREI-MS: m/z 515; 517; 519 [M+] 79Br79Br;
79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C23H17Br2ClNO

79

Br79Br (M+H+) 516.0879 found

516.0899. 1H NMR (CDCl3, 500 MHz) δ 2.99 (s, 3H, CH3), 5.41 (s, 2H, CH2), 7.09 (s, 4H, H2’/
H3’/H5’/H6’), 7.41 (d, J = 8.5 Hz, 2H, H3’’/H5’’), 7.49 (s, 1H, H4), 7.61 (s, 1H, H6), 7.92 (s,
1H, H vinyl), 8.29 (d, J = 8.5 Hz, 2H, H2’’/H6’’).13C NMR (126 MHz, CDCl3): δ 21.3 (CH3),
44.8 (CH2), 113.8, 114.9, 121.5, 124.7, 126.5* (C2’/C6’), 129.0* (C3’’/C5’’), 129.5* (C3’/C5’),
130.8, 134.1* (C2’’/C6’’), 134.4, 136.4 (C4’), 137.5, 138.5, 139.2 (CH-vinyl), 140.1, 142.3,
168.6 (C2).

Synthesis of 1–(4-methylbenzyl)-3-(4-methylphenylmethylidene) 5,7-dibromoindolin-2-one
(251a and 251b)
The title compounds (251a and 251b) were synthesised from
1-(4-methylbenzyl)-5,7-dibromo-indoline-2,3-dione (242) and pmethylbenzaldehyde according to the method C and purified by
flash chromatography on silica gel (DCM. EtOAc/DCM 9:1) to
give two isomers (E:Z)

195 |

Chapter 7

Experimental

E isomer 251a (0.022 g, 36%, an orange solid), Rf 0.85 (DCM). LREI-MS: m/z 495; 497; 499
[M+]

79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C24H20Br2NO

79

Br79Br (M+H+)

495.9903 found 495.9912. 1H NMR (CDCl3, 500 MHz) δ 2.30 (s, 3H, CH3), 2.44 (s, 3H, CH3),
5.43 (s, 2H, CH2), 7.09 (s, 4H, H2’/ H3’/ H5’/ H6’), 7.30 (d, J = 9 Hz, 2H, H2’’/H6’’), 7.46 (s,
1H, H4), 7.51 (d, J = 9 Hz, 2H, H3’’/ H5’’), 7.82 (s, 1H, H6), 7.98 (s, 1H, H-vinyl). 13C NMR
(CDCl3, 126 MHz): δ 20.1 (CH3), 20.3 (CH3), 44.1 (CH2), 114.8 (C5), 124.5 (C3), 124.8 (C7),
126.3 (C3a), 126.5 (C6), 126.8* (C2’/C6’), 129.1 (C4), 128.8* (C2’’/C6’’), 129.2* (C3’/C6’),
129.9* (C3’’/C5’’), 131.0 (C2’), 131.2 (C2’’), 132.6, 134.5 (C5’), 137.0 (C5’’), 141.3 (C7a,
C1’’), 170.2 (C2).

Z isomer 251b Yield 0.0081 g (14%, an orange solid). LREI-MS: m/z 495; 497; 499 [M+]
79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C24H20Br2NO

79

Br79Br (M+H+) 495.9886

found 495.9899. 1H NMR (CDCl3, 500 MHz) δ 2.31 (s, 3H, CH3), 2.41 (s, 3H, CH3), 5.45 (s,
2H, CH2), 7.09 (s, 4H, H2’/ H3’/H5’/H6’), 7.27 (d, J = 8.5 Hz, 2H, H3’’/H5’’), 7.49 (s, 1H,
C4), 7.57 (s, 1H, H-vinyl), 7.62 (s, 1H, H6), 8.26 (d, J = 8.5 Hz, H2’’/H6’’).

Synthesis of 1–(4-methylbenzyl)-3-(4-methylphenylmethylidene) 5,7-dibromoindolin-2-one
(252a and 252b)
The title compounds (252a and 252b) were synthesised from
1-(4-methylbenzyl)-5,7-dibromo-indoline-2,3-dione (242) and
p-ethylbenzaldehyde according to the method C and purified by
flash chromatography on silica gel (DCM. EtOAc/DCM 9:1) to
give two isomers.

Z isomer 252a Yield 0.025 g (39%, a dark yellow solid), Rf 0.91 (DCM). LREI-MS: m/z 509;
511; 513 [M+]

79

Br79Br;

79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C25H22Br2NO (M+H+)

495.9912 found 495.9898. 1H NMR (CDCl3, 500 MHz) δ 1.23 (t, J = 7.5 Hz, 3H, CH3), 2.33 (s,
3H, CH3), 2.76 (q, J = 7.5 Hz, 2H, CH2), 5.46 (s, 2H, CH2), 7.12 (s, 4H, H2’/H3’/H5’/H6’), 7.35
(d, J = 8.5 Hz, 2H, H3’’/H5’’), 7.48 (s, 1H, H4), 7.85 (s, 1H, H6), 8.01 (s, 1H, H-vinyl), 8.25
(d, J = 8.5 Hz, 2H, H2’’/H6’’). 13C NMR (126 MHz, CDCl3): δ 19.3 (CH3), 20.5 (CH3), 29.1
(CH2), 43.6 (CH2), 103.1 (C5), 114.2 (C3), 124.1 (C3a), 124.5 (C7), 126.2 (C6), 126.6*
(C3’’/C5’’), 128.7* (C2’/C6’), 129.5* (C2’’/C6’’), 129.9* (C3’/C5’), 130.6, 131.8 (C4), 133.5,
134.3 (C2’’), 136.5 (C5’), 141.2 (C7a), 147.8 (C5’’), 169.5 (C2).

E isomer 252b somer Yield 0.0103 g (16%, dark yellow solid). LREI-MS: m/z 509; 511; 513
[M+] 79Br79Br; 79Br81Br; 81Br81Br. 1H NMR (CDCl3, 500 MHz) δ 1.32 (t, J = 7.5 Hz, 3H, CH3),
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2.32 (s, 3H, CH3), 2.76-2.78 (m, 2H, CH2), 5.39 (s, 2H, CH2), 7.12 (s, 4H, H2’/H3’/H5’/H6’),
7.34 (d, J = 8.5 Hz, 2H, H2’’/H6’’), 7.45 (s, 1H, H4), 7.57 (d, J = 8.5 Hz, 2H, H3’’/H5’’), 7.85
(s, 1H, H6), 8.01 (s, 1H, H-vinyl).

Synthesis of 3,5-dimethylpyrrole-2-carboxaldehyde (257)
The title compound 257 was synthesised according to the protocol of Terenin
et al.418 Phosphorus oxychloride (10 mmol) was added dropwise with stirring
and cooling to dry DMF (25 ml). The product was stirred for 30 min at 0ºC
and then a solution of 2,4-dimethylpyrrole (2 mmol) in DMF (3 ml) was added dropwise. The
product was stirred for another 24 h at 20ºC and poured onto crushed ice. The aqueous solution
was neutralized with sodium carbonate and the precipitate formed was filtered off, washed with
warm water, dried, and purified by column chromatography to give 0.0369g, 67%. LREI-MS:
m/z 123.15 [M+]. 1H NMR (DMSO) δ: 2.31 (s, 6H, CH3), 5.85 (s, 1H, Arc), 9.46 (s, 1H,
COOH).

Synthesis

of

(Z)-1-(4-methoxybenzyl)-3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene-

5,7-dibromoindolin-2-one (253)
The

title

compound

(253)

was

synthesised

from

1-(4-methoxybenzyl)-5,7-dibromo-indoline-2,3-dione (241)
and 3,5-dimethyl-1H-pyrrole-2-carbaldehyde according to
the method C and purified by flash chromatography on
silica gel (DCM) to give a dark yellow solid (0.1405 g,
57%, m.p. 205-207 ºC, Rf 0.59 (DCM/Hex 5:2). LREI-MS:
m/z 514; 516; 518 [M+]

79

Br79Br;

HRESI-MS: calcd for C23H21Br2N2O2

79

Br81Br;

81

Br81Br.

79

Br79Br (M+H+) 514.9933 found 514.9903. 1H NMR

(CDCl3, 500 MHz) δ 2.34 (s, 3H, CH3), 2.36 (s, 3H, CH3), 3.75 (s, 3H, OCH3), 5.46 (s, 2H,
CH2), 6.01 (s, 1H, H4’’), 6.82 (d, J = 9 Hz, 2H, H3’/H5’), 7.09 (d, J = 8.5 Hz, 2H, H2’/H6’),
7.31 (s, 1H, H-vinyl), 7.32 (s, 1H, H4), 7.51 (s, 1H, H6). 13C NMR (CDCl3, 126 MHz): δ 11.9
(CH3), 14.3 (CH3), 43.9 (CH2), 55.4 (OCH3), 102.8, 108.4, 113.9 (C4’’), 114.2* (C3’/C5’),
114.6, 118.8 (C6), 124.5 (C4), 127.5* (C2’/C6’), 127.7 (p), 130.1 (C1’), 130.5 (7a), 132.1
(C1’’), 134.7, 135.3, 139.5, 158.8 (C4’), 168.6 (C2).

Synthesis of 1-(4-methoxybenzyl)-3-((1H-pyrrol-2-yl)methylene-5,7-dibromoindolin-2-one
(254)
The title compound (2) was synthesised from 1-(4-methoxybenzyl)-5,7-dibromo-indoline-2,3dione (241) and 1H-pyrrole-2-carbaldehyd according to the method C and purified by flash
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chromatography on silica gel (DCM) to give a dark yellow solid (0.1013 g, 54%, m.p. 199-201
ºC, Rf 0.57 (DCM/Hex 5:2). LREI-MS: m/z 486; 488; 490 [M+] 79Br79Br; 79Br81Br; 81Br81Br.
HRESI-MS: calcd for C21H17Br2N2O2

79

Br79Br (M+H+) 486.9594 found 486.9657. 1H NMR

(CDCl3, 500 MHz) δ 3.78 (s, 3H, OCH3), 5.50 (s, 2H, CH2),
6.43-6.45 (m, 1H, H5’’), 6.85 (d, J = 9 Hz, 2H, H3’/H5’),
6.87 (m, 1H, H6’’), 7.15 (d, J = 8.5 Hz, 2H, H2’/ H6’), 7.24
(broad d, 1H, H4’’), 7.45 (s, 1H, H4), 7.48 (s, 1H, H1-vinyl),
7.59 (s, 1H, H6).

13

C NMR (CDCl3, 126 MHz): δ 43.9

(CH2), 55.3 (CH3), 103.0, 112.6 (C5’’), 113.1, 114.1*
(C3’/C5’), 115.0, 119.8 (C6), 122.7 (C6’’), 127.2 (C4’’), 127.6* (C2’/C6’), 128.2 (C1’’), 129.6
(C3a), 129.9 (C1’), 133.6 (C4), 135.1 (7a), 158.2 (C4’), 168.1 (C2).

Synthesis

of

1-(4-methylbenzyl)-3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene-5,7-

dibromoindolin-2-one (255)
The title compound (255) was synthesised from 1-(4-methylbenzyl)-5,7-dibromo-indoline-2,3dione

(242)

and

according to the

3,5-dimethyl-1H-pyrrole-2-carbaldehyde
method

C

and

purified

by flash

chromatography on silica gel (DCM, DCM/EtOAc 5:1) to give
a dark yellow solid (0.12 g, 68%), 186-188°C, Rf 0.70
(DCM/Hex 5:2). LREI-MS: m/z 498; 500; 502 [M+] 79Br79Br;
79

Br81Br;

81

Br81Br. HRESI-MS: calcd for C23H21Br2N2O

79

Br79Br (M+H+) 498.0009 found 498.0021. 1H NMR (CDCl3, 500 MHz) δ 2.27 (s, 3H, CH3),

2.32 (s, 3H, CH3), 3.33 (s, 3H, CH3), 5.46 (s, 2H, CH2), 5.99 (s, 1H, H4’’), 7.02 (d, J = 8.5 Hz,
2H, H3’/H5’), 7.06 (d, J = 8.5 Hz, 2H, H2’/H6’), 7.30 (s, 1H, H4), 7.48 (s, 1H, H6), 7.50 (s,
1H, H-vinyl). 13C NMR (CDCl3, 126 MHz): δ 11.8 (C7’’), 14.2 (C8’’), 21.2 (CH3), 44.2 (CH2),
102.8, 108.3, 113.8 (C5’’), 114.5, 118.7 (C6), 124.4 (C4), 126.1* (C2’/C6’), 127.7 (pyrrole),
129.4* (C3’/C5’), 130.4 (C3), 132.0 (C1’’), 134.7 (C1’), 134.9 (C4’), 135.5, 136.6 (pyrrole),
139.3 (pyrrole), 168.5 (C2).

Synthesis of 2-oxoindoline-5-sulfonyl chloride (258)
The title compound 258 was synthesised according to the protocol by
Liang et al.155 2-Oxindole was added slowly to the cooled sulfonic
acid and mixture stirred at rt for 4h. Mixture was poured into the
crushed ice and then extracted with EtOAc. The organic layer was
dried and solvent removed in vacuo. The product was purified by column chromatography using
DCM/EtOAc to yield an orange solid (0.28 g, 89%). LREI-MS: m/z 231 [M+]. 1H NMR
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(DMSO-d6, 500 MHz) δ 3.45 (s, 2H, C3), 6.97 (d, 1H, J = 8.5 Hz, H5), 7.50 (d, 1H, J = 7.5 Hz,
H6), 7.55 (s, 1H, H4), 9.5 (s, 1H, NH).

Synthesis of N-(4-methoxyphenyl)-2-oxoindoline-5-sulfonamide (259)
The title compound 259 was synthesised according to the
protocol by Ivachtchenko et al.432 2-Oxoindoline-5sulfonyl chloride (258) (1 equiv.) was dissolved in
EtOH/H2O 1:1 mixture and to the stirred solution 4methoxyaniline was added (2equiv.). After one hour
stirring at the rt, mixture was extracted with EtOAc, organic layer washed with brine, dried over
MgSO4 and solvent removed in vacuo. The product was purified by column chromatography
(DCM; DCM:EtOAc 5:1) to yield an orange powder (0.074 g, 54%), Rf 0.32 (DCM/EtOAc 3:1)
LREI-MS: m/z 318 [M+]. HRESI-MS: calcd for C15H14N2O4S (M+H+) 318.0674 found
318.0675.1H NMR (DMSO) δ 3.53 (s, 2H, H3), 3.65 (s, 3H, OCH3), 6.78 (d, J = 8.5 Hz, 2H,
C2’/C6’), 6.94 (d, J = 8.5 Hz, 1H, ArH isatin), 6.96 (d, J = 8.5 Hz, 2H, C3’/C5’), 7.49-7.51 (m,
2H, ArH isatin).

Synthesis of (E and Z)-3-(4-hydroxybenzylidene)-N-(4-methoxyphenyl)-2-oxoindoline-5sulfonamide (260)
The title compound (260) was synthesised
from N-(4-methoxyphenyl)-2-oxoindoline-5sulfonamide

(259)

and

4-aminophenol

according to method B and purified by
column chromatography (DCM/EtOAc 4:1; 1:2) to give a red solid (0.0159, 24%), Rf 0.46
(DCM/EtOAc 4:1) LREI-MS: m/z [M+] 422. HRESI-MS: calcd for C22H18N2O5S (M+H+)
422.0910 found 422.0941. 1H NMR (DMSO): δ 6.78 (d, J = 9 Hz, 2H, H3’/H5’, E), 6.81 (d, J =
9 Hz, 2H, H3’/H5’, Z), 6.86 (m, 2H, H3’’/H5’’, E+Z), 6.91-6.94 (m, 3H, H2’/H6’,H7, Z), 6.976.99 (m, 2H, H2’/H6’, E), 7.00 (d, J = 7.5 Hz, H7, E), 7.44 (d, J = 9 Hz, 2H, H2’’/H6’’, Z), 7.47
(d, J = 7.5, 1H, H6, Z), 7.54 (d, J = 8.5 Hz, 2H, H6, E), 7.61 (s, 1H, CH, Z), 7.79 (s, 1H, CH, E),
7.90 (s, 1H, C4, Z), 7.98 (s, 1H, C4, E), 8.43 (d, J = 8.5 Hz, 2H, H2’’/H6’’, E). 13C NMR (126
MHz, DMSO): δ 58.1* (CH3, E+Z), 109.7, 110.6, 114.9* (C3’/C5’, E+Z), 116.1* (C3’’/C5’’,
E), 116.5* (C3’’/C5’’, Z), 118.3, 118.4, 121.1 (C4, E), 121.1 (C4, Z), 123.6, 124.1 (C2’/C6’, E),
124.7* (C2’/C6’, Z), 125.1, 125.9, 126.4, 127.8, 129.1, 129.3, 130.9, 131.1, 132.1, 132.6, 136.1,
139.6 (CH, Z), 141.1 (CH, E), 142.5, 143.7 (C7a, E), 146.4 (C7a, Z), 157.1 (C4’, E), 157.3 (C4’,
Z), 160.6 (C4’’, Z), 161.6 (C4’’, E), 168.1 (C2, E), 169.7 (C2, Z).
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Synthesis of 5-(morpholinosulfonyl)indolin-2-one (261)
The title compound (261) was synthesised from 2-oxoindoline5-sulfonylchloride
Ivachtchenko et al.

and
432

morpholine

by

the

method

of

and purified by column chromatography

(DCM/EtOAc 4:1; 1:2) to give a yellow powder (0.1295 g, 27%), Rf 0.21 (DCM/EtOAc 3:1)
LREI-MS: m/z [M+] 282. HRESI-MS: calcd for C12H15N2O4S (M+H+) 282.0674 found
282.0678. 1H NMR (CDCl3, 500 MHz) δ 3.51 (s, 2H, H3), 3.29 (t, J = 3.5 Hz, 4H, H2’/H6’),
3.73-3.75 (m, 4H, H3’/H5’), 6.76 (d, J = 9 Hz, 1H, H6), 7.61 (s, J = 8.5 Hz, 1H, H7), 7.92 (s,
1H, H4).
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Figure 9.1. Maps showing three algal collection sites, Picture 1: Red circle represents part of Australia
where samples were collected438, Picture 2: Three collections spots are marked with a red flower.439
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9.1 10% Methanol extract of Haliclona sp.
The chemical composition of the six column fractions of 10% methanol extract obtained from
Haliclona sp. analysed by EI-MS is presented in the Table 9.1.

Table 9.1: EI-MS analysis of column chromatography fraction the 10% methanol extract obtained from Haliclona sp.
No
Compounds identified
1
10-Methylheptadecanoate
2
Androst-5-en-3β-ol
3
24-Methyl-26,27-dinorcholesta-5,23-dien-3β-ol
4
24-Ethylcholesta-5-en-3β-ol
5
Cholesta-5,20,24-trien-3β-ol
6
1-Phenanthrenecarboxylic acid
7
Cholesta-5-en-3β-ol
8
24-Methyl-3,25-bis(acetyloxy)-5-hydroxy-cholesta-6-one
9
1,3,4,6-Tetraacetyl-α-d-glucosamine
10
Pentaacetylgalactose
*Fraction numbers refer to column chromatography combined fractions.

#1
√
√
√
√
-

#2
√
√
-

#3
√
√
-

#4
√
-

#5
√
√
-

#6
√

9.2 50% Methanol extract of Haliclona sp.
The chemical composition of the six column fractions of 50% methanol extract obtained from
Haliclona sp. analysed by EI-MS is presented in the Table 9.2.

Table 9.2: EI-MS analysis of column chromatography fraction the 50% methanol extract obtained from Haliclona sp.
No
Compounds identified
1
3-Hydroxy-2(1H)-pyridinethionein
2
Hexadecanoic acid
3
Octadecanoic acid
4
2’-Deoxy-adenosine
5
1-Bromohexadecane
6
Cholesta-5,20,24-trien-3β-ol
7
14-Bromopentadecanoic acid
8
Eicosanoic acid
9
24-Ethylcholesta-5-en-3β-ol
10
24-Ethylcholesta -7-en-3β-ol.
11
2-Hydrazino-8-hydroxy-4phenylquinoline
12
2-Methoxy-4-phenoxy-1,5-naphthyridine
13
Cholestane-3,5-diol
14
24-Methylcholesta-7,22-dien-3β-ol
15
22,23-Cyclopropyl-24-ethylcholesta-5-en-3β-ol
*Fraction numbers refer to column chromatography combined fractions.

# 1*
√
√
√
-

#2
√
-

#3
√
√
-

#4
√
√
-

#5
√
√
-

#6
√
√
√
√
√

9.3 10% Methanol column fractions of Ircinia/Sarcotragus sp.
The chemical composition of the six column fractions of 10% methanol extract obtained from
Ircinia/Sarcotragus sp. analysed by EI-MS is presented in the Table 9.1.
Table 9.3: EI-MS analysis of the 10% methanol column fractions of Ircinia/Sarcotragus sp.
Compounds identified
fraction 1
fraction 2
fraction 3
24-Methylcholesta-5,22-diene
√
6,10,14-Trimethyl-2-pentadecanone
√
Tetradecanoic acid
√
Cholesta-5-en-3β-ol
√
√
Cholesta-5,7-dien-3β-ol
√
24-Methylcholesta-5,7-22-trien-3-ol
√
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9.4 Water extracts from Haliclona sp., Ircina/Sarcotragus sp. and Geodia sp.

Chemical composition of the three deep-sea sponge water extracts was analysed by high
resolution ESI-QTof-MS; the tentatively identified compounds are presented in Table 9.4.
Compounds were identified by comparing HRMS data with those from the Dictionary of
Natural Compounds.
Table 9. 4: EI-MS analysis of the water extracts from Haliclona sp., Ircina/Sarcotragus sp. and Geodia sp.
Ret.
Compound name
MW
A
B
time
16.5 1H-Indole-3-carboxaldehyde; N-Ac
187
√
18.0 Adenine; 6-N-Benzoyl
239
18.8 2-Debromo-dispacamide A/9,10-dihydrokeramadine
326
√
19.8 6,6'-Dibromoindigotin; N,N'-Di-Ac
504
√
19.9 Pseudoceratinine B
504
√
21.4 2-Acetyl-3,5,8-trihydroxy-1,4-naphthoquinone
248
√
22.0 2′-Deoxyinosine
256
24.1 Echinosulfone A
498
√
√
25.8 Purpuramine H
622
√
27.3 2-Amino-16-methyl-1,3-octadecanediol
746
√
28.6 Tasipeptin A
870
√
√
30.2 2'-Deoxycytidine; β-D-form, 3',4N,5'-Tribenzoyl
539
√
31.2 Adenosine; N6-Benzyl
357
37.6 Hyrtiosin B
320
√
42.1 Ageliferin; 1'-N-Me
632
√
43.6 Didemnimide A
278
√
48.3 Pseudoceratinine B
502
A: Haliclona sp,; B: Ircinia/Sarcotragus sp.; C: Geodia sp.

C
√
√
√
√

9.5 Protein kinase B inhibition testing
Phosphor-Akt levels were determined by the Western blotting to indicate Akt activity.
Cells treated with isatin derivatives were lysed by NP40 lysis buffer containing protein inhibitor
cocktail, beta-glycerophosphate and PMSF. Proteins were separated by Biorad sodium dodecyl
sulfate-polyacrylamide gel electrophoresis. After electrophoresis, proteins were transferred onto
nitrocellulose membranes using a Biorad transfer electrophoresis unit (100 V for 1 hour). The
membranes were then washed in TBST and incubated with 5% BSA for 1 hour followed by
overnight incubation (4°C) with anti-pAkt473 antibody. The membranes were washed by TBST
for three times (5 minutes each time) and then incubated for 1 hour with a HRP-linked second
antibody. After three times of wash with TBST, the membranes were incubated with ECL for 1
minute and exposure to x-ray film. The protein levels were determined by densities of bands
showed in x-ray film and adjusted by beta-actin as loading control.
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9.6 Setup of the 96-well microplates used in the MTS assay

9.7 Table of IC50 values of the isatin compounds screened for cytotoxicity against MDAMB-231 breast cancer cell lines
Table 9.7 shows IC50 values of the isatin compounds screened for cytotoxicity against
MDA-MB-231 breast cancer cell lines in comparison with their values against U937 human
lymphoma cancer cell lines.

Table 9.5: IC50 values of the isatin compounds against MDA-MB-231 breast cancer cell lines
Cytotoxicity
Cytotoxicity
Cpd. no
Cpd. no
IC50 (µM)
IC50 (µM)
MDA-MB-231
U937
MDA-MB-231
U937
19.2
3.8
na
28.3
178
223
17.6
10.2
31.4
18.8
205
224
26.1
15.1
11.6
8.9
208
234
27.5
20.0
19.1
16.1
209
235
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